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Abstract 
The incidence of invasive fungal infections (IFIs), such as candidemia and aspergillosis, is rising 
worldwide. Moreover, the mortality rate associated with these infections is high (≥ 50%), which can 
mainly be explained by the lack of sufficient antifungal drugs and adequate diagnostic techniques. 
Indeed, nowadays only echinocandins and lipid formulations of amphotericin B can be used to 
efficiently treat IFIs, therefore urging for the development of novel antifungal drug treatments. At the 
diagnostic site, the standard technique for IFI detection is a culture-based method. It generally takes 
2-4 days before the results are available, which can be a crucial period for the patient’s outcome. In 
this PhD research we have focused on antimicrobial peptides (AMPs) for the development of both 
AMP-based novel antifungal drugs as well as diagnostic techniques for IFI treatment. AMPs have 
broad-spectrum antifungal activities, are generally non-toxic to human cells and are effective in vivo. 
Moreover, as these peptides are rapidly killing fungal cells, AMPs are characterized by a low frequency 
of resistance occurrence. In our research group, we mainly focus on a group of AMPs originating from 
plants, called plant defensins. The latter are also characterized by their binding to specific targets at 
the fungal cell, making them interesting candidates for both diagnosis and curing of IFIs. 
As microbial cells often appear in biofilm structures, which are more tolerant to antimicrobial drugs than 
planktonic cultures, the first aim of this PhD was to investigate potential antibiofilm activity of plant 
defensins. The plant defensins RsAFP2 and HsAFP1 can indeed inhibit Candida albicans biofilm 
formation, but cannot disrupt mature biofilms. Moreover, both plant defensins act synergistically with 
the common antifungal drugs caspofungin and amphotericin B. We further delineated the minimal 
peptide sequence of HsAFP1 important for synergistic activity with caspofungin against C. albicans 
biofilms as a 19-mer peptide, HsLin06_18. In addition, various strategies were investigated to improve 
HsLin06_18’s in vivo efficacy, however, so far none of them was successful. In conclusion, plant 
defensin (-derivatives) are interesting peptides for further development to an antifungal drugs in both 
mono and combination treatments to combat fungal (biofilm-related) infections.  
A crucial step in the development of novel drugs is the unravelling of their mode of action. Therefore, 
in this PhD, our second aim was to further unravel the antifungal mode of action of the plant defensin 
HsAFP1 as well as identify tolerance mechanisms used by yeasts to resist HsAFP1 treatments, using 
Saccharomyces cerevisiae and C. albicans as model yeasts. We found that HsAFP1 interacts with 
phosphate-containing phospholipids, such as phosphatidic acid and phosphatidylinositol phosphates. 
In addition, HsAFP1’s internalization seems crucial for its antifungal action and is followed by 
immediate membrane permeabilization of the target yeast. Via transcriptome analysis of HsAFP1-
treated C. albicans cells and additional genetic and/or biochemical tests, we showed that 
glycosylphosphatidylinositol (GPI)-anchored proteins play an important role in HsAFP1’s antifungal 
activity. In addition, we demonstrated that HsAFP1 treatment of yeast cells affects the vacuolar function 
and induces various endoplasmic reticulum stress tolerance mechanisms. 
The third aim of this PhD was the development of a novel detection technique for fungal infections, 
leading to more effective and rapid diagnostics. Using RsAFP2 as a fungal-specific bioligand, we 
developed a plant defensin-based ELISA bioassay for yeast cell detection with a detection limit of 
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approx. 50 C. albicans cells/mL. The next step would be the translation of this ELISA assay to a more 
rapid and sensitive technology, using a fiber-optic surface plasmon resonance (FO-SPR) approach. 
In conclusion, we show that plant defensins are of great interest in the development of novel 
antifungal/antibiofilm drugs. We further identified biological activities and mode of actions of the plant 
defensin HsAFP1, important to gain more insight in fungal killing strategies and hence, interesting for 
drug development. In addition, we successfully evaluated the plant defensin RsAFP2 as bioligand for 
fungal-specific detection. 
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Samenvatting 
De incidentie van invasieve schimmelinfecties (ISIs), zoals candidemia en aspergillose, stijgt 
wereldwijd. Bovendien is het sterftecijfer dat geassocieerd is met deze infecties hoog (≥ 50%), wat 
voornamelijk komt door het gebrek aan effectieve antifungale geneesmiddelen en geschikte 
diagnosetechnieken. Tegenwoordig kunnen inderdaad enkel echinocandines en liposomale vormen 
van amfotericine B gebruikt worden ter behandeling van ISIs, hetgeen wijst op een duidelijke nood aan 
de ontwikkeling van nieuwe types van antifungale geneesmiddelen. Daarnaast is de huidige standaard 
diagnosetechniek voor de detectie van ISI een cultuur-gebaseerde methode. Het duurt gemiddeld  
2-4 dagen voor de resultaten hiervan beschikbaar zijn, wat een cruciale periode kan zijn voor de 
overleving van de patiënt. In dit doctoraal onderzoek hebben we ons gericht op antimicrobiële peptiden 
(AMPs) voor de ontwikkeling van zowel AMP-gebaseerde nieuwe antifungale geneesmiddelen als 
diagnosetechnieken voor de behandeling van ISIs. AMPs hebben een breedspectrum antifungale 
activiteit, zijn in het algemeen niet toxisch voor menselijke cellen en hebben in vivo activiteit. Bovendien 
doden deze peptiden gistcellen snel af, waardoor AMPs gekarakteriseerd zijn door een lage frequentie 
van resistentie-ontwikkeling. In onze onderzoeksgroep wordt voornamelijk gefocust op een groep van 
AMPs afkomstig van planten, genaamd plantdefensinen. Deze worden bovendien gekenmerkt door 
hun binding op specifieke plaatsen van de schimmel-/gistcel, wat hen interessante kandidaten maakt 
voor zowel de diagnose als behandeling van ISIs. 
Aangezien microbiële cellen vaak voorkomen onder de vorm van biofilms en deze laatsten toleranter 
zijn aan antimicrobiële geneesmiddelen, was het eerste doel van dit doctoraat het nagaan van 
potentiële antibiofilm-activiteit van plantdefensinen. De plantdefensinen RsAFP2 en HsAFP1 kunnen 
inderdaad Candida albicans biofilmvorming tegengaan, maar kunnen geen mature biofilms 
vernietigen. Bovendien werken beide plantdefensinen synergistisch in combinatie met de gekende 
antifungale geneesmiddelen caspofungin en amfotericine B. Verder hebben we de minimale peptide- 
sequentie van HsAFP1 die belangrijk is voor synergistische activiteit met caspofungin tegen  
C. albicans biofilms afgebakend als een 19-mer peptide, HsLin06_18. Daarnaast hebben we 
verschillende strategieën gebruikt voor de verbetering van de in vivo activiteit van HsLin06_18, maar 
tot nu toe bleek geen van deze succesvol. We concluderen dat plantdefensine(n) (-afgeleiden) 
interessante peptiden zijn om verder te ontwikkelen tot antifungale geneesmiddelen, die zowel in 
enkelvoudige als in gecombineerde behandelingen gebruikt kunnen worden ter bestrijding van (biofilm-
gerelateerde) schimmelinfecties.  
Een cruciale stap in de ontwikkeling van nieuwe geneesmiddelen, is de ontrafeling van hun 
werkingsmechanisme. Daarom was het tweede doel van dit doctoraat de ontrafeling van het 
werkingsmechanisme van het plantdefensine HsAFP1 alsook de identificatie van de 
tolerantiemechanismen gebruikt door de gist om zich te wapenen tegen HsAFP1 behandelingen, 
daarbij gebruik makend van de modelorganismen Saccharomyces cerevisiae en C. albicans. We 
hebben aangetoond dat HsAFP1 interageert met fosfaat-bevattende fosfolipiden, zoals fosfatidezuur 
en fosfatidylinositolfosfaten. Bovendien lijkt de internalisatie van HsAFP1 cruciaal voor zijn antifungale 
activiteit en wordt dit proces direct gevolgd door membraanpermeabilisatie van de doelwitgist. Via 
transcriptoomanalyse van de HsAFP1-behandelde C. albicans cellen en bijkomende genetische en 
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biochemische testen, hebben we aangetoond dat glycosylfosfatisylinositol (GPI)-verankerde eiwitten 
een belangrijke rol spelen in de antifungale activiteit van HsAFP1. Bovendien toonden we aan dat 
HsAFP1-behandeling van gistcellen de vacuolaire functie aantast en verschillende stress-
tolerantiemechanismen van het endoplasmatisch reticulum induceert. 
Het derde doel van dit doctoraat was de ontwikkeling van een nieuwe techniek voor de detectie van 
schimmelinfecties, leidend tot een effectievere en snellere diagnose. Met RsAFP2 als schimmel-
specifieke bioligand hebben we een plantdefensine-gebaseerde ELISA-test ontwikkeld voor de 
detectie van gistcellen met een detectielimiet van ongeveer 50 C. albicans cellen/mL. De volgende 
stap zou de translatie van deze ELISA-test zijn naar een snellere en gevoeligere techniek, gebaseerd 
op een “optische vezel-oppervlakte resonantie (FO-SPR)”-benadering. 
Concluderend hebben we in dit doctoraat aangetoond dat plantdefensinen zeer interessante 
kandidaten zijn voor de ontwikkeling van nieuwe antifungale/antibiofilm geneesmiddelen. We hebben 
verder nog biologische activiteiten en werkingsmechanismen van het plantdefensine HsAFP1 
geïdentificeerd, om zo meer inzicht te krijgen in schimmel-afdodingsstrategieën wat interessant is voor 
verdere geneesmiddelenontwikkeling. Bovendien hebben we het plantdefensine RsAFP2 succesvol 
gebruikt als bioligand voor schimmel-specifieke detectie.  
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The incidence of invasive fungal infections (IFIs) is increasing worldwide. The mortality rate associated 
with these IFIs is high (25-50%) [1, 2]. Two main reasons for the latter are the lack of effective antifungal 
drugs and adequate and fast diagnostic techniques. Nowadays, only three main classes of antifungal 
drugs are available on the market and these classes are all associated with various disadvantages 
such as low antibiofilm activity, fungistatic instead of fungicidal character, resistance occurrence, 
toxicity and high costs [3, 4]. Moreover, the currently used diagnostic techniques are poor in terms of 
sensitivity, specificity and time-to-result (e.g. it takes 2-4 days to get the results from the standard 
detection technique, which can be a critical period for the patient) [5]. Hence, to reduce the mortality 
rate associated with IFI, there is a need for the development of novel antifungal therapies as well as 
faster and more sensitive diagnostic techniques. 
IFIs are mainly caused by Candida and Aspergillus species, with C. albicans being the most prominent 
species [6]. However, the incidence of infections caused by non-albicans Candida species is rising  
[7, 8]. Candida species preferentially appear as biofilms, which are populations of microbial cells 
attached to a (a)biotic surface and embedded by a self-produced extracellular matrix. Biofilms are often 
found in device-related infections, such as on catheters or orthopedic implants [9, 10], and are difficult 
to treat because of their tolerance to the action of antifungal drugs. To treat such biofilm-related 
infections, only two classes of antifungal drugs can currently be used: echinocandins (such as 
caspofungin) and polyenes (only liposomal formulations of amphotericin B) [11, 12].  
The increase and spread of antimycotic resistance necessitates the search for new sources of potent, 
broad-spectrum antimicrobials. Several antimicrobial peptides (AMPs) have been shown to be effective 
against multi-drug resistant microorganisms and have low propensity to resistance development, 
probably due to their unique mode of action, which is different from well-known antimicrobial drugs 
[13]. In this PhD thesis, we focused on AMPs derived from plants, called plant defensins, as according 
to the World Health Organization, plants are excellent sources for the development of a wide variety 
of drugs [14]. Plant defensins, small cationic peptides which are part of the immune system of plants, 
have interesting characteristics such as broad-spectrum antifungal activity [15-18], low in vitro 
frequency of resistance occurrence [19], non-toxicity [19, 20] and in vivo efficacy [21]. Moreover, their 
3D structure is stabilized by 4 or 5 disulphide bridges, thereby ensuring their activity in extreme 
conditions with regard to pH, temperature and serum proteases [18, 21]. All these features make plant 
defensins extremely interesting for antifungal drug development. 
Regarding the problem of drug resistance, we focused in this PhD on the plant defensins HsAFP1 and 
RsAFP2, originating from coral bell (Heuchera sanguinea) and radish (Raphanus sativus), 
respectively. HsAFP1 has a low in vitro frequency of resistance occurrence [19] and RsAFP2 induces 
cell death following interaction with fungal pathogenicity factors. Hence, fungal strains acquiring 
resistance to RsAFP2 will be non-infective and therefore low in vivo frequencies of resistance 
occurrence are attributed to RsAFP2. Previous studies on HsAFP1 and RsAFP2 showed that both 
plant defensins interact with different fungal membrane targets and induce fungal cell death/growth 
inhibition via different mechanisms [18, 19, 22-27]. Insight in the specific mode of action of these 
compounds increases our understanding of effective fungal killing mechanisms in general, which is an 
important step towards novel antifungal drug development. 
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The first aim of this PhD was to further characterize the activity (such as antibiofilm activity) of the plant 
defensins HsAFP1 and RsAFP2 and unravel their mode of action using Saccharomyces cerevisiae 
and C. albicans as model organisms. As RsAFP2’s mode of action has been studied extensively in the 
past [18, 21, 23-25, 27, 28], in this PhD thesis, we mainly focused on unraveling the antifungal mode 
of action of HsAFP1. The second aim of this PhD was the development of an assay for fungal cell 
detection, based on plant defensins as fungal-specific biorecognition elements. Here we selected 
RsAFP2, as the targets of this plant defensin are fully characterized and present in almost all yeast 
and fungal species, allowing effective identification of fungal pathogens in diverse samples. 
This PhD thesis consists of 5 peer-reviewed papers and 2 additional result chapters. An overview of 
all chapters in given in Figure 1. The present Chapter 1 gives an overview of all themes comprised in 
this thesis, thereby linking all chapters. Chapter 2 provides an updated summary on plant defensins, 
thereby focusing mainly on their antifungal mode of action and clinical applications. Three main result 
sections are presented in this thesis, including two sections on plant defensins (characterization of the 
antibiofilm activity and unravelling of the antifungal mode of action) and one section on diagnostics 
based on plant defensins. As Candida species occur mostly as biofilms, potential antibiofilm activity of 
RsAFP2 as well as synergistic interactions of this peptide with common antifungal drugs, such as 
amphotericin B and caspofungin, is presented in Chapter 3. Similarly, for HsAFP1, potent antibiofilm 
activity and synergistic activity with antifungal drugs is described in Chapter 4. The regions of HsAFP1 
important for antibiofilm and synergistic activity with caspofungin were further delineated in Chapter 5. 
Moreover, the synergistic interaction of the smallest HsAFP1-derived peptide (HsLin06_18) and 
caspofungin was studied in more detail in both in vitro and in vivo models, as this is a first step in the 
development of novel antifungal (combination) treatments. Next, the antifungal mode of action of 
HsAFP1 was examined by focusing on HsAFP1’s antifungal membrane target and uptake mechanisms 
in S. cerevisiae cells (Chapter 6) and on HsAFP1-induced/repressed pathways in C. albicans (Chapter 
7). Besides antifungal drug-related research, this thesis also focused on fungal infection detection 
techniques. The plant defensin RsAFP2, from Raphanus sativus, known to specifically bind with fungal 
targets, was used to develop assays for fungal cell detection (Chapter 8).  
In Chapter 9, the main conclusions and future perspectives of this thesis are summarized, thereby 
focusing on the use of plant defensins in agricultural and clinical applications to combat fungal-related 
diseases. For the latter, we further elaborated on plant defensin-based antifungal drugs and diagnostic 
techniques. 
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Figure 1: Overview of the PhD thesis. 
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2 Antifungal plant defensins: increased insight in their 
mode of action as basis for their use to combat 
fungal infections1 
 
                                                     
1 This chapter is part of a publication in Future Micobiology as: 
Cools, T.L., Struyfs, C. Cammue, B.P.A. and Thevissen, K. (2017). Antifungal plant defensins: 
increased insight in their mode of action as basis for their use to combat fungal infections. 
Future Microbiology 12 (5). DOI: 10.2217/fmb-2016-0181. 
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Abstract 
Plant defensins are small, cationic peptides with a highly conserved 3D structure. They have been 
studied extensively in the past decades. Various biological activities have been attributed to plant 
defensins, such as anti-insect and antimicrobial activities, but they are also known to affect ion 
channels and display anti-tumor activity. This review focusses on the structure, biological activity and 
antifungal mode of action of some well-characterized plant defensins, with particular attention to their 
fungal membrane target(s), their induced cell death mechanisms as well as their antibiofilm activity. As 
plant defensins are in general not toxic to human cells, show in vivo efficacy and have low frequencies 
of resistance occurrence, they are of particular interest in the fight against fungal infections.  
Keywords: plant defensins, antifungal mode of action, therapeutic potential 
2.1 Introduction 
An ancient and widespread defence strategy among eukaryotes is the production of small, cysteine-
rich peptides with antimicrobial activity. These antimicrobial peptides (AMPs) are part of the innate 
immune system of fungi, animals and plants [29]. Plant AMPs are classified as non-functional 
precursor-derived peptides [30]. Based on sequence similarity, cysteine residues, disulphide bond 
patterns and tertiary structure fold, plant AMPs can be divided into seven subgroups, called: thionines, 
hevein-like peptides, knottin-type peptides, lipid transfer proteins, α-hairpinin, snakins and plant 
defensins [31], the latter being the focus of this review. In the past the thionin family was presumed to 
consist of α-, β- and γ-thionins. However, the discovery in 1995 that γ-thionins (e.g. from Raphanus 
sativus) were more structurally related to insect and mammalian defensins than to α- and β-thionins, 
led to their renaming to “plant defensins” [32].  
As the 3D structure of defensins originating from different kingdoms (e.g. fungi, animals and plants) is 
well conserved, it was suggested that they originated from one common ancestor. However, by 
analysing the tertiary structure similarities and secondary structure orientation, Shafee and colleagues 
recently discovered that defensins consist of two evolutionary independent superfamilies, which are 
structurally and functionally closely related by the extreme convergent evolution [33]. The major 
differences in both groups are (i) the orientation and connectivity of the disulphide bridges, (ii) the 
length of the intercysteine loops (cfr. infra) and (iii) the distribution among eukaryotes. Trans-defensins, 
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the smallest superfamily, contains vertebrate defensins and invertebrate defensins, while the cis-
defensins, the biggest superfamily, consists of plant, fungal and the majority of invertebrate defensins. 
The group of the plant defensins can be further divided into two classes, according to the structure of 
the precursor proteins. The largest class (class I) consists of an endoplasmic reticulum (ER) signal 
sequence followed by the mature defensins domain, while the smallest class (class II) contains an 
additional acidic C-terminal propeptide (CTPP) of about 33 amino acids that is proteolytically removed 
during maturation. So far, this C-terminal propeptide was only found in precursors of plant defensins 
from Solanaceous species, such as Nicotiana alata (e.g. the plant defensin NaD1) and Petunia hybrida 
(e.g. the plant defensins PhD1 and PhD2), expressed in floral tissues [34]. Moreover, a cytoprotective 
role, during its transport in the plant secretory pathway, and a vacuolar targeting function are ascribed 
to this C-terminal propeptide [35]. By more in depth analysis of both the sequence and the biological 
functions of most characterized plant defensins, these peptides were divided in 18 different groups. 
This classification is useful for structure-function predictions [36]. Besides ‘true’ plant defensins, 
defensin-like peptides are also studied. Both peptide groups contain comparable intron sizes and 
positions and conserved cysteine residues, with defensin-like peptides also possessing an additional 
N-terminal signal sequence. Moreover, structural requirements of defensin-like peptides are less strict 
and less well-defined compared to plant defensins [37, 38]. 
2.2 Structure 
Defensins consist of an αβ-motif (CSαβ) with an α-helix and a triple-stranded antiparallel β-sheet. 
Trans-defensins are characterized by a C-terminal β-sheet that is bound to an oppositely oriented  
α-helix, while for cis-defensins this C-terminal β-sheet is bound to the α-helix that is oriented in the 
same way [33]. These structures are stabilized by disulphide bridges, with cis-defensins comprising 
longer and more diverse intercysteine loops compared to trans-defensins. Plant defensins consist of 
four or five disulphide bridges (top lines in Figure 1), with PhD1 and PhD2 being the only known plant 
defensins containing five disulphide bridges [39]. These disulphide bridges ensure the high stability of 
plant defensins, which retain their biological function under extreme conditions, like exposure to high 
temperatures [18] or serum [21]. In addition, NMR or X-ray crystallography analysis of various plant 
defensins, such as PhD1 [39], NaD1 [40], TPP3 [41], RsAFP1 [42], RsAFP2 [43], HsAFP1 [20], MtDef4 
[44], Psd1 [45] and SPE10 [46] (corresponding PDB codes in Table 1), revealed that the  
well-conserved disulphide bond pattern makes the peptide structure rigid, except for the amino acids 
located in the loop regions between the α1 and β2 and between β2 and β3. This flexible β2-β3 loop 
seems important for the activity of the corresponding peptide (cfr. infra). In contrast to the  
well-conserved 3D structure, a low level of amino acid sequence similarity is found among plant 
defensins (Figure 1). Only the cysteine residues and glycine at position 16 are conserved among plant 
defensins (marked in dark blue in Figure 1). 
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Figure 2: Sequence alignment of various plant defensins mentioned in this review, using the T-coffee alignment tool. 
(Top) Disulphide bridges between the corresponding cysteine residues are presented as black lines. (Right) Number of amino 
acids in the plant defensin. (Below) 2D structures, with arrows representing the positions of the β-sheets and the helix 
representing the position of the α-helix. (-) Denote gaps in the alignment. Important amino acids of the plant defensin are 
highlighted: blue: conserved residues (dark blue: highly conserved and light blue: slightly conserved); purple: region important 
for antifungal activity; turquoise: phosphatidic acid (PA)-interaction motif; green: phosphatidylinositol(4,5)bisphosphate 
(PI(4,5)P2)-interaction motif NaD1/TPP3; red: region important for antibiofilm activity and synergy with common antimycotics and 
red boxes: oligomerization. 
2.3 Biological activity 
Plant defensins are present in all plant families and have reportedly important roles in both plant 
growth/development and host defence responses. The former is related to diverse processes from fruit 
ripening, inhibition of plant root growth to inhibition of pollen tube burst [47-50]. Undoubtly, plant 
defensins are best known for their broad antimicrobial activity (cfr. infra) and are regarded as efficient 
mediators of the plant innate immune system against insects and invading microorganisms. Enzymes 
present in the gut of insect herbivores, such as α-amylase and trypsin, can be inhibited by some plant 
defensins [51, 52]. With regard to their antimicrobial activity, most plant defensins are characterized by 
a broad activity spectrum, including antibacterial (e.g. DmAMP1 [18], CtAMP1 [18] and AhAMP1 [18]), 
antifungal (e.g. DmAMP1 [18], RsAFP2 [18], HsAFP1 [18], MtDef4 [16], Psd1 [15], ZmES1-4 [53] and 
NaD1 [17]) and antiprotozoal activity (e.g. PvD1) [54]. Interestingly, however, some plant  
defensin(-like) peptides, such as ZmES1-4 [48, 53], are involved in both reproduction and defence 
processes in plants. Moreover, similar (downstream) cell death mechanisms are induced upon 
penetration of pathogenic fungal hyphae in plant tissues as well as in certain reproductive responses 
[55]. Therefore, Bircheneder and colleagues suggest that these signalling processes of peptides in 
plants were evolved from ancient defence mechanisms [55].  
 
  
 
 
Table 1: Summary of the main characteristics of various plant defensins, described in this review. These pertain to their 3D structure (with the corresponding PDB (Protein Data Bank) code), 
the fungal membrane target, oligomer formation (in the absence/presence of their lipid target), internalization in fungi and intracellular target and the antifungal mode of action and fungal tolerance 
mechanisms (marked in bold and italics). GlcCer: glucosylceramide; PI(4,5)P2: phosphatidylinositol(4,5)bisphosphate; M(IP)2C: mannosyldiinositolphosphorylceramide; PA: phosphatidic acid; MAPK: 
mitogen-activated protein kinase; CWI: cell wall integrity; ROS: reactive oxygen species; NO: nitrogen oxide; HOG: high osmolarity/glycerol.  
Defensin Species of origin PDB code (structure) Fungal membrane 
target 
Oligomerization Uptake/target in 
fungi 
Antifungal mode of action / tolerance mechanism References 
MsDef1 Medicago sativa 1H3R (theoretical 
model) 
GlcCer,  
PI(3,5)P2* 
  Disruption Ca2+ homeostasis, membrane permeabilization, 
inhibition conidial germination and cell fusion, MAPK (CWI 
pathway) 
[16, 47, 56, 
57] 
NaD1 Nicotiana alata 1MR4; (4CQK; 4AAZ: 
4AB0, 4Z1X) 
PI(4,5)P2* Oligomer of 7 dimers 
with 14 PI(4,5)P2’s 
Yes Membrane permeabilization, ROS and NO production (oxidative 
stress), MAPK (HOG pathway) 
[40, 58-63] 
TPP3 Solanum 
lycopersicum 
4UJ0  PI(4,5)P2 Dimer with 2 
PI(4,5)P2’s 
 Membrane permeabilization [41, 59] 
RsAFP2 Raphanus sativus 2N2R GlcCer Dimers and tetramers No ROS, metacaspase-independent apoptosis, ceramide 
accumulation, cell wall stress and septin mislocalization, Ca2+ 
influx, K+ efflux, membrane permeabilization, MAPK (CWI 
pathway) 
[18, 23-25, 
27, 28, 43, 
64] 
RsAFP1 Raphanus sativus 1AYJ  Dimers and tetramers   [28, 42] 
DmAMP1 Dahlia merckii  M(IP)2C, ergosterol   Ca2+ influx, K+ efflux, membrane permeabilization [18, 64-68] 
HsAFP1 Heuchera 
sanguinea 
2N2Q    ROS, apoptosis, mitochondrial dysfunction, membrane 
permeabilization, MAPK (HOG and CWI pathway) 
[18, 20, 22, 
26] 
NaD2 Nicotiana alata  PA*    [59, 63] 
MtDef4 Medicago 
truncatula 
2LR3 PA*  Yes; (partially) 
energy-dependent 
Disruption Ca2+ homeostasis, membrane permeabilization, 
inhibition cell fusion, inhibition conidial germination and cell fusion 
[44, 56, 57, 
69] 
AtPDF2.3 Arabidopsis 
thaliana 
 M(IP)2C   K+ channel inhibitor [70]; [71] 
Psd1 Pisum sativum 1JKZ GlcCer, ergosterol  Yes; Cyclin F Cell cycle arrest, K+ channel inhibitor [15, 45, 72-
74] 
SPE10 Pachyrrhizus erosu 3PSM  Dimers   [46] 
PvD1 Phaseolus vulgaris     ROS and NO production (oxidative stress), membrane 
permeabilization 
[75] 
(*) Note that, except for TPP3, all these plant defensins interact in vitro also with other phospholipids; the most prominent interacting phospholipid is indicated in this table.
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In addition, some plant defensins are also reported to increase metal tolerance of plants or inhibit ion 
channels. The plant defensins AhPDF1.1 and AhPDF1.2 were identified to confer zinc tolerance in yeast 
as well as in plants, by interfering with adaptive responses in the endoplasmic reticulum to zinc overload 
[76]. Various plant defensins or plant defensin-like peptides can interfere with ion channel functions. For 
example, the plant defensin-like ZmES4 has been identified to interact and subsequently open the 
potassium channel Kzm1 in synergid cells, leading to K+ influx and finally pollen tube burst in maize [48]. 
The blockage of ion channels seems a similar feature of toxins and some plant defensins, such as 
MsDef1, γ-Z1, γ-Z2, AtPDF2.3 and Psd1. MsDef1 was identified to interfere with Ca2+ homeostasis by 
blocking mammalian L-type Cav1,2 channels in a similar way as the viral toxin KP4, while the structurally 
related RsAFP2 and MtDef2 could not [47]. Na+ channel inhibition capacity on rat tumor cells is identified 
for some plant defensins (γ-Z1 and γ-Z2) [77], while K+ channel interference capacity is known for 
AtPDF2.3 and Psd1 (Table 1 and Figure 2B/D) [71]. More specifically, AtPDF2.3 physically blocks Kv1.2 
and Kv1.6 potassium channels [71], a phenomenon described previously for various toxins from 
scorpions, snakes, cone snails and sea anemones. Besides their similarities in biological activities, 
defensins (and more particular insect defensins) are structurally closely related to scorpion K+ toxins and 
therefore thought to originate from a common ancestor. In order to study the evolution of scorpion toxins 
affecting K+ channels, Zhu and colleagues introduced the scorpion toxin signature in an insect defensin 
without K+ inhibition activity, called navidefensin2-2 [78]. This insect-derived neurotoxin can bind to  
K+ channels in the same way as scorpion toxins [78]. This demonstrates the possibility to engineer 
defensins with desired properties. As the structurally related (plant) defensins possess various biological 
activities, their rigid structure can serve as a scaffold that contains flexible regions with multiple 
functions. For plant defensins, the region important for biological activity is mainly located in the γ–core 
region (Figure 1) and is therefore the region of interest to modify during the engineering process.  
Note that some plant defensins are also characterized by potent anticancer activity, such as NaD1 [60], 
TPP3 [41] and limycin [79] as they can inhibit proliferation of human tumor cells.  
  
 
 
Figure 2: Antifungal mode of action of various plant defensins, described in this review, according to their fungal membrane target. Fungal tolerance mechanisms, when identified, are 
indicated in red. (A) PA: Phosphatidic acid; (B) MI(IP)2C: Mannosyldiinositolphosphorylceramide; (C) PI(4,5)P2: Phosphatidylinositol(4,5)bisphosphate; (D) GlcCer: Glucosylceramide. 
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2.4 Antifungal mode of action  
 
As fungi are the most common microbial pathogens of plants, this review will further focus on the 
antifungal activity of plant defensins (Box 1). The antifungal activity of plant defensins is not limited to 
plant pathogens, such as Botrytis cinerea, Fusarium culmorum and Penicillium digitatum [18]; they are 
also active against human fungal pathogens, such as Candida albicans and C. krusei, as well as 
against the non-pathogenic model fungus/yeast Saccharomyces cerevisiae [19, 22, 65]. Depending on 
their target organism, the antifungal mode of action of plant defensins can differ. El-Mounadi and 
colleagues recently discovered that the antifungal mode of action of the plant defensin MtDef4 against 
Neurospora crassa differs from that against F. graminearum, indicating that one particular plant 
defensin can exert multiple antifungal actions depending on the fungal species [69]. The main 
characteristics of several well-studied plant defensins, discussed in this review, are summarized in 
Table 1 and Figure 2.  
The first step in the antifungal mode of action, is the interaction of the plant defensin with a fungal 
membrane target. In 1997, using radioactively-labelled HsAFP1 and DmAMP1, Thevissen and 
colleagues discovered specific binding sites of plant defensins on fungal membranes [26]. It has been 
postulated that plant defensins interact with their γ–core region (Figure 1) with different membrane 
lipids, mediating cell death [60]. Extensive research on plant defensin – target interactions revealed 
two groups of fungal lipid targets, namely sphingolipids (as reviewed in [80]) and phospholipids  
[41, 44, 60]. Sphingolipids are eukaryotic membrane lipids that consist of a ceramide backbone 
together with a polar head group. Based on their head group, they can be divided into two groups: 
phosphosphingolipids and glycosphingolipids. The first group contains an oligosaccharide as polar 
head group and can be subdivided into three main classes, called: inositolphosphorylceramides (IPC), 
mannosylinositolphosphorylceramides (MIPC) and mannosyldiinositolphosphorylceramides (M(IP)2C). 
The synthesis of M(IP)2C, the major sphingolipid in Saccharomyces cerevisiae, requires the enzyme 
Ipt1 [81]. The second group, the glycosphingolipids, contain a sugar (i.e. glucose or galactose) or a 
ionisable (i.e. phosphate or sulphate) head group, with glucose-containing glucosylceramide (GlcCer) 
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being the most common glycosphingolipid in fungi and synthesized by GlcCer synthase (Gcs). The 
major component of eukaryotic membranes are the phospholipids (PLs), consisting of a glycerol 
backbone linked to two fatty acids and one polar head group. Depending on the polar head group, 
various PL species are known, including phosphatidic acid (PA), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylglycerol (PG) and phosphoinositides 
(PI). The latter can be subdivided into phosphatidylinositol (PI), PI phosphate (PIP), PI bisphosphate 
(PIP2) and PI triphosphate (PIP3), with PI, PIP and PIP2 present in yeast. 
By using specific yeast deletion mutants devoid of particular enzymes responsible for sphingolipid 
biosynthesis, the involvement of a specific sphingolipid species in the mode of action of a particular 
plant defensin could be established. To confirm these potential interactions, biochemical tests such as 
reverse ELISAs [27], lipid overlays (e.g. PIP Strips) [44, 59, 60] or liposome assays [59, 60], with both 
the plant defensin and the purified sphingolipid/phospholipid were conducted. In this way, M(IP)2C was 
identified as fungal target for DmAMP1 [66] and AtPDF2.3 [70], while GlcCer was discovered to be the 
target for RsAFP2 [27] and MsDef1 [82] (Table 1 and Figure 2B/D). Using NMR spectroscopy as an 
alternative approach, in which surface interactions of plant defensins with small unilamellar vesicles 
(SUV) containing different lipids are measured, GlcCer and ergosterol are identified as Psd1’s 
antifungal targets [72, 73]. Note that sphingolipids, such as GlcCer, are pathogenetic determinants and 
therefore essential for in vivo infection. Hence, the in vivo frequency of resistance occurrence against 
plant defensins is thought to be low as mutants with defective sphingolipid biosynthesis are not 
infective anymore and will therefore not survive in vivo [83].  
PLs are essential in vital processes of all living organisms. Therefore, deletion mutants which do not 
produce a particular PL species are not viable and, thus, cannot be used to identify potential PL targets 
as was done for sphingolipids as target of some plant defensins. An alternative approach to determine 
PL-plant defensin interactions is the use of lipid overlay assays, containing various biological relevant 
lipids. By incubating these membranes with the plant defensins of interest, lipid-peptide interaction can 
be detected immunologically. Using such assays, PL binding partners were identified for the plant 
defensins NaD1 [41], NaD2 [59], TPP3 [41], MsDef1 [44] and MtDef4 [44] (Table 1 and Figure 2A/C). 
Note that a particular plant defensin can interact with various lipids, as exemplified for NaD1, NaD2, 
MsDef1 and MtDef4. However, the interaction of MtDef4/NaD2, MsDef1 and NaD1 was found most 
pronounced for PA, PI(3,5)P2 and PI(4,5)P2, respectively, and these interactions were therefore studied 
in more detail. The RGFRRR-motif in the surface β2-β3 loop of MtDef4 was found to be important for 
PA binding, as MtDef4 variants RGFRRR/RGAARR; RGFRRR/AAAARR and RGFRRR/RGFRAA 
have reduced or lack PA binding capacities compared to the native MtDef4 [44]. Note that this 
RGFRRR-motif is also present in the plant defensins NaD2 and AtPDF2.3 (as highlighted in turquoise 
in Figure 1), suggesting PA interaction capacity of these peptides. Indeed, for NaD2, PA interactions 
were recently identified via lipid strips and liposome binding assays, although this interaction was 
suggested to be non-specific as NaD2-PIP’s interaction were equally strong as NaD2-PA interactions 
[59]. Using X-ray crystallography, the molecular interactions of NaD1 dimers with PI(4,5)P2 were 
defined, with the SKILRR-motif in the surface γ-core region of NaD1 responsible for this interaction 
[60]. This “S–[KR]–[ILVQ]–[ILVQ]–[KR]–[KR]”-motif (highlighted in green in Figure 1) is also present in 
TPP3, a plant defensin that specifically interacts with PI(4,5)P2, as well as in 13 other plant defensins, 
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all belonging to the plant defensin class II, containing a CTPP domain. Therefore, it is suggested that 
the presence of a CTPP domain and PI(4,5)P2-interaction motif are linked [59]. In addition, two NaD1 
molecules form dimers upon interaction with two PI(4,5)P2 molecules. In the presence of membrane 
structures, seven of these NaD1 dimer-PI(4,5)P2 molecules are involved in the oligomerization process 
(red boxes in Figure 1 and schematic representation in Figure 2C), resulting in permeabilization of 
liposomes and tumors cells [59, 60]. However, it was recently demonstrated that PI(4,5)P2 binding is 
not essential for the antifungal activity of NaD1 [63]. Some other plant defensins are also characterized 
to form oligomers, including SPE10 (dimers) [46], Cp-thionins (oligomers) [52] and RsAFP1/RsAFP2 
(dimers and tetramers) [28]. 
Upon target interaction, plant defensins are either internalized by fungal cells, as in the case of MtDef4 
[44], Psd1 [74] and NaD1 [61], or remain outside the cell, such as RsAFP2 [25] (Table 1 and  
Figure 2). MtDef4 can enter fungal cells by its RGFRRR-motif, which is also responsible for target (PA) 
binding [44]. As NaD2 and AtPDF2.3 also govern this RGFRRR-motif (as highlighted in turquoise in 
Figure 1), it seems that these plant defensins can also be internalized in susceptible fungi. The 
internalization process of MtDef4 is species-dependent as the presence of the PA-producing enzyme 
phospholipase D is required for MtDef4 internalization in N. crassa but not in F. graminearum. In 
addition, MtDef4 internalization is energy-dependent and requires endocytosis in N. crassa, while the 
internalization process is only partially energy-dependent in F. graminearum [69]. Another plant 
defensin that is reportedly internalized by fungal cells is Psd1, and more specifically in C. albicans WT 
cells, while C. albicans strains lacking Psd1’s target (GlcCer) are not able to internalize this peptide 
[73]. Upon fungal cell entry, Psd1 has been found to interact with nucleolar cyclin F, as determined via 
yeast-to-hybrid analysis [74]. The plant defensin NaD1 can enter fungal cells after specific interaction 
with the cell wall, followed by membrane permeabilization [61]. Moreover, this NaD1 uptake is reduced 
in yeast mutants lacking Agp2p, a plasma membrane protein regulating the transport of positively 
charged molecules, such as polyamine. It was suggested that by the deletion of AGP2, cationic 
molecules accumulate at the cell surface and subsequently cationic plant defensins are repelled [84].  
Among plant defensins, various mechanisms leading to fungal cell death are known. Similar to many 
antimycotics, such as miconazole and amphotericin B, the plant defensins HsAFP1 [22], RsAFP2 [24], 
NaD1 [62], PvD1 [75] and Lp-Def1 [85] induce the production of reactive oxygen species (ROS) in 
susceptible fungi (Table 1). High concentrations of ROS can damage DNA, RNA and proteins in the 
cell. As ROS production is one of the markers of apoptosis, the latter has been investigated in plant 
defensin-treated cells. Apoptosis is a programmed way of cell death in which the plasma membrane 
integrity is preserved and intracellular content is degraded in a well-organized way. The plant defensins 
HsAFP1 [22] and RsAFP2 [23] induce apoptosis (Table 1). More detailed investigations on RsAFP2-
induced apoptosis in C. albicans further indicated that this process is independent of the metacaspase 
Mca1 [23] and can result in the accumulation of the pro-apoptotic signalling molecule ceramide [25]. 
In contrast to apoptosis, necrotic cell death is characterized by an uncontrolled release of the 
intracellular content in the extracellular space due to membrane integrity loss. For plant defensins, it 
was suggested that necrosis is a non-specific, secondary effect of their mode of action that occurs 
rather at high peptide concentrations and long incubation times, as demonstrated for RsAFP2, HsAFP1 
and DmAMP1 [68]. However, as membrane permeabilization seems an important (early) step in the 
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antifungal killing process of some plant defensins, it was studied in more detail. At high peptide 
concentrations, NaD1 and TPP3 were shown to bind to liposomes containing PI(4,5)P2, thereby 
inducing membrane permeabilization [59]. When encountering patches of PI(4,5)P2, tight NaD1 
interactions appear, resulting in NaD1-lipid complex oligomerization, loss of membrane order and 
subsequent membrane leakage. As PI(4,5)P2 is located at in the inner leaflet of the cell membrane, 
initial and reversible interactions of NaD1 with other plasma membrane components are proposed [59]. 
TPP3 was found to better permeabilize PI(4,5)P2-containing vesicles than NaD1, which might be 
explained by the greater specificity and possible affinity of TPP3 for PI(4,5)P2 [41]. Besides fungal 
membranes, NaD1 and TPP3 can also permeabilize mammalian tumor cells. This process is preceded 
by the formation of large plasma membrane blebs [41, 60]. High concentrations of PvD1 were also 
reported to induce membrane permeabilization in fungi. Moreover, plasma membrane blebbing, 
shrinkage of the cytosol and disorganization of the nucleus and other organelles is part of PvD1’s 
antifungal killing process as well [75]. Other plant defensins that can induce fungal membrane 
permeabilization at low concentrations are MsDef1 and MtDef4, with MtDef4 being most efficient [56]. 
Besides the induction of ROS, apoptosis or necrosis, other effects of plant defensins on fungi have 
been described. Similar to other well-studied AMPs, such as histatin 5 [86] and lactoferrin [87], the 
plant defensins HsAFP1 [22] and Lp-Def1 [85] seem to target mitochondria as part of their antimicrobial 
effect, as they induce mitochondrial functionality loss. Moreover, the antifungal activity of HsAFP1 is 
abolished when administered together with the cytochrome oxidase inhibitor sodium azide, pointing to 
the need of functional mitochondria for HsAFP1’s antifungal action [22]. In line, active mitochondria are 
needed for the antifungal activity of NaD1, as was demonstrated with S. cerevisiae mutants lacking 
the mitochondrial genome [88]. As mentioned above, plant defensins can also interfere with divalent 
cation homeostasis. RsAFP2 and DmAMP1 were demonstrated to induce a rapid Ca2+ influx and  
K+ efflux in N. crassa hyphae (Table 1 and Figure 2B/C) [64, 68]. Moreover, it has been suggested that 
these peptides disturb the Ca2+ gradient over the hyphal membrane, necessary for polarized growth 
from the hyphal tip. This hypothesis was strengthened by the observed increase in Ca2+ uptake in  
F. culmorum hyphae after treatment with the RsAFP2[V39R] mutant compared to the native RsAFP2. 
Interestingly, this mutant also possesses higher antifungal activities than native RsAFP2 [89]. The plant 
defensin MsDef1 has been characterized to block Ca2+ channels in both fungal and mammalian cells 
in a similar way as the viral toxin KP4 [47]. Another common feature of plant defensins and toxins is 
the effect of divalent cations in the culture medium on their biological activity. To date, the antifungal 
activity of plant defensins, such as RsAFP2, HsAFP1, DmAMP1 and NaD1, is reported to be reduced 
in media containing high cation strengths [18, 62]. In line, the antifungal activity of the viral toxin KP4, 
inhibiting Ca2+ channels, is reduced in media containing an excess of calcium [90]. Other features of 
plant defensins are the induction of cell wall stress and septin mislocalization by RsAFP2 [25] and the 
induction of cell cycle arrest by Psd1 [74] (Table 1 and Figure 2D). 
2.5 Fungal tolerance mechanisms 
Upon the action of an antifungal compound, mechanisms will be induced in susceptible fungi to help 
them to cope with the adverse effects of the antifungal compound. After sensing of the antifungal 
compound, the information is processed by intracellular signal transduction cascades, leading to 
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changes in responses such as gene expression, metabolism, secretion, proliferation and apoptosis. 
Various reports indicate that mitogen-activated protein kinases (MAPK), a family of well-known 
conserved kinases that are activated upon phosphorylation, have important roles in governing 
tolerance to plant defensins [91] (Table 1 and Figure 2C/D). The MAPK pathways in yeast are involved 
in (i) the mating-pheromone response, (ii) filamentous growth, (iii) cell wall integrity (CWI) and the high 
osmolarity/glycerol (HOG) response. By screening a S. cerevisiae deletion mutant library, genes 
governing cell tolerance against HsAFP1 activity were detected. Five HsAFP1-tolerance genes 
implicated in MAPK pathways were identified, of which one operates in the HOG pathway and four in 
the CWI pathway [22]. Hayes and colleagues discovered that the HOG pathway, activated by osmotic 
or oxidative stress, functions in the protection of C. albicans against NaD1 as well [88]. Moreover, as 
this pathway is activated by some antimicrobial peptides, they suggest that the inhibition of the HOG 
pathway could be used to increase the activity of these peptides [88]. In the case of MsDef1, MtDef2 
and RsAFP2, only the CWI pathway appears to be involved in the protection of F. graminearum against 
these defensins, while the HOG pathway is not [92]. Another strategy of yeast cells to protect 
themselves against ROS-inducing conditions is the induction of a NO-dependent anti-oxidative 
mechanism. It was recently discovered that NO confers stress tolerance to yeast under elevated 
intracellular ROS levels, introduced by high temperature stress [93]. As the plant defensins NaD1 [88] 
and PvD1 [75] have been described to produce NO in susceptible yeast, NO production may be part 
of their fungal tolerance mechanism. 
2.6 Antibiofilm activity and synergistic activity of plant defensins 
In natural environments, microorganisms have the ability to form biofilms on (a)biotic surfaces. Biofilm 
are composed of cells surrounded by an extracellular matrix (ECM). These cells are physiologically 
different than those in planktonic cell cultures and, moreover, biofilms are characterized by high 
tolerance towards antimicrobial treatments. Therefore, components that are active against planktonic 
cells are not necessarily active against biofilm cells and vice versa. To test whether plant defensins 
can affect fungal biofilms, we recently examined this feature for HsAFP1 [20], RsAFP1 [43] and 
RsAFP2 [43]. Interestingly, while none of these peptides can eradicate mature C. albicans biofilms, 
HsAFP1 and RsAFP2 can inhibit biofilm formation by C. albicans, while RsAFP1, which is also less 
active than RsAFP2 on planktonic cultures [28], cannot. Analysis of the activity of 24-mer linear peptide 
fragments derived from HsAFP1, indicated that its C-terminal part was responsible for inhibition of  
C. albicans biofilm formation (as marked in red in Figure 1). As RsAFP1 and RsAFP2 only differ in two 
amino acids, these residues (glutamine and arginine at positions 5 and 27 in RsAFP2, respectively) 
are important for both antifungal and antibiofilm activity. In addition, synergistic effects between 
antimycotics and plant defensins were investigated. Surprisingly, HsAFP1 [20], RsAFP2 [43] and 
RsAFP1 [43] act synergistically with antimycotics like caspofungin and/or amphotericin B, against both 
planktonic and biofilms cells, whereas various linear HsAFP1-derived peptides act synergistically with 
caspofungin in a biofilm setup [20]. Together, it seems that the sequence and structural requirements 
of plant defensins to enable synergistic interaction with antimycotics are not very strict, and differ for 
planktonic versus biofilm cells.  
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2.7 Applications 
 
In this review we have so far focused on the variety of mechanisms involved in plant defensin activity, 
important as a basis for their potential use to combat fungal infections. In this section, the therapeutic 
potential of plant defensins will be discussed (Box 2). Regarding the latter, interesting characteristics 
have been demonstrated for various plant defensins, such as low in vitro frequency of resistance 
occurrence [19], non-toxicity [19, 20] and in vivo efficacy [13]. For RsAFP2, it has been shown that the 
peptide is prophylactically effective against murine candidiasis when administrated intravenously [21]. 
In contrast to such a mono-therapy is the use of plant defensins in a combination therapy. The latter 
represents an alternative strategy in drug development in which two or more components with different 
mode of actions are used to treat patients. Preferably, the combination of such components leads to 
synergy, as described above for caspofungin or amphotericin B in combination with either RsAFP1, 
RsAFP2 or HsAFP1 [20, 43]. However, also other advantages are associated with a combination 
therapy over mono-therapy such as (i) broader spectrum of drug activity, (ii) lowered effective doses, 
(iii) reduced risk of resistance occurrence and (iv) more rapid antifungal effects [3, 94]. To date, 
combination therapies are already applied in treatments of various important diseases such as HIV, 
hepatitis C or cancer. Regarding the latter, AMP-based combination therapies have already been 
proven effective in vivo as exemplified by the combination of LL-37 and a CpG oligodeoxynucleotide 
to control ovarian tumors in mice [95]. Such combinatorial approaches are also suggested to be 
valuable for treatment of microbial infections as well (as reviewed in [3]). Currently, in vivo experiments 
with a [plant defensin-derived peptide + antimycotic] combination to reduce Candida biofilm formation 
on catheters are ongoing (Chapter 5). In addition, linear plant defensin-derived peptides might also be 
applied as novel drugs to treat fungal biofilms, as was shown for a 24-mer peptide containing the  
C-terminal part of HsAFP1 [20]. Similarly, a 12-14-mer peptide containing the γ-core region of 
DefMT2/6/7 is active against bacteria. Although the activity spectrum of the 12-14-mer peptide is 
reduced, its effective dose is even lower than that of the full length peptide [96]. From a drug 
development point of view, a smaller peptide length is favourable regarding reduction of production 
costs and simplification of the fabrication process. As pathogenic fungi are major invaders of plants, 
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plant defensins can be used in various agricultural applications as well, such as in the engineering of 
transgenic plant defensin-expressing crops (as reviewed in [97]). 
In addition, the antifungal activity of natural plant defensins can be improved. The loop regions between 
the disulphide bridges in plant defensins are suggested responsible for their antifungal activity  
(cfr. supra) and are therefore the main target for further optimizations. Recently, NaD1-NaD2 chimera 
peptides were produced, in which the loop regions of the most active peptide (NaD1) were replaced 
by the corresponding loop regions of the less antifungal active peptide (NaD2) [63]. Surprisingly, the 
antifungal activity of some NaD1-NaD2 chimeras was even better than that of the native NaD1 [63]. 
Therefore, shuffling of plant defensin sequences seems a good strategy to produce peptides with 
improved antifungal activities.  
In general, the development of new antifungal agents based on plant defensins seems a promising 
strategy. However, adverse effects such as allergenic reactions cannot be ruled out, as has been 
demonstrated for a peanut defensin interacting with IgE of patients with severe peanut allergy [98]. 
Another disadvantage of peptide-based drug is their potential proteolytic degradation in patients.  
To circumvent both problems, approaches involving (small) drugs that mimic the biological activity of 
plant defensin of interest (peptidomimetics) can be used as an alternative. Another strategy to control 
the peptide stability is the encapsulation of peptides in nanoparticles, as reviewed by Narayana and 
Chen [99]. 
2.8 Conclusions 
The plant defensin family comprises a highly diverse collection of peptides, of which various are 
characterized by broad-spectrum antifungal activity. Although their 3D structure is conserved, the 
mode of action of antifungal plant defensins is diverse. Various lipids of fungal membranes, such as 
sphingolipids and phospholipids, have been identified as plant defensin targets. After target interaction, 
most plant defensins but not all are taken up by the fungal cell. The mechanism of fungal cell death 
can differ as well: some plant defensins induce apoptosis while others lyse the target cell immediately 
after exposure. In addition, numerous plant defensin-specific characteristics have been described, 
such as plant defensin oligomerization, loss of mitochondrial functionality, disruption of divalent cation 
homeostasis, cell wall stress, septin mislocalization and cell cycle arrest.  
2.9 Future perspectives 
During the past decades, extensive research on plant defensins has been conducted. This led to the 
identification of novel plant defensins as well as the unravelling of their mode of action. The elucidation 
of their mode of action is a crucial first step towards their use in diverse applications. In medicine, plant 
defensins can be used as lead compounds for anti-infective drug development, as they exert good 
antifungal and antibiofilm activities, low chances of resistance occurrence, are non-toxic and are 
effective in vivo. Moreover, the biological activity of plant defensins can still be improved by sequence 
alternations. Apart from the report describing in vivo efficacy of RsAFP2 in a mouse fungal infection 
model [21], there are currently no other reports on the therapeutic potential of plant defensins. 
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However, the therapeutic use of other non-plant defensin based peptides has been described. In this 
regard, a peptoid polymer of N-substituted glycines that mimics the structure of AMPs but that is less 
prone to proteolysis by its non-natural structure, was found to significantly reduce invasive S. aureus 
infections in vivo [100]. In addition, various (non-plant defensin) AMP-based drugs are currently tested 
in clinical trials (as reviewed in [99]), which points to the potential use of AMP-based peptides to treat 
microbial infections. However, compared to small molecule-based drugs, peptides are costly to 
produce and can be degraded more easily. Plant defensins can be produced heterologously to ensure 
sufficient quantities [101]. A less expensive strategy is the use of linear plant defensin-derived peptides 
with good biological activities, as they can be produced via chemical synthesis. To reduce peptide 
degradation, the peptide can be stabilized by, for example, introducing non-natural amino acids and/or 
cyclization of the peptide. To circumvent the peptide-related disadvantages but still make use of the 
interesting characteristics of plant defensins, one can opt for a peptidomimetic approach in which small 
molecules are screened and/or specifically developed to harbour interesting plant defensin-like 
activities, based on accumulated fundamental knowledge on their modes of action, as reviewed in this 
manuscript. 
2.10 Executive summary 
 Structure: All plant defensins exhibit a well-conserved 3D structure, consisting of one α-helix 
and three β-sheets stabilized by four disulphide bridges.  
 Biological activities: Different biological activities are attributed to plant defensins, such as 
protection against insects and/or fungal pathogens, metal tolerance, ion channel inhibition and 
anti-tumor activity. 
 Antifungal activities: Various antifungal mode of actions have been elucidated for different 
plant defensins. ‘Common’ characteristics are their fungal membrane target, being 
sphingolipids or phospholipids, and the induction of the production of reactive oxygen species.  
 Fungal tolerance mechanisms: Upon plant defensin exposure, fungal cells will try to defend 
themselves against the adverse effects of the antifungal compound. Typically, mitogen-
activated kinase pathways are induced in this process.  
 Antibiofilm activity and combination therapies: Besides inhibition of planktonic fungal cells, 
plant defensins can also inhibit fungal biofilm formation and act synergistically with common 
antimycotics. 
 Applications: Plant defensins are interesting lead peptides for further development into 
antifungal therapy. 
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3 The plant defensin RsAFP2 inhibits fungal biofilm 
formation2 
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*Both authors contributed equally to this work 
Chapter 3 
22 
 
Contributions of individual authors to the manuscript ‘The plant defensin RsAFP2 inhibits 
fungal biofilm formation’. 
KV and TLC contributed equally to this work. 
This study was coordinated by BPAC, KT and BDC. NMR analysis was performed by PJH and DJC. 
Scanning electron microscopy of biofilms was performed by AB and JV. Production and purification of 
RsAFP2 was done by KV. Planktonic and biofilm experiments, and data analysis were performed by 
KV and TLC. Writing of the manuscript, redaction and revisions were done by KV. 
The inhibitory effect of RsAFP2 on fungal biofilm formation 
23 
 
The plant defensin RsAFP2 inhibits fungal biofilm formation 
Kim Vriens 1¶, Tanne L. Cools 1¶, Peta J. Harvey 2, David J. Craik 2, Annabel Braem 3, Jozef Vleugels 
3, Barbara De Coninck 1,4, Bruno P.A. Cammue 1,4, # and Karin Thevissen 1 
1 Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, 3001 Heverlee, 
Belgium 
2 Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia 
3 Department of Materials Engineering, KU Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, 
Belgium 
4 Department of Plant Systems Biology, VIB, Technologiepark 927, 9052 Ghent, Belgium 
¶ These authors contributed equally to this work. 
* Corresponding author: Prof. B.P.A. Cammue; bruno.cammue@kuleuven.be 
Abstract 
The radish defensin RsAFP2 was previously characterized as a peptide with potent antifungal activity 
against several plant pathogenic fungi and human pathogens, including Candida albicans. RsAFP2 
induces apoptosis and impairs the yeast-to-hypha transition in C. albicans. As the yeast-to-hypha 
transition is considered important for progression to mature biofilms, we analysed the potential 
antibiofilm activity of recombinant (r)RsAFP2, heterologously expressed in Pichia pastoris, against  
C. albicans biofilms. We found that rRsAFP2 prevents C. albicans biofilm formation with a BIC50 (i.e. 
the minimal rRsAFP2 concentration that inhibits biofilm formation by 50% as compared to control 
treatment) of 1.65 ± 0.40 mg/mL. Moreover, biofilm-specific synergistic effects were observed between 
rRsAFP2 and the antimycotics caspofungin and amphotericin B, pointing to the potential of RsAFP2 
as a novel antibiofilm compound. In addition, we characterized the solution structure of rRsAFP2 and 
compared it to that of RsAFP1, another defensin present in radish seeds. These peptides have similar 
amino acid sequences, except for two amino acids, but RsAFP2 was previously found to be 2- to  
30-fold more potent than RsAFP1 against many fungi. A structural comparison of both defensins via 
NMR analysis revealed that also rRsAFP2 adopts the typical cysteine-stabilized αβ-motif of plant 
defensins, however, no structural differences were found between these peptides that might result in 
the observed differential antifungal potency. This suggests that their differential antifungal activities are 
probably due to the higher net positive charge of rRsAFP2. 
Key words: plant defensin, RsAFP2, recombinant protein production, NMR analysis, Candida 
albicans, fungal biofilm 
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3.1 Introduction 
Plant defensins are small, basic, cysteine-rich peptides with biological activity against a wide range of 
microorganisms [102-104]. To date, it is primarily their antifungal activity that has been studied and 
several fungal targets, such as membrane compounds and intracellular proteins, have been identified. 
It was shown that plant defensins specifically interact with fungal membrane sphingolipids [80, 105] 
and phospholipids [60], and that, upon interaction with the membrane, some plant defensins enter the 
cell and interact with nuclear or cytosolic proteins [44, 62, 74]. In addition, various plant defensins have 
been shown to induce apoptosis [22, 23] and/or the production of reactive oxygen species (ROS)  
[22, 24, 62, 65, 75], leading to fungal cell death. 
In this study, we focused on the radish defensins RsAFP1 and RsAFP2. A sequence alignment of 
these peptides, matching their cysteine residues (numbered I-VIII), is presented in Figure 1. Both 
peptides are present in radish seeds and previous analysis of their antifungal activity revealed that 
RsAFP2 is 2- to 30-fold more potent than RsAFP1 against several fungi [28]. The solution structure of 
RsAFP1 was elucidated in 1998 by Fant and colleagues, and was the first reported structure of a plant 
defensin [42]. As the amino acid sequence of RsAFP2 only differs by two amino acids to that of 
RsAFP1, we were interested in identifying structural difference(s) between these defensins in order to 
explain their differential antifungal potency. To this end, we heterologously produced RsAFP2 using 
Pichia pastoris as a host, resulting in a yield of at least 100 mg recombinant (r)RsAFP2 per liter of 
culture supernatant, elucidated its solution structure by NMR and compared it to that of RsAFP1. 
 
Figure 1: Sequence alignment of RsAFP1 and RsAFP2. Sequences were aligned matching their cysteine residues, using the 
COBALT alignment tool [106]. Cysteine pairing is shown at the top of the figure. Highly conserved residues in plant defensin 
sequences are shown in grey. Blue boxes indicate differences between the amino acid sequence of RsAFP1 and that of RsAFP2. 
During the past decade, the mechanism of action of RsAFP2 has been intensively studied. RsAFP2 
specifically interacts with the fungal sphingolipid glucosylceramide (GlcCer) [27], after which it induces 
the production of ROS [24], caspase-mediated apoptosis [23], and cell wall stress in C. albicans cells, 
the latter by activation of the cell wall integrity pathway [25]. RsAFP2 was also shown to activate MAP 
kinase signalling cascades in F. graminearum, excluding the Hog1 MAP kinase pathway [92]. In 
addition, RsAFP2 induces accumulation of phytoC24-ceramides, affects septin formation and 
localization and impairs the yeast-to-hypha transition in C. albicans [25].  
In view of the latter, RsAFP2 might prevent C. albicans biofilm formation, as the yeast-to-hypha 
transition, besides cell adhesion and production of the extracellular matrix, is considered important for 
progression to mature biofilms in C. albicans [107].  
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Biofilms are self-organized microbial communities encased by a polymeric matrix that grow on biotic 
or abiotic surfaces, such as catheters or other medical implants. In fungal biofilms, Candida spp. play 
a predominant role [10, 108-110]. These biofilms are highly resistant towards most conventional 
antimycotics, with few exceptions, including miconazole, caspofungin, anidulafungin, and liposomal 
formulations of amphotericin B [111-113]. Recently, we found that the coral bells defensin HsAFP1 
prevents C. albicans biofilm formation and increases caspofungin’s activity against C. albicans biofilms 
[20].  
Therefore, in this study, we additionally analysed the antibiofilm potential of rRsAFP2, and assessed 
its activity in a multi-drug approach with the conventional antimycotics caspofungin and amphotericin 
B against C. albicans biofilms.  
3.2 Materials and methods 
3.2.1 Strains and reagents 
Pichia pastoris strain GS115 (C181-00, Life Technologies, CA, USA) was used for heterologous 
production of RsAFP2. Fusarium graminearum WT and ∆gcs strain [82], i.e. a strain lacking 
glucosylceramide synthase, were used to evaluate the antifungal activity of the recombinant peptide. 
C. albicans strain SC5314 was used in all biofilm experiments. 
All culture media were purchased from LabM (UK), unless stated otherwise. For heterologous 
production, P. pastoris was cultured in YPD (1% yeast extract, 2% peptone and 2% glucose), BMGY 
(Buffered Glycerol complex Medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 1% glycerol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin) or BMMY 
(Buffered Methanol complex Medium; 1% yeast extract, 2% peptone, 0.5% methanol, 100 mM K3PO4 
pH 6, 4 x 10-5% biotin). F. graminearum was grown in half strength PDB (1.2% potato dextrose broth). 
Biofilm experiments were performed in MM (minimal medium) supplemented with 50 mM HEPES  
(pH 7) (MMH; 0.77 g/L complete amino acid supplement mixture (Bio 101 Systems), 6.7 g/L yeast 
nitrogen base w/o amino acids (Becton Dickinson, UK), 20 g/L glucose). 
3.2.2 Production and purification of recombinant (r) rRsAFP2 
rRsAFP2 was produced in Pichia pastoris and purified by cation exchange chromatography and 
reversed-phase chromatography, following the protocol previously described for production and 
purification of rHsAFP1 [20] with minor modifications: P. pastoris strain GS115 was used for expression 
of rRsAFP2 and induction of gene expression was performed for 72 h at 25°C, during which 2% 
methanol (v/v%) was added to the culture every 24 h to maintain induction. In addition, an automated 
peristaltic pump (Spectrum Laboratories, CA, USA) and a Vivaflow 200 cassette with a 2 kDa cut-off 
Hydrosart membrane (Invitrogen, CA, USA) were used for ultrafiltration. Purification of rRsAFP2 using 
cation exchange chromatography and reversed-phase chromatography resulted in peaks at 
approximately 28% and 33% elution buffer, respectively. Following this protocol, at least 100 mg of 
rRsAFP2 was obtained per liter of culture supernatant. 
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3.2.3 Antifungal activity assays 
To assess the antifungal activity of rRsAFP2 against F. graminearum, a two-fold dilution series of the 
peptide in sterile water was prepared in 96-well plates, after which 10 µL of peptide was mixed with  
90 µL of half strength PDB containing 104 spores/mL of F. graminearum. The IC50 value, which is the 
concentration that inhibits 50% growth as compared to control treatment, was determined by 
microscopy after 48 h. The antifungal activity of rRsAFP2 against C. albicans was analysed according 
to the standard CLSI (Clinical and Laboratory Standards Institute) protocol M27-A3 with minor 
modifications [114]: the tests were performed in MMH, a suitable medium for assessing antifungal 
activity of plant defensins [66], and an inoculum of approximately 106 cells/mL was supplemented with 
DMSO, resulting in a similar DMSO concentration as for the antibiofilm activity assays, i.e. 0.5% 
DMSO. The MIC50 value, i.e. the minimal concentration required to inhibit 50% growth as compared 
to control treatment, was determined by measuring the optical density at 490 nm (OD490 nm) after 24 h. 
3.2.4 Antibiofilm activity assays 
3.2.4.1 Biofilm inhibition assay 
The Biofilm Inhibition Concentration 50 value (BIC50; the minimum concentration required to reduce 
biofilm formation by 50% as compared to the control treatment) of rRsAFP2 was determined using the 
antibiofilm assay as described by Delattin and co-workers, with minor modifications [115]: the dilution 
series of the peptide was prepared in sterile water and the inoculum was supplemented with DMSO, 
resulting in a similar DMSO concentration as for the checkerboard assays, i.e. 0.5% DMSO. Biofilm 
inhibition assays were carried out in MMH. 
3.2.4.2 Biofilm eradication assay 
The Biofilm Eradication Concentration 50 value (BEC50; the minimum concentration required to 
diminish pre-grown biofilms by 50% as compared to the control treatment) of rRsAFP2 was determined 
using the BEC50 determination assay as described by De Cremer and co-workers, with a minor 
modification [116]: biofilm eradication assays were carried out in MMH.  
3.2.4.3 Checkerboard antibiofilm assay 
C. albicans biofilms or C. albicans planktonic cultures were grown as described above. A combination 
of rRsAFP2 and compound (caspofungin or amphotericin B), two-fold diluted across the columns and 
rows of a 96-well plate, respectively, was added to the biofilms after 1 h or 24 h of adhesion to analyse 
biofilm inhibition or biofilm eradication, respectively. After 24 h incubation at 37°C, the biofilms were 
quantified using CTB (CellTiter-Blue; Promega, WI, USA), as described earlier [115]. Synergy was 
determined by calculating the Fractional Inhibitory Concentration Index (FICI) using the formula 𝐹𝐼𝐶𝐼 =
𝐹𝐼𝐶𝐴 + 𝐹𝐼𝐶𝐵 = 𝐶𝐴 𝐵𝐼𝐶𝐴⁄ + 𝐶𝐵 𝐵𝐼𝐶𝐵⁄ , where 𝐵𝐼𝐶𝐴 and 𝐵𝐼𝐶𝐵 are the BICs of the drugs A and B alone, 
respectively, and 𝐶𝐴 and 𝐶𝐵 are the concentrations of the drugs A and B at iso-effective combinations, 
respectively [117]. Note that 𝐶𝐵 values were derived from the whole dose-response curves, whereas 
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𝐶𝐴 values represent the actual concentration of drug A (i.e. RsAFP2) in the checkerboard experiments, 
as indicated in Tables 1-3. 
3.2.5 Scanning electron microscopy (SEM) 
Qualitative analysis of samples was performed using scanning electron microscopy (XL30-FEG, FEI). 
Samples were prepared according to the protocol described by De Brucker and colleagues [118]. 
Briefly, biofilms were grown on titanium discs for 24 h. After rinsing these discs in PBS, they were fixed 
in gluteraldehyde (2.5% v/v in a cacodylate buffer), rinsed in PBS and subsequently dehydrated in a 
series of ethanol/H2O solutions with increasing alcohol content, followed by air drying. Finally, a thin 
conductive Au-Pd film was sputtered (Edwards S150) on the samples and SEM was operated at 
standard high-vacuum settings and using 10 mm working distance and 20 keV accelerating voltage. 
3.2.6 Data analysis 
Data were analysed with GraphPad Prism 6 (GraphPad Software, Inc., CA, USA) using nonlinear 
regression to generate sigmoidal curves, employing the model 𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚) (1 + 10(log 𝐼𝐶50−𝑋)∗𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒)⁄ . The concentrations required to cause 50% growth 
inhibition (MIC50), biofilm prevention (BIC50) and biofilm eradication (BEC50) were derived from the 
whole dose-response curves. Unpaired Student t-tests were performed to analyse significant 
differences between the MIC50, BIC50 and BEC50 of caspofungin or amphotericin B alone and the 
combination of these compounds with rRsAFP2 in the checkerboard assays. In all cases, P < 0.05 was 
defined as statistically significantly different.  
3.2.7 Characterization of rRsAFP2 by NMR 
rRsAFP2 (1 mg) was dissolved in 500 L of 10% D2O/90% H2O (~pH 4) for NMR experiments. All 
spectra were recorded on a Bruker Avance-600 spectrometer at 298 K or 288–308 K for variable 
temperature experiments. Two-dimensional NMR experiments included TOCSY using a MLEV-17 spin 
lock of 80 ms, NOESY with a mixing time of 200 ms, ECOSY, 13C-HSQC, and 15N-HSQC. Solvent 
suppression was achieved using excitation sculpting and spectra were acquired with 4096 complex 
data points in F2 and 512 increments in the F1 dimension. The t1 dimension was zero-filled to 1024 
real data points, and 90˚ phase-shifted sine bell window functions were applied prior to Fourier 
transformation. Spectra were also recorded in 100% D2O to identify slowly exchanging amide protons. 
Chemical shifts were referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate (DSS). Processed 
spectra were analysed and assigned using CcpNmr Analysis [119]. Spectra were assigned using the 
sequential assignment protocol [120]. 
3.2.8 Structure calculations 
Structure calculations were based on distance restraints derived from NOESY spectra recorded in both 
10% and 100% D2O. Initial structures were generated using torsion angle dynamics in the program 
CYANA [121], followed by addition of restraints for the disulphide bonds, hydrogen bonds as indicated 
by slow D2O exchange and sensitivity of amide proton chemical shift to temperature, chi1 restraints 
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and stereo-specific assignments of α-methylene protons from ECOSY and NOESY data, and 
backbone phi and psi dihedral angles restraints generated using the program TALOS+ [122]. The final 
structural family was generated within the program CNS [123] using torsion angle dynamics followed 
by refinement and energy minimization in explicit solvent and protocols as developed for the 
RECOORD database [124]. Final structures were analysed for stereochemical quality using 
MOLPROBITY [125], visualized using MOLMOL [126], and the 20 structures with lowest energy and 
best quality chosen to represent the solution structure of rRsAFP2. Coordinates and NMR chemical 
shift assignments have been submitted (PDB ID: 2n2r ; BMRB entry 25609). 
3.3 Results 
3.3.1 rRsAFP2 shows GlcCer-dependent antifungal activity  
rRsAFP2 was produced in Pichia pastoris and subsequently purified using cation exchange and 
reversed-phase chromatography. A yield of at least 100 mg of rRsAFP2 was obtained per liter of culture 
supernatant. The antifungal activity of rRsAFP2 was tested against F. graminearum and compared to 
the antifungal activity of native RsAFP2 purified from radish seeds [28]. Similar IC50 values are 
observed for the recombinant and native peptide against F. graminearum, i.e. 2 µg/mL = 0.35 µM (data 
not shown). In addition, we found that the F. graminearum ∆gcs mutant is equally resistant to rRsAFP2 
as native RsAFP2, indicating that rRsAFP2 shows GlcCer-specific antifungal activity, as has been 
demonstrated for native RsAFP2 [27, 82]. 
3.3.2 rRsAFP2 prevents Candida albicans biofilm formation 
As RsAFP2 blocks the yeast-to-hypha transition in C. albicans [25], which is important for biofilm 
formation [107], we analysed the activity of rRsAFP2 against C. albicans biofilms. Since rRsAFP2 does 
not show antifungal or antibiofilm activity in RPMI medium (data not shown), we performed all assays 
in MMH, a suitable medium for assessing antifungal activity of plant defensins [66]. We found that 
rRsAFP2 does not show antifungal activity against planktonic C. albicans cultures in this medium up 
to 2 mg/mL, and the MIC50 value is therefore defined as > 2 mg/mL (data not shown). Subsequently, 
we investigated the ability of rRsAFP2 to prevent or eradicate C. albicans biofilms in MMH medium. 
We found that rRsAFP2 can prevent C. albicans biofilm formation, resulting in a BIC50 value of 1.65 ± 
0.40 mg/mL. Eradication of C. albicans biofilms by rRsAFP2 is not observed up to 2 mg/mL (i.e. BEC50 
of rRsAFP2 is > 2 mg/mL). 
SEM images of biofilms grown for 4 h in the presence or absence of rRsAFP2 (1.65 mg/mL) were 
taken to further investigate the effect of the peptide on C. albicans biofilm formation. In the presence 
of 1.65 mg/mL rRsAFP2, C. albicans cells adhering to the discs do not grow as biofilms as hyphal 
formation is completely inhibited by the peptide. Instead, only C. albicans cells in the yeast phenotype 
are detected at the surface of the discs. In contrast, in the absence of rRsAFP2, C. albicans cells form 
a dense biofilm network covering the entire discs (Figure 2). 
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Figure 2: Scanning electron microscopy images of 4 h-old Candida albicans biofilms, grown in the presence or absence 
(untreated) of 1.65 mg/mL rRsAFP2. Images at multiple magnifications (500x, 1000x and 2000x) are presented. 
Chapter 3 
30 
 
3.3.3 rRsAFP2 acts synergistically with caspofungin against Candida albicans biofilms 
As rRsAFP2 prevents C. albicans biofilm formation, we further analysed the effect of rRsAFP2 on the 
biofilm inhibitory and eradicating activity of caspofungin and amphotericin B, two commercially 
available antimycotics belonging to the echinocandin and polyene class of antifungal agents, 
respectively [127], that are characterized by antibiofilm activity. However, a multidrug approach can be 
used to improve the efficacy of these antimycotics against biofilm-associated infections, which are 
often difficult to treat [128]. To this end, checkerboard assays were performed and the corresponding 
FICI values were calculated to determine whether rRsAFP2 acts synergistically with these antimycotics 
against C. albicans biofilms, i.e. FICI ≤ 0.5 (Figure 3 and Table 1-2).  
 
Figure 3: Synergy between rRsAFP2 and caspofungin or amphotericin B for Candida albicans biofilm inhibition (A and B) 
and biofilm eradication (C). Metabolic activity was measured by CTB assay. Sigmoidal curves were generated using data of 
three independent experiments (n=3), using the model 𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + (𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚) (1 + 10(log 𝐼𝐶50−𝑋)∗𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒)⁄  in GraphPad 
Prism. Dose response curves of caspofungin (A and C) or amphotericin B (B) in the presence of synergistic concentrations of 
rRsAFP2 are presented. Black arrows represent synergy. Coloured lines represent different rRsAFP2 doses, with  
green: 10 µg/mL; red: 5 µg/mL; blue: 2.5 µg/mL and black: 0 µg/mL. 
  
 
 
 
Table 1: Synergistic activity of rRsAFP2 with caspofungin or amphotericin B against Candida albicans SC5314 biofilms, resulting in biofilm formation inhibition* 
Compound(s) [rRsAFP2] (µg/mL) BIC50 CAS or AmB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.76 ± 0.16 NA NA  
CAS + rRsAFP2 10 0.13 ± 0.03 5.7 0.18  
 
5 0.20 ± 0.01 3.9 0.26  
 
2.5 0.32 ± 0.03 2.4 0.42  
 
1.25 0.63 ± 0.04 1.2 0.82 NS 
 
0.625 0.66 ± 0.18 1.2 0.86 NS 
 
0.3125 0.74 ± 0.22 1.0 0.96 NS 
AmB alone 0 1.74 ± 0.34 NA NA  
AmB + rRsAFP2 10 0.77 ± 0.10 2.3 0.45  
 5 0.81 ± 0.08 2.2 0.47  
 2.5 1.15 ± 0.17 1.5 0.66 NS 
 1.25 1.33 ± 0.16 1.3 0.76 NS 
 0.625 1.62 ± 0.44 1.1 0.93 NS 
 0.3125 1.72 ± 1.23 1.0 0.99 NS 
*BIC50 values were determined by CTB assay; n = 3 independent experiments; BIC50, minimal inhibitory concentration that inhibits biofilm formation by 50%; NA, not applicable; CAS: caspofungin; 
AmB: amphotericin B. Synergistic compound combinations are presented in bold. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences 
between the compound alone and the combination of compound and rRsAFP2; no significant differences were found (NS).  
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Table 2: Synergistic activity of rRsAFP2 with caspofungin against Candida albicans SC5314 biofilms, resulting in eradication of C. albicans biofilm cells* 
Compound(s) [rRsAFP2] (µg/mL) BEC50 CAS (µM) ± SEM Fold change FICI (<) Significance level 
CAS alone 0 0.29 ± 0.01 NA NA  
CAS + rRsAFP2 10 0.10 ± 0.02 2.8 0.36  
 
5 0.12 ± 0.03 2.5 0.41  
 
2.5 0.19 ± 0.05 1.6 0.64 NS 
 
1.25 0.21 ± 0.04 1.4 0.71 NS 
 
 
0.625 0.25 ± 0.02 1.2 0.86 NS 
0.3125 0.27 ± 0.02 1.1 0.92 NS 
*BEC50 values were determined by CTB assay; n = 3 independent experiments; BEC50, minimal concentration that eradicates biofilms by 50%; NA, not applicable; CAS: caspofungin. Synergistic 
compound combinations are presented in bold. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences between the compound alone and the 
combination of compound and rRsAFP2; no significant differences were found (NS).  
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Synergistic effects between rRsAFP2 and caspofungin are observed in both biofilm inhibition and 
biofilm eradication assays (Table 1 and 2): a range of 2.5 µg/mL to 10 µg/mL rRsAFP2 reduces the 
BIC50 of caspofungin by 2.4- to 5.7-fold, whereas 5 µg/mL and 10 µg/mL rRsAFP2 reduce the BEC50 
of caspofungin by 2.5- and 2.8-fold, respectively. In addition, 5 µg/mL and 10 µg/mL rRsAFP2 act 
synergistically with amphotericin B with regard to inhibiting C. albicans biofilm formation, thereby 
reducing the amphotericin B BIC50 by 2.3- and 2.2-fold, respectively (Table 1). As eradication of  
C. albicans biofilms by amphotericin B was not observed in MMH medium up to 50 µM amphotericin 
B, we did not perform additional checkerboard assays with rRsAFP2 and amphotericin B to analyse 
the biofilm eradication potential of the combinatorial approach. Note that when C. albicans biofilms are 
grown in RPMI medium, biofilm eradication by amphotericin B is observed at concentrations less than 
5 µM.  
To assess whether the synergistic effects observed between rRsAFP2 and caspofungin or 
amphotericin B against C. albicans biofilms are biofilm-specific, a similar checkerboard assay was 
carried out on planktonic C. albicans cells (Table 3). Although no synergistic effects are observed 
between rRsAFP2 and caspofungin or amphotericin B against a planktonic C. albicans culture, we 
found that 0.3125 µg/mL, 0.625 µg/mL and 1.25 µg/mL rRsAFP2 reduce the caspofungin MIC50 
significantly. No significant differences are observed between the MIC50 of amphotericin B alone and 
that in combination with rRsAFP2. As FICI values do not indicate synergy between rRsAFP2 and 
caspofungin or amphotericin B, we conclude that synergy between rRsAFP2 and caspofungin seems 
biofilm-specific. 
  
 
 
Table 3: Synergistic activity of rRsAFP2 with caspofungin against Candida albicans SC5314 planktonic cultures* 
*MIC50 values were determined by measuring the OD490 nm; n = 3 independent experiments; MIC50, minimal inhibitory concentration that inhibits planktonic growth by 50%; NA, not applicable; CAS: 
caspofungin; AmB: amphotericin B. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences between the compound alone and the combination 
of compound and rRsAFP2; the significance level is presented (* represents P < 0.05; NS, no significant difference). 
Compound(s) [rRsAFP2] (µg/mL) MIC50 CAS or AmB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.05 ± 0.01 NA NA  
CAS + rRsAFP2 2.5 0.04 ± 0.00 1.5 0.67 NS 
 
1.25 0.03 ± 0.00 1.6 0.62 * 
 
0.625 0.03 ± 0.00 1.6 0.64 * 
 
0.3125 0.04 ± 0.00 1.5 0.66 * 
 
0.15625 0.04 ± 0.01 1.5 0.67 NS 
 
0.078125 0.04 ± 0.01 1.4 0.71 NS 
AmB alone 0 0.61 ± 0.14 NA NA  
AmB + rRsAFP2 2.5 0.46 ± 0.11 1.3 0.76 NS 
 1.25 0.56 ± 0.10 1.1 0.92 NS 
 0.625 0.58 ± 0.12 1.0 0.96 NS 
 0.3125 0.64 ± 0.13 0.9 1.06 NS 
 0.15625 0.62 ± 0.23 1.0 1.02 NS 
 0.078125 0.60 ± 0.14 1.0 0.99 NS 
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3.3.4 Characterization of rRsAFP2 by NMR 
The solution structure of rRsAFP2 was determined by NMR analysis and compared with that of 
RsAFP1 [42]. The proton NMR spectrum of rRsAFP2 (Figure 4A) shows good dispersion in the amide 
region, indicative of a highly structured peptide, and two-dimensional spectra enabled full proton 
assignment (S1 Table). The TOCSY and NOESY spectra of rRsAFP2 are presented in Figure 4B and 
4C, respectively. 
 
Figure 4: Characterization of rRsAFP2 by NMR analysis at 600MHz, 10% D2O/90% H2O, pH 4.0, 298K. (A) Proton NMR 
spectrum of rRsAFP2; (B) Fingerprint region of the TOCSY spectrum of rRsAFP2; (C) Fingerprint region of the NOESY spectrum 
of rRsAFP2, showing sequential connectivity pattern. 
Secondary chemical shift analysis was used to confirm that there was a high degree of similarity in the 
elements of secondary structure of rRsAFP2 as compared to those of RsAFP1 [42] (Figure 5A). The 
three-dimensional structure of rRsAFP2 was calculated from 655 distance restraints, 17 hydrogen 
bond pairs, and 90 dihedral angle restraints. The disulphide connectivities (I-VIII, II-V, III-VI, IV-VII) 
were also included as restraints in the structure calculations. Two of the peptide’s three proline residues 
(Pro7 and Pro50) are confirmed to be in the trans conformation, based on diagnostic Hαi-1-Hδi NOE 
crosspeaks. Pro41 is in a cis confirmation based on Hαi-1-Hαi crosspeaks. The final family of structures 
has good structural and energy statistics, as shown in Supplementary Table S2. 
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Figure 5: Comparison of RsAFP1 and rRsAFP2 secondary shift analysis and NMR structures. (A) Secondary shift analysis 
of rRsAFP2, pH 4.0 at 298K, as compared to that of RsAFP1 [42]. The amino acid sequence of RsAFP2 is displayed, with the 
substituted residues of RsAFP1 shown in brackets. White bars represent RsAFP1; grey bars represent RsAFP2; (B) NMR 
structures of rRsAFP2. A family of 20 lowest energy structures superimposed over all backbone heavy atoms. The N- and  
C-termini are labelled N-ter and C-ter respectively, and the disulphide bonds are shown in yellow; (C) Comparison of rRsAFP2 
(dark blue) and RsAFP1 (grey) structures is shown in ribbon format. The loops connecting the secondary structural elements 
are labelled, as are the residues corresponding to changes between the two peptides. 
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The structures overlay well over the entire molecule, with a RMSD for the backbone atoms of 1.16 ± 
0.40 Å (Figure 5B). Analysis of the structures with PROMOTIF [129] identified a 16.5 Å length of  
α-helix between Asn18 and Leu28 and a triple-stranded anti-parallel β-sheet comprising residues 
Leu3-Arg6, His33-Cys36, and Cys45-Pro50. These structural elements are connected by three loop 
regions. Loop 2, which connects the α-helix to strand 2, is better defined than either loop 1 (linking 
strand 1 to the α-helix) or loop 3 (linking strand 2 to strand 3). Loop 3 contains a type VIa1 β-turn but 
is also the region of greatest mobility. Figure 5C reveals that the backbone structures of the RsAFP1 
and rRsAFP2 overlay well with an RMSD of 1.69 Å across the entire molecule and 1.17 Å across the 
structured elements. 
3.4 Discussion 
We generated recombinant (r) RsAFP2, a plant defensin from the seeds of radish [28], in Pichia 
pastoris with a yield of at least 100 mg of rRsAFP2 per liter of culture supernatant. The antifungal 
activity of rRsAFP2 is similar to that of native RsAFP2 with regard to antifungal potency and GlcCer 
dependency. As RsAFP2 was shown to impair the yeast-to-hypha transition in C. albicans [25], which 
is considered important for progression to mature biofilms [107], we analysed the potential antibiofilm 
activity of rRsAFP2 against C. albicans biofilms. In these experiments, we used minimal medium 
supplemented with HEPES (MMH), as we found that rRsAFP2 did not show antifungal and antibiofilm 
activity in RPMI. The latter is a reference medium, frequently used to assess the antibiofilm activity of 
compounds, as it mimics the in vivo environment. However, RsAFP2 was previously shown to be 
effective against a murine model of candidiasis [21], suggesting that media other than RPMI can be 
relevant for the assessment of antifungal and/or antibiofilm activity of peptides. In this respect, it has 
already been reported that the type of medium can influence the potency of antimicrobial peptides and 
that their in vivo potency can transcend their in vitro activity. For instance, the proline-rich antimicrobial 
peptide A3-APO was found to have a modest activity against Escherichia coli and Acinetobacter 
baumannii in vitro in Mueller-Hinton broth, whereas in mouse models of systemic and wound infections 
it showed superior efficacy compared to conventional antibiotics [130, 131]. Similarly, Malik and 
colleagues found that certain anuran peptides demonstrated weak in vitro inhibitory activity against 
Staphylococcus aureus in cation-adjusted Mueller-Hinton broth, but had potent antibacterial activity 
against S. aureus in a murine wound infection model [132]. This suggests that, as opposed to in vitro 
activity testing of small molecules, it can be better to use other, ‘non-conventional’, media for in vitro 
activity testing of peptides.  
We found that rRsAFP2 can prevent C. albicans biofilm formation with a BIC50 value of 1.65 ±  
0.40 mg/mL, whereas eradication of biofilms by this peptide was not observed up to 2 mg/mL. SEM 
images of C. albicans biofilms showed that biofilms grown in the presence of 1.65 mg/mL rRsAFP2 
consist of cells adhered to the surface without the formation of a hyphal network, and as such, no true 
biofilm is formed. In contrast, cells in untreated biofilms are able to form a dense hyphal network. These 
observations can be explained by the fact that RsAFP2 was previously shown to block the yeast-to-
hyphae transition in C. albicans [25]. Checkerboard analyses indicated that a synergy exists between 
rRsAFP2, and caspofungin or amphotericin B, to prevent C. albicans biofilm formation. Moreover, 
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rRsAFP2 acts synergistically with caspofungin in the eradication of C. albicans biofilms as well. This 
synergy is apparent at low rRsAFP2 concentrations, i.e. 2.5 µg/mL to 10 µg/mL. Synergy between 
rRsAFP2 and caspofungin or amphotericin B was not observed against planktonic C. albicans cells, 
pointing to a biofilm-specific synergy. Interestingly, rRsAFP2 alone cannot eradicate C. albicans 
biofilms up to a concentration of 2 mg/mL, whereas a combinatorial approach of a 200-fold lower 
rRsAFP2 concentration with caspofungin results in efficient eradication of C. albicans biofilms. Similar 
observations are made for C. albicans biofilm prevention, as synergistic activity with amphotericin B 
and caspofungin is evident at 2.5 µg/mL to 10 µg/mL rRsAFP2, whereas the rRsAFP2 BIC50 is at least 
150-fold higher (i.e. 1.65 ± 0.40 mg/mL). We recently reported on the antibiofilm activity of another 
plant defensin, HsAFP1, which can inhibit C. albicans biofilm formation, but cannot eradicate  
C. albicans biofilms [20]. In that study, rHsAFP1 was shown to act synergistically with caspofungin in 
the prevention and eradication of C. albicans biofilms [20]. In line, the plant-derived decapeptide 
OSIP108 was shown to act synergistically with caspofungin and amphotericin B in vitro and in vivo in 
a Caenorhabditis elegans – C. albicans biofilm infection model, while OSIP108 alone cannot eradicate 
C. albicans biofilms [133]. Similarly, AS10, a derivative of the mouse cathelicidin-related antimicrobial 
peptide, was found to act synergistically with caspofungin and amphotericin B in eradication of  
C. albicans biofilms, whereas the latter is not observed when AS10 is applied alone [134]. Hence, 
diverse antimicrobial peptides seem to act synergistically with caspofungin or amphotericin B in 
prevention and/or eradication of C. albicans biofilms, suggesting that these peptides induce a 
weakening of the biofilm cells and/or biofilm matrix, resulting in facilitated targeting and killing of the 
biofilm cells by caspofungin and amphotericin B. All these data suggest that antimicrobial peptides, 
such as plant defensins, are interesting peptides as novel antibiofilm agents, in particular for their use 
in a multidrug approach to combat C. albicans biofilm-related infections. Interestingly, plant defensins 
are in general non-toxic towards mammalian cells, and certainly not at the concentrations used in this 
study. Specifically regarding RsAFP2, we previously demonstrated that it can be used to successfully 
treat candidiasis in mice after intravenous injection without any detrimental effect on the animal [21]. 
Since RsAFP2 was found to be 2- to 30-fold more potent than RsAFP1 against several fungi, and their 
amino acid sequences only differ by two amino acids [28], we were interested in elucidating the solution 
structure of rRsAFP2 and comparing it to that of RsAFP1 reported by Fant and colleagues [42]. As 
such, we focused on the structural difference(s) that might result in the observed differential antifungal 
potency. NMR analysis revealed that rRsAFP2 has a comparable structure to that of RsAFP1, 
consisting of an α-helix and three β-strands held together in a typical cysteine-stabilized αβ motif. 
There are no discernible differences in the structured elements, nor in loop 2 or loop 3 (Figure 5C). 
The backbone of loop 1 adopts a slightly different configuration, but this variance may be due to the 
flexibility of this long loop region. Interestingly, loop 3 is highly similar between these two defensin 
peptides. Apart from the N-terminus (pyroglutamate in RsAFP1 and glutamine in rRsAFP2), which has 
been shown to have no effect on activity [135], the primary structures differ at only two positions. 
Specifically, a glutamine in rRsAFP2 replaces glutamate 5 in RsAFP1 and an arginine replaces 
asparagine 27. In both defensins, these residues are found on the helix and strand 1 and their 
substitution induces no structural differences. Moreover, the side chains of these residues extend with 
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similar spatial orientation (Figure 5C). It has been proposed that the interactions between radish 
defensins and their fungal target sites are based in part on electrostatic interactions [42, 89]. Indeed, 
these changes at position 5 and 27 result in a higher net positive charge of rRsAFP2 relative to RsAFP1 
and this change is more likely to be responsible for differences in biological activities than structural 
alterations. At this stage, we cannot exclude the possibility that the differences in activity reflect 
residue-specific interactions involving the two substituted positions. For example, it has been 
established that some defensins, such as RsAFP2, specifically interact with sphingolipids [80, 105] or 
phospholipids [60] and the amino acid differences might modulate such an interactions. 
In conclusion, we have shown here that P. pastoris is an ideal host for the production of highly 
structured peptides like plant defensins, resulting in their correct folding and highly specific activity. In 
addition, we showed that RsAFP2 is an interesting peptide for the development of novel antibiofilm 
agents, as it prevented C. albicans biofilm formation and acted synergistically with caspofungin and 
amphotericin B in prevention of C. albicans biofilms. In addition, synergistic interactions were also 
observed between rRsAFP2 and caspofungin in the eradication of C. albicans biofilms. These findings 
point to a novel approach that makes use of plant defensins alone or in combination with conventional 
antimycotics to combat fungal biofilms. 
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3.5 Supplementary material 
Supplementary Table S1: 1H assignments for rRsAFP2 in 10% D2O /90% H2O, pH 4.0 at 298K. 
 Chemical shifts  
Residue NH H H others 
Gln1  4.40 2.08, 2.08 CH2 2.58, 2.40; NH2 7.33, 6.80 
Lys2 8.38 4.31 1.87, 1.78 CH2 1.46, 1.46; CH2 1.72, 1.71; CH2 3.02, 3.01; NH3
+ 
7.55 
Leu3 8.40 5.12 1.84, 1.35 CH 1.69; CH3 0.74, 0.68 
Cys4 9.76 5.09 2.98, 2.98  
Gln5 8.71 4.66 1.62, 1.62 CH2NH2 7.30, 6.76 
Arg6 9.12 4.83 1.91, 1.74 CH2 1.69, 1.57; CH2 3.04, 2.91; NH 7.02
Pro7  4.49 2.31, 1.92 CH2 2.15, 1.92; CH2 3.85, 3.64 
Ser8 8.62 4.73 4.11, 3.71  
Gly9 10.64 4.41, 3.91  
Thr10 8.19 4.51 4.16 CH3 1.14 
Trp11 8.14 4.12 3.25, 3.11 CH 7.10; NH 8.58; CH 7.36; CH 7.24; CH 7.82; 
CH 6.80 
Ser12 7.39 4.64 3.56, 3.56  
Gly13 8.41 4.18, 3.88  
Val14 8.56 4.05 2.14 CH3 1.09, 0.98 
Cys15 8.24 4.93 2.91, 1.86  
Gly16 8.63 4.40, 3.70  
Asn17 7.33 4.87 3.03, 2.81 NH2 7.89, 7.11 
Asn18 9.00 4.25 3.14, 2.72 NH2 7.62, 7.04 
Asn19 8.45 4.39 2.91, 2.82 NH2 7.75, 7.11 
Ala20 8.00 4.32 1.77  
Cys21 7.27 4.17 2.20, 2.09  
Lys22 8.37 3.20 1.92, 1.92 CH2 1.30, 1.22; CH2 1.73, 1.73; CH2 3.04, 3.04; NH3
+ - 
Asn23 8.31 4.40 2.89, 2.80 NH2 7.59, 6.88 
Gln24 8.20 4.12 2.39, 2.39 CH2NH2 7.81, 6.58 
Cys25 8.74 4.22 2.88, 2.53  
Ile26 8.18 3.83 1.72 CH2CH3CH3 
Arg27 8.68 4.13 1.99, 1.91 CH2 1.81, 1.65; CH2 3.25, 3.19; NH 7.30 
Leu28 8.57 4.71 2.20, 1.67 CH 1.77; CH3 0.99, 0.93 
Glu29 7.03 4.82 2.76, 2.65 CH2 2.38, 2.28 
Lys30 7.48 4.23 2.25, 2.15 CH2 1.43, 1.43; CH2 1.74, 1.73; CH2 3.06, 3.06; NH3
+ 
7.55 
Ala31 7.92 3.98 0.81  
Arg32 8.24 4.47 1.81, 1.62 CH2 1.81, 1.65; CH2 1.76, 1.70; NH 7.45 
His33 7.68 4.61 3.11, 2.42 CH 5.92; CH 7.76 
Gly34 6.31 5.30, 3.85  
Ser35 9.05 4.13 3.73, 3.73  
Cys36 8.55 5.48 2.85, 2.75  
Asn37 9.11 4.96 2.75, 2.75 NH2 -, - 
Tyr38 8.77 4.25 3.02, 2.57 CH 6.60; CH 6.69 
Val39 7.71 3.89 1.88 CH3 0.87, 0.87 
Phe40 8.44 3.96 3.02, 2.89 CH 7.30; CH 7.42 
Pro41  3.87 1.98, 1.02 CH2 1.71, 1.50; CH2 3.36, 3.28
Ala42 8.29 4.75 1.33 
His43 8.66 4.94 3.31, 3.16 CH 7.33; CH 8.27
Lys44 8.79 4.66 1.88, 1.54 CH2 1.51, 1.41; CH2 1.67, 1.67; CH2 2.95, 2.95; NH3
+ 
7.65 
Cys45 9.19 4.72 2.20, 1.59 
Ile46 8.73 4.21 2.09 CH2CH3CH3 
Cys47 8.58 5.38 3.01, 2.75 
Tyr48 7.99 5.30 2.68, 2.49 CH 6.75; CH 6.71
Phe49 9.21 4.94 3.29, 2.69 CH 7.22; CH 7.42
Pro50 - 4.87 2.38, 2.11 CH2 2.38, 1.95; CH2 4.11, 3.80
Cys51 8.35 4.55 3.38, 3.20  
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Supplementary Table S2: Statistical analysis of 20 lowest energy structures of rRsAFP2  
NMR distance & dihedral constraints  
Distance restraints, total NOE 655 
intra-residue 185 
inter-residue  
sequential (|i-j|) 220 
medium-range (|i-j|≤4) 72 
long-range (|i-j|≥5) 178 
Hydrogen bondsa 34 
Dihedral angle restraints, total 90 
 42 
 29 
χ 19 
  
Structure statisticsb  
Deviations from idealized geometry 
bond lengths (Å) 0.011 ± 0.000 
bond angles (deg) 1.14 ± 0.03 
impropers (deg) 1.42 ± 0.08 
NOE (Å) 0.011 ± 0.001 
cDih (Å) 0.104 ± 0.089 
Mean energies (kcal/mol)  
Overall -1779 ± 34 
bonds 22.5 ± 1.4 
angles 67.4 ± 4.1 
improper 28.6 ± 3.0 
Van Der Waals -245.8 ± 8.0 
NOE 0.09 ± 0.02 
cDih 0.21 ± 0.28 
electrostatic -1880 ± 35 
Violations   
NOE violations exceeding 0.3Å 0 
Dihedral violations exceeding 2.0o 0 
Average pairwise rmsd (Å)  
backbone atoms  1.16 ± 0.40 
heavy atoms  1.85 ± 0.52 
  
Stereochemical Qualityc  
Ramachandran favoured, % 90.0 ± 3.7 
Ramachandran outliers, % 1.4 ± 2.3 
Unfavourable sidechain rotamers, % 0.3 ± 0.8 
Clashscore, all atomsd 13.5 ± 3.1 
MolProbity score 2.19 ± 0.10 
Percentile 65 ± 6 
a two restraints were used per hydrogen bond 
b statistics are given as mean  standard deviation 
c according to MolProbity (http://molprobity.biochem.duke.edu) 
d defined as the number of steric overlaps > 0.4 Å per thousand atoms 
 42 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 43 
 
 
 
 
 
 
Chapter 4 
 
4 Synergistic activity of the plant defensin HsAFP1 and 
caspofungin against Candida albicans biofilms and 
planktonic cultures3 
 
                                                     
3 This chapter is part of a publication in PLoS One as: 
Vriens, K.*, Cools, T.L. *, Harvey, P.J., Craik, D.J., Spincemaille, P., Cassiman, D., Braem, A., 
Vleugels, J., Nibbering, P.H., Drijfhout, JW., De Coninck, B., Cammue, B.P.A. and Thevissen, 
K. (2015). Synergistic activity of the plant defensin HsAFP1 and caspofungin against Candida 
albicans biofilms and planktonic cultures. PLoS One 10 (8): e0132701. DOI: 
10.1371/journal.pone.0132701. 
*Both authors contributed equally to this work 
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Abstract 
Plant defensins are small, cysteine-rich peptides with antifungal activity against a broad range of yeast 
and fungi. In this study we investigated the antibiofilm activity of a plant defensin from coral bells 
(Heuchera sanguinea), i.e. HsAFP1. To this end, HsAFP1 was heterologously produced using Pichia 
pastoris as a host. The recombinant peptide rHsAFP1 showed a similar antifungal activity against the 
plant pathogen Fusarium culmorum as native HsAFP1 purified from seeds. NMR analysis revealed 
that rHsAFP1 consists of an α-helix and a triple-stranded antiparallel β-sheet stabilised by four 
intramolecular disulphide bonds. We found that rHsAFP1 can inhibit growth of the human pathogen 
Candida albicans as well as prevent C. albicans biofilm formation with a BIC50 (i.e. the minimum 
rHsAFP1 concentration required to inhibit biofilm formation by 50% as compared to control treatment) 
of 11.00 ± 1.70 µM. As such, this is the first report of a plant defensin exhibiting inhibitory activity 
against fungal biofilms. We further analysed the potential of rHsAFP1 to increase the activity of the 
conventional antimycotics caspofungin and amphotericin B towards C. albicans. Synergistic effects 
were observed between rHsAFP1 and these compounds against both planktonic C. albicans cells and 
biofilms. Most notably, concentrations of rHsAFP1 as low as 0.53 µM resulted in a synergistic activity 
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with caspofungin against pre-grown C. albicans biofilms. rHsAFP1 was found non-toxic towards human 
HepG2 cells up to 40 µM, thereby supporting the lack of a general cytotoxic activity as previously 
reported for HsAFP1. A structure-function study with 24-mer synthetic peptides spanning the entire 
HsAFP1 sequence revealed the importance of the γ-core and its adjacent regions for HsAFP1 
antibiofilm activity. These findings point towards broad applications of rHsAFP1 and its derivatives in 
the field of antifungal and antibiofilm drug development. 
Key words: plant defensin, HsAFP1, proton NMR analysis, Candida albicans, fungal biofilm, 
recombinant protein production, structure-function relationship 
4.1 Introduction 
Plant defensins are small, basic, cysteine-rich peptides with a conserved structure known as a 
cysteine-stabilized αβ-motif [42, 136, 137]. Although the tertiary structure of some plant defensins  
[39, 40, 42, 44, 45] is known, the structure of many defensins is yet to be determined. Plant defensins 
exhibit antimicrobial activity against a wide range of microorganisms [102-104], whereas they are in 
general non-toxic to human cells [19, 138, 139]. To date, there has been a particular focus on their 
antifungal activity and several fungal targets have been identified, including membrane sphingolipids 
and phospholipids [27, 60, 66, 80, 82, 105, 140]. Upon interaction with the fungal membrane, plant 
defensins are either internalized into the cell and interact with cytosolic or nuclear proteins, or they 
remain localized at the cell wall or membrane of the fungus [25, 44, 62, 74]. The mechanisms by which 
plant defensins induce fungal cell death are diverse, but common aspects are observed. These include 
the production of reactive oxygen species (ROS) and the induction of apoptosis [101].  
Despite the fact that their mechanisms of antifungal action have been studied extensively, no reports 
exist about the activity of plant defensins against fungal biofilms. Biofilms are self-organised microbial 
communities embedded in a polymeric matrix that grow on a biotic or abiotic surface, such as catheters 
or other medical implants. Many fungal species are able to form biofilms, however, Candida spp. play 
a predominant role in mixed-species fungal biofilms [10, 108-110]. Such biofilm cells are tolerant 
towards most conventional antimycotics and there are only few novel agents that can be used to treat 
biofilm-related infections. To date, only miconazole, caspofungin, anidulafungin and liposomal 
formulations of amphotericin B are used to effectively treat these infections [111-113], and hence, there 
is a need to identify novel antibiofilm compounds. 
In this study, we used the defensin from coral bells, HsAFP1, which was previously characterized by 
Osborn and colleagues [18], and assessed its potential antibiofilm activity. HsAFP1 inhibits the growth 
of various plant pathogenic fungi, including Botrytis cinerea, Verticillium albo-atrum and Fusarium 
culmorum, and causes swelling of germ tubes and hyphae in the latter [18]. In addition, it was reported 
that HsAFP1 shows antifungal activity against Saccharomyces cerevisiae and the human pathogen  
C. albicans, and induces apoptosis in the latter [22]. Furthermore, it was shown that HsAFP1 has a 
low in vitro frequency of resistance occurrence in planktonic C. albicans cultures (i.e. less than 1 in 
2,000,000 mutants) [19]. In an attempt to unravel HsAFP1’s mode of antifungal activity, this defensin 
was tested against the complete S. cerevisiae deletion mutant library for identification of yeast mutants 
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with altered HsAFP1 sensitivity [22]. In this study, 84 yeast genes were identified that were found to 
be implicated in governing HsAFP1 tolerance or sensitivity of yeast [22]. Since HsAFP1 has a potent 
antifungal activity towards C. albicans, we further analysed its potential activity towards C. albicans 
biofilms. To this end, we heterologously expressed HsAFP1 using the yeast Pichia pastoris and 
determined the solution structure of recombinant (r) rHsAFP1 by NMR analysis. Subsequently, we 
tested the activity of the plant defensin alone and in combination with conventional antimycotics against 
C. albicans biofilms. In view of the latter, a multi-drug approach in which multiple compounds are 
administered and a synergistic effect is observed, can be effectively used to combat biofilm-related 
infections [141]. Finally, we conducted a structure-function study, using 24-mer synthetic peptides 
spanning the entire HsAFP1 region. The HsAFP1 derivatives were tested against C. albicans 
planktonic cultures and biofilms, and their potential to synergistically enhance the activity of 
caspofungin was analysed.  
4.2 Materials and methods 
4.2.1 Strains and reagents 
Pichia pastoris strain X33 was used for heterologous production of HsAFP1. Fusarium culmorum strain 
K0311 was used to evaluate the antifungal activity of the recombinant peptide and to compare it with 
that of native HsAFP1 purified from seeds, in a fungal growth inhibitory assay [18]. C. albicans strain 
SC5314 was used in all biofilm experiments. rHsAFP1 toxicity testing was performed on HepG2, 
human hepatoma cells [142], purchased from ATCC (catalogue number HB-8065; Rockville, MD, 
USA).  
All culture media were purchased from LabM (UK), unless stated otherwise. For heterologous 
production, P. pastoris was cultured in YPD (1% yeast extract, 2% peptone and 2% glucose), BMGY 
(buffered complex glycerol medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 1% glycerol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin) or BMMY 
(buffered complex methanol medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 0.5% methanol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin).  
F. culmorum was grown in half strength PDB (1.2% potato dextrose broth). Biofilm experiments were 
performed in RPMI-1640 medium (Roswell Park Memorial Institute-1640 medium; pH 7) with  
L-glutamine and without sodium bicarbonate (purchased from Sigma Aldrich, St.-Louis, MO, USA), 
buffered with MOPS (Sigma Aldrich, St.-Louis, MO, USA). Amphotericin B and caspofungin (Cancidas) 
were purchased from Sigma Aldrich (St. Louis, MO, USA) and Merck (Beeston Nottingham, UK), 
respectively. HepG2 cells were grown in MEM (Minimal Essential Medium, Gibco, Invitrogen; CA, 
USA), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin, and cultured using standard cell culture conditions (37°C, 5% CO2, 95% humidity). The 
Cell Proliferation Kit II (XTT) and Cell Proliferation ELISA BrdU (colorimetric) kit were purchased from 
Roche Diagnostics (Mannheim, Germany). 
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4.2.2 Production and purification of recombinant (r) rHsAFP1 
The PCR fragment encoding mature HsAFP1 was cloned in frame with the α-factor secretion signal 
present in the pPICZαA transfer vector, after which the plasmid was integrated into the genome of 
Pichia pastoris X33 strain via double homologous recombination. This transgenic P. pastoris strain 
was grown in YPD overnight at 30°C and 250 rpm. BMGY medium was inoculated with the overnight 
culture to an optical density at 600 nm (OD600 nm) of 0.5 and grown for 24 h at 30°C and 200 rpm. Cells 
were pelleted by sterile centrifugation at 8000 rpm for 10 minutes at room temperature and re-
suspended in BMMY medium, thereby concentrating the culture 4-fold and inducing gene expression. 
The culture was grown for 96 h at 25°C, and 2.5% methanol (v/v%) was added to the culture every  
24 h to maintain induction of gene expression. After induction, cells were pelleted at 8000 rpm for  
10 minutes at 4°C and the cleared supernatant, containing the peptides of interest, was filter sterilized 
through a Steritop-GP 0.22 µm Express PLUS membrane Bottle-top filter (EMD Millipore, MA, USA). 
The filtered supernatant was then subjected to automated tangential flow filtration using an automated 
peristaltic pump (Spectrum Laboratories, CA, USA) and a hollow fiber module with 1 kDa cut-off mPES 
membranes (Spectrum Laboratories, CA, USA). During the ultrafiltration, the sample was concentrated 
a 15-fold and subsequently dialyzed against 50 mM sodium acetate pH 5. 
rHsAFP1 was purified by cation exchange chromatography, using 75 mL SP sepharose High 
Performance resin (GE Healthcare, UK) packed in a XK26/20 column (GE Healthcare) and 50 mM 
sodium acetate buffers at pH 5. The flow rate was maintained at 5 mL/min. Elution of the peptides was 
carried out by a washing step with 10% (v/v%) elution buffer (50 mM sodium acetate, 1 M sodium 
chloride, pH 5) for 10 column volumes (CV), followed by a linear gradient to 50% (v/v%) elution buffer 
in 15 CV, resulting in a peak at approximately 29% (v/v%) elution buffer. The eluted fraction was further 
purified by reversed phase chromatography employing a Gemini C18 250x10 column (Phenomenex, 
CA, USA) and acetonitrile (ACN) for elution of the bound peptides. The flow rate was maintained at 
4.6 mL/min. Elution of the peptides was carried out by a washing step at 15% (v/v%) ACN for 1.9 CV, 
followed by a linear gradient to 35% (v/v%) ACN in 2.3 CV. Elution of rHsAFP1 occurred at 28%. The 
eluted fraction was vacuum dried by centrifugal evaporation (SpeedVac Savant, Thermo Fisher 
Scientific, MA, USA), re-dissolved in MilliQ water and subjected to a micro bicinchoninic acid assay 
(Pierce, Thermo Scientific, USA) according to the manufacturer’s instructions, to determine the protein 
concentration. Bovine serum albumin served as a reference protein. At least 40 mg/L of culture of 
purified rHsAFP1 was obtained.  
4.2.3 Characterization of rHsAFP1 by NMR 
Dry powder (1 mg) of rHsAFP1 was dissolved in 500 µL of 10% D2O/90% H2O (~pH 4) for NMR 
experiments. Spectra were recorded at 298 K on a Bruker Avance-600 spectrometer. Two-dimensional 
NMR experiments included total correlation spectroscopy (TOCSY [143]) using a MLEV-17 spin lock 
sequence [144] with a mixing time of 80 ms; nuclear Overhauser effect spectroscopy (NOESY [145]) 
with a mixing time of 150, 200, or 300 ms; exclusive correlation spectroscopy (ECOSY [146]); and 13C 
and 15N heteronuclear single-quantum coherence (HSQC [147]). Solvent suppression was achieved 
using excitation sculpting with gradients [148]. Spectra were acquired with 4096 complex data points 
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in F2 and 512 increments in the F1 dimension. Slowly exchanging amide protons were identified by 
spectra also recorded in 100% D2O. 
Spectra were processed using TopSpin (Bruker) software. The t1 dimension was zero-filled to 1024 
real data points, and 90˚ phase-shifted sine bell window functions were applied prior to Fourier 
transformation. Chemical shifts were referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate 
(DSS). Processed spectra were analysed and assigned using CcpNmr Analysis [119]. Spectra were 
assigned using the sequential assignment protocol [120]. 
4.2.4 Structure calculations 
Structure calculations were based on distance restraints derived from NOESY spectra recorded in both 
10% and 100% D2O. Initial structures were generated using the program CYANA [121], followed by 
addition of restraints for the disulphide bonds, hydrogen bonds as indicated by slow D2O exchange 
and sensitivity of amide proton chemical shift to temperature, chi1 restraints from ECOSY and NOESY 
data, and backbone phi and psi dihedral angles restraints generated using the program TALOS+ [122]. 
The structural family was generated using torsion angle dynamics, refinement and energy minimization 
in explicit solvent and protocols as developed for the RECOORD database [124] within the program 
CNS [123]. A family of structures consistent with the experimental restraints was then visualized using 
MOLMOL [126] and assessed for stereochemical quality using MolProbity [125]. Coordinates and NMR 
chemical shift assignments have been submitted (PDB ID: 2n2q; BMRB ID: 25605). 
4.2.5 Antifungal activity assays 
To test whether rHsAFP1 is as potent as HsAFP1 purified from the seeds of coral bells, we analysed 
the antifungal activity of both peptides against F. culmorum, following the standard CLSI protocol  
M28-A2 [114], with minor modifications as previously described by Osborn and colleagues [18]: an 
inoculum of approximately 104 spores/mL of F. culmorum was suspended in half strength PDB and 
added to a two-fold dilution series of rHsAFP1 in water. Seed-derived HsAFP1 was purified according 
to the protocol as previously described by Osborn and colleagues [18]. The IC50 value, which is the 
concentration required for 50% growth inhibition as compared to control treatment, was determined by 
measuring the optical density at 490 nm (OD490 nm) after 48 h of incubation and was confirmed 
microscopically. The antifungal activity of rHsAFP1 against C. albicans was subsequently analysed 
according to the standard CLSI protocol M27-A3 [114] with minor modifications: an inoculum of 
approximately 106 cells/mL was suspended in RPMI-1640 medium and added to a two-fold dilution 
series of rHsAFP1 in water. The DMSO concentration was similar to that in the biofilm assays, i.e. 
0.5% DMSO. The MIC50 value, i.e. the minimum concentration required to reduce planktonic growth 
by 50% as compared to control treatment, was determined by measuring the OD490 nm after 24 h of 
incubation. 
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4.2.6 Antibiofilm activity assays 
4.2.6.1 Biofilm inhibition assay 
The Biofilm Inhibitory Concentration 50 value (BIC50; the minimum concentration required to reduce 
biofilm formation by 50% as compared to control treatment) of rHsAFP1 was determined using the 
following antibiofilm assay: a C. albicans SC5314 overnight culture, grown in YPD, was diluted to an 
optical density (600 nm) of 0.1 in RPMI 1640 medium and 100 μL of this suspension was added to the 
wells of a round-bottomed microtiter plate (TPP, Tradingen, Switzerland). After 1 h of adhesion at 37°C, 
the medium was aspirated and the biofilms were washed with 100 μL phosphate-buffered saline (PBS) 
to remove non-adherent cells. Fresh RPMI-1640 medium, followed by a rHsAFP1 concentration series 
was added to the biofilms. The DMSO concentration was similar to that in the checkerboard assays, 
i.e. 0.5%. Biofilms were allowed to grow for 24 h at 37°C and were subsequently washed with PBS 
and quantified with CellTiter-Blue (CTB; Promega, WI, USA)) [149] by adding 100 μL of CTB diluted 
1/10 in PBS to each well. After 1 h of incubation in the dark at 37°C, the fluorescence was measured 
with a fluorescence spectrometer (λEx/λEm: 535/590 nm). The fluorescence values of the samples were 
corrected by subtracting the average fluorescence value of the CTB of uninoculated wells (blank). The 
percentage of surviving biofilm cells was calculated relative to the control treatment (0.5% DMSO). 
4.2.6.2 Biofilm eradication assay 
The Biofilm Eradicating Concentration 50 value (BEC50; the minimum concentration required to reduce 
the viability of the cells in a pre-grown biofilm by 50% as compared to control treatment) of rHsAFP1 
was determined using the BEC50 determination assay as described by De Cremer and co-workers 
[116]. Briefly, a C. albicans SC5314 overnight culture, grown in YPD, was diluted to an optical density 
(600 nm) of 0.1 in RPMI-1640 medium and 100 μL of this suspension was added to the wells of a 
round-bottomed microtiter plate (TPP, Tradingen, Switzerland). After 1 h of adhesion, the biofilms were 
washed with 100 μL PBS to remove non-adherent cells, followed by addition of 100 µL RPMI-1640 
medium. The biofilms were allowed to grow for 24 h at 37°C. Next, an rHsAFP1 concentration series 
in RPMI was added to the biofilms. The DMSO concentration was similar to that in the checkerboard 
assays, i.e. 0.5%. The biofilms were incubated for another 24 h at 37°C, after which they were washed 
and quantified with CTB as described above.  
4.2.6.3 Checkerboard assay 
C. albicans biofilms or C. albicans planktonic cultures were grown as described above. A combination 
of rHsAFP1 and antimycotic (caspofungin or amphotericin B), two-fold diluted across the columns and 
rows of a 96-well plate, respectively, was added to the planktonic culture or to the biofilms. Biofilms 
were treated either after 1 h or 24 h starting from the adhesion phase to analyse biofilm inhibition or 
biofilm eradication, respectively. After 24 h incubation at 37°C, the MIC50 values were determined by 
measuring the OD490 nm, whereas BIC50 and BEC50 values were determined using CTB as described 
above. In all experiments, the DMSO concentration was kept at 0.5%. Synergy was determined by 
calculating the Fractional Inhibitory Concentration Index (FICI) [133, 150], in which the actual 
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concentration of compound A (i.e. rHsAFP1) in the checkerboard experiment was used, as indicated 
in Tables 1-3 and Table 4. 
4.2.7 Scanning electron microscopy (SEM) 
Qualitative analysis of samples was performed using scanning electron microscopy (XL30-FEG, FEI). 
Samples were prepared using a protocol previously described [118]. Briefly, the biofilm-containing 
titanium discs were rinsed in PBS and fixed in gluteraldehyde (2.5% v/v in a cacodylate buffer). 
Samples were rinsed three times in PBS, and subsequently dehydrated in a series of ethanol/H2O 
solutions with increasing alcohol content, followed by air drying. Finally, a thin conductive Au-Pd film 
was sputtered (Edwards S150) on the samples and SEM was operated at standard high-vacuum 
settings and using 10 mm working distance and 20 keV accelerating voltage. 
4.2.8 rHsAFP1 toxicity in HepG2 cells 
HepG2 cells were seeded at 10,000 cells/well in 96 well-plates and incubated for 24 h. Subsequently, 
cells were treated with water (untreated) or rHsAFP1 (0.01 µM - 40 µM) for 24 h after which cell viability 
or cell proliferation was determined using the “Cell Proliferation Kit II (XTT)”, as described previously 
[151], or the “Cell Proliferation ELISA BrdU (colorimetric) kit”, according to the manufacturer’s 
instructions, respectively. 
4.2.9 Structure-function analysis of HsAFP1 
Synthesis and purification of the 24-mer peptides (HsLin01-HsLin06) spanning the HsAFP1 amino acid 
sequence was performed as described previously [152]. Cysteine residues were replaced by  
α-aminobutyric acid to avoid formation of disulphide bonds.  
4.2.10 Data analysis 
Data were analysed with GraphPad Prism 6 (GraphPad Software, Inc., CA, USA). For dose-response 
data, sigmoidal curves were generated using nonlinear regression. The concentration required to 
cause 50% planktonic growth inhibition (IC50 or MIC50), reduction of biofilm formation (BIC50) and 
biofilm eradication (BEC50) as compared to control treatment was derived from the whole dose-
response curves. In all experiments, mean ± standard error of the mean (SEM) for n ≥ 3 is presented. 
Unpaired Student t-tests were performed to analyse significant differences between the IC50 value of 
native HsAFP1 and that of recombinant HsAFP1, and between the MIC50, BIC50 and BEC50 of 
caspofungin or amphotericin B alone and the combination of these compounds with rHsAFP1 or its 
derivatives in the checkerboard assays. To analyse significant differences in cell viability or cell 
proliferation between untreated and rHsAFP1-treated HepG2 cells in the rHsAFP1 toxicity assays, 
unpaired Student t-tests were performed. In all cases, P < 0.05 was defined as statistically significant. 
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4.3 Results 
4.3.1 rHsAFP1 shows potent antifungal activity against filamentous fungi 
rHsAFP1 was produced in Pichia pastoris and subsequently purified using cation exchange and 
reversed phase chromatography. A yield of at least 40 mg/L of culture of purified rHsAFP1 was 
obtained. The antifungal activity of HsAFP1 against a broad range of fungi, including the 
fungus Fusarium culmorum, has been reported previously [18]. In this respect, Osborn and colleagues 
showed that native HsAFP1 can inhibit growth of F. culmorum with an IC50 value of  
1 µg/mL = 0.17 µM [18]. Hence, to assess the potency of rHsAFP1, we tested the antifungal activity of 
rHsAFP1 and native HsAFP1 against F. culmorum according to the method of Osborn [18]. We found 
the IC50 values of the recombinant and native peptide against F. culmorum not to be significantly 
different, i.e. 0.45 ± 0.13 µM and 0.23 ± 0.02 µM respectively, with a P-value of 0.1707, and hence, 
rHsAFP1 seems as potent as native HsAFP1. 
4.3.2 Characterization of rHsAFP1 by NMR 
The solution structure of rHsAFP1 was solved via NMR analysis, a technique that has been previously 
used to characterize the structures of other plant defensins, including RsAFP1, MtDef4, Psd1 and 
NaD1 [40, 42, 44, 45]. A sequence alignment of HsAFP1 with these peptides and RsAFP2 is presented 
in Figure 1A, showing the disulphide bond pattern common for plant defensins [153, 154].  
The NMR spectra of rHsAFP1 showed the sample to be of high purity and good dispersion in the amide 
region was indicative of a highly structured peptide. Two-dimensional spectra were recorded at several 
temperatures in the range 283K to 303K to obtain full proton assignments. The proton assignments for 
rHsAFP1 are presented in supplemental information (Supplementary Table S1). Secondary chemical 
shift analysis was then used to locate elements of secondary structure. Hα secondary shifts are 
calculated by subtracting the chemical shift of the alpha proton from “random coil” values [155]. 
Deviations greater than 0.1 ppm from random coil are indicative of structured peptides, with positive 
values present for beta type structures and negative values for helical structures. The secondary Hα 
shifts of rHsAFP1 are shown in Figure 2 and indicate that the solution structure of rHsAFP1 consists 
of both α-helix and β-strand elements. 
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Figure 1: Sequence alignment of HsAFP1 with other plant defensins. (A) Amino acid sequence alignment of NaD1 [40], 
Psd1 [45], MtDef4 [92], RsAFP1 [28], RsAFP2 [28] and HsAFP1 [18], matching their cysteine residues (numbered I-VIII). Multiple 
alignment was performed using the COBALT alignment tool [106]. Cysteine-pairing is shown at the top of the figure. Highly 
conserved residues are shown in grey; (-) denote gaps in the alignment. Blue boxes represent peptide fragments that exhibit 
antifungal activity similar to the parental peptide, and hence, are important for antifungal activity [44, 56, 72, 156]. The orange 
box indicates the position of the γ-core. (B) Amino acid sequence alignment of HsAFP1 and the HsAFP1 linear peptide fragments 
(HsLin01-HsLin06). Multiple alignment was performed using the COBALT alignment tool [106]. Highly conserved residues are 
shown in grey; (-) denote gaps in the alignment. The orange box indicates the position of the γ-core.  
The three-dimensional structure of rHsAFP1 was calculated from 614 distance restraints, 15 hydrogen 
bond pairs, and a total of 90 dihedral angle restraints (Supplementary Table S2). The disulphide 
connectivities (I-VIII, II-V, III-VI, IV-VII) were fully consistent with the NOE data and were included as 
restraints in the structure calculations. Similarly to RsAFP1 [42], one proline (Pro9) is present in the 
trans configuration and the second (Pro44) has a cis peptide bond. Figure 3A shows the ensemble of 
structures superimposed over the backbone heavy-atoms of all residues (rmsd 1.16 ± 0.40 Å). A ribbon 
representation of the lowest energy structure is shown in Figure 3B. Analysis of the structures shows 
that 96% of residues fall in the most favoured regions of the Ramachandran plot and a mean MolProbity 
score of 1.8 indicates good structural quality. rHsAFP1 forms a compact globular fold with a three turn 
α-helix spanning residues Ser20-Arg30 and a triple-stranded anti-parallel β-sheet (β1 = Leu5-Pro9;  
β2 = Ala38-His40; β3 = Lys47-Gln53) forming another element of secondary structure. The four 
disulphide bonds are arranged in a typical cysteine-stabilized αβ motif in that the α-helix is tethered to 
the β-sheet by two disulphide bonds to the central strand (Cys23-Cys39 and Cys27-Cys50). There are 
three loops present in the molecule that link β-strand 1 with the helix, the helix to β-strand 2, and the 
β-strands 2 and 3. These loops are reasonably well-defined although the loop that incorporates a β-
turn between strand 2 and 3 is apparently more flexible as judged by greater disorder in the structural 
ensemble in this region. 
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Figure 2: Secondary shift analysis of rHsAFP1, pH 4.0 at 298K. Regions of α-helix and β-strand are indicated at the top of 
the figure. 
 
Figure 3: Three-dimensional structure of rHsAFP1. (A) A family of 20 lowest energy structures superimposed over all 
backbone heavy atoms; (B) A ribbon representation with disulphide bonds shown in yellow. The termini are labelled as N and 
C. Diagrams were generated using MOLMOL. 
4.3.3 rHsAFP1 prevents Candida albicans biofilm formation 
At first, we assessed the antifungal activity of rHsAFP1 against planktonic C. albicans cells. rHsAFP1 
showed antifungal activity against planktonic C. albicans cultures, with a MIC50 value of 18.00 ±  
4.60 µM. Subsequently, we investigated the ability of rHsAFP1 to prevent or eradicate C. albicans 
biofilms. rHsAFP1 inhibited C. albicans biofilm formation, resulting in a BIC50 value of 11.00 ± 1.70 
µM. Fifty percent eradication of C. albicans biofilms by this peptide, as compared to control treatment, 
was not observed at the highest tested concentration, i.e. 109.00 µM (i.e. BEC50 of rHsAFP1 is  
> 109.00 µM) (data not shown). 
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In order to investigate the effect of rHsAFP1 on the growth of C. albicans biofilms, SEM images of 
biofilms grown for 4 h in the presence or absence of rHsAFP1 (11.8 µM) were taken. As shown in 
Figure 4, cells in the untreated biofilms were able to form a dense hyphal network, covering the titanium 
discs. In contrast, no true biofilm was formed in the presence of 11.8 µM rHsAFP1, as in this case, 
biofilms mainly consisted of cells attached to the titanium disc without formation of a hyphal network.  
Figure 4: Scanning electron microscopy images of 4 h-old biofilms, grown in the presence or absence (untreated) of 
11.8 µM rHsAFP1. Images at multiple magnifications (500x, 1000x and 2000x) are presented. 
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4.3.4 rHsAFP1 acts synergistically with caspofungin or amphotericin B against Candida albicans  
As rHsAFP1 prevented C. albicans biofilm formation, we further investigated the effect of rHsAFP1 on 
the biofilm inhibitory and eradicating activity of conventional antimycotics, such as caspofungin and 
amphotericin B. To this end, checkerboard assays were performed and the corresponding FICI values 
were calculated to determine whether rHsAFP1 acts synergistically with these compounds against  
C. albicans biofilms (Figure 5 and Tables 1-2).  
Figure 5: Synergy between rHsAFP1 and caspofungin or amphotericin B, for (A) biofilm inhibition, as determined by CTB 
assay; (B) biofilm eradication, as determined by CTB assay; and (C) growth inhibition of planktonic cultures. Growth was 
analysed by measuring the OD490 nm. Sigmoidal curves were generated using data of at least three independent experiments  
(n ≥ 3), using the model Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) in GraphPad Prism. Dose response curves of 
caspofungin in the presence of synergistic concentrations of rHsAFP1 are presented. Black arrows represent synergy. Coloured 
lines represent different rHsAFP1 doses, as follows: brown: 16.8 µM; red: 8.4 µM; orange: 4.2 µM; dark yellow: 2.1 µM; green: 
1.05 µM; turquois: 0.53 µM; blue: 0.26 µM and black: 0 µM. 
In the biofilm inhibition assays (Table 1), synergistic effects (FICI ≤ 0.5) were observed between 
rHsAFP1 and caspofungin: rHsAFP1 increased the activity of caspofungin at concentrations of  
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1.05 µM and 2.1 µM, resulting in a 2.5-fold and 3.7-fold reduction of the caspofungin BIC50, 
respectively. Although not synergistic, 0.53 µM, 4.2 µM and 8.4 µM rHsAFP1 also reduced the BIC50 
of caspofungin significantly (P < 0.05). No synergistic effects were observed between rHsAFP1 and 
amphotericin B in the biofilm inhibition assays, however, a range of 1.05 µM to 8.4 µM rHsAFP1 
significantly reduced the amphotericin B BIC50. Moreover, we also found that rHsAFP1 acted 
synergistically with caspofungin or amphotericin B in the eradication of C. albicans biofilms (Table 2): 
all rHsAFP1 concentrations tested (i.e. a range from 0.53 µM to 16.8 µM rHsAFP1) increased the 
biofilm eradicating capacity of caspofungin and although only 8.4 µM rHsAFP1 displayed synergy with 
amphotericin B, multiple concentrations significantly reduced the BEC50 of amphotericin B.  
To assess whether the synergistic effects observed between rHsAFP1 and amphotericin B or 
caspofungin against C. albicans biofilms were biofilm-specific, a similar checkerboard assay was 
performed on planktonic C. albicans cells (Table 3). Synergistic effects were observed between 
rHsAFP1 and caspofungin or amphotericin B against planktonic C. albicans cells and hence, synergy 
between rHsAFP1 and these compounds seems not biofilm-specific. Synergy between rHsAFP1 and 
amphotericin B was observed at lower rHsAFP1 concentrations as compared to those observed 
between rHsAFP1 and caspofungin. Interestingly, the concentration range of rHsAFP1 that acted 
synergistically with caspofungin against planktonic C. albicans cells was more restricted as compared 
to a C. albicans biofilm setup: all rHsAFP1 concentrations tested (i.e. 0.53 µM to 16.8 µM) increased 
caspofungin’s activity against C. albicans biofilms in the biofilm eradication assays, whereas only  
2.1 µM and 4.2 µM rHsAFP1 acted synergistically with caspofungin against planktonic C. albicans 
cells. In addition, only 1.05 µM and 2.1 µM rHsAFP1 enhanced caspofungin activity against C. albicans 
biofilms in the biofilm inhibition assays. This indicates that synergy between caspofungin and rHsAFP1 
is more evident in the eradication of C. albicans biofilms. In contrast, synergy between amphotericin B 
and rHsAFP1 was more pronounced against planktonic C. albicans cultures, as various rHsAFP1 
concentrations (i.e. 0.53 µM to 2.1 µM) acted synergistically with amphotericin B against planktonic  
C. albicans cells and only 8.4 µM rHsAFP1 increased amphotericin B activity against C. albicans 
biofilms in the biofilm eradication assay. No synergistic effects between amphotericin B and rHsAFP1 
were observed in the biofilm inhibition assays. 
  
 
 
Table 1: Synergistic activity of rHsAFP1 with caspofungin or amphotericin B against Candida albicans SC5314 biofilms, resulting in biofilm formation inhibition*  
Compound(s) [rHsAFP1] (µM) BIC50 CAS or AmB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.72 ± 0.05 NA NA  
8.4 0.05 ± 0.00 15.8 0.86 *** 
4.2 0.10 ± 0.01 7.1 0.54 *** 
2.1 0.20 ± 0.01 3.7 0.47  
1.05 0.28 ± 0.04 2.5 0.49  
0.53 0.42 ± 0.02 1.7 0.64 ** 
0.26 0.65 ± 0.07 1.1 0.93 NS 
AmB alone 0 1.23 ± 0.15 NA NA  
8.4 0.60 ± 0.07 2.1 1.28 ** 
4.2 0.53 ± 0.05 2.3 0.83 ** 
2.1 0.56 ± 0.04 2.2 0.65 ** 
1.05 0.67 ± 0.06 1.8 0.64 * 
0.53 0.81 ± 0.11 1.5 0.71 NS 
0.26 0.93 ± 0.11 1.3 0.78 NS 
*BIC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BIC50, minimum inhibitory concentration that is required to inhibit biofilm formation by 
50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two compounds; NA, not applicable; CAS, caspofungin; AmB, amphotericin 
B. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences between the 
effect of the compound alone and the combination of compound and rHsAFP1; the significance level is presented (*, ** and *** represent P < 0.05, P < 0.01 and P < 0.001, respectively; NS, no 
significant difference). 
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Table 2: Synergistic activity of rHsAFP1 with caspofungin or amphotericin B against Candida albicans SC5314 biofilms, resulting in eradication of biofilm cells*  
Compound(s) [rHsAFP1] (µM) BEC50 CAS or AmB (µM) ± SEM Fold change FICI (<) Significance level 
CAS alone 0 0.40 ± 0.08 NA NA  
16.8 0.04 ± 0.01 9.7 0.26  
8.4 0.06 ± 0.00 7.2 0.22  
4.2 0.07 ± 0.00 5.7 0.21  
2.1 0.10 ± 0.01 4.0 0.27  
1.05 0.12 ± 0.01 3.3 0.32  
0.53 0.15 ± 0.02 2.7 0.37  
AmB alone 0 1.67 ± 0.30 NA NA  
16.8 0.61 ± 0.17 2.7 0.52 * 
8.4 0.66 ± 0.22 2.5 0.47  
4.2 0.82 ± 0.19 2.1 0.53 * 
2.1 0.95 ± 0.28 1.8 0.59 NS 
1.05 1.07 ± 0.29 1.6 0.65 NS 
0.53 1.28 ± 0.28 1.3 0.77 NS 
*BEC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BEC50, minimum concentration that is required to reduce viability of 24 h-old biofilm 
cells by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two compounds; NA, not applicable; CAS, caspofungin; AmB, 
amphotericin B. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences 
between the effect of the compound alone and the combination of compound and rHsAFP1; the significance level is presented (*, ** and *** represent P < 0.05, P < 0.01 and P < 0.001, respectively; 
NS, no significant difference). 
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Table 3: Synergistic activity of rHsAFP1 with caspofungin or amphotericin B against Candida albicans SC5314 planktonic cultures*  
Compound(s) [rHsAFP1] (µM) MIC50 CAS or AmB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.02 ± 0.01 NA NA  
8.4 0.01 ± 0.00 8.6 0.58 NS 
4.2 0.01 ± 0.00 4.0 0.48  
2.1 0.01 ± 0.00 2.6 0.50  
1.05 0.01 ± 0.00 1.8 0.63 NS 
0.53 0.02 ± 0.00 1.2 0.86 NS 
0.26 0.02 ± 0.01 1.1 0.90 NS 
AmB alone 0 0.44 ± 0.06 NA NA  
8.4 0.14 ± 0.01 3.2 0.78 ** 
4.2 0.15 ± 0.01 3.0 0.57 ** 
2.1 0.15 ± 0.01 2.9 0.47  
1.05 0.17 ± 0.01 2.6 0.44  
0.53 0.18 ± 0.02 2.4 0.44  
0.26 0.25 ± 0.01 1.8 0.58 * 
*MIC50 values were determined by measuring the OD490 nm; mean ± SEM for n ≥ 3 independent experiments is presented; MIC50, minimum inhibitory concentration that is required to reduce planktonic 
growth by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two compounds; NA, not applicable; CAS, caspofungin; AmB, 
amphotericin B. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences 
between the effect of the compound alone and the combination of compound and rHsAFP1; the significance level is presented (* and ** represent P < 0.05 and P < 0.01, respectively; NS, no 
significant difference). 
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4.3.5 rHsAFP1 does not affect HepG2 cell viability and proliferation 
Various plant defensins are reported to be non-toxic to human cells due to their fungal membrane-
specific interactions [19]. As no records exist yet on potential toxicity of HsAFP1, we analysed the 
effect of rHsAFP1 on human hepatoma cells (HepG2) and found that rHsAFP1 did not affect HepG2 
cell viability nor cell proliferation up to 40 µM, the highest rHsAFP1 concentration tested in this setup. 
No statistically significant differences were found in cell viability and proliferation between untreated 
and rHsAFP1-treated cells (Supplementary Figure S1). 
4.3.6 The γ-core and adjacent regions are important for rHsAFP1 antibiofilm activity 
In order to gain insights in the structure-function relationship of HsAFP1 against C. albicans planktonic 
and biofilm cells, we conducted a structure-function relationship study using HsAFP1-derived linear 
fragments. The selection of fragments was based on the procedure used by Schaaper et al. [157]. We 
synthesized 24-mer peptides with an 18-mer overlap, spanning the entire HsAFP1 amino acid 
sequence and analysed these peptides for their activity towards F. culmorum and C. albicans 
planktonic cultures and biofilms. The sequences of the linear fragments (HsLin01-HsLin06) are 
presented in Figure 1B. Figure 6 shows a diagram in which the HsLin peptides are imposed on the 
rHsAFP1 structure, according to their amino acid sequence. Note that (i) the cysteine residues are 
replaced by α-aminobutyric acid to avoid formation of disulphide bonds and that (ii) the CSαβ scaffold 
is not present in the HsLin peptides, and therefore, the peptides do not adopt the same conformation 
as the mature rHsAFP1. 
Figure 6: Representation of the HsLin peptides imposed on the rHsAFP1 structure, according to the amino acid 
sequence. HsLin peptides are shown as a thick blue line in the same orientation as rHsAFP1; other residues of rHsAFP1, not 
present in the HsLin peptide, are shown as a thin blue line. Note that (i) the cysteine residues are replaced by α-aminobutyric 
acid to avoid formation of disulphide bonds and that (ii) the CSαβ scaffold is not present in the HsLin peptides, and therefore, 
the peptides do not adopt the same conformation as the mature rHsAFP1. 
None of the linear HsAFP1-derived fragments inhibited the growth of F. culmorum up to the highest 
tested concentration, 1.5 µM, whereas rHsAFP1 inhibited growth of this fungus with an IC50 value of 
0.45 ± 0.13 µM. In addition, these truncated peptides did not inhibit the growth of C. albicans in contrast 
to full-length rHsAFP1. Hundred percent growth inhibition of C. albicans planktonic cells was observed 
at 70 µM for rHsAFP1, whereas concentrations up to 350 µM of the peptides were not sufficient to 
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cause 100% growth inhibition. Furthermore, only HsLin06 inhibited C. albicans biofilm formation to the 
same extent as rHsAFP1: the BIC50 values of HsLin06 and rHsAFP1 were 10.80 ± 3.59 µM and  
11.00 ± 1.70 µM, respectively (Table 4), suggesting that the sequence comprising HsLin06 is important 
for antibiofilm activity. HsLin03 and HsLin05 showed antibiofilm activity as well, however, with a 10- to 
15-fold higher BIC50 value than that of rHsAFP1 or HsLin06. Other fragments did not inhibit biofilm 
formation up to 175 µM, the highest tested concentration. We further analysed the potential of the 
peptides to increase the activity of caspofungin to prevent biofilm formation. We found that HsLin06, 
but also HsLin01 and HsLin05, acted synergistically with caspofungin to inhibit C. albicans biofilm 
formation in a range of 0.75 µM to 1.5 µM (Figure 7 and Table 5 for HsLin06 and Supplementary  
Figure S2 for the other HsLin). We did not observe synergistic effects between the other linear 
fragments and caspofungin for preventing biofilm formation (Supplementary Figure S2).  
Table 4: Structure-function relationship study of HsAFP1-derived fragments against Candida albicans biofilms* 
Peptide BIC50 (µM) ± SEM Significance level 
rHsAFP1 11.00 ± 1.70  
HsLin01 >175 *** 
HsLin02 >175 *** 
HsLin03 96.78 ± 15.90 ** 
HsLin04 >175 *** 
HsLin05 160.00 ± 33.36 * 
HsLin06 10.80 ± 3.59 NS 
*BIC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BIC50, minimum 
inhibitory concentration that is required to inhibit biofilm formation by 50% as compared to control treatment. Unpaired Student 
t-tests were performed to analyse significant differences between the effect of the linear fragments and rHsAFP1; the 
significance level is presented (*, ** and *** represent P < 0.05, P < 0.01 and P < 0.001, respectively; NS, no significant 
difference). 
  
 
 
 
Table 5: Synergistic activity of HsLin06 with caspofungin against Candida albicans SC5314 biofilms, resulting in biofilm formation inhibition* 
Compound(s) [HsLin06] (µM) BIC50 CAS (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.90 ± 0.05 NA NA  
175 0.04 ± 0.00 25.67 16.25 *** 
87.5 0.03 ± 0.00 27.87 8.14 ** 
43.75 0.07 ± 0.01 14.27 4.13 *** 
21.88 0.07 ± 0.01 13.50 2.11 *** 
10.94 0.07 ± 0.02 13.67 1.09 *** 
5.47 0.07 ± 0.02 13.03 0.59 *** 
 1.5 0.13 ± 0.00 7.76 0.28  
0.75 0.22 ± 0.01 4.45 0.31  
0.38 0.48 ± 0.04 2.04 0.57 * 
0.19 0.68 ± 0.09 1.43 0.78 NS 
0.09 1.05 ± 0.10 0.93 1.18 NS 
0.05 0.93 ± 0.05 1.05 1.05 NS 
*BIC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BIC50, minimum inhibitory concentration that is required to inhibit biofilm formation by 
50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two compounds; NA, not applicable; CAS, caspofungin. Values in bold 
represent synergistic effects between two compounds. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyse significant differences between the effect of the 
compound alone and the combination of compound and rHsAFP1; the significance level is presented (*, ** and *** represent P < 0.05, P < 0.01 and P < 0.001, respectively; NS, no significant 
difference). 
 
H
s
A
F
P
1
 a
n
d
 c
a
s
p
o
fu
n
g
in
 a
c
t s
y
n
e
rg
is
tic
a
lly
 a
g
a
in
s
t C
a
n
d
id
a
 a
lb
ic
a
n
s
 
6
3
 
Chapter 4 
 64   
 
Figure 7: Synergy between caspofungin and HsLin06 for biofilm inhibition. Metabolic activity was measured using CTB. 
Sigmoidal curves were generated using data of at least three independent experiments (n ≥ 3), using the model Y=Bottom+(Top-
Bottom)/(1+10^((LogIC50-X)*HillSlope)) in GraphPad Prism. Dose response curves of caspofungin in the presence of synergistic 
concentrations of HsLin06 are presented. Black arrows represent synergy. Coloured lines represent different HsLin doses, as 
follows: blue: 1.5 µM; purple: 0.75 µM and black: 0 µM. 
4.4 Discussion 
We have generated recombinant (r) HsAFP1, a plant defensin from the seeds of coral bells (Heuchera 
sanguinea) [18], in Pichia pastoris with a yield of at least 40 mg/L of culture of purified peptide. The 
recombinant peptide rHsAFP1 was characterized by potent antifungal activity, similar to that of HsAFP1 
purified from seeds. NMR analysis revealed that rHsAFP1 adopts the characteristic cysteine-stabilised 
αβ-motif, similar to other plant defensins [40, 42, 44, 45]. The NMR results, together with the results of 
the antifungal activity assays, led us to conclude that P. pastoris is an ideal heterologous production 
system for plant defensins as highly structured and active peptides were obtained, without affecting 
their antifungal activity. 
Plant defensins might be of interest in the development of novel antimycotics, as they are in general 
non-toxic towards human cells [19, 138, 139] and there is a strong need for novel agents to combat 
fungal infections. The latter is of great importance in fungal biofilm-related infections, as only few 
compounds can be used to treat these diseases [111-113]. It was already shown that the plant defensin 
HsAFP1 is characterized by potent antifungal activity towards C. albicans [22], and more interestingly, 
by a low in vitro frequency of resistance occurrence in planktonic C. albicans cultures [19]. Hence, we 
investigated the potential antibiofilm activity of rHsAFP1 against C. albicans biofilms. rHsAFP1 
prevented C. albicans biofilm formation, resulting in a BIC50 value of 11.00 ± 1.70 µM, whereas the 
peptide was not able to eradicate C. albicans biofilms. SEM images of C. albicans biofilms indicated 
that control biofilms were able to form a dense hyphal network within 4 h after adhesion to the surface, 
whereas biofilms grown in the presence of rHsAFP1 mainly consisted of cells attached to the surface 
without formation of a hyphal network. It needs to be further investigated whether this observation is 
due to inhibition of the yeast-to-hypha transition by rHsAFP1.  
Note that the latter has been previously reported for the plant defensin RsAFP2 in planktonic  
C. albicans cultures [25], and might indicate a similar mechanism of action for RsAFP2 and rHsAFP1, 
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although different fungal membrane targets might be involved [22]. Checkerboard assays revealed 
that, although all tested concentrations of rHsAFP1 acted synergistically with caspofungin in 
eradication of C. albicans biofilms, only specific rHsAFP1 doses proved synergistic with caspofungin 
in inhibiting C. albicans biofilm or planktonic cell growth. The underlying molecular mechanism resulting 
in the improved activity of rHsAFP1 in combination with caspofungin for eradicating biofilms is not 
clear. In the case of amphotericin B, most pronounced synergies with rHsAFP1 were apparent against 
planktonic C. albicans cells, although still in a rather limited rHsAFP1 concentration range. We found 
that rHsAFP1 did not affect the cell viability and cell proliferation of human hepatoma cells (HepG2) up 
to 40 µM, the highest concentration tested in this setup, suggesting that rHsAFP1 is not toxic to human 
cells. This is in line with previous reports on the non-toxicity of plant defensins towards human cells 
[19, 138, 139]. 
A structure-function relationship study with 24-mer peptides spanning the entire HsAFP1 amino acid 
sequence showed that the γ-core and its adjacent regions are important for antibiofilm activity, as only 
HsLin06 had a similar antibiofilm activity to that of rHsAFP1. In addition, we found that antifungal and 
antibiofilm activity of rHsAFP1 against C. albicans are probably not linked, as HsLin06 inhibited biofilm 
formation to the same extent as rHsAFP1 without inhibiting planktonic growth. Checkerboard analyses 
revealed that HsLin01, HsLin05 and HsLin06 acted synergistically with caspofungin in the prevention 
of C. albicans biofilm formation. Hence, it seems that antibiofilm activity is not essential to increase the 
activity of caspofungin against C. albicans biofilms, indicating that antibiofilm activity and the ability to 
cause synergistic effects with caspofungin are not linked. Synergy between caspofungin and other 
compounds, including toremifene citrate, tyrocidines, posaconazole, cefoperazone-sulbactam 
(CPZ/SAM), piperacillin-tazobactam (PIP/TAZ) and colistin, against Candida biofilms has been 
described before [115, 158-160] and might point to a general effect of caspofungin against fungal 
biofilms. In this respect, we recently identified a biofilm-specific enhancement of caspofungin activity 
by toremifene citrate against C. albicans and C. glabrata biofilms, resulting in up to 20-fold reduction 
of the caspofungin BIC50 [115]. Similarly, it was reported that CPZ/SAM and PIP/TAZ enhance 
caspofungin activity in vitro and in vivo against C. albicans. In that study, CPZ/SAM is suggested to 
have more affinity for the same efflux pump as caspofungin, leading to an increase in intracellular 
levels of caspofungin and hence, synergy between caspofungin and CPZ/SAM [159]. In another report, 
Chen and colleagues demonstrated that posaconazole exhibits synergistic antifungal activity with 
caspofungin in vitro and in vivo against C. albicans [160]. In addition, it was reported that tyrocidines 
exhibit a pronounced synergistic biofilm-eradicating activity in combination with caspofungin and 
amphotericin B against C. albicans biofilms [158]. In the latter study, a more pronounced synergy 
between tyrocidines and caspofungin was observed as compared to amphotericin B, and, as 
amphotericin B and tyrocidines both target cell membranes, it was hypothesized that the observed 
effect was due to competition for this target. This hypothesis might also be valid for our observations, 
as plant defensins specifically target the fungal membrane [105] and a higher synergy between 
rHsAFP1 and caspofungin was observed as compared to rHsAFP1 and amphotericin B.  
Finally, Zeidler and co-workers reported synergy between echinocandins and colistin against Candida 
spp.. They suggested that this synergy is a result of echinocandin-mediated weakening of the cell wall 
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that leads to facilitated colistin-targeting of fungal membranes, which in turn reinforces the antifungal 
activity of echinocandins [161]. Whether this is the case for rHsAFP1, needs to be further investigated.  
This study is the first to report the activity of a plant defensin towards fungal biofilms in vitro and 
indicates, together with other reports on the antifungal and/or antibiofilm activity of human and insect 
defensins [162-169], the relevance of using defensins as an approach to combat fungal biofilm-
associated infections. We showed that rHsAFP1 inhibited C. albicans planktonic growth and biofilm 
formation, and did not affect the viability and proliferation of human HepG2 cells in vitro. The latter 
indicates that HsAFP1 does not exhibit a general cytotoxicity, which is supported by its lack of inhibitory 
activity to bacteria [18]. It was already shown that the plant defensin RsAFP2 is prophylactically 
effective against murine candidiasis [21], pointing to the in vivo potential of plant defensins. Moreover, 
we showed that rHsAFP1 acted synergistically with caspofungin against C. albicans biofilms and 
planktonic cells. In addition, we found that certain linear HsAFP1-derived fragments also increased the 
activity of caspofungin to prevent biofilm formation. A combinatorial approach to combat fungal 
infections is often more effective and decreases the chance of resistance occurrence [141]. Our results 
indicate a potentiating effect of rHsAFP1 and its derivatives on caspofungin, which should be further 
investigated in vivo. Taken together, rHsAFP1 and its derivatives are interesting peptides for further 
development as an antifungal or antibiofilm agent for use alone or in a multi-drug approach to combat 
fungal infections. 
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4.5 Supplementary material 
Supplementary Table S1: 1H assignments for rHsAFP1 in 10% D2O/90% H2O, pH 4.0 at 298K. 
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Supplementary Table S2: Statistical analysis of rHsAFP1 structures.  
 
 
 
S2 Table Statistical analysis of rHsAFP1 structures*  
Experimental restraints  
Total no. distance restraints 602 
Intraresidue 162 
Sequential 173 
Medium range, i-j<5 66 
Long range, i-j≥5 201 
Hydrogen bond restraints 30 
Disulphide bond restraints 24 
Dihedral angle restraints  
Phi 45 
Psi 37 
Chi1 19 
Total number of restraints per residue 14.0 
Rms deviation from mean structure, Å  
Backbone atoms 1.04 ± 0.24 
All heavy atoms 1.66 ± 0.24 
Stereochemical qualitya  
Residues in most favoured Ramachandran region, % 85.5 ± 3.1 
Ramachandran outliers, % 1.5 ± 1.8 
Unfavourable sidechain rotamers, % 9.0 ± 5.7 
Clashscore, all atoms 2.4 ± 1.4 
Overall MolProbity score 2.27 ± 0.18 
*All statistics are given as mean ± SD. 
aAccording to MolProbity [1]. 
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Supplementary Figure S1: rHsAFP1 does not affect HepG2 cell viability and cell proliferation. HepG2 cells were treated 
with water (control treatment) or rHsAFP1 (0.01 µM – 42 µM) for 24 h. Cell viability and cell proliferation were determined by 
XTT staining and BrdU staining, respectively, and results were expressed relative to cells receiving control treatment. Mean and 
SEM of three experiments in quadruplicate is shown. No statistically significant differences were found in cell viability and cell 
proliferation between untreated (control treatment) and rHsAFP1-treated cells up to the highest tested rHsAFP1 concentration 
(i.e. 40 µM) (Unpaired Student t-test; P < 0.05 was defined as statistically significant). 
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Supplementary Figure S2: Synergy between caspofungin and HsLin01 (A), HsLin02 (B), HsLin03 (C), HsLin04 (D) and 
HsLin05 (E) for Candida albicans biofilm inhibition. Metabolic activity is measured using CTB. Sigmoidal curves were 
generated using data of at least three independent experiments (n ≥ 3), using the model Y=Bottom+(Top-
Bottom)/(1+10^((LogIC50-X)*HillSlope)) in GraphPad Prism. Dose response curves of caspofungin in the presence of synergistic 
concentrations of HsLin are presented. Black arrows represent synergy. Coloured lines represent different HsLin doses, as 
follows: brown: 43.75 µM; orange: 21.88 µM; dark yellow: 10.94 µM; green: 5.47 µM; blue: 1.5; purple: 0.75 µM µM and black: 
0 µM. 
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4 This chapter is part of a published article in Frontiers in Microbiology as: 
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biofilms. Frontiers in Microbiology. DOI: 10.3389/fmicb.2017.02051. 
Chapter 5 
 72   
 
Contributions of individual authors to the manuscript ‘A linear 19-mer plant defensin-derived 
peptide acts synergistically with caspofungin against Candida albicans biofilms’: 
This study was coordinated by BPAC and KT. In vitro biofilm assays in microtiter plates as well as on 
catheters, fungal activity assays and flow cytometry experiments were performed by TLC. Linear 
peptides were synthesized by JWD and the in vivo catheter experiments were performed by TLC, CS, 
SK, CLR and PVD. Confocal microscopy was performed by TLC and PVD. Liposome experiments 
were done by TLC, MHSR and CB. Data analysis, writing of the manuscript, redaction and revisions 
were done by TLC. 
  
HsLin06_18 acts synergistically with caspofungin against Candida albicans biofilms 
73 
 
A linear 19-mer plant defensin-derived peptide acts synergistically with 
caspofungin against Candida albicans biofilms 
Tanne L. Cools1, Caroline Struyfs1,2, Jan Wouter Drijfhout3, Soňa Kucharíková4,5, Celia Lobo 
Romero4,5, Patrick Van Dijck4,5, Marcelo H. S. Ramada6,7, Carlos Bloch Jr. 7, Bruno P.A. Cammue1,2* 
and Karin Thevissen1 
1 Centre of Microbial and Plant Genetics, KU Leuven, Leuven, Belgium. 
2 Department of Plant Systems Biology, VIB, Ghent, Belgium. 
3 Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, 
The Netherlands. 
4 Laboratory of Molecular Cell Biology, KU Leuven, Leuven, Belgium. 
5 VIB-KU Leuven Center for Microbiology, Leuven, Belgium. 
6 Graduate Program in Genomic Sciences and Biotechnology, Catholic University of Brasilia, Brasilia, 
Brazil. 
7 Mass Spectrometry Laboratory, Embrapa Genetic Resources and Biotechnology, Brasilia, Brazil.  
* Corresponding author: Prof. B.P.A. Cammue; bruno.cammue@kuleuven.be 
Abstract 
Public health problems are associated with device-associated biofilm infections, with Candida albicans 
being the major fungal pathogen. We previously identified potent antibiofilm combination treatment in 
which the antifungal plant defensin HsAFP1 is co-administered with caspofungin, the preferred 
antimycotic to treat such infections. In this study, we identified the smallest linear HsAFP1-derived 
peptide that acts synergistically with caspofungin or anidulafungin against C. albicans as HsLin06_18, 
a 19-mer peptide derived from the C-terminal part of HsAFP1. The [caspofungin + HsLin06_18] 
combination significantly reduced in vitro biofilm formation of C. glabrata and C. albicans on catheters, 
as well as biofilm formation of a caspofungin-resistant C. albicans strain. The [caspofungin + 
HsLin06_18] combination was not cytotoxic and reduced biofilm formation of C. albicans in vivo using 
a subcutaneous rat catheter model, as compared to control treatment. Mode of action research on the 
[caspofungin + HsLin06_18] combination pointed to caspofungin-facilitated HsLin06_18 internalization 
and immediate membrane permeabilization. All these findings point to broad-spectrum antibiofilm 
activity of a combination of HsLin06_18 and caspofungin. 
Keywords: fungal infections, Candida, antimicrobial peptides, biofilms, catheters  
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5.1 Introduction 
Upon contact, microorganisms have the ability to form biofilms on both biotic and abiotic substrates 
[170, 171]. The population of patients suffering from biofilm-related diseases is growing, mainly by the 
increased use of immunosuppressive therapies and medical devices, such as catheters and implants, 
which can act as a substrate for biofilm formation [172-174]. Such device-mediated infections can 
result in a systemic infection. To ensure good recovery of the patients, removal of the device is most 
often required [175, 176]. 
Candida species are the most common fungal biofilm-associated pathogens, with C. albicans being 
the most prevalent [177]. However, infections caused by non-albicans Candida species are 
increasingly observed in the clinic [7, 8, 178, 179]. Fungal biofilms are characterized by increased 
tolerance to various antifungal agents (antimycotics) and hence, are very difficult to eradicate. Only 
few conventional antimycotics, such as echinocandins (e.g. caspo-, mica- and anidulafungin) and 
liposomal formulations of amphotericin B, can be used to treat such fungal biofilm-related infections 
[11, 12]. However, there are drawbacks associated with these antimycotics, including their costs, 
toxicity and/or resistance occurrence [3, 4]. Therefore, there is a need for the identification and 
characterization of novel antifungal agents, which are also effective against fungal biofilms. An 
alternative strategy to combat fungal biofilms is combination therapy in which two compounds with 
different mode of actions are combined [3]. Many advantages are associated with these combination 
therapies over mono therapies, such as (i) broadening spectrum of drug activity, (ii) synergy, (iii) 
lowered effective doses, (iv) reduced risk of resistance occurrence and (v) more rapid antifungal effects 
[128, 180, 181]. 
As postulated by the World Health Organization, plants are considered to be excellent sources for 
development of a wide diversity of drugs [14]. In this context, the family of plant defensins is considered 
as a rich source of antifungal peptides, characterized by broad-spectrum activity against plant and 
human fungal pathogens [15, 18, 19, 75]. Some of these peptides display potent activity against 
biofilms of C. albicans [20, 43] and are in general non-toxic to human cells [19, 20]. They have a low 
in vitro frequency of resistance occurrence [19] and possess good in vivo efficacy [21]. In this study we 
focussed on the plant defensin HsAFP1 isolated from Heuchera sanguinea. Besides being 
characterized by antibiofilm activity, HsAFP1 has the ability to act synergistically with amphotericin B 
and caspofungin against planktonic and biofilm cultures, with HsLin06, a linear peptide spanning the 
C-terminal part of HsAFP1, being responsible for both activities [20]. The purpose of the current study 
was to further investigate the synergistic potential of HsLin06 on the caspofungin’s antibiofilm activity 
in view of clinical applications. Therefore we first delineated the minimal amino acid sequence of 
HsLin06 that is responsible for this synergistic activity. To this end, we assessed the activity of a series 
of truncated HsLin06-based peptide variants and the smallest active HsLin06-variant (HsLin06_18) 
was selected for further experiments. Furthermore, after confirming that this peptide was not cytotoxic 
to human cells, its efficacy in combination with caspofungin was assessed against biofilms formed on 
catheters in both in vitro and in vivo setups. Moreover, we investigated the synergistic potential of 
HsLin06_18 with other echinocandins used in the clinic as well the activity spectrum of the [caspofungin 
+ HsLin06_18] combination against different Candida species including the caspofungin-resistant 
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strains. Finally, we further unravelled the mode of action of the [caspofungin-peptide] combination in 
more detail, including a structure-activity relationship study, confocal microscopy-based internalization 
and membrane permeabilization assays. 
5.2 Material and methods 
5.2.1 Strains and reagents 
Following Candida strains were used in this study: C. albicans SC5314 WT [182], C. albicans 
caspofungin-resistant mutant M177 [183], C. dubliniensis NCPF 3949 [184], C. glabrata BG2 [185] and 
C. krusei IHEM 6104 (Belgian Coordinated Collections of Microorganisms, Brussels, Belgium). 
HsLin06_18 cytotoxicity tests were performed on HepG2 cells [142], purchased from ATCC (HB-8065; 
Rockville, USA). 
C. albicans was grown overnight in YPD (1% yeast extract, 2% peptone and 2% glucose), with all 
compounds purchased from LabM (UK). All biofilm experiments were performed in RPMI-1640 medium 
(Roswell Park Memorial Institute-1640 medium; pH 7) with L-glutamine and without sodium 
bicarbonate (purchased from Sigma Aldrich, St Louis, USA), buffered with MOPS (MP Biomedicals 
Europe, France). Caspofungin (cancidas), micafungin (mycamine) and anidulafungin (ecalta) were 
purchased from Merck (UK), Astellas Pharma Europe (The Netherlands) and Pfizer (UK), respectively. 
16-24-mer HsLin06-derived linear peptides (HsLins) were synthesized, according to the Fmoc protocol, 
and purified as described previously [152]. To label HsLin06_18 with the fluorescent dye fluorescein 
(FITC), the resin-bound peptide was elongated with Fmoc-beta-alanine. After removal of the Fmoc 
protection, the N-terminus of the peptide was reacted with FITC to incorporate the label. TFA-mediated 
cleavage of the peptide from the resin and removal of the side chain protecting groups, as well as 
reversed phase HPLC-purification of the labelled peptide was performed as described previously [152]. 
For the in vitro catheter experiments, bovine serum (Sigma Aldrich, USA) was used. The dye propidium 
iodide, used in the flow cytometry and microscopy experiments, was purchased from Sigma Aldrich 
(USA). 
5.2.2 In vitro biofilm inhibition assay in microtiter plates 
The biofilm inhibition assay in polystyrene microtiter plates was performed as described previously 
[20], except for the quantification method. Briefly, Candida cells were incubated at OD600 nm=0.1 in 
RPMI-1640 in round-bottomed microtiter plates (TPP, Tradingen, Switzerland). After 1 h of adhesion 
at 37°C, biofilms were washed and subsequently incubated for 24 h with fresh RPMI-1640 containing 
HsLin and/or an echinocandin [20]. All C. albicans biofilms were quantified by incubating the treated 
biofilms for 1 h at 37°C with 1/100 dilution of the metabolic dye CellTiter-Blue (CTB; Promega, Madison, 
USA) in PBS [20], except for the C. albicans and non-albicans Candida species biofilms in Figure 5, 
which were quantified using XTT. In the latter, 110 µL of a XTT solution (0.25 mg/mL in PBS, 1 µM 
menadione; Sigma Aldrich, USA) was added to the biofilms. After 1 h at 37°C, the absorption  
(OD490 nm) of 100 µL of the converted XTT solution was measured. Next, the Biofilm Inhibitory 
Concentration 50 (BIC50) value, i.e. the concentration of the compound required for 50% biofilm 
formation inhibition, compared to the control treatment (0.5% DSMO), was determined. Checkerboard 
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assays were performed for [echinocandin + HsLin] combinations [20], and the fold change of 
echinocandin’s BIC50 was determined, i.e. the ratio of echinocandin’s BIC50 in the absence/presence 
of the peptide. To test synergistic interactions between two agents against biofilm formation, the 
Fractional Inhibitory Concentration Index (FICI) was calculated [115, 150]. 
5.2.3 Fungicidal activity assay 
Exponentially growing C. albicans SC5314 WT cells were incubated at OD600 nm=1 in RPMI-1640 with 
caspofungin (0.01 µM), HsLin06_18-FITC (4.6 µM) or its combination for 10-40 minutes at 37°C and 
200 rpm. Both at the start and at all measuring points, surviving yeast cells was determined via plating 
assays. In a plating assay, 10-fold dilution series of yeast cells in PBS were prepared, after which  
100 µL was plated on YPD plates. After 1 day of incubation at 37°C, the number of colony forming 
units (CFU) was counted and cell death was calculated relative to time zero (t0). MFC50 values, 
indicating the minimum fungicidal concentration resulting in 50% cell death, were determined. In 
parallel with the plating assay, confocal microscopic or flow cytometric analysis were performed on the 
samples.  
5.2.4 Confocal microscopy 
HsLin06_18 localization studies were performed on C. albicans SC5314 WT cells treated with the 
[caspofungin + HsLin06_18] combination or its corresponding mono treatments, both on planktonic 
and biofilm cultures. In parallel, membrane permeabilization was investigated via the fluorescent dye 
propidium iodide (Pi). For the biofilm setup, biofilms were grown and treated for 24 h with caspofungin 
(0.625 µM), HsLin06_18-FITC (0.5 µM) or its combination, in microtiter plates (as described in the 
material and methods section “in vitro biofilm inhibition assay in microtiter plates”). After a PBS-washing 
step, these biofilms were incubated for 20 minutes at 20°C with 100 µL Pi solution (30 µg/mL Pi in 
PBS). Next, the biofilms were resuspended by up- and down pipetting, after which they were visualized 
by confocal microscopy with the FluoView FV1000 confocal microscope (Olympus IX81) and its 
software. We used a 60x magnification objective and 3.5x computer zoom. The 488 nm laser line of 
the Argon laser was used for visualization of BODIPY and the 559 nm laser for Pi. For the planktonic 
setup, exponentially growing cells were incubated at OD600 nm=1 in RPMI-1640 with caspofungin  
(0.01 µM), HsLin06_18-FITC (4.6 µM) or its combination (as described in the material and methods 
section ‘fungicidal activity assay’), together with Pi (2 µg/mL) for 40 minutes. Next, cells were pelleted 
and concentrated 10-times in PBS, after which they were visualized by confocal microscopy.  
5.2.5 Flow cytometry 
Membrane permeabilization and HsLin06_18 internalization were determined via flow cytometric 
analysis on planktonic C. albicans SC5314 WT cells. Exponentially growing cells were exposed to 
caspofungin (0.01 µM), HsLin06_18-FITC (4.6 µM) or its combination (as described in the material and 
methods section ‘fungicidal activity assay’), and to propidium iodide (Pi) (2 µg/mL), after which they 
were subjected to flow cytometry on a BD InfluxTM cell sorter. Per treatment, 10,000 cells were 
monitored for fluorescence at 530/40 nm (FL2_λex = 488 nm) and 610/20 nm (FL11_ λex = 561 nm) for 
the detection of HsLin06_18-FITC internalization (FITC+) and membrane permeabilization (Pi+), 
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respectively. Data from cells treated with 4.6 µM HsLin06_18-FITC were used as background signal. 
5.2.6 In vitro biofilm inhibition assay on catheters 
Polyurethane catheters, overnight incubated in bovine serum, were infected with C. albicans or  
C. glabrata cells (5×104 cells/mL) in RPMI-1640 medium [186]. After an adhesion phase (90 minutes 
at 37°C), these catheters were washed and subsequently treated with caspofungin (0.4 µM), 
HsLin06_18 (0.5 µM), its combination or control treatment (0.5% DMSO) for 24 h at 37°C, after which 
the number of cells per individual biofilm was determined by CFU [186]. All experiments were 
performed in quadruplicate with at least three biological repeats. 
5.2.7 HsLin06_18 cytotoxicity assays 
Drug cytotoxicity testing was performed as described previously [20]. Briefly, human hepatoma 
(HepG2) cells were treated for 24 h with caspofungin, HsLin06_18, its combination or control treatment 
(1% DMSO). Cell viability was determined by MTT staining (Roche Diagnostics, Germany) and 
expressed relative to the control treatment. All experiments were performed in quadruplicate with at 
least three biological repeats. 
5.2.8 In vivo biofilm inhibition assay 
All animal experiments were in accordance with the KU Leuven animal care guidelines and approved 
by the Ethical Committee of the KU Leuven (P069/2016). In vivo C. albicans biofilms were formed 
inside catheter pieces in immunosuppressed female Sprague–Dawley rats (200 g) as described 
previously [187]. Briefly, serum pre-incubated catheters were infected with C. albicans cells  
(5×104 cells/mL) prepared in RPMI-1640 medium during the adhesion period (90 minutes at 37°C). 
After a washing step, 9 catheter pieces were implanted into the back area of one rat. Inhibition of in 
vivo C. albicans biofilm formation was initiated immediately after the implant. Caspofungin, 
HsLin06_18, the combination or the control (0.9% NaCl and 0.2% DMSO) treatment were administered 
intravenously or subcutaneously (in the surroundings of the catheters), once daily for 7 days. Catheters 
were explanted from euthanized animals and the number of cells per individual biofilm was determined 
by CFU [187]. In vivo experiments were performed once (in total three animals/group). 
5.2.9 Data analysis 
Data were analysed with GraphPad Prism 6. Significant differences were determined on means ± SEM 
with P < 0.05 as considered statistically significant. For the in vitro biofilm inhibition assay in microtiter 
plates, significance between the caspofungin and the [caspofungin + HsLin] combination treatment 
was determined via unpaired student t-tests on BIC50 ± SEM values. For the kinetic experiments, the 
first time point at which HsLin06_18-FITC internalization and/or membrane permeabilization are 
significantly different from t0 were determined via two-way ANOVA followed by Dunnett multiple 
comparison for each treatment. For the flow cytometric experiments on WT and fks1 mutant cells, 
significant differences in the size of the subpopulations between both strains, were determined via two-
way ANOVA followed by Sidak multiple comparison for each treatment. For the in vitro and in vivo 
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[caspofungin + HsLin06_18] combination test on catheters, CFUs and 95% confidence intervals (CI) 
values were analysed for all treatments via one-way ANOVA followed by Tukey multiple comparison, 
while for the in vitro and in vivo caspofungin test on catheters, CFUs ± SEM values of all caspofungin 
concentrations were analysed relative to the control treatment via one-way ANOVA followed by 
Dunnett multiple comparison. For the cytotoxicity test, HepG2 cell viability was analysed for all tested 
concentrations via one-way ANOVA followed by Tukey multiple comparison.  
5.3 Results 
5.3.1 Different regions in HsLin06 are responsible for antibiofilm and synergistic activity with 
caspofungin  
In previous studies we showed that the antifungal plant defensin HsAFP1 is characterized by antibiofilm 
activity and by synergistic activity with caspofungin against C. albicans biofilms [20]. By scanning the 
entire HsAFP1 sequence with six 24-mer linear peptides, the C-terminal part of HsAFP1 
(corresponding to HsLin06) was identified as the region important for HsAFP1’s antibiofilm activity and 
synergy with caspofungin. Here, we tested a series of 44 HsLin06-variants (HsLin06_01-44) with  
N- or C-terminal truncations of the HsLin06 amino acid sequence, ranging from 16-23 amino acids 
(Table 1). Their antibiofilm activity in microtiter plates was evaluated by determining BIC50 values, i.e. 
the minimal peptide concentration resulting in inhibition of 50% biofilm formation. Their potential to 
increase the antibiofilm activity of caspofungin against C. albicans biofilms was evaluated by comparing 
the reduction of the BIC50 of caspofungin in the presence and absence of the HsLin06-variant, 
represented as fold change values (Table 1). Note that we only used sub-inhibitory peptide 
concentrations that maximally inhibited C. albicans biofilm formation by 20%. 
We found that none of the tested HsLin06-variants was characterized by significantly better antibiofilm 
activity than HsLin06. Equally potent antibiofilm activity was found for 17 HsLin06-variants (light grey 
in Table 1), whereas 27 HsLin06-variants performed worse than HsLin06. In addition, we found that 
five HsLin06-variants, namely HsLin06_02/06/10/13 and HsLin06_18 (dark grey in Table 1), reduced 
the BIC50 of caspofungin by approx. 10-fold irrespective whether they displayed potent or less potent 
antibiofilm activity on their own (quantified by their BIC50 values), with HsLin06_18 being the shortest 
active peptide (containing 19 amino acids). With respect to production costs, smaller peptides are most 
interesting. Therefore HsLin06_18 was selected as the best peptide that increased caspofungin’s 
antibiofilm activity.  
Figure 1: HsAFP1 core regions responsible for prevention of Candida albicans biofilm formation (red box) and synergy 
with caspofungin (blue box), identified by screening HsLin06-variants (Table 1) for both activities. Both regions are 
situated within the γ-core of plant defensins (yellow box). Grey regions represent conserved amino acids among plant defensins.  
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To test whether HsLin06_18 acts synergistically with caspofungin against biofilms, corresponding FICI 
values were determined (Supplementary Table S1). For 0.5 µM and 0.25 µM HsLin06_18, FICI values 
were lower than 0.5, pointing to its synergistic interaction with caspofungin against C. albicans biofilms. 
Table 1: Candida albicans biofilm formation inhibition of HsLin06-variants alone or in combination with caspofungin, 
using microtiter plates e 
   HsLin alone 
Caspofungin + 
HsLin  
Name #aaa Sequenceb BIC50c HsLin (µM) Fold changed 
HsLin06 24 0.53 2.56 
HsLin06_01 23 0.71 4.98 
HsLin06_02 23 0.56 10.62 
HsLin06_03 22 0.56 2.52 
HsLin06_04 22 0.38 1.01 
HsLin06_05 22 0.46 2.47 
HsLin06_06 21 1.16 11.14 
HsLin06_07 21 0.50 1.16 
HsLin06_08 21 0.48 1.22 
HsLin06_09 21 >2 7.99 
HsLin06_10 20 0.84 12.49 
HsLin06_11 20 0.78 1.09 
HsLin06_12 20 0.71 1.17 
HsLin06_13 20 >2 12.15 
HsLin06_14 20 >2 3.65 
HsLin06_15 19 0.90 1.04 
HsLin06_16 19 1.03 1.72 
HsLin06_17 19 >2 1.49 
HsLin06_18 19 >2 10.42 
HsLin06_19 19 >2 3.15 
HsLin06_20 19 >2 1.44 
HsLin06_21 18 >2 1.49 
HsLin06_22 18 0.63 4.37 
HsLin06_23 18 1.11 2.06 
HsLin06_24 18 >2 5.36 
HsLin06_25 18 >2 5.83 
HsLin06_26 18 1.52 5.31 
HsLin06_27 18 >2 2.01 
HsLin06_28 17 2.01 1.55 
HsLin06_29 17 0.95 1.73 
HsLin06_30 17 0.80 2.58 
HsLin06_31 17 >2 6.96 
HsLin06_32 17 >2 3.10 
HsLin06_33 17 >2 7.22 
HsLin06_34 17 >2 2.72 
HsLin06_35 17 >2 3.34 
HsLin06_36 16 1.01 1.92 
HsLin06_37 16 1.52 1.50 
HsLin06_38 16 0.66 2.21 
HsLin06_39 16 >2 3.99 
HsLin06_40 16 >2 3.79 
HsLin06_41 16 >2 2.85 
HsLin06_42 16 >2 2.96 
HsLin06_43 16 >2 2.96 
HsLin06_44 16 >2 2.03 
a #aa, number of amino acids. 
b Sequence, amino acid sequence of the HsLin06-variants (full HsAFP1 sequence showed in Figure 1) in which X = α-ABA. 
c BIC50 values, i.e. the minimum inhibitory concentration resulting in 50% biofilm inhibition compared to the control treatment. 
d Fold change values, i.e. the reduction of the BIC50 of caspofungin by co-incubation with HsLin06 or HsLin06-variants. 
e HsLin06-variants with a similar BIC50 as HsLin06 (0.5 * BIC50(HsLin06) < BIC50(HsLin) < 2 * BIC50(HsLin06)) are marked in 
light grey. Fold change values larger than 10 (i.e. 10-fold improvement of caspofungin’s antibiofilm activity) are marked in dark 
grey. HsLin06_18, the smallest HsLin06-variant with fold change values > 10, is marked in bold. Data are means for n = 3 
independent experiments. 
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Based on all the data in Table 1, we delineated the core sequence of HsAFP1 for antibiofilm activity 
as GACHYQFPSVKCFCKR (Figure 1, boxed in red) and for increased antibiofilm activity in 
combination with caspofungin as AYGGACHYQFPSVKCFC (Figure 1, boxed in blue), with cysteines 
being replaced by X=α-ABA in all HsLins. Both core sequences are only partially overlapping 
(GACHYQFPSVKCFC), suggesting that both activities contained in HsLin06 are not fully linked. 
However, both regions are still situated in the γ-core region, which is a region that is important for the 
antifungal activity of many plant defensins [56, 156]. 
5.3.2 Structure-activity relationship study of HsLin06_18  
To get more insight into the structure-activity relationship of HsLin06_18, we performed a full alanine 
scan of HsLin06_18, resulting in 19 HsLin06_18-variants (HsLin06_18_01-19), which were 
subsequently tested for their antibiofilm activity in combination with caspofungin (Table 2). None of the 
amino acid replacements in HsLin06_18 resulted in an abolishment of its activity in combination with 
caspofungin. Moreover, the fold change values of all peptides were in the same range, indicating that 
the exact amino acid sequence of HsLin06_18 seems not that important. 
Table 2: Candida albicans biofilm formation inhibition of HsLin06_18-variants in combination with caspofungin, in an 
in vitro microtiter plate assaya  
  
Caspofungin + 
HsLin 
Name Sequence Fold changeb 
HsLin06_18 FAYGGAXHYQFPSVKXFXK 7.49 
HsLin06_18_01 AAYGGAXHYQFPSVKXFXK 5.91 
HsLin06_18_02 FGYGGAXHYQFPSVKXFXK 8.99 
HsLin06_18_03 FAAGGAXHYQFPSVKXFXK 6.63 
HsLin06_18_04 FAYAGAXHYQFPSVKXFXK 7.66 
HsLin06_18_05 FAYGAAXHYQFPSVKXFXK 5.54 
HsLin06_18_06 FAYGGGXHYQFPSVKXFXK 7.70 
HsLin06_18_07 FAYGGAAHYQFPSVKXFXK 7.65 
HsLin06_18_08 FAYGGAXAYQFPSVKXFXK 5.03 
HsLin06_18_09 FAYGGAXHAQFPSVKXFXK 5.66 
HsLin06_18_10 FAYGGAXHYAFPSVKXFXK 8.18 
HsLin06_18_11 FAYGGAXHYQAPSVKXFXK 4.90 
HsLin06_18_12 FAYGGAXHYQFASVKXFXK 4.75 
HsLin06_18_13 FAYGGAXHYQFPAVKXFXK 11.72 
HsLin06_18_14 FAYGGAXHYQFPSAKXFXK 5.89 
HsLin06_18_15 FAYGGAXHYQFPSVAXFXK 7.07 
HsLin06_18_16 FAYGGAXHYQFPSVKAFXK 6.17 
HsLin06_18_17 FAYGGAXHYQFPSVKXAXK 7.22 
HsLin06_18_18 FAYGGAXHYQFPSVKXFAK 6.31 
HsLin06_18_19 FAYGGAXHYQFPSVKXFXA 6.65 
HsLin06_18_20 FAYGGACHYQFPSVKXFCK 1.97 
HsLin06_18_21 FAYGGAXHYQFPSVKCFCK NSc 
HsLin06_18_22 FAYGGACHYQFPSVKCFXK 1.77 
a Amino acid replacements in HsLin06_18_01-19, as compared to HsLin06_18, are marked in bold. Amino acid replacements 
resulting in elevated activity are boxed in grey. Cysteines involved in disulphide bridges for cyclization are underlined for 
HsLin06_18_20-22. Data are means for n ≥ 2 independent experiment.  
b Fold change values represent the reduction of the BIC50, i.e. the minimum inhibitory concentration resulting in 50% biofilm 
inhibition compared to the control treatment, of caspofungin by co-incubation with HsLin06_18 or HsLin06_18-variants. 
c NS, not synthesized. 
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5.3.3 Effect of HsLin06_18 on the antibiofilm activity of other echinocandins 
Besides caspofungin, other echinocandins such as micafungin and anidulafungin are used in the clinic 
to treat patients suffering from invasive fungal infections [188]. Therefore, we examined the effect of 
HsLin06_18 on anidulafungin’s and micafungin’s antibiofilm activity. We found that HsLin06_18 
significantly increased the antibiofilm activity of anidulafungin (Figure 2B and Supplementary Table 
S2). Although increased antibiofilm activity of micafungin in combination with HsLin06_18 was 
observed (Figure 2C), this effect was not significant, as the BIC50 value of micafungin was not 
significantly decreased in the presence of HsLin06_18 (Supplementary Table S2). Therefore, the 
[caspofungin + HsLin06_18] combination was selected as the best combination to inhibit C. albicans 
biofilm formation and used for further experiments in this study. 
5.3.4 Sub-inhibitory caspofungin doses facilitate HsLin06_18 internalization  
To get more insight in the mode of action of the [caspofungin + HsLin06_18] combination, we 
investigated peptide internalization and membrane permeabilization of treated C. albicans cells. Our 
recent results show that HsAFP1-derived peptides, in contrast to native HsAFP1, are not internalized 
by yeast cells nor possess antifungal activity [189]. Therefore, we investigated whether caspofungin 
increased HsLin06_18’s internalization in C. albicans biofilm cells using N-terminally FITC-labelled 
HsLin06_18, which is equally potent than unlabelled HsLin06_18 (data not shown). We treated  
C. albicans biofilms with HsLin06_18-FITC in the absence or presence of caspofungin and visualized 
the biofilm cells with confocal microscopy. In addition, to correlate HsLin06_18-FITC internalization 
with yeast cell death, the biofilm cells were co-stained with the red fluorescent dye propidium iodide 
(Pi), staining cells with permeabilized membranes (and thus dead). Only C. albicans biofilm cells that 
received the [caspofungin + HsLin06_18-FITC] combination were characterized by green and red 
fluorescence indicating that they internalized the peptide and had compromised membranes  
(Figure 3). Biofilm-specific hyphal cells were apparent in the biofilms treated with sub-inhibitory 
caspofungin or HsLin06_18-FITC doses, while no hyphal cells were found in the biofilms treated with 
the [caspofungin + HsLin06_18-FITC] combination. Next we examined whether the [caspofungin + 
HsLin06_18-FITC] combination is also active against planktonic C. albicans cells. First, we determined 
the minimal doses of caspofungin and HsLin06_18-FITC that result in killing of exponentially grown  
C. albicans as [0.01 µM caspofungin + 4.6 µM HsLin06_18-FITC]. In line with the biofilm results, 
HsLin06_18-FITC internalization and membrane permeabilization occurred only in planktonic  
C. albicans cells that were treated with the [0.01 µM caspofungin + 4.6 µM HsLin06_18-FITC] 
combination and not when treated with caspofungin or HsLin06_18-FITC alone. 
 
 
 
 
 
 
Figure 2: The [echinocandin + HsLin06_18] combination affects Candida albicans biofilms, determined in an in vitro microtiter plate assay. Dose-response curves of the echinocandin (caspofungin 
(A), anidulafungin (B) and micafungin (C)) are presented with different colours for different HsLin06_18 concentrations; orange = 1.25 µM, red = 0.313 µM, blue = 0.156 µM and black = 0 µM HsLin06_18. 
Black arrows represent the HsLin06_18’s potentiation effect on echinocandin’s action, i.e. the shift of the echinocandin concentration needed for 50% reduction of metabolic activity between the echinocandin 
and the [echinocandin + 1.25 µM HsLin06_18] treatment. Data are means ± SEM for n = 3 independent experiments.
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Figure 3: HsLin06_18-FITC uptake and membrane permeabilization in Candida albicans biofilms treated with the 
[caspofungin + HsLin06_18-FITC] combination. Confocal microscope images of 24 h-treated C. albicans biofilms with  
0.625 µM caspofungin (CAS) and/or 0.5 µM HsLin06_18-FITC (HsLin-FITC) and 30 µg/mL propidium iode (Pi). Bar: 5 µm. 
To study the relationship between HsLin06_18 internalization and membrane permeabilization in more 
detail, we monitored the kinetics of treated planktonic C. albicans cells every 10 minutes via flow 
cytometry (Figure 4 and Supplementary Figure S1). Our flow cytometric data revealed  
4 subpopulations: (i) intact cells with HsLin06_18_FITC associated to their surface or internalized (HsL-
F) (Pi-/HsL-F+; black curve), (ii) cells with compromised membranes, but without HsLin06_18_FITC 
associated to their surface or internalized (Pi+/HsL-F-/; grey curve), (iii) cells with compromised 
membranes and HsLin06_18_FITC associated to their surface or internalized (Pi+/HsL-F+; orange 
curve) and (iv) intact cells without HsLin06_18_FITC associated to their surface or internalized  
(Pi-/HsL-F-; not presented) (Figure 4). Only for the C. albicans cells that received the [caspofungin + 
HsLin06_18-FITC] combination, the population of cells that internalized or accumulated the peptide at 
the cell surface and had compromised membranes was significantly increased after 20 minutes  
(P = 0.0168) and this population was increasing over time (Figure 4c). This treatment also resulted in 
a significantly increased population of cells with only compromised membranes (P = 0.0182). However, 
over time, this population (approx. 13%) remained constant. In the case of treatment with HsLin06_18-
FITC alone, a (small) population of cells (approx. 5%) appeared after 30 minutes of incubation that had 
only internalized or accumulated the peptide at the cell surface (P = 0.0482) (Figure 4A). In the case 
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of treatment with caspofungin alone, the population of cells with compromised membranes was not 
significantly increased after 40 minutes (Figure 4B). Overall, these data indicate that membrane 
permeabilization occurs only by the [caspofungin + HsLin06_18-FITC] combination and this event 
appears simultaneously with HsLin06_18-FITC internalization. 
In addition, we determined the caspofungin dose that results in a similar fungicidal activity as that of 
the [caspofungin (0.01 µM) + HsLin06_18-FITC (4.6 µM)] combination. We found that upon 40 minutes 
of treatment, 80% of the population treated with the combination was dead as determined via plating 
assays (Supplementary Figure S2A), whereas concentrations up to 50 µM of caspofungin alone only 
resulted in 30% cell death (Supplementary Figure S2B). These data point to superior and fast 
fungicidal activity of the [caspofungin (0.01 µM) + HsLin06_18-FITC (4.6 µM)] combination against  
C. albicans planktonic cultures as compared to caspofungin alone, even when caspofungin is applied 
at 5,000-fold higher doses.  
5.3.5 The [caspofungin + HsLin06_18] combination affects biofilms of various non-albicans Candida 
species and a resistant C. albicans mutant 
Fungal infections caused by non-albicans Candida species are rising [7, 8, 178, 179]. Therefore, we 
tested the [caspofungin + HsLin06_18] combination against biofilm formation of C. dubliniensis,  
C. krusei and C. glabrata. We found that HsLin06_18 significantly increased the antibiofilm activity of 
caspofungin against all tested Candida species (Figure 5 and Supplementary Table S3). Similar to  
C. albicans, the BIC50 of caspofungin was reduced by approx. 5-10-fold in combination with 
HsLin06_18 against all tested Candida species. Together, these data point to a broad-spectrum 
superior antibiofilm activity of the [caspofungin + HsLin06_18] combination. 
Echinocandins are the recommended drug to treat invasive fungal infections [190]. However, in many 
settings such as prolonged and/or repeated drug exposure, fungal cells can acquire resistance 
resulting in therapeutic failure [191]. Using a caspofungin-resistant strain with mutations in Fks1, the 
caspofungin target, we tested the activity of the [caspofungin + HsLin06_18] combination. Although 
the BIC50 value of caspofungin was increased in the fks1 mutant, HsLin06_18 could still increase the 
antibiofilm activity of caspofungin in a synergistic way (FICI values for 5 µM and 2.5 µM  
HsLin06_18 < 0.5) (Supplementary Table S4). These data indicate that HsLin06_18 acts synergistically 
with caspofungin against biofilms of caspofungin-resistant C. albicans mutants. 
 
  
 
 
 
 
Figure 4: Kinetics of HsLin06_18-FITC uptake and membrane permeabilization in planktonic Candida albicans cells treated with 0.01 µM caspofungin (CAS) and/or 4.6 µM HsLin06_18-FITC 
(HsL-F) and 2 µg/mL propidium iodide (Pi), determined via flow cytometry. For all treatments, the % of cells is presented that: only have permeabilized membranes (grey), both have permeabilized 
membranes and HsLin06_18-FITC associated to their surface or internalized (orange) or only HsLin06_18-FITC associated to their surface or internalized (black). The highlighted area represents the 
percentage of yeast survival as compared to t0. Data are means ± SEM for n = 3 independent experiments. To analyse significant differences in the size of the subpopulations between the t0 and other 
time points, one-way ANOVA followed by Dunnett multiple comparison was performed, with brackets (in the colour of the corresponding subpopulation) representing significance for that subpopulation. 
Only the primary time point that is significantly different from t0 is presented, with * representing P < 0.05. 
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Figure 5: The [caspofungin + HsLin06_18] affects (A) Candida albicans, (B) Candida dubliniensis, (C) Candida krusei 
and (D) Candida glabrata biofilms in an in vitro microtiter plate assay, using XTT quantification. Dose-response curves 
of caspofungin are presented, with different colours for different HsLin06_18 concentrations; orange = 1.25 µM, red = 0.313 µM, 
blue = 0.156 µM and black = 0 µM HsLin06_18. Black arrows represent the HsLin06_18’s potentiation effect on caspofungin’s 
action, i.e. the shift of the caspofungin concentration needed for 50% reduction of metabolic activity between the caspofungin 
and the [caspofungin + 1.25 µM HsLin06_18] treatment. Data are means ± SEM for n = 3 independent experiments. 
Using flow cytometry (Supplementary Figure S3), we found that most [caspofungin + HsLin06_18-
FITC]-treated fks1 mutant cells both had internalized the peptide and showed compromised 
membranes (approx. 40%), which is in line with the WT data (Figure 4C). Moreover, also a small but 
substantial subpopulation of cells that only internalized HsLin06_18-FITC or accumulated the peptide 
at the cell surface was present in the fks1 mutants (approx. 8%), while few cells only had permeabilized 
membranes (approx. 0.4%) (Supplementary Figure S3). In contrast to C. albicans WT, the caspofungin 
dose (0.5 µM) alone did not induce membrane permeabilization of the resistant fks1 mutant, as < 0.2% 
of the fks1 mutant cells had permeabilized membranes (Supplementary Figure S3). These results 
indicate that [caspofungin + HsLin06_18] acts in a similar way against C. albicans WT and caspofungin-
resistant strains.  
5.3.6 The [caspofungin + HsLin06_18] combination affects biofilms in an in vitro catheter assay 
As biofilms are often formed on medical devices [172], we examined the activity of the [caspofungin + 
HsLin06_18] combination against C. albicans biofilm formation on serum pre-incubated catheters. To 
this end, C. albicans biofilms, grown on a 1 cm catheter piece, were treated with either caspofungin, 
HsLin06_18, [caspofungin + HsLin06_18] or 0.5% DMSO (control treatment), after which the amount 
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of viable biofilm cells was determined via plating assays. First, the sub-lethal doses of caspofungin and 
HsLin06_18 in this setup were identified as 0.4 µM (Supplementary Figure S4) and 0.5 µM  
(Figure 6A), respectively. Two µM of HsLin06_18 already reduced the amount of viable biofilm cells on 
the catheters by 8-fold. Next, we found that the [caspofungin (0.4 µM) + HsLin06_18 (0.5 µM)] 
combination resulted in a significant (> 98-fold) reduction of viable biofilm cells, compared to the control 
and mono treatments (Figure 6A). In addition, the [caspofungin + HsLin06_18] combination also 
significantly reduced the amount of viable C. glabrata biofilm cells by > 99-fold, compared to the control 
or mono treatments (Figure 6B). Together, these data confirm the superior activity of the [caspofungin 
+ HsLin06_18] combination against Candida biofilms in a setup mimicking in vivo conditions as serum 
pre-incubated catheter pieces were used. 
Figure 6: The [caspofungin (CAS) + HsLin06_18] affects Candida albicans (A) and C. glabrata (B) biofilms in an in vitro 
catheter assay. The amount of the viable biofilm cells on the catheters treated with 0.4 µM CAS, 0.5 µM HsLin06_18, its 
combination or the control (0.5 % DMSO) was determined via CFU counting. Horizontal lines indicate the median values for 
log10 numbers of CFU ± SEM obtained per catheter piece, for n = 3 independent experiments. Significant differences between 
all treatments were determined via one-way ANOVA followed by Tukey multiple comparison, with * representing P < 0.05. 
5.3.7 The [caspofungin + HsLin06_18] combination does not affect human hepatoma cells 
We first investigated potential toxicity of HsLin06_18 on human HepG2 cells. HsLin06_18 was not 
cytotoxic up to 50 µM (which is 100-fold higher than used in the in vitro catheter assay) (Supplementary 
Figure S5). Next, cytotoxicity of the [caspofungin + HsLin06_18] combination was tested against 
HepG2 cells. The EC50, i.e. the half maximal effective concentration, of HsLin06_18 (EC50 > 50 µM) 
was not altered by the presence of caspofungin (up to 41.2 µM, which is 100-fold higher than used in 
the in vitro catheter assay). These results demonstrate non-toxicity of HsLin06_18 on these human 
cells, even in combination with caspofungin. 
5.3.8 The [caspofungin + HsLin06_18] combination reduces Candida albicans biofilms in an in vivo 
setup  
We first tested the fungicidal activity of the [caspofungin + HsLin06_18] combination in serum. In 
contrast to RPMI media, in which the combination reduced cell survival by 80% as compared to the 
control or mono treatments (Supplementary Figure S2), the combination did not reduce cell survival in 
serum (data not shown). As HsLin06_18 might be degraded in serum, HsLin06_18 was further studied 
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in terms of peptide stability. To this end, two strategies were investigated being cyclization of the 
peptide and the use of unnatural amino acids, as such types of peptides are known to be less prone 
to degradation. Cyclic HsLin06_18 was produced by forming one disulphide bridge between two 
cysteine amino acids, marked in grey in Table 2. From all three possible combinations of cysteines, 
HsLin06_18_21 could not be produced as the cysteine residues were too nearby to form a proper 
disulphide bond. The other cyclic peptides HsLin06_18_20 and HsLin06_18_22 were produced and 
screened for synergistic activity with caspofungin. Unfortunately, HsLin06_18_20 nor 22 could improve 
caspofungin’s antibiofilm activity (Table 2), indicating that cyclization is not a good strategy to improve 
HsLin06_18’s stability. Next, we replaced all L-amino acids of HsLin06_18 by D-amino acids, while in 
another peptide (i.e. retro-inverso peptide) both the L-amino acids were replaced by D-amino acids 
and the order of the amino acids was reversed. Both peptides strongly inhibited C. albicans biofilm 
formation (BIC50(HsLin06_18_23) = 0.4 µM and BIC50(HsLin06_18_24) = 0.7 µM) when administered 
alone, while they did not act synergistically with caspofungin (data not shown).  
In conclusion, improving HsLin06_18’s stability either via cyclization or via introduction of unnatural 
amino acids could not be obtained without affecting its activity. Hence, we proceeded with the in vivo 
studies with unmodified linear HsLin06_18 and assessed whether the [caspofungin + HsLin06_18] 
combination exhibits in vivo efficacy using a subcutaneous rat catheter model. First, the sub-lethal 
dose of (intravenously (IV) administered) caspofungin in this setup was identified as 0.25 mg/kg/day 
(Supplementary Figure S6). For the combination treatment, this sub-lethal caspofungin dose was 
supplemented with 2.5 mg/kg/day HsLin06_18 (IV administered). We found that C. albicans biofilm 
formation on catheter pieces in rats receiving the [caspofungin + HsLin06_18] combination was 
significantly reduced as compared to rats receiving the control (Figure 7) and reduced (although not 
significantly) as compared to rats receiving mono treatments (P = 0.2916 and P = 0.1413 for the 
caspofungin and the HsLin06_18 mono treatment, respectively). In a second in vivo experiment, we 
increased the HsLin06_18 dose to 10 mg/kg/day (IV administered) but this did not result in increased 
antibiofilm activity of the combination as compared to mono treatments (data not shown).  
As serum seems to inactivate the peptide in vitro, potential peptide degradation by serum components 
in vivo was circumvented in a third in vivo experiment by subcutaneous instead of intravenous 
administration of the peptide. In addition, we also increased the IV caspofungin dose to 0.5 mg/kg/day. 
In this experiment, C. albicans biofilm formation on catheter pieces in rats receiving the [caspofungin 
+ HsLin06_18] combination was reduced (although not significantly) as compared to catheter pieces 
in rats receiving mono treatments (P = 0.1822 and P = 0.1925 for the caspofungin and the HsLin06_18 
mono treatment, respectively) (Supplementary Figure S7). However, only in rats receiving the 
[caspofungin + HsLin06_18] combination, we observed sterility of some of the catheter fragments. In 
conclusion, the [caspofungin + HsLin06_18] combination reduces C. albicans biofilm formation in vivo, 
but the activity of the peptide seems reduced in these conditions.  
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Figure 7: Effect of intravenous administration of caspofungin (CAS) and HsLin06_18 on Candida albicans biofilm 
formation inhibition, using catheter pieces in a subcutaneous rat catheter model. Rats, containing nine catheter pieces 
each, were treated with 0.25 mg/kg/day CAS, 2.5 mg/kg/day HsLin06_18, its combination or the control (0.9% NaCl and  
0.2% DMSO) for 7 days, after which survival of viable biofilm cells on the catheters was determined via CFU counting. Horizontal 
lines indicate the median values for log10 numbers of CFU and 95% CI obtained per catheter piece, for n = 27 catheter pieces. 
Significant differences between all treatments were determined via one-way ANOVA followed by Tukey multiple comparison, 
with * representing P < 0.05. 
5.4 Discussion 
Only three main classes of antimycotics (azoles, echinocandins and polyenes) are currently used to 
treat fungal infections. Only the echinocandins and liposomal formulations of the polyene amphotericin 
B are effective against fungal biofilm-related infections [11, 12]. Hence, novel approaches to treat 
fungal biofilms are needed. The approach used in this study is a combination treatment, in which two 
compounds with different mode of actions are administrated simultaneously, thereby aiming at 
reducing potential cytotoxic side effects while increasing effectivity [94]. In this study, we investigated 
the combination of caspofungin and linear HsAFP1-derived peptides (HsLins). Plant defensins, such 
as HsAFP1, are characterized by broad-spectrum antifungal activity [18], in vivo efficacy [21] and low 
in vitro frequency of resistance occurrence [19]. Moreover, we recently discovered that HsAFP1 and 
HsLin06, the C-terminal part of HsAFP1, possess antibiofilm activity as well as synergistic activity with 
caspofungin [20]. In this study, we found that both activities are uncoupled and further focussed on 
HsLin06-derived peptides with superior antibiofilm activity in combination with caspofungin. We 
identified HsLin06_18 as the smallest peptide that can reduce the BIC50 of caspofungin against  
C. albicans biofilms at least 10-fold and acts synergistically with caspofungin. Replacing one of the 
amino acids of HsLin06_18 by alanine did not change its superior antibiofilm activity in combination 
with caspofungin, suggesting that the exact amino acid sequence is not very important for this activity. 
The superior antibiofilm activity of the [caspofungin + HsLin06_18] combination is not limited to  
C. albicans, as it was also found against C. dubliniensis, C. krusei and C. glabrata. This points to broad-
spectrum antibiofilm applications of the combination of caspofungin and HsLin06_18. Moreover, 
HsLin06_18’s also increased the antibiofilm activity of other echinocandins, such as anidulafungin. 
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Echinocandin potentiation has been demonstrated before by other peptides, such as colistin and DsS3 
(1-16). Zeidler and colleagues suggested that echinocandins can weaken fungal cell walls, which can 
lead to enhanced fungal membrane targeting of these peptides [161]. In line, Harris and Coote 
demonstrated enhanced DsS3 (1-16) uptake when the peptide was combined with caspofungin or 
anidulafungin [192].  
We recently demonstrated that native HsAFP1 is accumulating at S. cerevisiae’s cell surface before 
being internalized, which is immediately followed by membrane permeabilization [189]. Here, we 
showed that only in the presence of sub-inhibitory caspofungin doses, HsLin06_18 was internalized 
and caused membrane permeabilization of C. albicans cells. We suggest that caspofungin weakens 
fungal cell walls via inhibition of β-1,3-glucan synthase, as was suggested by Zeidler and colleagues 
[161], thereby increasing HsLin06_18’s binding to fungal membranes and subsequently promoting the 
peptide’s uptake. We also showed peptide internalization and membrane permeabilization for 
caspofungin-resistant mutants treated with the [caspofungin + HsLin06_18] combination, pointing to 
its broad activity spectrum. Moreover, as we showed the presence of a subpopulation of fks1 mutant 
cells that only internalized the peptide, we suggest that, in line with HsAFP1 [189], HsLin06_18’s 
internalization is occurring prior to membrane permeabilization. 
Badrane and colleagues recently observed that moderate caspofungin doses rapidly result in elevated 
phosphatidylinositol(4,5)bisphosphate (PI(4,5)P2) levels as well as in the activation of the cell wall 
integrity (CWI) pathway in C. albicans [193]. As the native plant defensin HsAFP1 is known to interact 
with various phospholipids, including PI(4,5)P2 (Chapter 6), increasing the levels of these 
phospholipids by moderate caspofungin doses (both in WT but also in fks1 mutant strains) might result 
in increased, potentially PIP-dependent, peptide internalization. Our preliminary results using 
Differential Scanning Calorimetry (as described in [189]) show indeed that HsLin06_18 can interact 
with lipid vesicles containing PI(4,5)P2 (data not shown), supporting this hypothesis. However, 
additional experiments addressing HsLin06_18-PI(4,5)P2 interactions in vivo need to be performed in 
follow-up studies. 
To mimic clinically relevant conditions [187], we also tested the activity of the combination against  
C. albicans biofilms grown on medical devices such as catheter pieces. We observed that the 
combination of HsLin06_18 and caspofungin significantly reduced C. albicans biofilm formation in vitro 
as compared to the control or mono treatments. Next, we investigated the effect of the combination in 
a subcutaneous rat catheter model, which is a relevant in vivo model for investigating fungal biofilm-
related infections [187]. We found significantly reduced C. albicans biofilm formation on the catheters 
in rats receiving the combination treatment consisting of sub-inhibitory doses of caspofungin  
(0.25 mg/kg/day) and HsLin06_18 (2.5 mg/kg/day) as compared to rats receiving the control treatment. 
As we demonstrated that caspofungin, HsLin06_18 or its combination are not toxic for human 
(hepatoma) cells, higher HsLin06_18 doses (10 mg/kg/day) were used in a second experiment. 
However, increasing the HsLin06_18 dose did not result in increased antibiofilm activity of the 
[caspofungin + HsLin06_18] combination in vivo. Using another HsLin06_18 route of administration in 
rats did also not result in improved antibiofilm activity of the combination, indicating that HsLin06_18 is 
probably not very stable under in vivo conditions. Unfortunately, cyclization of the peptide nor the use 
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of unnatural amino acids could stabilize the peptide without affecting its activity. Whether HsLin06_18 
can be stabilized without affecting its antibiofilm activity needs be investigated further. As we previously 
showed that the plant defensin RsAFP2 is prophylactically effective in mice against candidiasis when 
administered systemically at 7 or 14 mg/kg/day [21], stable plant defensin-derived peptides might be 
effective as well under in vivo conditions. 
5.5 Conclusions 
Plant defensins such as HsAFP1 and its variants, show potential to treat fungal biofilm-related 
infections. In mono treatment, we earlier demonstrated that HsAFP1 and its variants can inhibit  
C. albicans biofilm formation on polystyrene and titanium surfaces, without being toxic to human cells 
[20]. In the present study we show that a combination treatment consisting of HsAFP1 (variants) and 
caspofungin is effective against fungal biofilm formation on polystyrene and catheter substrates in vitro 
and in vivo. Hence, this study clearly indicates that HsAFP1 (variants) have a great potential in broad-
spectrum antifungal/antibiofilm treatments. 
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5.6 Supplementary material 
 
Supplementary Figure S1: Kinetics of HsLin06_18-FITC internalization and membrane permeabilization from  
1 representative experiment on planktonic Candida albicans cells treated with 0.01 µM caspofungin (CAS), 4.6 µM 
HsLin06_18-FITC or [4.6 µM HsLin06_18-FITC + 0.01 µM CAS] and 2 µg/mL propidium iodide (Pi), determined via flow 
cytometry. Percentages shown represent cells from 1 experiment that are FITC+/Pi- (left upper corner), FITC+/Pi+ (right upper 
corner) and FITC-/Pi+ (right lower corner) respectively.  
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Supplementary Figure S2: Cell death induced by (A) the control treatment (Ctr; MQ water), moderate caspofungin (CAS) 
doses and/or HsLin06_18 or (B) high caspofungin doses on planktonic Candida albicans cultures. (a) Survival of  
40 minutes-treated cells was determined via CFU counting and results were expressed relative to t0. (b) The dose-response 
curve of caspofungin on the survival of C. albicans planktonic cells is presented. Results from one representative experiment 
out of 2 are shown.  
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Supplementary Figure S3: HsLin06_18-FITC uptake and membrane permeabilization in planktonic Candida albicans WT 
and fks1 mutant cells, determined via flow cytometry. Cells were treated for 40 minutes with 0.5 µM caspofungin and 46 µM 
HsLin06_18-FITC (HsL-F) and 2 µg/mL propidium iodide (Pi). Following subpopulations are presented: (i) cells that only have 
HsLin06_18-FITC associated to their surface or internalized (HsL-F uptake), (ii) both have permeabilized membranes and 
HsLin06_18-FITC associated to their surface or internalized (HsL-F uptake + membrane permeabilization) or (iii) only have 
permeabilized membranes (membrane permeabilization). Data are means ± SEM, for n = 3 independent experiments. To 
analyse significant differences in the size of the subpopulations between both strains, two-way ANOVA followed by Sidak 
multiple comparison was performed, with * representing P < 0.05. 
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Supplementary Figure S4: Effect of caspofungin on Candida albicans biofilm formation inhibition in vitro on catheter 
pieces. Survival of the viable biofilm-associated cells on the catheters was determined via CFU counting. Horizontal lines 
indicate the median values for log10 numbers of CFU ± SEM obtained per catheter piece, for n = 3 independent experiments. 
Significant differences between the control treatment and all caspofungin treatments were determined via one-way ANOVA 
followed by Dunnett multiple comparison, with * representing P < 0.05. 
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Supplementary Figure S5: HsLin06_18 does not affect HepG2 cell viability. HepG2 cells were treated with HsLin06_18 
(0.09 µM – 50 µM) or control treatment (1% DMSO) for 24 h. Cell viability was determined by MTT staining and results were 
expressed relative to the control treatment. Data are means ± SEM of n = 4 independent experiments. Significant differences 
between all treatments were determined via one-way ANOVA followed by Tukey multiple comparison, with * representing  
P < 0.05. 
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Supplementary Figure S6: Effect of intravenous administration of caspofungin on Candida albicans biofilm formation 
inhibition, using catheter pieces in a subcutaneous rat catheter model. Rats, containing nine catheters each, were treated 
with 0-1 mg/kg/day caspofungin for 7 days, after which survival of viable biofilm-associated cells on the catheters was determined 
via CFU counting. Horizontal lines indicate the median values for log10 numbers of CFU and 95% CI obtained per catheter piece, 
for n = 18 catheter pieces. Significant differences between the control treatment and all caspofungin treatments were determined 
via one-way ANOVA followed by Dunnett multiple comparison, with * representing P < 0.05. 
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Supplementary Figure S7: Effect of intravenous and subcutaneous administration of caspofungin (CAS) and 
HsLin06_18, respectively, on Candida albicans biofilm formation inhibition, using catheter pieces in a subcutaneous 
rat catheter model. Rats, containing nine catheter pieces each, were treated with caspofungin (0.5 mg/kg/day), HsLin06_18 
(10 mg/kg/day), [caspofungin (0.5 mg/kg/day) + HsLin06_18 (10 mg/kg/day)] or control (Ctr; 0.9% NaCl and 0.2% DMSO) 
treatment for 7 days, after which survival of viable biofilm-associated cells on the catheters was determined via CFU counting. 
Horizontal lines indicate the median values for log10 numbers of CFU and 95% CI obtained per catheter piece, for n = 27 catheter 
pieces. Significant differences between all treatments were determined via one-way ANOVA followed by Tukey multiple 
comparison, with * representing P < 0.05. 
Supplementary Table S1: FICI values of the combination treatment of HsLin06_18 with caspofungin on Candida 
albicans biofilms, in an in vitro microtiter plate assay b 
Treatment [HsLin06_18] (µM) FICI a 
Caspofungin 0  
Caspofungin + HsLin06_18 0.5 0.37 
 0.25 0.31 
 0.13 0.67 
 0.06 0.70 
 0.03 1.13 
 0.02 0.88 
a FICI, Fractional Inhibitory Concentration Index. FICI ≤ 0.5 indicates synergy between HsLin06_18 and caspofungin (marked in 
bold).  
b Data are means for n = 3 independent experiments. 
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Supplementary Table S2: Potentiation activity of HsLin06_18 with different echinocandins: caspofungin, anidulafungin 
and micafungin on Candida albicans biofilms, in an in vitro microtiter plate assay 
Treatment BIC50 (echinocandin) (µM) ± SEM a P-value b 
Caspofungin 0.96 ± 0.040  
Caspofungin + 1.25 µM HsLin06_18 0.11 ± 0.046 0.0002 
Anidulafungin 0.93 ± 0.120   
Anidulafungin + 1.25 µM HsLin06_18 0.38 ± 0.146 0.0449 
Micafungin 0.40 ± 0.088   
Micafungin + 1.25 µM HsLin06_18 0.17 ± 0.040 0.0791 
a BIC50 values, i.e. the minimum inhibitory concentration resulting in 50% biofilm inhibition compared to the control treatment 
for n = 3 independent experiments.  
b Significant differences between the mono treatment with an echinocandin and the combination treatment with the echinocandin 
and HsLin06_18 were determined via an unpaired student t-test, with P < 0.05 as considered significantly different (marked in 
bold). 
Supplementary Table S3: Potentiation activity of HsLin06_18 with caspofungin (CAS) on biofilms of various Candida 
strains, in an in vitro microtiter plate assay  
Strain Treatment BIC50 (CAS) (µM) ± SEM a P-value b 
Candida albicans CAS 0.70 ± 0.092   
 CAS + 1.25 µM HsLin06_18 0.11 ± 0.009 0.0029 
Candida dubliniensis  CAS 0.92 ± 0.017  
 CAS + 1.25 µM HsLin06_18 0.09 ± 0.009 < 0.0001 
Candida krusei CAS 1.09 ± 0.012  
 CAS + 1.25 µM HsLin06_18 0.30 ± 0.022 < 0.0001 
Candida glabrata CAS 1.00 ± 0.115  
 CAS + 1.25 µM HsLin06_18 0.15 ± 0.033 0.0020 
a BIC50 values, i.e. the minimum inhibitory concentration resulting in 50% biofilm inhibition compared to the control treatment 
for n = 3 independent experiments.  
b Significant differences between the mono treatment with caspofungin and the combination treatment with caspofungin and 
HsLin06_18 were determined via an unpaired student t-test, with P < 0.05 as considered significantly different (marked in bold). 
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Supplementary Table S4: FICI values of the combination treatment of HsLin06_18 with caspofungin (CAS) on Candida 
albicans WT and fks1 mutant (mut), in an in vitro microtiter plate assay  
Strain Treatment [HsLin06_18] (µM) BIC50 (CAS) (µM) ± SEM a P-value b FICI c 
WT CAS 0 0.83 ± 0.096   
 CAS + HsLin06_18 5 0.09 ± 0.009 < 0.0001 1.10 
  2.5 0.10 ± 0.009 < 0.0001 0.61 
  1.25 0.11 ± 0.010  < 0.0001 0.38 
  0.63 0.13 ± 0.009 < 0.0001 0.28 
  0.31 0.30 ± 0.093 < 0.0001 0.40 
  0.16 0.43 ± 0.039 < 0.0001 0.54 
fks1 mut CAS 0 7.40 ± 1.361   
 CAS + HsLin06_18 5 1.5 ± 1.181 0.0001 0.31 
  2.5 2.58 ± 0.043 0.0014 0.40 
  1.25 3.68 ± 0.654 0.0158 0.52 
  0.63 4.01 ± 0.417 0.0308 0.55 
  0.31 4.81 ± 0.608 0.1376 0.66 
  0.16 4.93 ± 0.519 0.1680 0.67 
a BIC50 values, i.e. the minimum inhibitory concentration resulting in 50% biofilm inhibition compared to the control treatment 
for n = 3 independent experiments.  
b Significant differences between the mono treatment with caspofungin and the combination treatment with caspofungin and 
HsLin06_18 were determined via an unpaired student t-test, with P < 0.05 as considered significantly different (marked in bold). 
c FICI, Fractional Inhibitory Concentration Index. FICI ≤ 0.5 indicate synergy between HsLin06_18 and caspofungin (marked in 
bold).  
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5.7 Additional data 
We demonstrated that HsLin06_18 acts synergistically with caspofungin against C. albicans biofilm 
formation in RPMI media, but not in the presence of serum. This can be due to negatively charged 
proteins, such as albumins, and/or proteases, which are present in serum. Here, we investigated which 
of these serum components is responsible for the loss of HsLin06_18’s synergistic activity with 
caspofungin against C. albicans biofilm formation. At first, the effect of albumins on HsLin06_18’s 
activity was investigated by using RPMI media supplemented with Bovine Serum Albumin (BSA). We 
found that HsLin06_18 could no longer increase caspofungin’s antibiofilm activity in the presence of 
BSA (Supplementary Figure S8A-B); the synergy between caspofungin and HsLin06_18 was 
completely abolished. These data indicate that HsLin06_18 probably binds to BSA, thereby negatively 
affecting its activity. As BSA completely abolished the synergy between caspofungin and HsLin06_18, 
we did not further investigate the effect of serum proteases. 
A common strategy to improve the efficacy of peptides in vivo, without affecting their biological activity, 
is peptide PEGylation. PEGylation is well-known to stabilize peptides, thereby reducing their 
degradation by proteases leading to increased half-lives in vivo [194, 195]. As PEGylation increases 
solubility of peptides as well as shields its surface [196], this modification can decrease peptide-
albumin interactions. Therefore, we tested whether PEGylation of HsLin06_18 could disrupt potential 
HsLin06_18-albumin interactions without affecting the synergy between caspofungin and HsLin06_18 
against C. albicans biofilm formation. To this end, 6 different PEGylated HsLin06_18 peptides were 
produced, all having 1 or 2 PEG molecules that either consisted of 11 or 27 C-atoms attached to their 
C- and/or N-terminus (HsLin06_18-P1-6; Supplementary Table S5). These PEGylated peptides were 
tested in RPMI and in BSA-supplemented RPMI. Our preliminary data indicate that all  
HsLin06_18-P1-6 were even more active than non-PEGylated Hsin06_18 in the absence of BSA 
(Supplementary Table S5). However, in BSA-supplemented RPMI, neither HsLin06_18 nor the 
PEGylated variants (HsLin06_18-P1-2) could increase caspofungin’s antibiofilm activity against  
C. albicans (Supplementary Figure S8). 
Next we assessed whether the activity of native HsAFP1 is influenced by serum albumins. Our 
preliminary data indicate that HsAFP1, in contrast to HsLin06_18, was still active in BSA-supplemented 
RPMI (albeit to a lesser extent than in RPMI) (Supplementary Figure S9). These data indicate that 
native plant defensins can still be effective in vivo, as was previously demonstrated for native RsAFP2 
[20].  
In conclusion, our data show that in the presence of negatively-charged BSA, HsLin06_18 cannot 
increase caspofungin’s antibiofilm activity against C. albicans in vitro. Moreover, this negative effect of 
BSA on HsLin06_18’s potentiation activity cannot be prevented by PEGylation of HsLin06_18. In 
addition, we show that HsAFP1’s capacity to increase the antibiofilm activity of caspofungin was only 
partially abolished in the presence of BSA, pointing to its in vivo potential (as discussed further in 
Chapter 9). 
 
   
 
 
Supplementary Figure S8: PEGylation of HsLin06_18 did not increase caspofungin’s antibiofilm activity against Candida albicans in albumin-supplemented RPMI. Antibiofilm tests were performed 
in (A, C, E) RPMI or (B, D, F) RPMI + 40 mg/mL BSA. The PEGylated peptides tested were HsLin06_18-P1 and HsLin06_18-P2 (Supplementary Table S5). Dose-response curves of caspofungin are presented 
with different colours for different HsLin06_18(-P) concentrations; orange = 1.25 µM, red = 0.313 µM, blue = 0.156 µM and black = 0 µM HsLin06_18. Black arrows represent the HsLin06_18(-P)’s potentiation 
effect on caspofungin’s action, i.e. the shift of the caspofungin concentration needed to obtain 50% reduction of metabolic activity between the caspofungin and the [caspofungin + 1.25 µM HsLin06_18(-P)] 
treatment. Data are from one experiment. 
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Supplementary Table S5: Candida albicans biofilm formation inhibition of PEGylated HsLin06_18-variants in 
combination with caspofungin in RPMI, using microtiter plates a  
  Caspofungin + HsLin 
Name Sequence Fold change b 
HsLin06_18               FAYGGAXHYQFPSVKXFXK 4.09 
HsLin06_18_P1 PEG11- FAYGGAXHYQFPSVKXFXK-PEG11 6.92 
HsLin06_18_P2 PEG27- FAYGGAXHYQFPSVKXFXK-PEG27 11.25 
HsLin06_18_P3               FAYGGAXHYQFPSVKXFXK-PEG11 8 
HsLin06_18_P4               FAYGGAXHYQFPSVKXFXK-PEG27 8 
HsLin06_18_P5 PEG11- FAYGGAXHYQFPSVKXFXK 14.55 
HsLin06_18_P6 PEG27- FAYGGAXHYQFPSVKXFXK 7.04 
a PEGylation of the C- and/or N-terminus of HsLin06_18 with PEG molecules containing 11 or 27 C-atoms. Data are from n = 1 
experiment.  
b Fold change values represent the reduction of the BIC50, i.e. the minimum inhibitory concentration resulting in 50% biofilm 
inhibition compared to the control treatment, of caspofungin by co-incubation with HsLin06_18 or PEGylated  
HsLin06_18-variants. 
 
Supplementary Figure S9: HsAFP1 can still increase caspofungin’s antibiofilm activity against Candida albicans in the 
presence of albumin, while HsLin06_18 cannot. Antibiofilm tests were performed in (A, C) RPMI or (B, D) RPMI + 40 mg/mL 
BSA. Dose-response curves of caspofungin are presented with different colours for (A, B) different HsLin06_18 concentrations; 
green = 5 µM, yellow = 2.5 µM, orange = 1.25 µM and black = 0 µM or (C, D) different HsAFP1 concentrations; blue = 8.4 µM, 
purple = 4.2 µM, pink = 2.1 µM and black = 0 µM. Black arrows represent the HsLin06_18/HsAFP1’s potentiation effect on 
caspofungin’s action, i.e. the shift of the caspofungin concentration needed to obtain 50% reduction of metabolic activity between 
the caspofungin and the [caspofungin + 5 µM HsLin06_18 or 8.4 µM HsAFP1] treatment. Data are from one experiment.
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6 The antifungal plant defensin HsAFP1 is a 
phosphatidic acid-interacting peptide5  
                                                     
5 This chapter is part of a published article in Frontiers in Microbiology as: 
Cools, T.L., Vriens, K., Struyfs, C., Verbandt, S., Ramada, M.H.S., Brand, G.D., Bloch, C., 
Koch, B., Traven, A., Drijfhout, J.W., Demuyser, L., Kucharikova, S., Van Dijck, P., Spasic, D., 
Lammertyn, J., Cammue, B.P.A. and Thevissen, K. (2017) The antifungal plant defensin 
HsAFP1 is a phosphatidic acid-interacting peptide. Frontiers in Microbiology. DOI: 
10.3389/fmicb.2017.02295 
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Contributions of individual authors to the manuscript ‘The antifungal plant defensin HsAFP1 is 
a phosphatidic acid-interacting peptide inducing membrane permeabilization’: 
This study was coordinated by BPAC and KT. Lipid overlay assay were performed by TLC and CS, 
rELISA assays and flow cytometry experiments were performed by TLC, HsLin peptides were 
synthesized by JWD, vesicle assays were performed by TLC, MHSR, GDB and CB, confocal 
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Abstract 
HsAFP1, a plant defensin isolated from coral bells (Heuchera sanguinea), is characterized by broad-
spectrum antifungal activity. Previous studies indicated that HsAFP1 binds to specific fungal 
membrane components, which had hitherto not been identified, and induces mitochondrial dysfunction 
and cell membrane permeabilization. In this study, we show that HsAFP1 reversibly interacts with the 
membrane phospholipid phosphatidic acid (PA), which is a precursor for the biosynthesis of other 
phospholipids, and to a lesser extent with various phosphatidylinositolphosphates (PIP’s). Moreover, 
via reverse ELISA assays we identified two basic amino acids in HsAFP1, namely histidine at position 
32 and arginine at position 52, as well as the phosphate group in PA as important features enabling 
this interaction. Using a HsAFP1 variant, lacking both amino acids (HsAFP1[H32A][R52A]), we showed 
that, as compared to the native peptide, the ability of this variant to bind to PA and PIP’s is reduced  
(≥ 74%) and the antifungal activity of the variant is reduced (≥ 2-fold), highlighting the link between 
PA/PIP binding and antifungal activity. Using fluorescently labelled HsAFP1 in confocal microscopy 
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and flow cytometry assays, we showed that HsAFP1 accumulates at the cell surface of yeast cells with 
intact membranes, most notably at the buds and septa. The resulting HsAFP1-induced membrane 
permeabilization is likely to occur after HsAFP1’s internalization. These data provide novel mechanistic 
insights in the mode of action of the HsAFP1 plant defensin. 
Keywords: plant defensins, yeast, antifungal mode of action, lipid membrane target, peptide 
internalization, membrane permeabilization  
6.1 Introduction 
Plant defensins are peptides (45-54 amino acids), which are suggested to be part of the immune 
system of plants. They possess a broad-spectrum antimicrobial activity [102-104], but are in general 
non-toxic for plant or human cells [19-21]. Plant defensins are highly structured peptides that exhibit a 
common fold consisting of a cysteine-stabilized αβ-motif [36] and possess abundant positively charged 
and hydrophobic amino acids. In the past decades, the antifungal mode of action of various plant 
defensins has been studied (as reviewed by Vriens et al. [101]). Plant defensins such as NaD1 [60], 
TPP3 [41] and MtDef4 [44], isolated from tobacco, tomato and barrel clover, respectively, interact with 
fungal phospholipids, whereas others such as RsAFP2 [27], Psd1 [72] and DmAMP1 [66, 105], isolated 
from radish, pea and dahlia, respectively, interact with fungal-specific sphingolipids like 
glucosylceramides and mannosyldiinositolphosphoryl ceramides in the membranes of susceptible 
fungi. Upon interaction with their respective fungal membrane lipid, plant defensins can either be 
internalized into the fungal cells, thereby affecting intracellular targets in the cytosol or nucleus as in 
the case of MtDef4 [44], NaD1 [61] and Psd1 [74], or remain on the outside of the fungal cells, as in 
the case of RsAFP2 [25]. For NaD1 [62], PvD1 (from bean) [75], DmAMP1 [65], HsAFP1 [22], Lp-Def1 
(from cream nut) [85] and RsAFP2 [23, 24] it has been reported that they subsequently induce the 
production of reactive oxygen species (ROS) and/or apoptosis at relatively low doses, while membrane 
permeabilization occurs at high concentrations [64, 84]. The latter is suggested to be a non-specific 
secondary effect rather than the primary cause of microbial killing [68].  
HsAFP1, a plant defensin isolated from the seeds of coral bells (Heuchera sanguinea), can inhibit a 
broad range of fungi, including the model yeast Saccharomyces cerevisiae and the most common 
human pathogen Candida albicans [18, 19, 154]. This peptide is not toxic to human cells [20] and is 
characterized by a low in vitro frequency of spontaneous occurrence of resistance [19]. Moreover, it 
can inhibit C. albicans biofilm formation [20], which points to its potential for further drug development. 
In view of the latter, it is important to understand its mechanism of action, and in particular to identify 
its fungal interaction partner(s) and downstream signalling pathways resulting in fungal growth 
inhibition. Previously, we have demonstrated that HsAFP1 interacts with high-affinity binding sites on 
membranes of susceptible fungi (Kd = 29 nM) [26]. This interaction is specific, competitive, reversible 
and saturable, pointing to a specific receptor-ligand interaction. However, the target in the fungal 
membrane for HsAFP1 remained elusive as, in contrast to RsAFP2, Psd1 and DmAMP1, fungal-
specific sphingolipids appear not to be involved in HsAFP1’s mode of action [22].  
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In the present study, a lipid binding partner of HsAFP1 was identified, after which the domains of both 
HsAFP1 and the lipid species involved in this interaction were characterized. Internalization of HsAFP1 
was investigated in S. cerevisiae, as well as HsAFP1-induced membrane permeabilization resulting in 
cell death.  
6.2 Material and methods 
6.2.1 Strains and reagents 
In this study, the yeast Saccharomyces cerevisiae strain BY4741 and the filamentous fungal pathogen 
Fusarium culmorum K0311 were used. Yeasts were cultured at 30°C in YPD (yeast extract (10 g/L), 
peptone (20 g/L) and glucose (20 g/L) or YPD/PDB (potato dextrose broth (19.2 g/L), yeast extract  
(2 g/L), peptone (4 g/L) and glucose (4 g/L)) adjusted to pH 7 with 50 mM HEPES, while filamentous 
fungi were cultured at 22°C in PDB (12 g/L). The plant defensins HsAFP1 and HsAFP1[H32A][R52A] 
were recombinantly produced in Pichia pastoris and purified using the protocol described by Vriens et 
al. [20]. Linear HsAFP1-derived peptide fragments (HsLin’s) were synthesized and purified as 
described previously by Goblyos et al. [152]. Cysteine residues were replaced by α-aminobutyric acid 
(α-ABA; X) to avoid disulphide bond formation in the linear peptides. 
All lipids and PIP Strips were purchased from Echelon (Salt Lake City, USA), except for 
dimyristoylphosphatidylcholine (PC), dimyristoylphosphatidylglycerol (PG), dimyristoylphosphatidic 
acid (PA) used for the DSC experiments and methyl-PA (Avanti Polar Lipids, Alabaster, USA). rELISA 
assays were performed in Nunc-Immuno TM plates Polysorp. Bovine serum albumin (BSA), 
NaH2PO4.2H2O and Tween 20 were used for buffer preparations, while 4-nitrophenyl phosphate  
(4-NPP) disodium salt, 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) 
were used as enzyme substrates in colour reactions for quantification. Antiserum, raised in rabbits 
injected with HsAFP1 (as was previously done for antisera against the plant defensins RsAFP2 and 
DmAMP1 [197]), and anti-rabbit IgG-alkaline phosphatase were used respectively as primary and 
secondary antibody. For HsAFP1 internalization and membrane permeabilization studies, propidium 
iodide (Pi), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and BODIPY-FL-EDA were used.  
6.2.2 PIP Strip overlay assay for HsAFP1 lipid binding partner identification 
HsAFP1 lipid binding partners were determined via lipid overlay assay by using PIP Strips, containing 
100 pmol spots of all phospholipids. The manufacturer’s instructions were adjusted as follows  
(i) 1.7 µM HsAFP1 and BCIP/NBT were used as lipid interaction partner and enzyme (alkaline 
phosphatase (AP)) substrate, respectively, (ii) the enzymatic colour reaction was performed in alkaline 
phosphate buffer pH 9.5 with BCIP (0.2 g/L) and NBT (0.3 g/L) as substrate and (iii) after 5 minutes 
this reaction was stopped with an EDTA (6 µg/L) solution. As positive controls, 1 µL of HsAFP1  
(16.8 µM) or secondary antibodies (1/20 diluted) were spotted separately on top of the PIP Strips (not 
on the control membrane). When the spots were dry, the lipid overlay assay was performed as 
described above. HsAFP1-lipid binding was determined via pixel intensity quantification of every spot 
via Image Studio Lite software. 
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6.2.3 Reverse ELISA (rELISA) assay for quantification of HsAFP1 or HsAFP1[H32A][R52A] binding 
HsAFP1- or HsAFP1[H32A][R52A]-lipid binding was quantified in a rELISA assay, adapted from the 
protocol described by Thevissen et al. [27]. First, the lipid solution (8 µg/mL; dissolved in methanol) 
was dried overnight at room temperature in Polysorp ELISA plates. All subsequent steps were 
performed at 37°C. After lipid coating, a blocking step with 3% BSA in phosphate-buffered saline (PBS) 
pH 7.4 for 2-3 h was performed. Next, a 2-fold dilution series of HsAFP1 was prepared in 10% blocking 
buffer (or in 0.2 M – 0.0125 M phosphate buffers for phosphate binding experiments) and added to the 
rELISA wells for 1.5 h. Subsequently, the wells were incubated with primary antibody (1/3000 diluted; 
1 h), secondary antibody (1/3000 diluted; 1 h), and 4-NPP as AP substrate (1 mg/mL; 10 minutes). 
Absorbance at 405 nm was used as read out. For the rELISA assays, the highest values of the negative 
controls, samples without HsAFP1, were used as background signal and subtracted from the samples. 
For all competitive rELISA assays, 2-fold dilution series of HsAFP1 in the absence or presence of a  
4-fold excess of the competitor (compared to the highest concentration of HsAFP1) was added to the 
rELISA wells in the peptide binding step. In these experiments, the values of the negative controls, 
samples with 4x competitor, were used as background signal. For all rELISA assays, the % of HsAFP1-
lipid binding was calculated relative to the HsAFP1-PA signal obtained at the highest HsAFP1 
concentration (12.5 µM).  
6.2.4 Lipid vesicles 
Two types of vesicles were prepared using following molar ratios of the phospholipids: PC/PG 75/25 
[59] and PC/PG/PA 75/15/10. A total of 20 mg lipid powder was dissolved in chloroform/methanol 2/1 
and subsequently dried as a lipid film using a rotavap and 3 h of vacuum drying. Next, the lipid film 
was dissolved in 2-3 mL of 50 mM HEPES pH 7 [59] + 0.005 M NaCl.  
6.2.5 Differential Scanning Calorimetry (DSC) 
Thermograms were obtained using a VP-DSC (MicroCal Inc., MA, USA) device as described by Brand 
and colleagues [198], except for the scanning rate (0.5°C/min) and the peptide concentration (40 µM).  
6.2.6 Fluorescent labelling of HsAFP1 with the fluorophore BODIPY 
HsAFP1 was fluorescently labelled via its carboxyl groups with the fluorophore BODIPY-FL-EDA as 
described by van der Weerden and colleagues [61]. 
6.2.7 Fungal growth inhibition assay 
The antifungal activity of HsAFP1[H32A][R52A] and BODIPY-HsAFP1 against F. culmorum were 
determined as described by Vriens and colleagues [20]. 
6.2.8 Minimum Fungicidal Concentration (MFC) 
Exponentially growing S. cerevisiae cells in YPD were incubated (OD600 nm=1) in PDB/YPD with 
HsAFP1 or with HsAFP1[H32A][R52A] for 150 minutes. Both at the start and at the end of the 
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treatment, surviving yeast cells were determined via plating assays. In a plating assay, 10-fold dilution 
series of yeast cells in PBS were prepared, after which 100 µL was plated on YPD plates. After 2 days 
of incubation at 30°C, the number of colony forming units (CFU) was counted and cell death was 
calculated relative to time zero (t0). MFC50 values indicating the minimum fungicidal concentration 
resulting in 50% cell death, were determined.  
6.2.9 Cell treatment for confocal microscopy or flow cytometry experiments 
Exponentially growing yeast cells in YPD were incubated (OD600 nm=1) in PDB/YPD with HsAFP1 or 
with BODIPY-HsAFP1 (B-Hs; 4 - 48 µM), propidium iodide (Pi) (2 µg/mL) for 150 minutes (endpoint) 
unless stated otherwise. In parallel to confocal microscopy or flow cytometry experiments, plating 
assays were performed to determine MFC50 values, as described above.  
6.2.10 Confocal microscopy of Saccharomyces cerevisiae cells treated with BODIPY-HsAFP1 
HsAFP1 localization studies were performed on yeast cells treated with BODIPY-HsAFP1  
(4, 16 or 48 µM) and Pi (2 µg/mL) as described above. After 60-150 minutes of treatment, cells were 
visualized by confocal microscopy with the FluoView FV1000 confocal microscope (Olympus IX81) 
and its software. We used a 60x magnification objective and 1-6x computer zoom. The 488 nm laser 
line of the Argon laser was used for visualization of BODIPY and the 559 nm laser for Pi. To ensure 
that there is no spectral overlap between the green and red channel of our microscope, we examined 
fluorescence of BODIPY-HsAFP1 and Pi in both channels and only observed a fluorescent signal for 
BODIPY-HsAFP1 in the green channel and a fluorescent signal for Pi in the red channel and not vice 
versa. Hence, no cross-talk between the channels was found in our experimental setup. 
6.2.11 Flow cytometry of Saccharomyces cerevisiae cells treated with BODIPY-HsAFP1  
HsAFP1 uptake and HsAFP1-mediated membrane permeabilization in yeast cells were determined via 
flow cytometric analysis. Yeast cells were treated with BODIPY-HsAFP1 (B-Hs) and Pi, as described 
above, and subjected to flow cytometry on a BD InfluxTM cell sorter. Approx. 10,000 cells were 
monitored for fluorescence at 530/40 nm (FL2_λex = 488 nm) and 610/20 nm (FL11_ λex = 561 nm) for 
the detection of BODIPY-HsAFP1 uptake (B-Hs+) and membrane permeabilization (Pi+), respectively. 
Data from cells treated with MQ were used as background signal. For the kinetic experiments in  
Figure 8, the cell cultures were divided in 4 subpopulations (B-Hs-/Pi-, B-Hs+/Pi-, B-Hs-/Pi+ and B-
Hs+/Pi+) based on the fluorescence intensities of the control (MQ) treatment, which was B-Hs-/Pi-.  
6.2.12 Data analysis 
Data were analysed with GraphPad Prism 6 and mean ± standard error of mean (SEM) were 
represented for n ≥ 2 experiments. We assumed that all data are normally distributed. To analyse 
significant differences between the reference HsAFP1-PA binding (at 12.5 µM HsAFP1) and HsAFP1 
bindings in other conditions, unpaired student t-test with Welch’s correction (if only two conditions were 
compared) or one-way ANOVA followed by Dunnett multiple comparison (if more than two conditions 
were compared) was performed. *, **, *** and **** represent P < 0.05, P < 0.01, P < 0.001 and  
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P < 0.0001, respectively. Data of the thermal scans (DSC experiments) were normalized for the vesicle 
concentration, baseline subtracted (linear connect) and subsequently fitted with a non two-state model 
using the MicroCal OriginTM software. To determine significant differences between MIC50 values of 
native and BODIPY-labelled HsAFP1, an unpaired student t-tests was used. Flow cytometric data were 
presented as means ± SEM of the % of (BODIPY-HsAFP1 or Pi) positive cells relative to the whole cell 
population. One-way ANOVA with Dunnett multiple comparison was used to determine significant 
differences in the size of the subpopulations compared to those at the lowest BODIPY-HsAFP1 
concentration or time zero. 
6.3 Results  
6.3.1 HsAFP1 interacts with phospholipids  
We assessed potential binding between HsAFP1 and specific lipids using PIP Strips, containing 
phosphoinositides and other biologically important lipids. HsAFP1 bound to PA and several 
phosphatidylinositolphosphate (PIP)-derivatives, including PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, 
PI(4,5)P2 and PI(3,4,5)P3 (Figure 1A-B). This was further confirmed using reverse ELISA (rELISA), in 
which lipids are immobilized to the wells of microtiter plates and bound HsAFP1 is detected 
immunologically. This type of ELISA was previously used to characterize the binding of RsAFP2 to 
fungal glucosylceramides (GlcCer) [27]. Using rELISA assays, we assessed HsAFP1 binding to the 
above indicated lipid species, except for PI(3,4)P2. Consistent with the PIP Strip overlay assay, 
HsAFP1 bound to PA (orange bar in Figure 1C) as well as to several PIP-derivatives containing at 
least one phosphate (P) group (red bars in Figure 1C). However, binding of HsAFP1 to PA was most 
pronounced and therefore further investigated. The PIP Strip and rELISA data on HsAFP1-PA 
interactions were further confirmed using lipid vesicles. Using Differential Scanning Calorimetry (DSC), 
the thermotropic behaviour of these vesicles in the absence and presence of HsAFP1 was determined. 
Using a non-two state fitting model, two phase transition temperatures (Tm1 and Tm2) were determined. 
Shifts in Tm values are indicative for membrane interactions. We observed small Tm1 and Tm2 shifts 
(ranging between 0.3-0.4°C) for the phosphatidylcholine (PC)/phosphatidylglycerol (PG) (75/25) 
vesicles upon addition of HsAFP1, while the Tm1 and Tm2 shifts (ranging between 1.0-1.6°C) were 
larger in the case of the PA-containing PC/PG/PA (75/15/10) vesicles (Supplementary Figure S1). 
Together, these results point to a HsAFP1-PA interaction in non-membrane (as in the rELISA assays) 
as well as in membrane (lipid bilayer) conditions. 
6.3.2 HsAFP1 interacts with the phosphate group of phosphatidic acid via its most C-terminal 
arginine 
To identify the HsAFP1 domain responsible for the binding to PA, we tested competition for PA binding 
between HsAFP1 and different linear 24-mer HsAFP1-derived peptide fragments spanning the entire 
HsAFP1 sequence (HsLin01-06; Figure 2). HsAFP1 was co-incubated with an excess of these linear 
HsAFP1-derived fragments and the amount of HsAFP1 bound to PA in the presence of the linear 
fragments was quantified via rELISA. As the HsAFP1 antiserum interacted to a limited extent with 
various HsLin peptides, these background values were subtracted from the corresponding data. We 
found that only HsLin06 (P < 0.0001) significantly reduced the binding of HsAFP1 to PA, indicating that 
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the C-terminal part of HsAFP1 is important for PA binding (orange bar in Figure 3A). Additionally, we 
performed a sequential competitive rELISA in which HsAFP1 was incubated with PA for 30 minutes 
prior to the addition of an excess of HsLin06, allowing HsAFP1 to bind to PA first. We found that bound 
HsAFP1 could be expelled by excess of HsLin06 (Supplementary Figure S2) and this to a similar extent 
as in a simultaneous rELISA assay (Figure 3A), indicating that the binding of HsAFP1 to PA is 
reversible.  
 
Figure 1: Lipid interaction partners of HsAFP1 determined via (A, B) protein-lipid overlay assay using PIP Strips and 
(C) rELISA assays. (A) The PIP Strips were incubated with HsAFP1 (lower membrane) or without HsAFP1 (top control 
membrane) and subsequently with HsAFP1 antiserum, anti-rabbit IgG-Alkaline Phosphatase and 4-nitrophenyl phosphate. 
Coloured spots represent HsAFP1 binding events, as indicated by black arrows (A), which were quantified via Image Studio Lite 
(B). (C) Optical density (OD405 nm) values representing the interaction of 12.5 µM HsAFP1 with the control (MeOH) and all tested 
phospholipids. Data are means ± SEM, for n ≥ 3 experiments. Significant differences between HsAFP1-MeOH and HsAFP1-
lipid interactions were determined via one-way ANOVA followed by Dunnett multiple comparison, with *** and **** representing 
P < 0.001 and P < 0.0001, respectively.  
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Figure 2: Amino acid sequence alignment of HsAFP1 with HsAFP1 mutant HsAFP1[H32A][R52A], HsAFP1-derived 
peptide fragments (HsLin01-HsLin06), HsLin06-derived peptide fragments (HsLin06_02;05;09;01;03;06;10 and 15) and 
the plant defensins NsD7, MtDef4 and NaD2. Grey bars indicate the highly conserved amino acids among plant defensins. 
The blue, green and the orange boxes represent the position of the PA binding domain, the amino acid substitutions and the  
γ-core, respectively. (-) denote gaps in the alignment. 
To further identify the domains of HsLin06 important for PA binding, we assessed competition for PA 
binding between HsAFP1 and HsLin06 variants that were incrementally shortened at their N-terminus 
(HsLin06_01;03;06;10;15; Figure 2) or C-terminus (HsLin06_02;05;09; Figure 2). Only C-terminally 
shortened HsLin06 variants 02 (P = 0.0002) and 05 (P = 0.0002) could compete with HsAFP1 for PA 
binding, and this to the same extent as HsLin06 (around 75-80%; orange bars in Figure 3B), while 
variant HsLin06_09 could not compete at all (P = 0.9998; grey bar Figure 3B). Since HsLin06_02 and 
05 differ from HsLin06_09 only in their C-terminal arginine (R, position 52 in HsAFP1), these data show 
that R52 is an important amino acid for PA binding. Of the HsLin06 variants shortened at their  
N-terminus, only HsLin06_01 (P < 0.0001) could compete with HsAFP1 for PA binding, and this to the 
same extent as HsLin06 (around 75-80%; orange bars Figure 3C), while all other variants 
(HsLin06_06;10;15) could only partially (around 35%; red bars in Figure 3C) do so (with P = 0.0229,  
P = 0.0024 and P = 0.0003, respectively). Hence, it seems that the N-terminal histidine of HsLin06  
(H, position 32 in HsAFP1) is important, but not essential for PA binding as HsLin06 variants 03; 06; 
10 and 15, which are all lacking this amino acid, can still partially compete with HsAFP1 for PA binding.
 
  
 
 
 
Figure 3: Amino acids of HsAFP1 important for phosphatidic acid (PA) binding, using competitive rELISA assays. Competition of 12.5 µM HsAFP1 with 50 µM HsLin01-06 (A), C-truncated HsLin06 
variants (HsLin06_02;05;09 in Figure 2; B) or N-truncated variants (HsLin06_01;03;06;10;15 in Figure 2; C), with both peptides co-incubated. Data are means ± SEM, for n ≥ 3 experiments. Data are expressed 
relative to the HsAFP1-PA binding without HsLin. Significant differences between HsAFP1 and HsAFP1 + 4x HsLin interactions were determined via one-way ANOVA followed by Dunnett multiple comparison, 
with *, *** and **** representing P < 0.05, P < 0.001 and P < 0.0001, respectively. (d) 3D structure of HsAFP1 with the positively charged amino acids (histidine (H) 32 and 40, lysine (K) 47, K51 and arginine 
(R) 52) of HsLin06 drawn in blue on its backbone, using the Chimera visualization program. Green clustered amino acids (H32 and R52) are important for PA binding while the red clustered (H40, K47 and 
K51) are not. 
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To confirm the important role of H32 and R52 for HsAFP1’s PA binding action, a HsAFP1 mutant 
peptide in which both H32 and R52 were replaced by alanine (A) was produced (HsAFP1[H32A][R52A] 
(Figure 2)) and subsequently tested for PA binding and antifungal activity. Binding of 
HsAFP1[H32A][R52A] to PA was reduced by 77% as compared to native HsAFP1 (Figure 4A). Also 
binding of HsAFP1[32A][R52A] to PI(3,5)P2 and PI(4,5)P2 was significantly reduced compared to native 
peptide (Figure 4A). Next, the MIC50 (minimum inhibitory concentration resulting in 50% cell growth 
reduction) on F. culmorum and the MFC50 (minimum fungicidal concentration resulting in 50% cell 
death) on S. cerevisiae were determined for HsAFP1[H32A][R52A] and native HsAFP1. Compared to 
the native peptide, the MIC50 and the MFC50 of HsAFP1[H32A][R52A] were 3.5-fold and 2-fold higher 
(Figure 4B), respectively, demonstrating reduced antifungal activity as well as reduced phospholipid 
(PA/PIP) binding for HsAFP1[H32A][R52A]. 
 
Figure 4: Reduced phospholipid binding capacity (A) and antifungal activity (B) of HsAFP1[H32A][R52A] compared to 
native HsAFP1. Data are means ± SEM, for n ≥ 3 experiments. (A) Optical density (OD405 nm) values representing the interaction 
of 12.5 µM HsAFP1 or HsAFP1[H32A][R52A] with all phospholipids tested (phosphatidic acid (PA), 
phosphatidylinositol(3,5)bisphosphate (PI(3,5)P2), phosphatidylinositol(4,5)bisphosphate (PI(4,5)P2)), determined via rELISA 
assays. Significant differences between HsAFP1 and HsAFP1[H32A][R52A] were determined via two-way ANOVA followed by 
Sidak multiple comparison, with *** and **** representing P < 0.001 and P < 0.0001, respectively. (B) Minimum Inhibitory 
Concentration of HsAFP1 or HsAFP1[H32A][R52A] resulting in 50% cell growth reduction (MIC50) of Fusarium culmorum and 
Minimum Fungicidal Concentration of HsAFP1 or HsAFP1[H32A][R52A] resulting in 50% cell death (MFC50) of Saccharomyces 
cerevisiae. Significant differences between HsAFP1 and HsAFP1[H32A][R52A] were determined via an unpaired student t-test 
with Welch’s correction, with * representing P < 0.05. 
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Next, we investigated structural requirements of PA enabling HsAFP1 binding, focusing on the 
phosphate group in PA. We investigated the binding of HsAFP1 to methyl-PA in which the hydroxyl 
group of the phosphate group of PA is methylated, resulting in a changed ionization state of PA and in 
a less accessible phosphate group. Binding of HsAFP1 to methyl-PA was significantly reduced as 
compared to PA (Figure 5A (P = 0.0046)), indicating that a free phosphate group in PA is important for 
HsAFP1 binding. Next, we assessed binding of HsAFP1 to PA in buffers with different phosphate 
concentrations. The higher the phosphate concentration of the buffer, the lower the amount HsAFP1 
bound to PA was measured (Figure 5B). This result indicates competition between PA and free 
phosphates for HsAFP1 binding. Together, these data point to the phosphate group in PA as the 
HsAFP1 binding feature.  
Figure 5: Phosphate-dependent binding of HsAFP1 to phosphatidic acid (PA), determined via rELISA assays. Interaction 
of 12.5 µM HsAFP1 with PA or methyl-PA (A) or for the interaction of HsAFP1 with PA in buffers with different phosphate 
concentrations (B). Data are means ± SEM, for n ≥ 3 experiments. Data are expressed relative to the HsAFP1-PA binding (A) 
or relative to the HsAFP1-PA binding in demi-water (0 M NaH2PO4) (dotted line) (B). Significant differences between PA and 
methyl-PA interactions were determined via an unpaired student t-test with Welch’s correction (A), while significant differences 
between demi-water (0 M NaH2PO4) and phosphate buffers were determined via one-way ANOVA followed by Dunnett multiple 
comparison (B), with ** and *** representing P < 0.01 and P < 0.001, respectively. 
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6.3.3 HsAFP1 is accumulating at the yeast cell surface and induces membrane permeabilization 
Given HsAFP1’s capacity to bind membrane phospholipids, we investigated potential membrane-
dependent localization of HsAFP1 in yeast cells. To this end, we labelled HsAFP1 with the green 
fluorescent marker BODIPY, as previously described for NaD1 [61] and confirmed that the label did 
not affect the antifungal activity of HsAFP1 nor its PA binding (Supplementary Figure S3).  
 
Figure 6: HsAFP1 localization in Saccharomyces cerevisiae cells treated for 150 minutes with high (48 µM) BODIPY-
HsAFP1 concentrations, resulting in approx. 10% yeast survival as compared to t0. Confocal microscope images of treated 
S. cerevisiae cultures were shown. Propidium iodide (Pi; 2 µg/mL) was used to identify membrane permeabilization. (A) Confocal 
images acquired with normal laser intensities (Alexa fluor 488-10% (argon laser)-HV451 and Pi-1% (559 nm laser)-HV405).  
(B) Confocal images taken at high laser intensities (Alexa fluor 488-10% (argon laser)-HV573 and Pi-1% (559 nm laser)-HV566), 
without impacting autofluorescence. Representative BODIPY-HsAFP1+/Pi- cells are indicated with arrows. Bar: 5 µm.  
At high (10x HsAFP1’s MFC50; 48 µM) BODIPY-HsAFP1 doses and normal laser intensities  
(Figure 6A), most yeast cells accumulated BODIPY-HsAFP1 intracellularly after 150 minutes of 
incubation, pointing to HsAFP1 uptake. To assess whether the latter is a result of HsAFP1-induced 
membrane permeabilization, which was reported at high HsAFP1 doses (> 8.4 µM under different 
experimental conditions) [64], we simultaneously assessed membrane permeabilization via (red 
fluorescent) propidium iodide (Pi) [199] and found that the yeast cells that accumulated BODIPY-
HsAFP1 intracellularly had permeabilized membranes (BODIPY-HsAFP1+/Pi+). However, some cells 
(< 1% of the BODIPY-HsAFP1+ population, as measured via flow cytometric analysis) showed 
intracellular HsAFP1 accumulation and intact membranes (BODIPY-HsAFP1+/Pi-; as indicated by 
arrows in Supplementary Figure S4). Additionally, at higher laser intensities, a second subpopulation 
of BODIPY-HsAFP1+/Pi- cells were apparent that accumulated BODIPY-HsAFP1 on their cell surface 
and had intact membranes (as indicated by arrows in Figure 6B). At this laser intensity no 
autofluorescence of the cells was visible (data not shown). Hence, at 48 µM BODIPY-HsAFP1, there 
seem to be two distinct subpopulations with intact membranes that either accumulate BODIPY-
HsAFP1 on their surface (which are characterized by low intensity green fluorescence and hence, only 
apparent when using high laser intensity) or accumulate BODIPY-HsAFP1 intracellularly 
The antifungal plant defensin HsAFP1 is a phosphatidic acid-interacting peptide 
117 
 
(characterized by higher intensity green fluorescence and hence, apparent when using normal laser 
intensity).  
To get more insight in BODIPY-HsAFP1’s localization, being at the cell surface and/or intracellularly, 
we performed additional confocal microscopy using an intermediate BODIPY-HsAFP1 dose (16 µM) 
and shorter treatment time (60 minutes). At normal laser intensities, only cells with intense green 
fluorescence signal were apparent (Figure 7A). These cells had permeabilized membranes and the 
BODIPY-HsAFP1 signal was intracellularly located. Additionally, at higher laser intensities, a 
subpopulation of Pi- cells with BODIPY-HsAFP1 located at the cell surface, mainly at the buds and 
septa (as indicated by the arrows in Figure 7B) was apparent.  
 
Figure 7: BODIPY-HsAFP1 is located intracellularly in membrane-permeabilized cells and at the cell surface of non-
membrane permeabilized Saccharomyces cerevisiae cells treated for 60 minutes with 16 µM BODIPY-HsAFP1, resulting 
in approx. 50% yeast survival as compared to t0. Confocal microscope images of treated S. cerevisiae cultures were shown. 
Propidium iodide (Pi; 2 µg/mL) was used to identify membrane permeabilization. (A) Confocal images acquired with normal laser 
intensities (Alexa fluor 488-10% (argon laser)-HV573 and Pi-1% (559 nm laser)-HV600). (B) Confocal images taken at high laser 
intensities (Alexa fluor 488-10% (argon laser)-HV700 and Pi-1% (559 nm laser)-HV600), without impacting autofluorescence. 
Representative BODIPY-HsAFP1 accumulation spots at the cell surface are indicated with arrows. Bar: 5 µm.  
To quantify the different BODIPY-HsAFP1/Pi populations over time in treated yeast cultures, we used 
flow cytometry (Figure 8). Treatment of yeast cultures with 48 µM BODIPY-HsAFP1 resulted in the 
appearance of a B-Hs+/Pi- subpopulation after 15 minutes (14% of the treated culture), whereas a  
B-Hs+/Pi+ subpopulation was apparent after 30 minutes (9% of the treated culture; P = 0.0007). Note 
that the B-Hs+ population might consist of cells that accumulate BODIPY-HsAFP1 on their surfaces 
and/or cells that accumulate BODIPY-HsAFP1 intracellularly. Treatment of yeast cultures with a low 
BODIPY-HsAFP1 concentration (4 µM) resulted in the appearance of a BODIPY-HsAFP1 (B-Hs)+/Pi- 
subpopulation after 30 minutes (P = 0.0228), whereas a B-Hs+/Pi+ subpopulation was apparent after 
150 minutes (22% of the treated culture; P > 0.0001).  
Together, the flow cytometry data showed that treatment of a yeast culture with BODIPY-HsAFP1 
results first in accumulation of BODIPY-HsAFP1 at the cell surface and/or intracellularly (B-Hs+), after 
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which membrane permeabilization occurs (Pi+). Microscopic analysis indicated that BODIPY-HsAFP1 
primarily associates with buds and septa, without affecting membrane integrity.  
 
Figure 8: Kinetics of HsAFP1 internalization and membrane permeabilization in Saccharomyces cerevisiae cells treated 
with (A) low (4 µM) or (B) high (48 µM) BODIPY-HsAFP1 (B-Hs) and 2 µg/mL propidium iodide (Pi), determined via flow 
cytometry. The grey dashed line represents the percentage of B-Hs+ yeast cells in the population, relative to control (MQ water) 
treatment, which can be further divided in two subpopulations: yeast cells with (Pi+; orange squares) and without (Pi-; black 
circles) compromised membranes. The highlighted area represents the percentage of yeast survival as compared to t0. Data 
are means ± SEM, for n = 3 experiments. To analyse significant differences in the size of the subpopulations between the time 
zero and other time points, one-way ANOVA followed by Dunnett multiple comparison was performed. 
6.4 Discussion 
Similar as for some other plant defensins, we showed that HsAFP1 interacts with various lipids using 
lipid overlay assays (PIP Strips) [41, 44, 59] as well as rELISA assays [27]. Using PIP Strips, 
PI(3,4,5)P3 was identified as the strongest interaction partner of HsAFP1 followed by PI(3,4)P2. As 
PI(3,4,5)P3 and PI(3,4)P2 are not present in yeast [200], PA seems the main HsAFP1-interactor. These 
results were further confirmed in a more quantitative assay (rELISA setup), also indicating PA as the 
strongest of the potential interaction partners of HsAFP1 tested. As both assays can give an indication 
of lipid specificity but lack biological environment, we additionally tested HsAFP1-PA interactions in a 
membrane context. We showed that HsAFP1 specifically interacted with vesicles containing PA. 
However, as these interactions could only be observed when using low salt concentrations, this 
interaction is presumably mediated via electrostatic binding. Moreover, as the area under the melting 
curve did not change by HsAFP1 addition, this interaction seems superficial. In addition, using rELISA 
assays, we demonstrated that HsAFP1 reversibly binds to PA, which is consistent with our previous 
findings on HsAFP1-membrane target interactions [26]. We further identified the region in HsAFP1 
responsible for PA binding via rELISA assays in which competition between HsAFP1 and HsAFP1-
derived peptide fragments for PA binding was assessed. We found that the C-terminal domain of 
HsAFP1 (HsLin06) can prevent binding of HsAFP1 to PA, indicating that this domain in HsAFP1 
mediates PA binding. Moreover, the arginine (R) at position 52 in HsAFP1 seems essential for PA 
binding, while the histidine (H) at position 32 in HsAFP1 seems favourable, but not essential for PA 
binding. Both amino acids are located in close proximity of each other on the HsAFP1 structure (green 
cluster in Figure 3D). The other positively charged amino acids in the C-terminal part of HsAFP1 (H40, 
lysine (K) 47 and K51), which seem not important for PA binding, are differently located (red cluster in 
Figure 3D). This is in line with reports of other proteins that bind to PA, such as mTOR, in which multiple 
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amino acids contribute to PA docking, with an arginine being necessary for this interaction [201]. 
Hitherto, three other plant defensins that interact with PA have been identified, namely NsD7 [202], 
MtDef4 [44] and NaD2 [59]. However, neither primary sequence homology nor structural alignments 
were found between the PA-interacting RGFRRR region (located in the γ-core) in MtDef4 [44], which 
is also present in NaD2 [59], and the corresponding region in HsAFP1 or NsD7 (Figure 2). A common 
feature of the PA binding region of HsAFP1, NsD7, MtDef4 and NaD2 is the presence of positively 
charged amino acids. This is in line with previous reports on the amino acid sequences of various PA 
effectors that indicated that there is no defined PA binding sequence, and only the presence of both 
positively charged amino acids and hydrophobic amino acids can enable PA binding in lipid 
environments [203, 204].  
Since the phosphomonoester (phosphate) head group of PA is negatively charged and therefore 
mainly responsible for electrostatic interactions with basic amino acid residues of PA effector proteins, 
we examined HsAFP1 interaction with methyl-PA, which bears a methyl-group substitution on the 
phosphate moiety [205], making the latter less negatively charged and less available for binding. As 
expected, this resulted in a reduction of HsAFP1 binding by more than 75%. Moreover, besides the 
interaction of HsAFP1 with the phosphate group of PA, we demonstrated that free phosphates in the 
buffer can compete with PA for HsAFP1 binding, pointing to phosphate-HsAFP1 interactions.  
Besides PA, HsAFP1 also bound to various other phospholipids, as was previously shown for MsDef1, 
MtDef4, NaD1 and NaD2 [41, 44, 59]. Moreover, we demonstrated for the HsAFP1[H32A][R52A] 
double mutant that H32 and R52 are important for PIP binding as well. This is not surprising as different 
PA effectors have also been shown to bind to other lipids, such as PIP’s [206]. In the case of HsAFP1, 
it seems that the phosphate group(s) present in PA and all PIP’s, enable(s) interactions with HsAFP1, 
since lipids containing at least one phosphate group were identified as HsAFP1 interaction partners in 
the PIP Strip overlay assays. Why HsAFP1 binds preferentially with PA in the rELISA assays has to 
be elucidated further. As shown for the PA-interacting plant defensin NsD7 [202], it might be that 
HsAFP1’s PA-binding site contains a small pockets size that can only accommodate a single 
phosphate group, which makes it selective for PA. Consistent with our data, it has been reported that 
NaD1 interacts with phosphate groups of PI(4,5)P2. This leads to oligomerization of NaD1:PI(4,5)P2 
complexes [60], which was recently found not essential for the antifungal activity of NaD1 [63].  
Most importantly, using the HsAFP1[H32A][R52A] double mutant, we showed that phospholipid (PA 
and PIP’s) interacting capacity of HsAFP1 is important for its antifungal activity. Based on our 
microscopic and flow cytometry analyses, we propose a 3-step killing process of the plant defensin 
HsAFP1 in S. cerevisiae (Figure 9). Firstly, HsAFP1 accumulates in low amounts at the yeast cell 
surface and this accumulation is most pronounced at the buds and septa. It has been shown that 
PI(4,5)P2 is enriched in septa, as this phospholipid is the main regulator of cytokinesis [207]. Next, 
HsAFP1 is internalized in yeast cells, immediately followed by membrane permeabilization as only a 
very small subpopulation (< 1%) of HsAFP1-treated yeast cells exist that show internalization of 
HsAFP1 with intact membranes. After permeabilization, additional BODIPY-HsAFP1 might diffuse 
further into the cells, resulting in cells with a very intense green fluorescence signal, as was apparent 
in microscopy performed at high BODIPY-HsAFP1 doses after 150 minutes of incubation. We 
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previously demonstrated that HsAFP1 treatment of a yeast culture results in a subpopulation of 
apoptotic cells (i.e. dead cells that are Pi-) [22]. In the current study, on average 10% of the HsAFP1-
treated cultures was found dead, as determined via plating assays (data not shown), while being Pi- 
(based on the corresponding flow cytometry analysis of the cultures). Whether these apoptotic cells 
internalized HsAFP1 is not clear. Hence, future work in our laboratory will be directed to the use of a 
systems biology approach to investigate the kinetics of BODIPY-HsAFP1 internalization and cell death, 
thereby also focusing on yeast apoptosis, using single cell digital microfluidics (DMF). 
 
Figure 9: Proposed 3-step killing process by BODIPY-HsAFP1 (B-Hs). (1) Small amounts of B-Hs accumulate at the yeast’s 
cell surface, with most B-Hs is located at the cellular buds/septa. (2) B-Hs is internalized in yeast cells, (3) immediately resulting 
in membrane permeabilization. A subpopulation of dead cells exists (± 10%) that have intact membranes, pointing to apoptotic 
cell death. Whether B-Hs resides at the surface or is internalized to induce apoptosis is not known (dashed lines). 
Similar to HsAFP1, peptide accumulation on the cell surface prior to membrane permeabilization and 
cell entry has been demonstrated for the plant defensin NaD1 [88]. As HsAFP1 internalization is 
probably not resulting from the HsAFP1-induced membrane permeabilization in S. cerevisiae, peptide 
translocation across cell membranes independent of membrane permeabilization should be part of 
HsAFP1 killing mechanism. Pore-independent peptide translocation has been reported for some 
antimicrobial peptides (AMPs) and is thought to be mediated by either endocytic or physical 
(spontaneous protein-membrane interaction) processes. Henriques and colleagues suggested that 
depending on the circumstances (such as peptide concentration and temperature), AMPs can be 
internalized via both routes [208]. We found that HsAFP1’s internalization is at least partially mediated 
by endocytosis as it was significantly reduced in a yeast mutant that is affected in endocytosis (Δend3) 
[209] (data not shown).  
In conclusion, we showed that HsAFP1 can bind to various lipids which contain at least one phosphate 
group, with PA being the lipid binding partner resulting in the most pronounced HsAFP1 binding. We 
identified two basic amino acids in HsAFP1, the histidine at position 32 and arginine at position 52, as 
well as the phosphate group in PA as important features enabling this interaction. Hence, we can 
conclude that the RGFRRR region, present in the PA-interacting plant defensins MtDef4 and NaD2 
and previously defined as the region important for PA binding and cell entry, is not the only domain 
enabling PA binding of plant defensins, as this region is not present in HsAFP1. Moreover, we showed 
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that HsAFP1 is accumulating at the yeast cell surface, primarily in buds and septa, which results in 
membrane permeabilization, potentially upon internalization of the peptide. 
6.5 Supplementary material 
 
Supplementary Figure S1: Thermograms of dimyristoylphosphatidylcholine (PC) / dimyristoylphosphatidylglycerol 
(PG) (75/25) (A, B) and PC / PG / dimyristoylphosphatidic acid (PA) (75/15/10) (C, D) vesicles in the absence (A, C) or 
presence (B, D) of HsAFP1, as determined via DSC experiments. Representative graphs of the phase transition of 0.5 mM 
liposomes in the absence (A, C) or presence of 40 µM HsAFP1 (B, D) are presented in black, with the corresponding fits (using 
a non two-state model) shown in red. Both the fit of the two peaks as well as the overall fit were presented in red. 
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Supplementary Figure S2: Reversible HsAFP1 – phosphatidic acid (PA) binding, determined via sequential rELISA 
assays. Competition of 12.5 µM HsAFP1 with an excess (4x) of HsLin06 for PA binding, with HsAFP1 administered 30 minutes 
prior to HsLin06. Data are means ± SEM, for n ≥ 3 experiments. Data are expressed relative to the HsAFP1-PA binding (black 
bar). Significant differences between HsAFP1 and HsAFP1 + 4x HsLin06 interactions were determined via an unpaired student 
t-tests with Welch’s correction, with ** representing P < 0.01. 
  
 
 
Supplementary Figure S3: BODIPY labelling of the plant defensin HsAFP1 did not affect antifungal activity nor PA interaction capacity. Data were means ± SEM, for n = 2 experiments. (A) Dose-
response curves of the antifungal activity of (BODIPY-)HsAFP1 on Fusarium culmorum. MIC50, Minimum Inhibitory Concentration required for 50% growth inhibition compared to control (MQ water) treatment 
(dotted line). An unpaired student t-test was performed to analyse significant differences in MIC50 values between HsAFP1 and BODIPY-HsAFP1, with P < 0.05 is significant. (B) Dose-response curves of 
(BODIPY-)HsAFP1 binding on PA, with all data expressed relative to the condition with the highest HsAFP1 binding (dotted line). For each plant defensin concentration significant differences were determined 
via two-way ANOVA followed by Sidak multiple comparison, with P < 0.05 is significant.  
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Supplementary Figure S4: BODIPY-HsAFP1 (B-Hs) internalization in Saccharomyces cerevisiae cells with intact membranes. Confocal microscope images of 150 minutes treated S. cerevisiae cultures 
with 48 µM BODIPY-HsAFP1, resulting in approx. 10% yeast survival as compared to t0, and propidium iodide (Pi; 2 µg/mL) to identify membrane permeabilization. Representative highly intense coloured  
B-Hs cells with intact membranes (B-Hs+/Pi-) are indicated with arrows.
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7 Transcriptome-based analysis reveals vacuolar 
dysfunction in HsAFP1-treated yeast 
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Contributions of external research groups to the chapter ‘Transcriptome-based analysis 
reveals vacuolar dysfunction in HsAFP1-treated yeast’. 
Replicative lifespan experiments were performed by Dr. Brian Wasko and Prof. Matt Kaeberlein 
(Department of Pathology, University of Washington, NE Pacific St. 1959, Seattle, 98195 WA, USA.) 
Quantification of fluorescently labelled GPI-anchored protein (mRFP-Als5p) release in supernatants 
by fluorescence spectroscopy was done by Subhash Chandra and Prof. Sneha S. Komath (School of 
Life Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India.) 
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Abstract 
The plant defensin HsAFP1 specifically interacts with phospholipids, such as phosphatidic acid and 
phosphoinositolphosphates. Moreover, this peptide induces the production of ROS and apoptosis in 
Candida albicans. In this study, the antifungal mode of action of the plant defensin HsAFP1 was further 
unravelled in C. albicans and in Saccharomyces cerevisiae, by using transcriptome analysis and 
additional complementary genetic and biochemical tests. Upon HsAFP1 treatment, various genes 
coding for cell surface proteins are differential expressed in C. albicans, including cell wall proteins 
such as glycosylphosphatidylinositol (GPI)-anchored proteins. Remodelling of GPI-anchored proteins 
was identified as an important process in HsAFP1’s antifungal action and their cleavage seems 
involved in C. albicans tolerance to HsAFP1. We also observed up-regulation of genes involved in  
C. albicans tolerance mechanisms, including pathways known to induce genes of the unfolded protein 
response, known to be important for coping with endoplasmic reticulum (ER) stress. By using  
S. cerevisiae deletion mutants, we demonstrated the importance of other ER stress tolerance 
mechanisms, such as the Slt2-dependent and the osmosensing MAPK pathways, for governing 
tolerance to HsAFP1. Whether HsAFP1 induces ER stress is not yet clear. In addition, cations such as 
Fe2+, Cu2+ and Zn2+, were found to interfere with HsAFP1’s antifungal activity in C. albicans, a 
phenomenon previously observed for other cations like Ca2+ and Mg2+. With vacuoles being the main 
cation storage organelles in yeast, we showed that HsAFP1 induces vacuolar dysfunction in  
C. albicans. These data provide novel insights in the mode of action of HsAFP1 as well as in yeast 
tolerance mechanisms. 
7.1 Introduction 
The plant defensin HsAFP1 affects a broad range of (non-) pathogenic yeast/fungal species, including 
the model yeast Saccharomyces cerevisiae and the most prominent human fungal pathogen Candida 
albicans [18, 19]. This plant defensin is also known to interact with high-affinity binding sites at fungal 
membranes [26]. In Chapter 6, we identified phosphatidic acid and phosphatidylinositolphosphates as 
lipid interaction partners of HsAFP1. Upon interaction with these targets, HsAFP1 is internalized in  
S. cerevisiae cells, immediately followed by membrane permeabilization (Chapter 6). HsAFP1 also 
induces the production of reactive oxygen species (ROS) and apoptosis in C. albicans [22]. By 
screening a S. cerevisiae deletion mutant library, yeast tolerance mechanisms towards HsAFP1 
treatment have been identified, including mitogen-activated protein kinase (MAPK) and general stress 
response pathways [22]. 
In this study, the antifungal action and yeast tolerance mechanisms of HsAFP1 were further unravelled 
via transcriptome analysis and additional genetic and biochemical tests. Based on these data, we 
demonstrated that HsAFP1 induces yeast tolerance mechanisms to endoplasmic reticulum (ER) stress 
as well as vacuolar dysfunction.  
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7.2 Materials and methods 
7.2.1 Strains and reagents 
The strains used in this study were listed in Table 1. Yeast cells were cultured in following liquid media: 
YPD (yeast extract (10 g/L; LabM, UK), peptone (20 g/L; LabM, UK) and glucose (20 g/L; Sigma-
Aldrich, USA), PDB/YPD (potato dextrose broth (19.2 g/L; BD, USA), yeast extract (2 g/L), peptone  
(4 g/L) and glucose (4 g/L)) adjusted to pH 7 with 50 mM HEPES (Sigma-Aldrich, USA) or synthetic 
complete (SC) medium (CSM (complete amino acid supplement mixture; MP Biomedicals, USA) 
(0.77 g/L), YNB (yeast nitrogen base without amino acids; MP Biomedicals, USA) (6.7 g/L) and glucose 
(20 g/L)) adjusted to pH 7 with 50 mM HEPES; at 30°C and 37°C for S. cerevisiae and C. albicans 
respectively. Yeast cells were grown on following solid media: SC agar plates without uracil for all 
Candida transformations, YPD agar plates containing 2% of 0.05% glucose (YPD + 15 g/L agar 
(Invitrogen, USA)) for all MFC50 and replicative lifespan experiments or PDB/YPD/HEPES agar plates 
(PDB/YPD with 50 mM HEPES pH 7 + 8 g/L agar) in the presence or absence of 2 mM 
FeSO4/CuSO4/ZnSO4 (Sigma-Aldrich, USA) for all spot assays. Bacterial (Escherichia coli) cells were 
cultured in LB (Luria Broth/Bertani; yeast extract (5 g/L; Lab M, UK), tryptone (10 g/L; Lab M, UK), 
NaCl (10 g/L; VWR International, USA)) medium in the presence or absence of 15 g/L agar. Iron 
chelators deferasirox and bathophenanthrolinedisulfonic acid (BPS) were purchased from Selleck 
Chemicals (Germany) and TCI (Japan), respectively, and the iron-siderophores ferricriocin or 
triacetylfusarinine C were kindly provided by H. Haas [210].  
HsAFP1 was produced recombinantly, as described previously [20].  
7.2.2 Construction of a mRFP-Als5p containing Candida albicans strain 
7.2.2.1 Construction of plasmid (pEcm331.mRFP.Als5c) 
The plasmid pEcm331.mRFP.Als5c was constructed from sequential modifications from the original 
plasmid pEcm331.GFP.Ecm331c [211]. pEcm331.GFP.Als5c was constructed by replacing the 
nucleotides at the C-terminus of Ecm331 (Ecm331c) by Als5c with a BamHI- and SmaI-digested PCR 
product encoding the 45 amino acids from the C-terminus with primers Als5-ssBamHI and Als5-ssSmaI 
(Table 2). Finally, pEcm331.mRFP.Als5c was constructed from pEcm331.GFP.Als5c by replacing GFP 
by mRFP with a SpeI- and BamHI-digested PCR product generated with primers yEmRFPSpeI and 
yEmRFPBamHI. 
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Table 1: Strains used in this study. 
Species Name Genotype Reference 
 SC5314 (WT) [182] 
 CEC253 Δplc2/Δplc3 [212] 
 CEC255 Δplc2 [212] 
Candida albicans CEC257 Δplc3 [212] 
 CEC369 (WT of Δplc’s) [212] 
 BWP17 (WT) [213] 
 BWP17 + mRFP-ALS5 mRFP-ALS5 This study 
 BY4741 (WT) Invitrogen 
 BY4741 Δbck1 Δbck1/Δbck1 Invitrogen 
 BY4741 Δbst1 Δbst1/Δbst1 Invitrogen 
 BY4741 Δcrz1 Δcrz1/Δcrz1 Invitrogen 
 BY4741 Δgcn4 Δgcn4/Δgcn4 Invitrogen 
 BY4741 Δgup1 Δgup1/Δgup1 Invitrogen 
 BY4741 Δhac1 Δhac1/Δhac1 Invitrogen 
 BY4741 Δhog1 Δhog1/Δhog1 Invitrogen 
 BY4741 Δire1 Δire1/Δire1 Invitrogen 
 BY4741 Δpbs2 Δpbs2/Δpbs2 Invitrogen 
 BY4741 Δper1 Δper1/Δper1 Invitrogen 
 BY4741 Δpmr1 Δpmr1/Δpmr1 Invitrogen 
 BY4741 Δrsb1 Δrsb1/Δrsb1 Invitrogen 
 BY4741 Δslt2 Δslt2/Δslt2 Invitrogen 
 BY4741 PERO1-GFP pDP010 integrated in genome This study 
 BY4741 PHSP12-GFP pDP012 integrated in genome This study 
 BY4742 (WT)  [214] 
 BY4743 (WT) Invitrogen 
 BY4743 Δdpm1 Δdpm1 Invitrogen 
 BY4743 Δgaa1 Δgaa1 Invitrogen 
 BY4743 Δgab1 Δgab1 Invitrogen 
 BY4743 Δgpi1  Δgpi1 Invitrogen 
Saccharomyces cerevisiae BY4743 Δgpi2 Δgpi2 Invitrogen 
 BY4743 Δgpi3 Δgpi3 Invitrogen 
 BY4743 Δgpi8   Δgpi8 Invitrogen 
 BY4743 Δgpi10 Δgpi10 Invitrogen 
 BY4743 Δgpi11 Δgpi11 Invitrogen 
 BY4743 Δgpi12 Δgpi12 Invitrogen 
 BY4743 Δgpi13 Δgpi13 Invitrogen 
 BY4743 Δgpi14 Δgpi14 Invitrogen 
 BY4743 Δgpi15 Δgpi15 Invitrogen 
 BY4743 Δgpi16 Δgpi16 Invitrogen 
 BY4743 Δgpi17 Δgpi17 Invitrogen 
 BY4743 Δgpi18 Δgpi18 Invitrogen 
 BY4743 Δgpi19 Δgpi19 Invitrogen 
 BY4743 Δgwt1 Δgwt1 Invitrogen 
 BY4743 Δmcd4 Δmcd4 Invitrogen 
 BY4743 Δpbn1 Δpbn1 Invitrogen 
 BY4743 Δpga1  Δpga1 Invitrogen 
 BY4743 Δsmp3 Δsmp3 Invitrogen 
 SCY62 (WT) [215] 
 H1246 Δare1/Δare2/Δdga1/Δlro1 [215] 
Escherichia coli DH5α  Invitrogen 
7.2.2.2 Primers 
Table 2: Primers used in this study.  
Name Sequence Purpose  
Als5-ssBamHI GCGGGATCCACCACATTAATTCAACAAG Forward primer for Als5 construction 
Als5-ssSmaI GCGCCCGGGTCATAGAAAGAAGAATAAT Reverse primer for Als5 construction 
yEmRFPSpeI GCGACTAGTATGGTTTCAAAAGGTGAAG Forward primer for mRFP construction 
yEmRFPBamHI GCGGGATCCTTTATATAATTCATCCATA Reverse primer for mRFP construction 
 
The plasmid was incubated for 12 h at 37°C with the restriction enzymes and corresponding Cutsmart 
buffer, purchased from NEB (USA). Next, this linear plasmid was ligated with either Als5c or mRFP by 
overnight incubation by T4 DNA ligase (Thermo Fisher Scientific, USA) at 16°C. The 
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pEcm331.mRFP.Als5c plasmid was transformed to Escherichia coli DH5α via the conventional heat 
shock method.  
7.2.2.3 Candida transformation via the lithium acetate method  
Exponentially growing C. albicans BWP17 cells in YPD were centrifuged, washed with distilled water 
and resuspended in 1 mL of LiAc (0.1 M). Cells were transferred to an Eppendorf tube, centrifuged 
and resuspended in 500 µL LiAc (0.1 M). 100 µL of these cells were incubated for 30 minutes at 30°C 
with: 5 µL (± 5 µg) pEcm331.mRFP.Als5c plasmid and 10µL ss salmon sperm DNA (boiled at 95°C for 
5 minutes before use [216]). Next, 700 µL PEG3350 : LiAc (1M) : MQ water (8:1:1) was added to the 
cells, after which they were incubated overnight at 30°C. The next day, cells were heat shocked  
(45 minutes at 42°C), centrifuged, washed and resuspended in 100 µL MQ water, immediately followed 
by plating on SC selection media (containing no uracil). After 48-72 h at 30°C, colonies were streaked 
on fresh SC selection media (containing no uracil). DNA was isolated from the transformed colonies 
and screened for the presence of the pEcm331.mRFP.Als5c plasmid via PCR with gene specific 
primers. 
7.2.3 Minimum Fungicidal Concentration (MFC) 
Exponentially growing C. albicans or S. cerevisiae cells in YPD were incubated (OD600 nm = 1) with 
HsAFP1 for 150 minutes in PDB/YPD with 50 mM HEPES pH 7 at 37°C or 30°C, respectively. Both at 
the start and at the end of the treatment, surviving yeast cells was determined via plating assays. In a 
plating assay, 10-fold dilution series of yeast cells in PBS were prepared, after which 100 µL was plated 
on YPD plates. After 2 days of incubation at 30°C, the number of colony forming units (CFU) was 
counted and cell death was calculated relative to time zero (t0). MFC50 values indicating the minimum 
fungicidal concentration resulting in 50% cell death, were determined.  
7.2.4 Cell treatment for transcriptome analysis 
Exponentially growing C. albicans SC5314 WT cells in YPD were incubated with 10 µg/mL HsAFP1 or 
MQ water (control) in PDB/YPD with 50 mM HEPES pH 7 (OD600 nm = 1) for 150 minutes at 37°C. After 
treatment, cells were washed with PBS and, subsequently, cell pellets were flash-freezed in liquid 
nitrogen before storage at -80°C until RNA isolation. Samples of 3 independent experiments were 
collected. In parallel to transcriptome analysis, plating assays were performed to determine MFC0 
values, as described above.  
7.2.5 RNA isolation 
RNA was isolated from treated cell pellets, as described above, using the Yeast RiboPure RNA 
Purification kit (AmBion) according to manufacturer’s instructions. Next, organic solvent were removed 
by ethanol precipitation, followed by RNA dissolving in 0.1% (v/v%) diethylpyrocarbonate (DEPC)-MQ 
water (Sigma-Aldrich, USA). The quality and integrity of RNA was determined via NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, USA), Experion Automated Electrophoresis System 
(Biorad, USA) and BioAnalyser (Agilent, USA). 
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7.2.6 Library preparation, RNA sequencing and data analysis 
Library preparation for RNA sequencing was performed using a Illumina (USA) TruSeq kit. Next, 
sequencing was performed in one lane of an Illumina NextSeq sequencer using sequencer kit H75. 
On average 4,497,979 reads per sample (75 bp) were generated. A first step in the preprocessing of 
the raw reads was quality trimming, in which low quality ends (Q < 20) were trimmed and adapters 
were trimmed at the end if there was ≥ 10 bp overlap and 90% match. Secondly, reads < 35 bp after 
trimming, poly-A reads, AmBiguous reads, low quality reads and artefacts were discarded. After 
preprocessing, 99% of all reads remained are these preprocessed reads were subsequently subjected 
to mapping analysis to the reference genome sequence of C. albicans SC5314_A21 using Tophat 
v2.0.13. Reads with non-primary mappings or with mapping quality of < 20 were discarded. On average 
91% of the preprocessed reads could be mapped to the reference genome. Using htseq0.6.1p1, the 
number of reads that are overlapping with gene features was determined. The last step in the data 
processing was the removal of genes that does not have > 1 count per million reads for all three 
replicates for at least one treatment (MQ water or HsAFP1). Differential expression of genes was 
determined after a within-sample [217] and between-sample [218] normalization, using EdgeR 
packages of Bioconductor. To select differentially expressed genes, a negatively binomial generalized 
linear model on normalized counts was used. To account for batch effects, an additional blocking factor 
for the independent experiments was incorporated in this statistical model. Genes with a False 
Discovery Rate [219] (FDR) < 0.05 and a |log2 (Fold Change)| > 1 (calculated by EdgeR) were 
considered as differentially expressed. To identify important processes in HsAFP1 treatment compared 
to the control treatment, the differentially expressed genes were subjected to Gene Ontology (GO) 
analysis using the Candida Genome Database GO Term Finder Tool [220].  
7.2.7 Minimal Inhibitory Concentration (MIC) 
The Minimal Inhibitory Concentration required to reduce planktonic cell growth by 50% (i.e. MIC50) of 
HsAFP1 as compared to the control (MQ water) was examined according to the standard CLSI protocol 
M27-A3 [221] with minor modifications: an inoculum of S. cerevisiae or C. albicans (OD600 nm = 0.1) 
was suspended in SC or PDB/YPD with 50 mM HEPES pH 7. These cultures were subsequently 
treated with HsAFP1 (2-fold dilution series in MQ water) in a microtiter plate. The MIC50 was 
determined by OD490 nm measurements after 24 h incubation at 30°C for S. cerevisiae or 37°C for  
C. albicans. The MIC50 of HsAFP1 in the presence of other compounds was examined via 
chequerboard assays, as described previously [20]. 
7.2.8 Cell treatment – peptide identification in supernatants  
Exponentially growing yeast cells in YPD were incubated (OD600 nm = 1) with HsAFP1 (50 µg/mL at 
30°C for S. cerevisiae BY4741 WT and 20 µg/mL at 37°C for C. albicans SC5314 WT) or MQ water 
(control) for 150 minutes in PDB/YPD with 50 mM HEPES pH 7. Next, supernatants were collected 
and filter sterilized using a 0.2 µM syringe tip filter (ME Dynagard; VWR International, USA).  
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7.2.9 Identification peptides in supernatants HsAFP1-treated cell cultures by LC/MS-MS 
For S. cerevisiae and C. albicans, 500 µL and 100 µL supernatants, respectively, were lyophilized, 
dissolved in MQ water and separated by SDS-PAGE on a 12% polyacrylamide gel, which was then 
stained with Coomassie Safestain (Invitrogen, USA). Each SDS-PAGE gel lane was entirely sliced and 
proteins were in-gel digested as previously described [222]. Peptides were desalted on stageTips [223] 
and dried under a vacuum concentrator. For LC-MS/MS analysis, resuspended peptides were 
separated by reversed phase chromatography on a Dionex Ultimate 3000 RSLC nano UPLC system 
connected in-line with an Orbitrap Elite (Thermo Fisher Scientific, USA). Database search was 
performed using Mascot (Matrix Science, USA), MS-Amanda [224] and SEQUEST in Proteome 
Discoverer v.1.4 against Uniprot Candida albicans strain SC5314 or SGD Saccharomyces cerevisiae 
BY4741 protein databases. Data was further processed and inspected in Scaffold4 (Proteome 
Software, USA). Peptide identifications were accepted if they could be established at greater than 
77.0% probability to achieve an FDR < 1.0% by the Scaffold Local FDR algorithm or if they have a 
greater probability than 99.0% to achieve an FDR < 1.0% and contained at least 5 identified peptides 
for S. cerevisiae, while peptide identifications were accepted if they could be established at greater 
than 97.0% probability to achieve an FDR < 1.0% by the Scaffold Local FDR algorithm or if they could 
be established at greater than 99.0% probability to achieve an FDR < 1.0% and contained at least 2 
identified peptides in the case of C. albicans. Protein probabilities were assigned by the Protein Prophet 
algorithm [225]. 
7.2.10 Quantification of mRFP-Als5p release in supernatants by fluorescence spectroscopy 
Exponentially growing mRFP-Als5p containing C. albicans BWP17 cultures in YPD were incubated 
with 150 µg/mL HsAFP1 or MQ water (control) in PDB/YPD with 50 mM HEPES pH 7 (OD600 nm = 1) 
for 2.5 – 10.5 h at 37°C. Next, we examined fluorescence of mRFP-Als5p - in the supernatants of the 
treated culture - at 587/610 nm via the fluorescent spectroscope RF5301PC (Shimadzu, Japan). In 
parallel to fluorescent spectroscopy, plating assays were performed to determine MFC50 values, as 
described above.  
7.2.11 Visualization of HsAFP1 internalization by confocal microscopy 
Internalization of HsAFP1 (via fluorescently labelled HsAFP1; BODIPY-HsAFP1) as well as membrane 
permeabilization (via the fluorescent dye propidium iodide (Pi)) were studied in S. cerevisiae BY4741 
WT and Δbst1 mutant yeasts as explained previously (Chapter 6).  
7.2.12 ER stress sensing 
7.2.12.1 Transformation of ER stress GFP-construct to Saccharomyces cerevisiae 
The plasmids containing the ER stress GFP-constructs (pDP010 and pDP012, containing PERO1-GFP 
and PHSP12-GFP, respectively; Table 1) were kindly provided by Prof. P. Walter [226] and Dr. D. Pincus 
[227]. These plasmids were cleaved with Pme1 for 2 h at 37°C, dephosphorylated with antarctic 
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phosphatase and subsequently transformed by the lithium-acetate method (7.2.2.3) to S. cerevisiae 
BY4741 cells. Next, these linear plasmids will integrate via the Leu2 locus into yeast’s genome. 
7.2.12.2 Quantification of ER stress activation in Saccharomyces cerevisiae  
Exponentially growing S. cerevisiae BY4741 WT cells, containing an ER stress GFP-construct 
(7.2.12.1), were incubated (OD600 nm = 1) with 25-100 µg/mL HsAFP1, 2.5-10 µM tunicamycin (Sigma-
Aldrich, USA), 5-20 µM dithiothreitol (DTT; Sigma-Aldrich, USA) or MQ water (control) at 30°C for  
150 minutes in PDB/YPD with 50 mM HEPES pH 7. After treatment, cells were washed and 
resuspended in PBS, after which the fluorescence of the treated culture was examined via the 
fluorescent spectroscope SynergyTMMx (Biotek,USA) at 470/510 nm. In parallel to fluorescent 
spectroscopy, plating assays were performed to determine MFC50 values, as described above. 
7.2.13 Lipid droplet visualization by microscopy 
Exponentially growing S. cerevisiae BY4741 WT cells in YPD were incubated (OD600 nm = 1) with  
100 µg/mL HsAFP1 or MQ water (control) at 30°C for 60 minutes in PDB/YPD with 50 mM HEPES  
pH 7 in the presence of 1 µg/mL nile red (Sigma-Aldrich, USA) or 0.5 µg/mL LD540 (this dye was kindly 
provided by C. Thiele [228]). After treatment, cells were washed and resuspended in PBS, after which 
they were visualized using a Zeiss Axio Imager Z1 fluorescence microscope using a 100x objective 
and band pass (BP) filter sets 38 (excitation wavelengths: BP 470/40 nm and emission wavelengths: 
BP 525/50 nm) and 43 (excitation wavelengths: BP 545/25 nm and emission wavelengths: BP  
605/70 nm) for nile red and LD540, respectively. 
7.2.14 HsAFP1 spot assay 
Spot assays were carried out on PDB/YPD/HEPES agar plates containing C. albicans SC5314 WT 
cells (OD600 nm = 0.15) in the presence or absence of 2 mM FeSO4/CuSO4/ZnSO4, with the metal 
concentration based on the protocol of Yasokawa and colleagues [229]. Five minutes after pouring the 
plates, 5 µL of a 2-fold concentration series of 10 mg/mL HsAFP1 was spotted on the agar plates and 
after drying, the plates were incubated at 30°C. After 20 h, the halos were evaluated for their inner 
diameter.  
7.2.15 Replicative lifespan experiments 
Replicative lifespan experiments were performed on S. cerevisiae BY4742 WT cells as described 
previously [230, 231]. All lifespan experiments were performed on YPD plates buffered with 50 mM 
HEPES containing 1 - 2.5 - 5 or 25 µg/mL HsAFP1 and 2% of glucose, except for the low glucose 
experiments. The latter experiments were carried out on YPD plates with only 0.05% of glucose.  
7.2.16 Vacuolar pH measurements 
The vacuolar pH was measured using the acetoxymethyl ester of 2’,7’-bis-(2-carboxyethyl)-5-,6-
carboxyfluorescein (BCECF-AM; Thermo Fisher Scientific, USA), adapted from the protocol described 
in [232]. Exponentially growing C. albicans SC5314 WT cells were incubated with 2.5-5-10-20 µg/mL 
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HsAFP1, 2 µM concanamycin A (positive control; Sigma-Aldrich, USA) or MQ water (negative control) 
for 150 minutes at 37°C in PDB/YPD with 50 mM HEPES pH 7 (OD600 nm = 1). After 2 h of incubation, 
50 µM BCECF-AM was added to all samples and subsequently incubated for another 30 minutes at 
37°C. Next, samples were centrifuged, washed and resuspended in PBS, followed by fluorescence 
measurements with the ratio of fluorescence intensity from excitation at 490 nm (I490 nm) to the intensity 
from excitation at 450 nm (I450 nm) (both measured at an emission wavelength of 535 nm) used as a 
measure of the vacuolar pH [232] and OD490 nm used as a measure of cell biomass. The fluorescence 
signal (I490 nm/I450 nm) was normalized for the amount of cell present in the sample (OD490 nm). 
7.2.17 Vacuole staining  
C. albicans vacuoles were visualized using the vacuolar dye N-(3-triethylammoniumpropyl)-4-(6-(4-
(diethylamino)phenyl)hexatrienyl)pyridinium dibromide (FM4-64; Thermo Fisher Scientific, USA), 
adapted from the protocols described in [233, 234]. Exponentially growing C. albicans SC5314 WT 
cells were incubated with 20 µM FM4-64 and 2.5-20 µg/mL HsAFP1, 2 µM concanamycin A (positive 
control; Sigma-Aldrich, USA) or MQ water (negative control) at 37°C in PDB/YPD with  
50 mM HEPES pH 7 (OD600 nm = 1). After 30 minutes of incubation, cell were centrifuged and washed 
3 times with PBS and subsequently incubated again with 2.5-20 µg/mL HsAFP1 or controls for another 
2 h at 37°C. Next, samples were centrifuged, washed and resuspended in PBS, followed by 
fluorescence microscopy, using a Zeiss Axio Imager Z1 fluorescence microscope using a 100x 
objective and band pass (BP) filter set 38 (excitation wavelengths: BP 470/40 nm and emission 
wavelengths: BP 525/50 nm). 
7.2.18 Data analysis 
Data were analysed with GraphPad Prism 6. Significant differences were determined on means ± SEM 
with P < 0.05 as considered statistically significant (represented by * in the figures). We assumed that 
all data are normally distributed. For the mRFP-Als5p quantification experiments, significant 
differences between HsAFP1 and the control treatment were determined at all time points via two-way 
ANOVA followed by Sidak multiple comparison. For all dose-response data, sigmoidal curve were 
generated via nonlinear regression and MFC50/MIC50 values were calculated from these fits. To 
determine significance differences between two MIC50(HsAFP1) values, unpaired student t-tests with 
Welch’s correction were performed. For the vacuolar pH experiments, significant differences between 
the negative control and all other treatments regarding vacuolar pH/CFU were determined via one-way 
ANOVA followed by Dunnett multiple comparison. 
7.3 Results 
7.3.1 Transcriptome analysis of HsAFP1-treated Candida albicans cells 
To identify cellular pathways that were induced or repressed in yeast cells upon HsAFP1 treatment, a 
transcriptome analysis was performed on C. albicans cells treated with HsAFP1 or MQ water (control). 
Firstly, the HsAFP1 dose resulting in 50% cell death after 150 minutes (i.e. MFC50 (minimum fungicidal 
concentration resulting in 50% cell death)) was determined as 10 µg/mL via plating assays (data not 
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shown). Next, for 3 independent experiments, cells treated with this concentration were collected and 
subsequently subjected to RNA isolation. RNA-sequencing (RNA-seq) generated an average of 
4,497,979 reads per sample, from which 81.5% was retained after preprocessing of the data and 
mapping of the reads to the annotated coding sequence of the C. albicans SC5314 genome. Using 
EdgeR, expression levels of all genes were generated, after which genes that were differentially 
expressed (FDR < 0.05 and |log(Fold Change)| > 1) upon HsAFP1 treatment were determined.  
570 genes were differentially expressed upon HsAFP1 treatment, with 370 being up-regulated and  
200 being down-regulated. A heat map of all differentially expressed genes was generated by R, with 
the Z-score (per gene) representing the number of standard deviations away from the mean of 
expression of the corresponding gene over all treatments (Figure 1A).  
 
Figure 1: Gene expression levels of Candida albicans SC5314 treated with 10 µg/mL HsAFP1 (Hs1) as compared to the 
control (Ctr) treatment, for 3 independent experiments. (A) Heat map of all differentially expressed genes. Coloured bars 
indicate the Z-score, representing the relative expression of a gene compared to the mean of expression for the corresponding 
gene over all six treatments. Green and red representing respectively down- and up-regulation in comparison to this mean.  
(B) Two-dimensional scaling plot of all 6 samples, with the distance between the samples on the plot approximating the variation 
in their gene expression levels [235]. Distances in the plot correspond to the leading logFC values, which is the average (root-
mean square) log2-Fold-Change for the 500 genes that were most divergent between each pair of samples. 
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To get an idea on the variation in gene expression levels, displayed as logFC values, in all samples, a 
multiple scaling plot was made (Figure 1B). Unfortunately, big variations were found between all 
repeats of 1 treatment, as they do not cluster together in this multiple scaling plot. However, for each 
experiment (i.e. batch), a similar trend in gene expression levels was found between HsAFP1 and the 
control treatment. Hence, for further analysis, we added these batch effects as a blocking factor in the 
statistical model for differential expression analysis. 
To discover the important features in HsAFP1’s mode of action, the top50-induced and -repressed 
genes (Supplementary Table S1-2, respectively) were selected, and Gene Ontology (GO) analysis was 
performed on these genes (Supplementary Table S3-4). Multiple top-induced genes encode for 
proteins located at the cell surface, including mannosyltransferases (MNN15, MNN4-4 and BMT7) 
and other enzymes (PGA13 and KRE1) that play a role in cell wall biosynthesis. Other induced genes 
coding for glycosylphosphatidylinositol (GPI)-anchored cell surface proteins are DAG7, PCL1, 
orf19.6840, ECM331, RBR1, PGA23, PGA39, PGA49 and orf19.675.1, from which DAG7, PCL1 and 
orf19.6840 are mating factor-related and orf19.675.1 is coding for an adhesin-like protein. Genes 
involved in lipid regulation and transport are also up-regulated by HsAFP1 treatment, including 
orf19.2726 (ortholog in S. cerevisiae regulates phosphatidylinositol(PI)-4-phosphate levels), RTA2 and 
RTA4 (sphingolipid base transport). A shift in lipid metabolism is not surprising as we recently 
discovered that HsAFP1 specifically interacts with phosphate-containing phospholipids such as 
phosphatidic acid and phosphatidylinositolphosphates (Chapter 6). Enhanced expression of two 
proteins involved in cell cycle progression and polarized growth, cyclins Pcl1p and Pcl2p, is induced 
by HsAFP1. Genes coding for proteins that are linked to metal ions (calcium-induced: orf19.851 and 
iron-regulated: orf19.675) and multidrug efflux pumps (MDR1) are up-regulated as well as genes 
from the oxidative stress-response (OYE23 and SOD5). Lastly, CEK1, coding for a MAPK kinase 
that plays a role in mating and invasive growth and YIP3, of which the ortholog in S. cerevisiae is 
involved in vesicle transport from the ER to the Golgi complex, are also up-regulated by HsAFP1.  
In the case of repressed genes, multiple genes also coding for cell surface proteins were repressed 
by HsAFP1, such as those coding for GPI-anchored proteins (PGA45, PGA26, PGA7, RBT5, ALS4 
and PLB4.5), adhesin-like proteins orf19.3988 and orf19.5267, chitinase CHT3 and proteins related to 
(phospho)lipid degradation (PLB1, PHO100, PHO112 and PLB4.5). In addition, phosphate 
metabolism (PHO112 and GIT1) and its transport protein (FGR2) are also down-regulated. Various 
virulence factors, such as host cell penetration (PLB1), adhesion (ALS2, ALS3 and ALS4), biofilm 
formation/dispersion (YWP1) and production of cytotoxic peptides (ECE1) were down-regulated by 
HsAFP1, which is not surprising as HsAFP1 can inhibit C. albicans biofilm formation [20]. The 
transcription of various hyphal proteins (ECE1, PGA7 and HWP1) is inhibited as well. Another group 
of HsAFP1-repressed genes are related to iron (ALS3, CFL2, FET34, FET99, FRE10, FRP1, FTR1, 
PGA10, RBT5 and RNR3) or copper homeostasis (CRP1 and FET34). In addition, one gene coding 
for ABC (multidrug) transporter CDR4 and three genes coding for oligopeptide transporters OPT4, 
OPT7 and IFC3, are also repressed by HsAFP1. 
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7.3.2 Gene ontology analysis 
To get a broader view on the pathways involved in HsAFP1’s mode of action in C. albicans, all 
differentially expressed genes (FDR < 0.05 and |log(Fold Change)| > 1) were subjected to Gene 
Ontology (GO) analysis (Supplementary Table S3-4). Groups of genes, clustered according to their 
cellular component, molecular function or biological process that were overrepresented by HsAFP1 
treatment, were identified (Figure 2). GO groups of genes that are up-regulated by HsAFP1 are 
presented in Figure 2A and Supplementary Table S3. They include genes coding for proteins located 
at the cell periphery (cell membrane, cell wall or cell cortex) such as cell wall and cell membrane 
proteins, as well as actin/septin bud neck proteins. This is in line with the results of the top50-induced 
gene analysis. Also genes encoding proteins with an important role in cell reproduction and growth, 
including polarized growth and cellular bud appear significantly up-regulated by HsAFP1 treatment, as 
well as genes involved in carbohydrate-derived metabolic processes, sulphur amino acid 
metabolic process and calcium transmembrane transport.  
When focussing on the GO groups of most down-regulated genes (Figure 2B and Supplementary Table 
S4), again many genes coding for cell periphery proteins are down-regulated, similar to the induced 
genes, generally indicating that the cell surface is significantly stressed and/or restructured by HsAFP1 
treatment. Genes involved in ribosome biosynthesis and rRNA processing, as well as nucleolar genes 
also appear significantly down-regulated, which might point to reduced transcription and translation. 
Similar to the top50-repressed gene analysis, an important group of down-regulated genes are those 
involved in iron assimilation and homeostasis, and transporter genes. The latter mediate transport of 
compounds such as (oligo) peptides, amides, metal ions, water, sugars and phosphate. 
In conclusion, various gene clusters are differentially expressed upon HsAFP1 treatment in C. albicans, 
from which the glycosylphosphatidylinositol (GPI)-anchored protein encoding gene cluster as well as 
the iron assimilation and homeostasis gene cluster were investigated further. Nineteen and 17 GPI-
anchored protein encoding genes are up- or down-regulated, respectively, by HsAFP1 treatment 
(Figure 3). We found altered expression of genes coding for biosynthesis of GPI-anchor building 
blocks, such as phosphatidylinositol (PI) (e.g. CDS1, CHO1, INO1 and PDR16) and 
phosphatidylethanolamine (PE) (orf19.6951), as well as up-regulation of genes involved in GPI-anchor 
biosynthesis genes (e.g. GPI13 and GPI15) (Figure 3). In this study, we further examined the role of 
GPI-anchored proteins in HsAFP1’s antifungal action. 10 out of the top50 down-regulated genes by 
HsAFP1 treatment are involved in iron assimilation and homeostasis (Figure 8A and Supplementary 
Table S2). Therefore, the role of iron in HsAFP1’s antifungal activity was examined as well. To confirm 
the transcriptomic analysis, most experiments were performed on C. albicans cells. However, as this 
was not always feasible, corresponding deletion mutants in S. cerevisiae cells were used as indicated 
further. 
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Figure 2: GO groups that were significantly overrepresented in either the up-regulated (A) or down-regulated (B) genes 
in Candida albicans SC5314 by HsAFP1, as determined via the GO Term Finder at the Candida Genome Database 
website (FDR < 0.05, Supplemental Table S3-4). Relative enrichment of GO groups (%) is based on the amount of annotated 
differentially expressed genes from the corresponding group as compared to the total amount of differentially expressed genes 
by HsAFP1 treatment. 
7.3.3 The role of GPI-anchored proteins in HsAFP1’s mode of action 
As the transcriptomic data point to effects of HsAFP1 on the expression of GPI-anchored proteins and 
GPI-anchor (building block) biosynthesis in C. albicans (Figure 3), we further studied a potential role 
of GPI-anchored proteins in HsAFP1’s antifungal mode of action. Firstly, the role of GPI-anchor 
biosynthesis and GPI-anchor remodelling was studied by screening corresponding haploid or 
heterozygous diploid (in the case of essential GPI biosynthesis genes) S. cerevisiae deletion mutants 
for altered HsAFP1 sensitivity (Table 3 and Supplementary Table S5). We found that deletion mutants 
in GPI-anchor remodelling genes, but not in GPI biosynthesis genes (Supplementary Table S5), are 
more resistant to HsAFP1 than WT yeast, with Δbst1 and Δper1 being at least 20-fold and Δgup1 being 
8-fold more resistant (Table 3). 
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Figure 3: Differentially expressed genes coding for glycosylphosphatidylinositol (GPI)-anchored proteins or their 
synthesis. Up- and down-regulated genes coding for: GPI-anchored proteins, GPI-anchor synthesis, GPI-anchor building block 
biosynthesis and PI-specific PLC, in 10 µg/mL HsAFP1-treated Candida albicans SC5314 WT cells, as compared to the control 
treatment. Coloured bars indicate the Z-score, representing the relative expression of a gene compared to the mean of 
expression for the corresponding gene over all six treatments.  
Table 3: Deletion of GPI-remodelling genes results in increased resistance of Saccharomyces cerevisiae BY4741 cells 
towards HsAFP1 treatment, determined via antifungal activity assays in SC with 50 mM HEPES pH 7. MIC50, Minimum 
inhibitory concentration required for 50% fungal growth reduction. Means ± SEM for n ≥ 3 experiment are presented. Unpaired 
student t-tests with Welch’s correction were performed to determine significant differences between HsAFP1’s MIC50 value of 
the WT and all mutants, with * representing P < 0.05. 
BY4741 strain MIC50 (µg/mL) ± SEM P-value Significance 
WT 25.4 ± 2.6    
Δbst1 > 595 < 0.0001 * 
Δper1 > 595 < 0.0001 * 
Δgup1 205.3 ± 35.2 0.0142 * 
Bst1p is an inositol deacylase that removes the acyl-chain from GPI-anchors in the endoplasmic 
reticulum (ER) immediately after GPI attachment to proteins. This inositol deacylation of GPI-anchored 
proteins is an important step in ER-to-Golgi transport [236]. In human cells it has been shown that the 
mutation of Pga1, the Bst1’s human functional ortholog, resulted in GPI-anchored proteins at the cell 
surface with abnormal GPI-anchors still containing an acyl group. These GPI-anchored proteins were 
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completely resistant to phosphatidylinositol (PI)-specific phospholipase C (PI-Plc) cleavage [237]. As 
our transcriptomic data reveal up-regulation of the PI-Plc genes PLC2 and PLC3 (2.31-fold and  
0.91-fold, respectively) in C. albicans, we hypothesized that the cleavage of GPI-anchored proteins at 
the cell surface, which might be impaired in resistance of Δbst1, could be crucial for HsAFP1’s 
antifungal activity. As the membrane-embedded part of yeast GPI-anchors consists of ceramides, 
cleavage of GPI-anchored proteins might result in increased ceramide levels [238], thereby inducing 
apoptosis [239, 240]. Increased phyto-C24 ceramide levels have been detected in C. albicans cells 
treated with the apoptosis-inducing plant defensin RsAFP2 [25]; however, their origin has never been 
elucidated. In the case of HsAFP1, we hypothesized that apoptosis induction might be the result of 
increased ceramide levels after PI-Plc cleavage of GPI-anchored proteins (see hypothesis 1 in  
Figure 4). 
Hence, we investigated whether HsAFP1 induces the release of GPI-anchored proteins in treated 
yeasts by using LC-MS/MS or fluorescence spectroscopy. Using LC-MS/MS, we identified the proteins 
present in the supernatants of: (i) C. albicans cells treated with 20 µg/mL HsAFP1 (2x MFC50) or the 
control (Supplementary Table S6) and (ii) S. cerevisiae cells treated with 100 µg/mL HsAFP1  
(4x MFC50) or the control (Supplementary Table S7). In the supernatants of the C. albicans cultures 
treated with HsAFP1 or the control, 1298 different proteins were identified, from which 393 were only 
present in the supernatants of the HsAFP1-treated cultures. We identified 2 GPI-anchored proteins 
(i.e. Pga52 and Exg2) in the supernatants of the HsAFP1 cultures treated with 20 µg/mL HsAFP1  
(2x MFC50), while none was present in the control (Supplementary Table S6). Note that we also 
investigated the GPI-anchored proteins in the supernatants of C. albicans cultures treated with  
10 µg/mL HsAFP1 (MFC50) and identified 1 GPI-anchored protein (i.e. Pga52). In the supernatants of 
the S. cerevisiae culture treated with HsAFP1 or the control, 87 different proteins were identified, from 
which 20 were only present in the supernatants of the HsAFP1-treated cultures. None of the  
87 identified proteins was a GPI-anchored proteins (Supplementary Table S7), indicating that the 
cleavage of GPI-anchored proteins does not play an important role in HsAFP1’s antifungal activity. To 
further make sure that HsAFP1 is not inducing cleavage of GPI-anchored surface proteins, the 
presence of mRFP-coupled GPI-anchored proteins (mRFP-Als5p) in the supernatants of HsAFP1-
treated C. albicans cultures was assessed using fluorescence spectroscopy. Our preliminary data 
indicate that mRFP-Als5p is only released in the supernatants at high HsAFP1 doses (> 150 µg/mL) 
and treatment times (> 150 minutes), indicating non-specific GPI-anchored protein releases (data not 
shown). Hence, from all these data, GPI-anchored protein cleavage seems not very important in 
HsAFP1’s mode of action.  
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Figure 4: Two hypothesis on the involvement of GPI-anchored proteins in HsAFP1’s mode of action. Hypothesis 1: 
Apoptosis induction by increased ceramide levels in HsAFP1-treated yeast, resulting from cleavage of GPI-anchored proteins. 
This cleavage is mainly accomplished by PI-Plc (phoshatidylinositol-phospholipase C) enzymes, from which the corresponding 
genes were up-regulated upon HsAFP1 treatment (Figure 3). Hypothesis 2: In WT yeast, HsAFP1 is internalized upon interaction 
with GPI-anchor(ed) (proteins), resulting in membrane permeabilization (MP). This HsAFP1-induced internalization and 
membrane permeabilization does not occur in cells containing different GPI-anchors, such as Δbst1 yeast and mammalian cells. 
Table 4: Deletion of PI-PLC genes results in decreased resistance of Candida albicans cells towards HsAFP1 treatment, 
determined via antifungal activity assays in SC with 50 mM HEPES pH 7. MIC50, Minimum inhibitory concentration required 
for 50% fungal growth reduction. Means ± SEM for n ≥ 3 experiment are presented. Unpaired student t-tests with Welch’s 
correction were performed to determine significance differences between HsAFP1’s MIC50 value of the WT and all mutants, 
with * representing P < 0.05. NS, not significant. 
C. albicans strain MIC50 (µg/mL) ± SEM P-value Significance 
WT (CEC369) 17.13 ± 3.41   
Δplc2/Δplc3 (CEC253) 9.92 ± 0.95 0.1612 NS 
Δplc2 (CEC255) 10.79 ± 2.02 0.2009 NS 
Δplc3 (CEC257) 11.69 ± 1.26 0.2471 NS 
To study this further, we assessed HsAFP1 sensitivity of C. albicans PI-PLC single and double deletion 
mutants, which should be impaired in cleavage of GPI-anchored proteins, and hence, be resistant in 
the case cleavage is crucial for HsAFP1’s antifungal activity. We found, however, a 2-fold reduction in 
Chapter 7 
142 
 
HsAFP1’s MIC50 values of the Δplc2, Δplc3 or Δplc2/Δplc3 mutants, as compared to the corresponding 
WT (Table 2), indicating that cleavage of GPI-anchored proteins is rather involved in yeast tolerance 
to HsAFP1 than in its antifungal mode of action. 
As the cleavage of GPI-anchored proteins seems not involved in HsAFP1’s antifungal mode action 
(hypothesis 1 in Figure 4), we investigated whether GPI-anchored proteins are important for HsAFP1 
internalization in the yeast cell (hypothesis 2 in Figure 4). We recently showed the importance of 
peptide internalization in HsAFP1’s antifungal action in S. cerevisiae (Chapter 6). Here, we investigated 
whether resistant S. cerevisiae Δbst1 cells were unable to internalize HsAFP1. To this end, we used 
green fluorescent BODIPY-HsAFP1 to determine HsAFP1 internalization and red fluorescent 
propidium iodide (Pi) to determine cells with permeabilized membranes, similar as in Chapter 6. In 
contrast to S. cerevisiae WT cells, neither internalization nor membrane permeabilization was 
observed in the resistant Δbst1 cells upon HsAFP1 treatment, as determined via confocal microscopy 
(Figure 5). These results indicate that Δbst1 cells are resistant to HsAFP1 treatments because the 
peptide is not taken up by these cells. Whether abnormal GPI-anchors are responsible for this peptide 
uptake abolishment (as proposed in hypothesis 2 in Figure 4) is not yet clear and will be deliberated 
further in the discussion sector (7.4). 
 
Figure 5: BODIPY-HsAFP1 uptake in Saccharomyces cerevisiae BY4741 WT and Δbst1 mutant cells treated with  
300 µg/mL BODIPY-HsAFP1 and 2 µg/mL propidium iodide (Pi). Confocal microscope images of 150 minutes treated  
S. cerevisiae WT and Δbst1 mutant cells with 300 µg/mL BODIPY-HsAFP1. Scale bar: 5 µm. 
In conclusion, GPI-anchor remodelling enzymes, such as Bst1, play an important role in HsAFP1’s 
antifungal activity. We demonstrate that the cleavage of GPI-anchored proteins is not part of HsAFP1’s 
mode of action in S. cerevisiae and C. albicans, but rather involved in C. albicans tolerance to HsAFP1. 
In addition, we show that HsAFP1 cannot be internalized in S. cerevisiae Δbst1 cells, explaining their 
tolerance to HsAFP1 treatments. 
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7.3.4 Endoplasmic reticulum stress tolerance pathways are induced upon HsAFP1 treatment 
Our transcriptomic data also reveal that HAC1 (role in Ire1-dependent unfolded protein response (UPR) 
activation), GCN4 (role in Gcn4-dependent UPR activation), CRZ1 and RTA2 (role in calcium-
calcineurin-dependent UPR activation) are up-regulated by HsAFP1 treatment in C. albicans, with all 
genes playing a role in yeast tolerance to endoplasmic reticulum (ER) stress (Figure 6). ER stress is 
induced in the presence of excess or misfolded proteins. These proteins are recognized by quality 
control systems in the ER that induce protein degradation and/or removal. Bst1p is such a quality 
control protein that is involved in the regulation of proteasomal degradation of GPI-anchored proteins 
[241]. As our transcriptomic data reveal up-regulation of ER stress tolerance mechanisms, we 
investigated whether ER stress induction is part of HsAFP1’s antifungal action. 
To cope with ER stress, S. cerevisiae cells induce various tolerance mechanisms, including UPR and 
non-UPR (Figure 6) [242, 243]. At least three independent pathways are known to induce UPR genes, 
including Ire1, Gcn4 and the calcium-calcineurin response [244, 245]. Non-UPR ER tolerance 
mechanisms include mitogen-activated protein kinase (MAPK) pathways, such as the Slt2-dependent 
and the osmosensing MAPK pathway, and lipid droplet (LD) formation. As ER stress induces several 
tolerance pathways, we investigated their role in yeast tolerance to HsAFP1 via transcriptome analysis 
in C. albicans and susceptibility tests in S. cerevisiae. Although genes that are responsible for UPR 
activation were found up-regulated by HsAFP1, as determined in C. albicans, their corresponding 
deletion mutants were not hypersensitive to HsAFP1, as determined in S. cerevisiae. On the contrary, 
genes that are responsible for non-UPR activation were not found up-regulated by HsAFP1 in  
C. albicans, while their corresponding deletion mutants in S. cerevisiae were hypersensitive to 
HsAFP1, as is described in more detail below.  
In the classic UPR pathway, UPR genes are regulated by an Ire1-dependent process, in which the 
transcription factor (TF) Hac1 is activated upon splicing by Ire1. Our transcriptomic data reveal that 
HAC1 is up-regulated in C. albicans by HsAFP1 treatment, while IRE1 is not. To validate whether the 
Ire1-dependent pathway is involved in yeast’s tolerance to HsAFP1, we evaluated HsAFP1 sensitivity 
of S. cerevisiae deletion mutants affected in UPR inducing genes. MIC50 values, i.e. minimal inhibitory 
concentration of HsAFP1 resulting in 50% yeast growth inhibition, of the Δire1 or Δhac1 mutants were 
not altered as compared to the corresponding WT (Table 5), indicating that the Ire1-dependent UPR 
activation is not important in governing tolerance to HsAFP1. Therefore Ire1-independent UPR 
activation was investigated. 
Chen and colleagues previously showed that in S. cerevisiae, upon ER stress, Ca2+ homeostasis 
genes (PMR1, SPF1 and CNB1) are required for cell survival, while none of these genes is 
transcriptionally up-regulated [242]. We further investigated the role of calcium homeostasis in yeast 
tolerance to HsAFP1 by evaluating HsAFP1 sensitivity of a S. cerevisiae deletion mutant affected in 
this pathway (Δpmr1). Pmr1 is an ATPase in the Golgi complex that clears Ca2+ from the cytosol [246]. 
The S. cerevisiae Δpmr1 mutant was found hypersensitive to HsAFP1 (7-fold decreased MIC50 values 
as compared to the WT) (Table 5), indicating its role in yeast’s tolerance. Note that, besides increased 
calcium storage, this mutant is also characterized by vacuolar fragmentation [247]. Our transcriptomic 
Chapter 7 
144 
 
data also reveal up-regulation of various (other) calcium transporter genes (CCH1, GDT1, YVC1, 
PMC1, MID1 and FLC2) in C. albicans (Figure 8A), with Cch1, Mid1, Yvc1 and Flc2 increasing cytosolic 
Ca2+ levels, and Gdt1 and Pmc1 decreasing cytosolic Ca2+ levels [246, 248, 249]. Therefore, we 
investigated HsAFP1 sensitivity of S. cerevisiae mutants affected in genes involved in the calcium-
calcineurin pathway (CRZ1 and RTA2; Figure 6) other than Ca2+-transporters. S. cerevisiae Δcrz1 and 
Δrsb1 mutants were found not hypersensitive to HsAFP1 (1.2-fold and 1.1-fold decreased MIC50 
values, respectively, as compared to the WT) (Table 5), with RSB1 being S. cerevisiae’s ortholog for 
RTA2, indicating that CRZ1 and RSB1 seem not involved in yeast tolerance to HsAFP1. On the 
contrary, our transcriptomic data reveal up-regulation of both CRZ1 and RTA2 in C. albicans. Similarly, 
Chen and colleagues recently showed that RTA2’s ortholog, RSB1, was up-regulated upon ER stress 
in S. cerevisiae [242]. These data point to the potential involvement of the calcium-calcineurin-
dependent UPR activation, mainly by Ca2+ transporters, in yeast tolerance to HsAFP1. 
Table 5: ER stress tolerance pathways are involved in the rescue of Saccharomyces cerevisiae BY4741 cells from 
HsAFP1 treatment, determined via antifungal activity assays in PDB/YPD with 50 mM HEPES pH 7. MIC50, Minimum 
inhibitory concentration required for 50% fungal growth reduction. Means ± SEM for n ≥ 3 experiment are presented. Unpaired 
student t-tests with Welch’s correction were performed to determine significance differences between HsAFP1’s MIC50 value of 
the WT and all mutants, with * representing P < 0.05 (marked in bold). NS, not significant. The ER stress tolerance pathway in 
which the genes play a role are indicated in the right column. 
BY4741 strain MIC50 (µg/mL) ± SEM P-value Significance Pathway 
WT 14.77 ± 0.49    
Δire1 14.07 ± 0.35 0.2836 NS Ire1-dependent UPR 
Δhac1 13.63 ± 0.12 0.068 NS Ire1-dependent UPR 
Δpmr1 1.656 ± 0.53 0.0137 * Calcium-calcineurin-dependent UPR 
Δcrz1 11.92 ± 1.22 0.1298 NS Calcium-calcineurin-dependent UPR 
Δrsb1 13.55 ± 0.76 0.2530 NS Calcium-calcineurin-dependent UPR 
Δgcn4 13.23 ± 0.42 0.0517 NS Gcn4-dependent UPR 
Δslt2 3.474 ± 0.65 < 0.0001 * Cell wall integrity MAPK pathway 
Δbck1 4.348 ± 0.21 < 0.0001 * Cell wall integrity MAPK pathway 
Δpbs2 6.983 ± 0.31 < 0.0001 * Osmosensing MAPK pathway 
Δhog1 5.969 ± 0.15 < 0.0001 * Osmosensing MAPK pathway 
 
 
  
 
 
 
Figure 6: Endoplasmic reticulum (ER) stress tolerance pathways in yeast. Unfolded protein response (UPR) gene induction by three independent pathways: (i) Ire1, (ii) calcium-calcineurin and (iii) Gcn4. 
Cell wall (CW) responsive gene induction by the Slt2-MAPK pathway and osmostress responsive gene induction by the osmosensing MAPK pathway. Formation of protective lipid droplets (LD) decreases cell 
death by removing excess of lipids and damaged proteins. Log(Fold Change) values of genes that were differentially expressed in HsAFP1-treated Candida albicans SC5314 cells, are presented, with 
underlined numbers representing up-regulation. Genes, from which the corresponding Saccharomyces cerevisiae deletion mutant is hypersensitive to HsAFP1, are presented in bold.  
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In a third UPR pathway, UPR genes were regulated by a Gcn4-dependent process, in which the TF 
Gcn4 is activated by Gcn2. This Gcn4-dependent pathway is known to be up-regulated under various 
stress conditions, including amino acid starvation, glucose limitations, UV irradiation and ER stress 
[244, 250, 251]. Our transcriptomic data reveal that GCN4 was up-regulated in C. albicans by HsAFP1 
treatment, while GCN2 was not. To validate whether the Gcn4-dependent pathway is also involved in 
yeast’s tolerance to HsAFP1, we evaluated HsAFP1 sensitivity of a S. cerevisiae Δgcn4 deletion 
mutant. The Δgcn4 mutant was found not hypersensitive to HsAFP1 (as MIC50 values were not altered 
as compared to the WT) (Table 5), indicating that the Gcn4-dependent UPR activation is not important 
in yeast tolerance to HsAFP1. These data indicate that the Gcn4 pathway is up-regulated upon 
HsAFP1 treatment in C. albicans, while this pathway is not involved in governing tolerance to HsAFP1 
in S. cerevisiae.  
A first UPR-independent mechanism to cope with ER stress involves MAPK pathways. The Slt2-MAPK 
pathway mainly functions in the maintenance of the cell wall integrity, but other functions including 
promotion of cell survival during nitrogen/carbon starvation, regulation of cell cycle progression and 
controlling of life span have been attributed to the Slt2-MAPK pathway as well [252-254]. Chen and 
colleagues previously showed that genes of this pathway (SLT2, BCK1, RLM1, HCS77, MID2, MKK2 
and MKK1) play a role in cell survival upon ER stress in S. cerevisiae as corresponding deletion 
mutants were hypersensitive to ER stress, but, except for SLT2, these genes are not up-regulated in 
WT yeast under ER stress [242]. Therefore, the role of the Slt2-MAPK pathway in cell survival of treated 
cells was determined by evaluating HsAFP1 sensitivity of S. cerevisiae deletion mutants affected in 
this pathway. Δslt2 and Δbck1 mutants were found hypersensitive to HsAFP1 (4.3-fold and 3.4-fold 
decreased MIC50 values, respectively, as compared to the WT) (Table 5), highlighting the importance 
of the Slt2-MAPK in governing tolerance to HsAFP1 in S. cerevisiae. Regulation of these genes was 
unaltered in C. albicans by HsAFP1 treatment. 
Chen and colleagues previously showed that genes of the osmosensing MAPK pathway (SSK22, 
SSK1, PBS2, HOG1 and SSK2) play a role in cell survival in S. cerevisiae, with PBS2 and HOG1 also 
being up-regulated upon ER stress [242]. Aerts and colleagues previously showed the importance of 
the negative regulation of the osmosensing MAPK pathway in yeast tolerance to HsAFP1, as  
S. cerevisiae Δptc1 and Δsnf4 mutants were hypersensitive to HsAFP1 as compared to the WT  
(Figure 6) [22], with PTC1 and SNF4 both negatively regulating HOG1 [255, 256]. In this study, the 
role of this pathway in cell survival of treated cells was determined by evaluating HsAFP1 sensitivity of 
S. cerevisiae deletion mutants affected in the osmosensing MAPK pathway. Δhog1 and Δpbs2 mutants 
were found hypersensitive to HsAFP1 (2.5–fold and 2.1–fold decreased MIC50 values, respectively, 
as compared to the WT) (Table 5), indicating the potential involvement of the osmosensing pathway in 
governing tolerance to HsAFP1. However, this phenomenon was not observed at cell’s transcriptional 
level, as the regulation of genes from the osmosensing pathway was found unaltered in C. albicans by 
HsAFP1 treatment.  
A sixth described yeast tolerance mechanism to help cells to cope with ER stress is the production of 
LDs. LDs are small organelles that remove excess of lipids and/or damages proteins from the ER by 
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transporting these toxic substances to the vacuole [257, 258]. Next, the vacuole degrades these lipids 
and/or damaged protein by a process that is called micro-autophagy or micro-lithophagy [257]. Good 
functioning ER and vacuoles are therefore crucial to survive under ER stress-inducing conditions. In 
addition, Ruggles and colleagues showed that pathways that impact on LD formation are important for 
preventing cells from lipid-induced cell death, with the fatty acid metabolism modulator ARV1 being 
most important in this process [259]. As a S. cerevisiae Δarv1 mutant was previously found 32-fold 
more sensitive to HsAFP1 as compared to WT [22], we hypothesized that HsAFP1 induces lipotoxicity, 
either by inducing ER stress or vacuolar dysfunction (7.3.5), resulting in apoptosis. Hence, we 
examined the role of LDs in yeast tolerance to HsAFP1 treatment. Firstly, LDs were visualized via 
microscopy in HsAFP1-treated S. cerevisiae cells by using nile red or LD540 as lipid droplet dyes. In 
most but not all experiments, higher LD levels were found in the HsAFP1-treated culture as compared 
to the control treatment (Figure 7). Secondly, we evaluated HsAFP1 sensitivity of S. cerevisiae deletion 
mutants with an altered LD content. S. cerevisiae Δsap185 (characterized for increases LD levels 
[260]), Δsap190 and Δsit4 (characterized for decreased LD levels [260]) mutants were found as 
sensitive as WT yeast to HsAFP1. In line, a S. cerevisiae quadruple deletion mutant 
(Δare1/Δare2/Δdga1/Δlro1) that is affected in neutral lipid synthesis, and hence unable to form LDs 
[215, 261], was found as sensitive as WT yeast to HsAFP1. Together, it is not clear whether LD 
formation is important for S. cerevisiae’s tolerance to HsAFP1.  
 
Figure 7: Lipid droplet formation in Saccharomyces cerevisiae BY4741 cells by HsAFP1 treatment. Yeast cells were 
treated with 100 µg/mL HsAFP1 or the control (MQ water) treatment for 60 minutes in PDB/YPD with HEPES pH 7. LDs were 
visualized via microscopy with the LD-specific dyes nile red or LD540. Bars: 2 µm or 5 µm.  
Together, our results demonstrate that, upon HsAFP1 treatment, some ER stress tolerance 
mechanisms are up-regulated, including the UPR (classic, calcium-calcineurin and Gcn4-dependent), 
as determined in C. albicans, while others, including MAPK (Slt2-dependent and osmosensing) 
pathways, are important for governing tolerance to HsAFP1, as determined in S. cerevisiae. In the 
future, we will investigate whether ER stress is induced upon HsAFP1 treatment, by measuring the 
activation of ER stress response genes. To this end, S. cerevisiae BY4741 WT cells containing a  
PERO1-GFP or PHSP12-GFP integrated in their genome, with ERO1 being an Ire1-dependent UPR target 
gene and HSP12 being an non-UPR (Msn) target gene [227], will be treated with HsAFP1 or the ER 
stress inducers, such as tunicamycin or dithiothreitol (DTT), and subsequently subjected to 
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fluorescence spectroscopy analysis. The intensity of the green fluorescent signal of GFP will be used 
as a measure of ER stress.  
In conclusion, we show that different ER stress tolerance pathways are involved in yeast tolerance to 
HsAFP1. Whether HsAFP1 induces ER stress will be examined in the future. 
7.3.5 HsAFP1 affects the vacuolar function 
As the transcriptomic data also reveal down-regulation of various iron homeostasis genes upon 
HsAFP1 treatment in C. albicans (Figure 8A), we further investigated the role of iron in HsAFP1’s mode 
of action. To this end, we used the iron chelators deferasirox and bathophenanthrolinedisulfonic acid 
(BPS), FeSO4 or used siderophore-chelated iron. We found that the MIC50 values of HsAFP1 against 
C. albicans are 1.5- to 2-fold decreased in the presence of deferasirox or BPS, respectively, and  
2.6-fold increased in the presence of excess iron (Figure 8B-C and Supplementary Table S8), pointing 
to an important role for iron in governing tolerance to HsAFP1. To test whether these effects are iron-
specific, we tested the effect of siderophore-chelated iron or other cations on the antifungal activity of 
HsAFP1 against C. albicans. Siderophore-chelated iron is known to increase cellular iron levels, 
without affecting the ion balance [262]. MIC50 values of HsAFP1 are not affected in the presence of 
the iron-siderophores ferricriocin or triacetylfusarinine C (data not shown), whereas MIC50 values 
against C. albicans are 2.2-10.9-fold increased in the presence of an excess of other divalent cations 
like copper and zinc (Figure 8C). Hence, it seems that the presence of divalent cations in general 
results in a reduced activity of HsAFP1 against C. albicans cells, with ZnSO4 being most effective 
(Figure 8B-C and Supplementary Table S8). This is in line with previous results on the negative effect 
of Ca2+ and Mg2+ on HsAFP1’s activity [18]. Hence, it is currently not clear how the HsAFP1-induced 
down-regulation of genes implicated in iron homeostasis related to a specific aspect of HsAFP1’s 
activity in C. albicans. 
Our transcriptomic data also reveal differential expression of various cation transporter genes in  
C. albicans (Figure 8A), indicating that cellular ion balances are impaired. As vacuoles are yeast’s main 
ion storage organelle, we hypothesized that HsAFP1 induces vacuolar dysfunction. The vacuolar pH 
in functional vacuoles is typically between 5.6 and 6.3, while elevated pH were addressed to affected 
vacuoles [232, 263]. V-ATPases, vacuolar proton pumps, are needed to maintain this low vacuolar pH. 
They consist of multiple subunits and their assembly depends on the low-abundant 
phosphatidylinositolphosphate (PIP), PI(3,5)P2, which is specifically located in the vacuoles [264]. 
PI(3,5)P2 levels are dramatically and transiently changing upon exposure to specific extracellular 
stresses [265, 266]. Decreased PI(3,5)P2 levels lead to enlarged vacuoles with vacuolar pH losses 
[264]. Our preliminary results indicate that PI(3,5)P2 levels are unaltered upon HsAFP1 treatment, as 
determined via fluorescently intensity measurements on PI(3,5)P2-GFP containing S. cerevisiae cells. 
Therefore, we suggest that decreased PI(3,5)P2 levels are mimicked by HsAFP1 binding, as we 
recently identified PI(3,5)P2-HsAFP1 interactions [189]. 
As dysfunctional vacuoles are characterized by elevated pH, we evaluated the vacuolar pH in HsAFP1-
treated C. albicans cells using the vacuolar dye BCECF-AM and the vacuolar H+-ATPase inhibitor 
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concanamycin A as a positive control [232]. We found that the vacuolar pH of HsAFP1-treated cells 
was increased, and this in a dose-dependent manner (Figure 9A). Only at high HsAFP1 doses  
(> 2 MFC50) the vacuolar pH was significantly different from the negative control treatment. Note that 
we previously demonstrated increased HsAFP1-sensitivity of various S. cerevisiae deletion mutants 
affected in vacuolar H+-ATPase [22]. Such mutants (Δvma) were recently found to have a reduced 
replicative lifespan (RLS) under dietary conditions (DR), which could be rescued by iron 
supplementation (Kaeberlein et al., personal communication; University of Washington, Seattle, 98195 
WA, USA). Hence, vacuolar function, iron transport and replicative lifespan under DR seem to be 
linked. Next, we investigated whether HsAFP1, which induces vacuolar dysfunction, also affects RLS 
under DR (0.05% glucose) in S. cerevisiae. Indeed, HsAFP1 only reduced RLS under DR by > 3-fold, 
while no effect on RLS was found under non-DR conditions (2% glucose) (Figure 10). Collectively, 
these results point to HsAFP1-induced vacuolar dysfunction, as determined in C. albicans, affecting 
RLS, as determined in S. cerevisiae. 
 
Figure 8: Reduced antifungal activity of HsAFP1 in the presence of cations. (A) Down-regulation of iron- and copper-related 
genes and up-regulation of calcium-related genes in HsAFP1-treated Candida albicans SC5314 cells as compared to the control 
(Ctr; MQ water) treatment. Colour bars indicate the Z-score, representing the relative expression of a gene compared to the 
mean of expression for the corresponding gene over all six treatments. (B, C) Reduced HsAFP1’s antifungal activity in the 
presence of 2 mM FeSO4, CuSO4 or ZnSO4. (B) 10 mg/mL HsAFP1 was spotted on PDB/YPD with 50 mM HEPES pH 7 agar 
plates containing C. albicans cells. The inner diameter of corresponding halos was scored after 20 h of incubation (white lines). 
Results from one representative experiment are shown. (C) Sigmoidal curve from the dose-response data of HsAFP1 are 
presented with different colours for different metal concentrations; orange = 2 mM, red = 1 mM, blue = 0.5 mM and  
black = 0 mM FeSO4/CuSO4/ZnSO4. Growth in the PDB/YPD with 50 mM HEPES pH 7 medium was analysed by measuring 
OD490 nm. Data are means ± SEM for n = 3 independent experiments. 
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Figure 9: Dose-dependent increase of the vacuolar pH (A) and decrease of survival (B) of Candida albicans SC5314 
cells upon 150 minutes-HsAFP1 treatment in PDB/YPD with 50 mM HEPES pH 7, determined via the vacuolar dye 
BCECF-AM and CFU counting, respectively. Concanamycin A (ConA) and MQ water were used as a positive and negative 
control, respectively. (A) Relative vacuolar pH of the treated cells was measured by the ratio of the fluorescence intensity from 
excitation at 490 nm (I490 nm) to intensity from excitation at 450 nm (I450 nm) (both measured at an emission wavelength of 535 nm) 
normalized for the cell culture biomass (measured at OD490 nm). (B) The amount of viable C. albicans cells after treatment was 
determined via CFU counting. Log10 numbers of CFU ± SEM are presented for n = 3 independent experiments. Significant 
differences in vacuolar pH/CFU between the negative control (MQ water) and all other treatments were determined via one-way 
ANOVA followed by Dunnett multiple comparison, with * representing P < 0.05. 
 
Figure 10: Decrease in replicative lifespan of Saccharomyces cerevisiae BY4742 cells by HsAFP1 treatment under 
dietary restriction (DR) conditions. Replicative lifespan of cells chronologically aged on YPD with 50 mM HEPES pH 7 agar 
plates in the presence or absence of 25 µg/mL HsAFP1 and containing 2% or 0.05% glucose (= dextrose (D)), with 0.05% 
glucose representing DR conditions. Results are presented from n = 1 experiment. 
7.4 Discussion and conclusions 
As the incidence of fungal infections is increasing and these infections receive less attention as 
compared to bacterial and viral diseases [2], there is a need for the development of novel antifungal 
drugs and fungicides. Unravelling the antifungal mode of action is a crucial first step in this process. 
Therefore, Aerts and colleagues previously screened a S. cerevisiae deletion mutant library and 
performed additional biochemical tests to identify important pathways in HsAFP1 antifungal mode of 
action as well as yeast tolerance mechanisms [22]. In this study, we further investigated the mode of 
action of HsAFP1 via transcriptome analysis and additional genetic and biochemical tests. Various 
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genes and/or pathways important for HsAFP1’s antifungal activity or yeast’s tolerance to HsAFP1 were 
identified in both studies, including cell wall organization, stress responses and vacuolar acidification. 
Moreover, Aerts and colleagues already showed that the S. cerevisiae mutant with deletions in the 
genes coding for the GPI-anchor remodelling protein Bst1, is 32-fold more resistant to HsAFP1 
treatment as compared to the WT [22].  
In this study, we identified various pathways involved in HsAFP1’s antifungal activity or in their 
tolerance to HsAFP1, including: biofilm formation, cell wall organization, ER stress and cation transport. 
Various cell wall-encoding genes are differentially expressed upon HsAFP1 treatment in C. albicans, 
from which GPI-anchored protein encoding genes were highly enriched. We prove that GPI anchor 
remodelling (by BST1, PER1 and GUP1) is essential for HsAFP1’s antifungal activity.  
We further elaborated on the role of Bst1 in HsAFP1’s mode of action, thereby focussing on GPI-
anchored proteins. We first hypothesized that cleavage of GPI-anchored proteins, which is supposed 
to be absent in Δbst1 cells based on similar data on human cells [237], is involved in HsAFP1’s action 
(hypothesis 1 in Figure 4). Surprisingly, we show that cleavage of GPI-anchored proteins is not involved 
in HsAFP1’s antifungal activity, but rather in yeast tolerance to HsAFP1. The importance of GPI-
anchored peptides in HsAFP1’s antifungal activity hints us to the GPI-anchored proteins as potential 
targets of HsAFP1. Target binding might result in peptide internalization and membrane 
permeabilization, as shown previously for HsAFP1 in WT S. cerevisiae cells (Chapter 6). As GPI 
anchors of S. cerevisiae Δbst1 cells are different from those of WT cells [236, 237], we hypothesize 
that this HsAFP1-GPI-anchored protein binding is impaired in resistant Δbst1 cells, thereby abolishing 
HsAFP1 internalization (hypothesis 2 Figure 4). In this study, we show that S. cerevisiae Δbst1 cells 
cannot internalize HsAFP1. To confirm the hypothesis on HsAFP1-GPI-anchored protein interactions 
as a basis for peptide internalization, additional experiments should be performed, such as co-
localization studies (using GPI-anchor antibodies [267, 268] and fluorescently labelled HsAFP1 
(Chapter 6)) and HsAFP1 internalization studies on yeast mutants with altered GPI-anchors, other than 
Δbst1. Note that GPI-anchors of fungi and mammalian cells are different [269], which might explain the 
non-toxic effect of HsAFP1 to human cells [20] as well.  
To cope with ER stress, S. cerevisiae cells can induce various tolerance mechanisms, including UPR 
and non-UPR pathways (Figure 6) [242, 243]. Our transcriptomic data reveal HsAFP1-induced up-
regulation of genes from all three (Ire1-, calcium-calcineurin- and Gcn4-dependent) UPR pathways in 
C. albicans, while our HsAFP1-sensitivity tests demonstrate the importance of the (non-UPR) Slt2-
dependent and the osmosensing MAPK pathways in yeast tolerance to HsAFP1 in S. cerevisiae. These 
contradictory results are not surprising as Chen and colleagues previously showed for S. cerevisiae 
that genes up-regulated upon ER stress were not necessarily those genes important for survival during 
this stress [242]. Whether the induction of ER stress tolerance pathways is resulting from HsAFP1-
induced ER stress is not yet clear and will be investigated further in a S. cerevisiae strain containing 
an ER stress construct coupled to GFP (as described previously [227]). 
Although various iron homeostasis genes are down-regulated upon HsAFP1 treatment, we could not 
identify effects of iron on HsAFP1’s mode of action, except for general cation-interfering effect, which 
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was already demonstrated previously for other cation such as Ca2+ and Mg2+ [18]. We propose that 
cations interfere with positively charged HsAFP1 for its binding to negatively charged cell surfaces, 
which is in line with our previous suggestions on electrostatic interactions between HsAFP1 and 
negatively charged phospholipids (Chapter 6). Moreover, the mode of action of various AMPs includes 
such electrostatic interaction [270, 271]. 
Besides iron homeostasis genes, HsAFP1 also induces down-regulation of genes involved in 
phosphate and copper transport and up-regulation of genes involved in calcium transport in  
C. albicans. This is in line with microarray data on C. albicans cells treated with the antifungal drug 
amphotericin B (AmB) [272]. Moreover, iron-regulating genes were also found down-regulated upon 
treatment with the antifungal drug caspofungin (CAS) [272]. This might explain (at least partially) the 
synergy between HsAFP1 and AmB/CAS on C. albicans (Chapter 4).  
With vacuoles being yeast’s main ion storage organelle, we further investigated their potential role in 
HsAFP1’s mode of antifungal activity. We show elevated vacuolar pH upon HsAFP1 treatment in  
C. albicans, pointing to HsAFP1-induced vacuolar dysfunction. However, only at high HsAFP1 doses  
(> 2 MFC50), the vacuolar pH is significantly different from the negative control treatment, suggesting 
that vacuolar dysfunction is rather a non-specific secondary effect than the primary cause of HsAFP1’s 
killing activity. Recently, dysfunctional vacuoles were linked to reduced replicate lifespans of yeasts 
under dietary restrictions, as was determined with S. cerevisiae deletion mutants affected in the 
vacuoles (Kaeberlein et al., personal communication; University of Washington, Seattle, 98195 WA, 
USA). Here, we demonstrate reduced RLS of HsAFP1-treated S. cerevisiae cells under DR, 
strengthening our hypothesis on HsAFP1-induced vacuolar dysfunction. Whether vacuoles were 
enlarged upon HsAFP1 treatment, as is the case for vacuoles with decreased PI(3,5)P2 levels [264], 
will be tested in future experiments via microscopy with the vacuolar dye FM4-64 [233, 234].  
In conclusion, plant defensins, such as HsAFP1, have great potential for the development of novel 
plant defensin-based antifungal drugs and fungicides. Therefore, the antifungal mode of action was 
further unravelled in this study. Our results highlight the importance of GPI-anchored proteins in 
HsAFP1’s mode of action. We hypothesize that HsAFP1 is targeting these cell surface GPI-anchored 
proteins and/or its GPI-anchor, thereby being internalized and killing the yeast cell. From all tested ER 
stress tolerance pathways, the UPR is up-regulated upon HsAFP1 treatment and the Slt2-dependent 
and the osmosensing MAPK pathways appear to be involved in yeast tolerance to HsAFP1. Whether 
HsAFP1 induces ER stress is not yet clear. Lastly, our preliminary experiments indicate that HsAFP1 
also affects the vacuolar function.  
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7.5 Supplementary material  
Supplementary Table S1: Top50 up-regulated genes by HsAFP1 treatment, as compared to the control (MQ water). 
Gene ID Gene Name Log(Fold Change)a FDRb 
orf19.849 orf19.849 6,89 1,18E-20 
orf19.5814.1 orf19.5814.1 5,96 1,53E-99 
orf19.1430 orf19.1430 5,58 3,37E-15 
orf19.675.1 orf19.675.1 5,41 2,16E-63 
orf19.3828 orf19.3828 5,28 5,55E-13 
orf19.6302 PGA39 5,08 1,74E-11 
orf19.711 orf19.711 4,98 4,86E-84 
orf19.3740 PGA23 4,53 2,19E-54 
orf19.5557 MNN4-4 4,29 7,07E-16 
orf19.6920 orf19.6920 4,21 8,81E-30 
orf19.5604 MDR1 4,14 2,06E-24 
orf19.6420 PGA13 4,02 2,54E-52 
orf19.753 MNN15 3,95 1,90E-29 
orf19.1539 orf19.1539 3,85 2,94E-22 
orf19.24 RTA2 3,78 1,33E-41 
orf19.1830 orf19.1830 3,77 1,08E-37 
orf19.1780 orf19.1780 3,72 9,33E-12 
orf19.2649 PCL1 3,71 8,22E-19 
orf19.5353 orf19.5353 3,69 5,47E-13 
orf19.1473 orf19.1473 3,67 3,43E-29 
orf19.2060 SOD5 3,65 1,25E-07 
orf19.3932.1 orf19.3932.1 3,63 1,48E-14 
orf19.1765 orf19.1765 3,57 2,49E-58 
orf19.535 RBR1 3,56 3,19E-20 
orf19.851 orf19.851 3,54 3,40E-22 
orf19.4404 PGA49 3,54 5,69E-08 
orf19.4688 DAG7 3,50 2,78E-38 
orf19.675 orf19.675 3,25 8,97E-34 
orf19.1766 orf19.1766 3,24 3,78E-24 
orf19.2726 orf19.2726 3,21 2,48E-28 
orf19.342 BMT7 3,17 8,32E-25 
orf19.7455 orf19.7455 3,11 7,06E-10 
orf19.2061 orf19.2061 3,08 5,90E-08 
orf19.6595 RTA4 3,03 1,41E-11 
orf19.4377 KRE1 3,03 2,16E-20 
orf19.1344 orf19.1344 3,02 1,34E-23 
orf19.4706 orf19.4706 2,99 1,69E-23 
orf19.6398 orf19.6398 2,99 1,69E-18 
orf19.4477 CSH1 2,97 1,25E-31 
orf19.6224 orf19.6224 2,96 2,51E-10 
orf19.3433 OYE23 2,94 5,28E-20 
orf19.6919 orf19.6919 2,92 9,66E-12 
orf19.5716 SAP4 2,91 4,35E-15 
orf19.4255 ECM331 2,90 6,37E-19 
orf19.6840 orf19.6840 2,89 8,91E-39 
orf19.2049 orf19.2049 2,87 1,71E-24 
orf19.403 PCL2 2,81 2,24E-08 
orf19.2886 CEK1 2,77 9,84E-24 
orf19.6222.1 orf19.6222.1 2,76 4,26E-06 
orf19.5874 orf19.5874 2,75 8,62E-18 
a log(Fold Change) = log2(Fold Change), with the Fold Change being the expression level of a specific gene upon HsAFP1 
treatment, as compared to the control treatment. 
b FDR, False Discovery Rate, FDR-adjusted P-value. 
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Supplementary Table S2: Top50 down-regulated genes by HsAFP1 treatment, as compared to the control (MQ water). 
Gene ID Gene Name Log(Fold Change)a FDRb 
orf19.689 PLB1 -7,21 2,51E-148 
orf19.4424 PHO100 -5,87 2,44E-56 
orf19.7071 FGR2 -3,62 7,22E-10 
orf19.5785 orf19.5785 -3,19 4,84E-12 
orf19.4212 FET99 -3,13 5,56E-10 
orf19.5636 RBT5 -2,97 2,00E-27 
orf19.5141 orf19.5141 -2,95 3,68E-13 
orf19.5674 PGA10 -2,92 3,04E-25 
orf19.1415 FRE10 -2,92 1,06E-40 
orf19.2475 PGA26 -2,87 2,88E-12 
orf19.1264 CFL2 -2,85 8,03E-28 
orf19.7219 FTR1 -2,84 5,71E-35 
orf19.1321 HWP1 -2,84 5,41E-43 
orf19.176 OPT4 -2,80 7,35E-26 
orf19.2870 orf19.2870 -2,80 8,75E-24 
orf19.7283 orf19.7283 -2,70 5,68E-09 
orf19.34 GIT1 -2,70 1,90E-06 
orf19.6688 orf19.6688 -2,54 7,95E-11 
orf19.3988 orf19.3988 -2,53 3,26E-06 
orf19.5845 RNR3 -2,43 4,29E-20 
orf19.4773 AOX2 -2,40 1,02E-15 
orf19.5634 FRP1 -2,38 1,52E-30 
orf19.5673 OPT7 -2,38 1,70E-05 
orf19.2968 orf19.2968 -2,38 1,72E-08 
orf19.1442 PLB4.5 -2,35 4,80E-28 
orf19.2451 PGA45 -2,27 7,70E-17 
orf19.3727 PHO112 -2,27 4,83E-07 
orf19.4555 ALS4 -2,26 3,23E-17 
orf19.5635 PGA7 -2,26 9,26E-25 
orf19.1097 ALS2 -2,24 5,84E-22 
orf19.2681 RBT7 -2,23 3,39E-06 
orf19.7586 CHT3 -2,22 1,36E-20 
orf19.7218 RBE1 -2,17 2,00E-27 
orf19.1368 orf19.1368 -2,15 1,43E-18 
orf19.4972 orf19.4972 -2,13 6,76E-06 
orf19.6817 FCR1 -2,07 6,76E-15 
orf19.3749 IFC3 -1,99 1,07E-16 
orf19.2177 orf19.2177 -1,97 2,88E-06 
orf19.3374 ECE1 -1,97 3,61E-16 
orf19.2467 PRN1 -1,95 3,45E-11 
orf19.510 orf19.510 -1,92 7,22E-06 
orf19.7447 JEN1 -1,89 0,000113 
orf19.4215 FET34 -1,88 2,58E-09 
orf19.1816 ALS3 -1,82 1,58E-17 
orf19.5267 orf19.5267 -1,79 2,88E-19 
orf19.7596 orf19.7596 -1,71 2,25E-07 
orf19.4784 CRP1 -1,69 7,90E-05 
orf19.5079 CDR4 -1,69 1,02E-10 
orf19.3618 YWP1 -1,69 2,93E-07 
orf19.6899 orf19.6899 -1,68 0,000102 
a log(Fold Change) = log2(Fold Change), with the Fold Change being the expression level of a specific gene upon HsAFP1 
treatment, as compared to the control treatment. 
b FDR, False Discovery Rate, FDR-adjusted P-value. 
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Supplementary Table S3: Gene Ontology (GO) analysis of the up-regulated genes. Gene ontology analysis was performed 
on all 369 significantly up-regulated genes by HsAFP1 treatment, as compared to the control (MQ water) (FDR < 0.05 and 
log(Fold Change) > 1) via the Candida Genome Database GO Term Finder Tool on www.candidagenome.org. Gene clusters 
(based on cellular component, biological process or molecular function) that were enriched in the HsAFP1-up-regulated genes 
is presented, with the cluster frequency being the relative amount of genes in the pool that corresponds to a specific gene cluster 
and the FDR (False Discovery Rate) corresponding to the significance by which the gene cluster was selected. FDR < 0.05 was 
considered as significantly enriched.  
GO category Cluster frequency FDR 
Cellular component   
Cell surface 8.1% 3.33e-07 
Cell wall 6.8% 3.11e-06 
Fungal-type cell wall 6.8% 3.11e-06 
External encapsulating structure 6.8% 3.52e-06 
Cell periphery 17.1% 0.00145 
Hyphal cell wall 3.3% 0.00404 
Cellular bud neck 4.9% 0.00649 
Plasma membrane 11.4% 0.00676 
Site of polarized growth 7.0% 0.00682 
Anchored component of plasma membrane 1.6% 0.01023 
Anchored component of membrane 1.6% 0.01442 
Intrinsic component of membrane 11.1% 0.01444 
Cellular bud 5.4% 0.01988 
Extracellular region 6.0% 0.04862 
Biological process   
Fungal-type cell wall organization or biogenesis 9.8% 1.09e-06 
Cell wall organization or biogenesis 10.3% 1.49e-06 
Fungal-type cell wall organization 7.6% 2.12e-05 
External encapsulating structure organization 7.6% 2.40e-05 
Cell wall organization 7.6% 2.40e-05 
Cell wall macromolecule metabolic process 4.3% 8.99e-05 
Polysaccharide metabolic process 4.3% 0.00038 
Cell wall polysaccharide metabolic process 3.0% 0.00133 
Cellular polysaccharide metabolic process 3.8% 0.00544 
Cell wall biogenesis 5.1% 0.00824 
Sulphur amino acid metabolic process 3.0% 0.01214 
Divalent inorganic cation homeostasis 2.7% 0.02620 
Fungal-type cell wall biogenesis 4.3% 0.04656 
Carbohydrate metabolic process 7.0% 0.05972 
Aminoglycan metabolic process 1.9% 0.06677 
Chitin metabolic process 1.9% 0.06677 
Cellular response to mechanical stimulus 1.1% 0.06743 
Amino sugar metabolic process 2.2% 0.07524 
Calcium ion transmembrane transport 1.4% 0.08466 
Cell wall chitin metabolic process 1.6% 0.08781 
Molecular function   
Calcium ion transmembrane transporter activity 1.6% 0.00482 
Hydrolase activity, hydrolysing O-glycosyl compounds 3.0% 0.01066 
Calcium channel activity 1.1% 0.02090 
Hydrolase activity, acting on glycosyl bonds 3.0% 0.07580 
Cation channel activity 1.1% 0.08989 
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Supplementary Table S4: Gene Ontology (GO) analysis of the down-regulated genes. Gene ontology analysis was 
performed on all 200 significantly down-regulated genes by HsAFP1 treatment, as compared to the control (MQ water)  
(FDR < 0.05 and log(Fold Change) < -1) via the Candida Genome Database GO Term Finder Tool on www.candidagenome.org. 
Gene clusters (based on cellular component, biological process or molecular function) that were enriched in the HsAFP1-up-
regulated genes is presented, with the cluster frequency being the relative amount of genes in the pool that corresponds to a 
specific gene cluster and the FDR (False Discovery Rate) corresponding to the significance by which the gene cluster was 
selected. FDR < 0.05 was considered as significantly enriched. 
GO category Cluster frequency FDR 
Cellular component   
Cell surface 17.5% 3.67e-19 
Cell periphery 26.0% 4.12e-09 
Plasma membrane 18.5% 7.13e-08 
Cell wall 10.0% 1.03e-07 
Fungal-type cell wall 10.0% 1.03e-07 
External encapsulating structure 10.0% 1.15e-07 
Extracellular region 11.5% 3.19e-07 
Preribosome, large subunit precursor 6.5% 2.26e-06 
Hyphal cell wall 5.0% 0.00040 
Yeast-form cell wall 4.5% 0.00044 
Preribosome 7.0% 0.00371 
Intrinsic component of membrane 13.5% 0.00771 
Plasma membrane part 5.5% 0.01270 
Nucleosome 2.0% 0.01438 
Integral component of membrane 12.5% 0.01925 
Intrinsic component of plasma membrane 3.5% 0.06221 
Biological process   
Ribosomal large subunit biogenesis 7.5% 1.71e-05 
Cellular iron ion homeostasis 5.0% 0.00014 
Maturation of LSU-rRNA from tricistronic rRNA transcript 
(SSU-rRNA, 5.8S rRNA, LSU-rRNA) 
4.5% 0.00026 
Iron ion homeostasis 5.0% 0.00026 
Amide transport 4.5% 0.00052 
Maturation of LSU-rRNA 4.5% 0.00065 
Iron assimilation by reduction and transport 2.0% 0.00140 
Peptide transport 3.5% 0.00208 
Oligopeptide transport 3.0% 0.00270 
Iron assimilation 2.5% 0.00299 
Cellular transition metal ion homeostasis 5.5% 0.00421 
Transition metal ion homeostasis 5.5% 0.00606 
Oligopeptide transmembrane transport 2.5% 0.00800 
Assembly of large subunit precursor of preribosome 2.0% 0.01841 
Transmembrane transport 12.5% 0.02483 
Single-species biofilm formation 6.5% 0.03428 
Transition metal ion transport 3.5% 0.05982 
Biofilm formation 6.5% 0.06197 
Iron ion transport 2.5% 0.06352 
Single-species submerged biofilm formation 6.0% 0.09999 
Molecular function   
Peptide transporter activity 3.5% 4.22e-05 
Amide transmembrane transporter activity 3.5% 6.53e-05 
Oligopeptide transporter activity 3.0% 0.00026 
Transmembrane transporter activity 12.5% 0.00987 
Transporter activity 14.0% 0.01140 
Oligopeptide transmembrane transporter activity 2.0% 0.02506 
Substrate-specific transmembrane transporter activity 11.0% 0.02900 
Peptide transmembrane transporter activity 2.0% 0.03678 
Substrate-specific transporter activity 12.0% 0.04483 
Transition metal ion transmembrane transporter activity 2.5% 0.06619 
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Supplementary Table S5: Sensitivity of Saccharomyces cerevisiae BY4743 WT and GPI biosynthesis deletion mutants 
towards HsAFP1 treatment, as was determined via antifungal activity assays in SC + 50 mM HEPES pH 7. MIC50, 
Minimum inhibitory concentration required for 50% fungal growth reduction. Means for n = 3 experiment are presented. Fold 
change values, i.e. reduction of MIC50 of HsAFP1 compared to BY4743 WT. 
BY4743 strain MIC50 (µg/mL) Fold change 
WT 20.88  
Δdpm1 22.56 0.93 
Δgaa1 28.73 0.73 
Δgab1 23.65 0.88 
Δgpi1 25.62 0.81 
Δgpi2 27.40 0.76 
Δgpi3 33.50 0.62 
Δgpi8 27.74 0.75 
Δgpi10 26.00 0.80 
Δgpi11 22.72 0.92 
Δgpi12 33.83 0.62 
Δgpi13 32.82 0.64 
Δgpi14 13.54 1.54 
Δgpi15 34.11 0.61 
Δgpi16 23.50 0.89 
Δgpi17 31.33 0.67 
Δgpi18 24.87 0.84 
Δgpi19 23.77 0.88 
Δgwt1 32.85 0.64 
Δmcd4 33.81 0.62 
Δpbn1 28.45 0.73 
Δpga1 32.52 0.64 
Δsmp3 32.57 0.64 
 
Supplementary Table S6: Proteins present in the supernatants of Candida albicans SC5314 cultures treated with 
HsAFP1. Yeast cells were treated with 20 µg/mL HsAFP1 or the control (MQ water) in PDB/YPD with 50 mM HEPES pH 7. 
1298 proteins were identified in the supernatants of the treated cultures via LC-MS/MS analysis and further data processing 
using Scaffold4, from which 393 were only present upon HsAFP1 treatment. The two glycosylphosphatidylinositol-anchored 
proteins were marked in bold. 
Accession Nr NTS a Protein Name Accession Nr NTS a Protein Name 
A0A0A6QCT5 2 EXG2 Q5AA01 3 RIM1 
A0A0A6M4K6 7 PGA52 Q5AH14 4 TOM40 
A0A0A6M9W4 28 ALA1 A0A0A6LZQ0 3 orf19.7459 
Q59R18 18 DED81 A0A0A6Q9X1 2 MSS116 
Q5A782 24 FUN12 A0A0A6LTA1 2 YHB1 
Q5A2A5 20 GRS1 Q5A5A0 4 PRX1 
Q5AFK6 20 RPA135 Q5A6S0 2 MRPL40 
A0A0A6MCM9 11 RPL2 Q5A092 3 MRP7 
Q5A900 11 RPS21 A0A0A6LWF4 3 orf19.2414 
A0A0A6QAT8 16 orf19.5260 A0A0A6M1L4 1 ATP17 
A0A0A6MLS8 17 orf19.7392 A0A0A6LX61 2 orf19.5660.1 
A0A0A6LTP3 22 orf19.7590 Q59YG5 2 TIM23 
Q5AF98 17 ZUO1 Q5ALV9 2 COX13 
A0A0A6MRC7 16 orf19.4931 A0A0A6M9B3 2 orf19.2150 
A0A0A6MRP6 11 TIF46 A0A0A6MQM4 2 QCR8 
A0A0A6M9S7 18 TUP1 Q5A646 2 MRP8 
A0A0A6Q3E2 14 SUB2 Q5AL30 2 orf19.4947 
Q5AG43 14 RPS5 A0A0A6ML36 2 QCR9 
Q5AFK1 13 CTR9 A0A0A6M645 2 COX8 
Q5AGF6 15 GCD11 A0A0A6MP49 2 orf19.3154 
Q5A6R1 8 RPL15A A0A0A6MPB3 2 MRP1 
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A0A0A6PCW5 14 orf19.512 Q5A6M6 23 SEC26 
Q5AB84 8 NSR1 A0A0A6LX12 14 VMA2 
Q5A1M1 4 TFS1 A0A0A6Q908 16 SEC18 
Q5A7K0 7 RPS24 A0A0A6MT65 9 ERO1 
Q5A389 7 RPS20 A0A0A6LM35 5 SEC14 
Q5ABC3 9 TUF1 Q5AND9 5 ARF2 
Q5ANG6 2 SEN1 Q5ALU8 7 STT3 
Q5A779 7 DRG1 A0A0A6PF50 5 GDA1 
Q5A934 5 ZPR1 A0A0A6MIT4 6 SMY2 
A0A0A6MRV8 9 NOP7 A0A0A6MNU9 5 orf19.2257 
A0A0A6MW59 8 TIF34 A0A0A6MJ50 2 SEC16 
A0A0A6MJL8 8 MAK11 A0A0A6LZZ8 4 SEC13 
A0A0A6MH88 5 RPL43A Q5ADN7 3 SRP68 
Q5A5P8 3 TIF11 Q59V63 3 EMP24 
A0A0A6MQ12 5 UTP21 Q59R99 4 VPH1 
A0A0A6M9A4 4 RPL25 A0A0A6P9J6 3 YPT31 
A0A0A6MLB1 3 TRM5 Q5AI00 2 YPT1 
A0A0A6QCZ0 6 ARX1 A0A0A6PN09 3 orf19.2168.3 
Q5ANE4 4 NOP14 A0A0A6PS36 3 SEC62 
A0A0A6M9V5 2 NUP82 Q5A1M5 4 CVB1 
A0A0A6QA34 3 YTM1 A0A0A6LCS7 2 SEC4 
A0A0A6MSM8 2 TIF35 Q5A789 4 DPM1 
A0A0A6LYP7 5 YRA1 Q59U59 5 APR1 
A0A0A6MTN8 6 orf19.5239 A0A0A6MBW2 3 VRG4 
A0A0A6M4M6 5 GBP2 Q5A006 2 RET3 
Q59Z35 3 SNF12 Q5AMQ2 2 CLC1 
A0A0A6MVF7 4 orf19.6220.4 A0A0A6PGX7 3 CPY1 
Q5ABC9 3 RPO41 Q59X92 3 ERV46 
Q59ZV3 3 NPL3 Q5AMR7 2 ERV29 
A0A0A6MPT8 5 EBP2 A0A0A6MTG1 2 ARL3 
A0A0A6LEX9 6 LOS1 Q5AB94 2 VPS29 
A0A0A6PFL3 6 SEC61 Q59T42 2 VPS35 
A0A0A6P843 3 EFB1 Q5ACV4 2 PEX30 
A0A0A6P8Y0 4 RRP3 Q59ZX5 4 YPT52 
A0A0A6MMN0 6 UTP4 A0A0A6QAI0 2 ERP5 
Q59R60 6 ENP2 Q5AMM9 2 MAK3 
A0A0A6ML58 4 NAN1 Q59ZG1 3 ERP3 
A0A0A6LY83 3 RPS30 A0A0A6MMS5 3 GTT11 
Q5AJA5 6 PRP43 A0A0A6MPM1 2 VTI1 
A0A0A6QC91 5 MBF1 Q59LB0 4 orf19.5689 
A0A0A6Q6E5 5 RPC40 A0A0A6M696 2 DCW1 
A0A0A6M618 1 orf19.6882.1 Q59Y27 2 ANP1 
Q59YN8 1 SGN11 Q59KU5 2 VMA6 
A0A0A6Q316 4 PWP1 Q5AJS1 10 RNA1 
Q5AG96 5 orf19.4283 Q5AMN0 9 POL30 
A0A0A6MDX3 4 RPL42 Q5ACX4 7 RFA1 
Q5AC00 4 MRT4 A0A0A6MTV6 8 DHH1 
Q5ANH5 1 RPP2B A0A0A6MG09 5 TOP1 
Q5ADU3 2 orf19.6748 A0A0A6NUU3 8 RVB2 
Q59UR3 2 SWI1 A0A0A6LCF7 6 NAP1 
Q59YL2 3 RPN8 A0A0A6LT47 7 orf19.3129 
Q5AAK4 3 MRPL9 A0A0A6MQ97 2 SNF2 
A0A0A6LV47 3 orf19.6415.1 Q59N42 5 GLC7 
Q59YJ9 3 GIS2 Q59ZG3 5 KAP104 
A0A0A6MHX7 3 orf19.3978 Q5A8H8 5 PBP2 
Q59Y40 2 UTP15 A0A0A6LWX3 3 CDC10 
Q59P36 3 MAK16 Q59VN4 5 HHF22 
Q5ADS5 2 NOP13 A0A0A6MQ10 7 POB3 
Q5ALV6 2 RPS26A Q59X42 4 SGT1 
Q5ADY1 1 UTP9 A0A0A6MJD6 4 PRI1 
Q59ZG6 2 RPF2 A0A0A6MK39 3 orf19.4622 
Q5A901 4 NAB2 A0A0A6MAQ1 2 RSC2 
Q5A462 2 RPB3 Q5ACU9 4 NDT80 
A0A0A6MU64 3 RPL37B Q5ALV8 2 CDC55 
A0A0A6LUU7 2 TIF6 A0A0A6PQU3 2 ARP4 
Q5AAR2 3 SCD6 Q5AA41 2 RGD1 
A0A0A6MUQ2 2 orf19.6234 Q59WE2 2 SKP1 
Q59Y36 2 PAF1 Q59W54 2 SMT3 
Q5AFH1 3 SGN12 A0A0A6MJ20 2 RCF3 
A0A0A6LWS6 2 orf19.500 A0A0A6M642 2 orf19.792 
A0A0A6MIZ0 3 MAP2 Q59UQ4 1 orf19.5666 
Q5ANL8 2 URB2 A0A0A6MLN5 3 SOD1 
Q5A6M9 3 NHP2 Q5A6Z6 12 YDJ1 
Q59LQ6 1 SUI1 Q5ACP0 6 AHA1 
A0A0A6QB66 2 orf19.6230 Q5A678 9 SSZ1 
A0A0A6MWZ8 2 ARP7 A0A0A6MRU7 6 DDR48 
A0A0A6MN61 7 ERG20 A0A0A6M9C2 8 CDC37 
Q5AFP7 18 GPH1 Q5AK16 9 CCT3 
Q5ADT4 6 GCY1 A0A0A6MPX2 6 GRE2 
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Q5A1L8 8 URA4 A0A0A6MUQ6 10 CAT1 
Q59QQ1 10 GLN1 A0A0A6L7X5 6 ALO1 
A0A0A6QCN7 7 GAL10 A0A0A6MIB3 5 HSP12 
A0A0A6MX15 11 RPN3 Q59XV1 6 CMK2 
Q59MU3 15 ARO10 A0A0A6MHA0 5 orf19.3649 
Q5ADR2 9 PRO2 Q5A8Z4 1 SOD2 
Q59NL9 6 orf19.6596 Q5A0I8 4 SGT2 
Q59T95 10 CYS4 Q5A8J9 4 SBA1 
A0A0A6M7Y3 11 IMH3 Q5AD39 4 MXR1 
Q5AIA2 11 HOM6 Q5AGY4 4 orf19.6554 
Q5A3K7 9 SER33 Q5A857 2 orf19.3272 
Q59KP3 12 TRP5 A0A0A6M5D5 3 SOD3 
A0A0A6LSH4 7 INO1 Q59WL5 2 ASR1 
A0A0A6PGE6 4 URA5 A0A0A6PQH4 2 HCH1 
Q5AET6 3 PNP1 Q59Z58 1 PST1 
Q5A0L0 7 RNR21 Q5ACN1 2 TRX1 
A0A0A6M2P2 10 RPT2 A0A0A6MCW1 14 CBF5 
Q5ACW9 5 ARO8 Q5AND4 10 RDI1 
A0A0A6Q2A1 6  LYS1 A0A0A6MUL3 9 TUB2 
Q5A747 6 OLE1 Q5A6P9 10 SRV2 
A0A0A6MMP9 3 PCT1 A0A0A6MAP4 6 CDC12 
A0A0A6MRU9 6 ARO3 Q5A094 5 SLA2 
A0A0A6L8H3 4 PRE8 A0A0A6MNT3 6 AIP2 
A0A0A6Q3B2 5 orf19.2755 A0A0A6LP27 2 COF1 
A0A0A6LCE6 3 IDP2 Q59Z11 1 ARP3 
Q5A850 7 GSY1 Q5AMD1 3 ENT2 
Q59YH1 7 SOL2 A0A0A6M5Y0 5 CRN1 
A0A0A6PLD2 2 HPT1 Q59V79 4 ARC40 
A0A0A6M9F7 2 GCV1 A0A0A6MUB7 2 SVL3 
Q5AJZ5 2 PRE1 Q5AAL2 1 YRB1 
Q59X47 4 KIS1 A0A0A6MK69 3 RVS167 
A0A0A6P5F2 3 orf19.3991 Q5A9X7 4 ARP9 
Q59YT2 2 PRE3 A0A0A6LCM2 1 MLC1 
Q5AC33 3 ADH7 A0A0A6PGQ0 3 orf19.3235 
A0A0A6PR39 5 UBP6 Q5AA47 3 ARC35 
A0A0A6LA75 1 BNA1 A0A0A6MPX1 2 END3 
Q5A472 2 ARO9 A0A0A6M689 2 SCP1 
Q5AND8 4 UFD2 Q5A215 2 ALF1 
Q5AD02 2 DAL2 A0A0A6MQ11 7 MNT1 
A0A0A6MPE6 2 MET10 Q5A3Z7 12 ERG13 
Q5AB90 3 GSF2 A0A0A6M278 7 PMT1 
A0A0A6MLI5 3 ERG8 A0A0A6MSH8 6 CHS3 
Q59P56 3 ILV1 A0A0A6LUJ1 3 orf19.590 
A0A0A6M9Q4 2 APA2 A0A0A6MB48 9 GLC3 
A0A0A6LVE5 3 TPS1 A0A0A6MN12 3 CDR1 
A0A0A6MKK9 3 THR1 A0A0A6M0H8 6 PMT2 
Q5A6S2 3 RPT4 Q59WK3 4 WBP1 
Q59NM2 2 PLB3 Q59YT5 7 OST1 
A0A0A6MKB8 2 PRO3 A0A0A6M9P7 6 orf19.1549 
Q59PQ2 2 PUP3 Q59L90 1 HET1 
A0A0A6MSR8 5 orf19.399 A0A0A6MN02 3 CHS5 
A0A0A6MAL2 3 orf19.3689 A0A0A6M114 5 LMO1 
Q5A868 2 SIS2 Q5A409 4 CHS2 
Q5A099 4 PRB12 A0A0A6MSS5 2 DFG5 
A0A0A6NSK6 4 ADH5 A0A0A6Q5H8 2 MNT2 
A0A0A6MRP5 2 HGT8 A0A0A6M9S5 2 BMT4 
A0A0A6MTM4 2 RPN1 A0A0A6MV13 1 MNN11 
A0A0A6PLI5 1 ADE8 A0A0A6QBE9 2 KTR4 
A0A0A6MLL4 2 CPA1 Q5AK26 1 OST3 
A0A0A6MVB2 1 RIB4 A0A0A6MFX1 4 CTR1 
A0A0A6NNC1 1 UBC4 Q59Q40 5 RTA2 
Q59L95 2 ARD Q5ANK2 4 PKC1 
A0A0A6MJ70 1 orf19.4316 A0A0A6PNQ6 5 RAS1 
Q59SD0 2 RPN12 A0A0A6LCD0 6 RHO1 
A0A0A6MN07 3 UGA1 Q5ABD7 2 CMP1 
A0A0A6PF19 3 orf19.7357 A0A0A6QBK0 4 FMA1 
A0A0A6MV79 3 CUE5 A0A0A6MPP5 4 IFR1 
Q5AN02 1 ILV6 Q5A8I0 2 SNF4 
A0A0A6LJ65 2 DOG1 A0A0A6LW72 2 ADP1 
A0A0A6MQN6 2 URE2 Q59ZI9 2 CKA2 
A0A0A6Q3G3 2 orf19.5665 A0A0A6LUS5 2 FRE7 
A0A0A6ML84 2 RUB1 A0A0A6M0Y0 2 MKC1 
A0A0A6MQN9 2 APT1 Q59S64 2 HRR25 
A0A0A6MHG1 14 QCR2 Q5A4H1 2 KRE6 
A0A0A6MWD0 7 HMG1 Q5AIQ3 1 orf19.6464 
Q5AEC9 7 NDE1 A0A0A6MFM0 1 orf19.1180 
Q5AJX0 9 HTS1 Q5AMR0 3 HGH1 
Q5A4I4 6 RCT1 A0A0A6QBB6 2 orf19.2794 
A0A0A6MSH4 9 MEF1 A0A0A6LWH7 1 NMT1 
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A0A0A6MPD1 8 CCP1 A0A0A6M5T3 4 RBP1 
Q5A7M2 5 TIM44 Q5A9D8 2 orf19.2527 
A0A0A6M226 5 ETR1 A0A0A6LVF0 2 orf19.6635 
Q59TD5 8 NDH51 A0A0A6MHI1 4  
Q5AH07 7 NUC2 A0A0A6MQI7 5  
Q59KV1 6 YCP4 A0A0A6Q7Q5 2 IFO2 
Q5A7P7 7 ATP5 A0A0A6PNW6 2 orf19.2125 
Q59ZJ2 4 CYT1 Q5AML3 2 orf19.4633 
Q5ALV5 2 COX4 Q5AAG7 2 orf19.7522 
Q5A2C7 3 RSM22 Q59WG0 4 HNT1 
Q59WW7 3 GPS2 Q5A885 2 SRP54 
Q5AJC2 2 AFG3 A0A0A6MKL1 3 orf19.577 
A0A0A6Q1E1 4 orf19.585 A0A0A6MR58 2 orf19.1368 
Q5APK5 5 COX5 Q5A0B0 2 UME1 
Q59TC4 3 LYS22 Q59XY7 2 orf19.1764 
Q5A967 3 CRC1 A0A0A6MQE2 2 orf19.3615 
A0A0A6MTF5 3 RSM25 A0A0A6LPK2 2 orf19.4263 
Q5ABB1 2 TTR1       
a NTS, i.e. normalized total spectra, relative enrichment of a specific protein in the supernatants of HsAFP1-treated cells. 
Supplementary Table S7: Proteins present in the supernatants of Saccharomyces cerevisiae BY4741 cultures treated 
with HsAFP1. Yeast cells were treated with 100 µg/mL HsAFP1 or the control (MQ water) in PDB/YPD with 50 mM HEPES  
pH 7. 87 proteins were identified in the supernatants of the treated cultures via LC-MS/MS analysis and further data processing 
using Scaffold4, from which 20 were only present upon HsAFP1 treatment. 
Accession Nr NTS a Protein Name 
YKR043C_BY4741 8 SHB17 
YJL167W_BY4741 6 ERG20 
YLR301W_BY4741 10 HRI1 
YEL047C_BY4741 15 FRD1 
YDR368W_BY4741 4.5 YPR1 
YHR179W_BY4741 4.5 OYE2 
YER062C_BY4741 4 GPP2 
YNL141W_BY4741 3.3 AAH1 
YNL134C_BY4741 3 YNL134C 
YGR234W_BY4741 3.3 YHB1 
YKL096W_BY4741 6 CWP1 
YBR053C_BY4741 2.2 YBR053C 
YJR070C_BY4741 4.2 LIA1 
YFR053C_BY4741 6 HXK1 
YGR208W_BY4741 5 SER2 
YHR047C_BY4741 9 AAP1 
YJR069C_BY4741 2.2 HAM1 
YKL157W_BY4741 7.5 APE2 
YFR044C_BY4741 3.75 DUG1 
YGL157W_BY4741 5 ARI1 
a NTS, i.e. normalized total spectra, relative enrichment of a specific protein in the supernatants of HsAFP1-treated cells. 
Supplementary Table S8: Significant reduction of the antifungal activity of HsAFP1 in the presence of FeSO4, CuSO4 or 
ZnSO4 for Candida albicans SC5314 cells, as was determined via antifungal activity assays in PDB/YPD with 50 mM 
HEPES pH 7. MIC50, Minimum inhibitory concentration required for 50% fungal growth reduction. Means ± SEM for n = 3 
experiment are presented. Unpaired student t-tests with Welch’s correction were performed to determine significance differences 
in the MIC50 value of HsAFP1 in the presence or absence of 2 mM FeSO4, CuSO4 or ZnSO4, with * representing P < 0.05 
(marked in bold). 
Treatment MIC50 (HsAFP1) (µg/mL) ± SEM P-value Significance 
HsAFP1 4.42 ± 0.43   
HsAFP1 + 2 mM FeSO4 11.23 ± 1.09 0.0146 * 
HsAFP1 + 2 mM CuSO4 9.58 ± 0.80 0.0036 * 
HsAFP1 + 2 mM ZnSO4 49.66 ± 2.06 0.0015 * 
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Contributions of external research groups to the chapter ‘Development and implementation of 
a diagnostic assay for fungal infections’. 
All FO-SPR experiments were performed in collaboration with Prof. Jeroen Lammertyn, Dr. Dragana 
Spasic, Dr. Filip Delport and Jiadi Lu (MeBioS-Biosensor group, Department of Biosystems,  
KU Leuven, Willem de Croylaan 42, 3001 Heverlee, Belgium).  
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Abstract 
One main reason for the high mortality rate associated with invasive fungal infections, is the lack of 
accurate and fast diagnostic techniques. Therefore, we developed a diagnostic assay based on the 
fungal-specific plant defensin RsAFP2 as bioligand and fiber-optic surface plasmon resonance  
(FO-SPR) as detection technology, called the FUNGDETECT sensor. Using this sensor, direct 
detection of Candida albicans cells was not possible. However, detection of fungal cells was 
accomplished via an indirect way, using competitive ELISA assays. In such experiments, yeasts cells 
were pre-incubated with a known RsAFP2 concentration, after which the non-bound RsAFP2 
molecules were quantified in a competitive ELISA experiment. A next step would be the implementation 
of the competitive assay on the FO-SPR technology. 
8.1 Introduction 
The incidence of invasive fungal infections (IFIs) is increasing worldwide. The vast majority of the IFIs 
is caused by Candida spp. (73%) and Aspergillus spp. (13%), with C. albicans being the most prevalent 
yeast species [6]. In Belgium, candidemia (IFIs caused by Candida spp.) occurs yearly in 5 on 100,000 
persons, in total representing 555 cases of which 213 resulting to death [273]. Immunocompromised 
patients suffering from for example cancer or HIV/AIDS, or patients with organ transplantations or at 
the intensive care unit are most susceptible for such IFIs ([274-276]). An early detection of the fungal 
infection and identification of the pathogen are crucial for the early initiation of the treatment, with the 
most appropriate drug, leading to full recovery of the patients.  
Nowadays, there are three main diagnostic techniques used in hospitals, being culture-, DNA- or 
antigen-based. These techniques are not sufficient for the detection of IFI, as none of them combines 
high sensitivity with fast time-to-result and easy handling. Hence, there is a need for a rapid, accurate 
and simple diagnostic tool to detect IFIs in patient samples. In collaboration with the MeBioS-Biosensor 
group (headed by Prof. Lammertyn, Department of Biosystems, KU Leuven), we therefore aimed at 
developing a prototype of point-of-care device for the detection of fungal infections using the fiber-optic 
surface plasmon resonance (FO-SPR) technology and antifungal plant defensins as a fungal-specific 
bioligands (called FUNGDETECT sensor). 
FO-SPR is a technology that can be used for the quantification of biomarkers and for the determination 
of kinetic parameters on the binding reactions. This technology, newly developed at the MeBioS-
Biosensor group, has already been used for the detection of DNA and antigens [277-280]. Furthermore, 
FO-SPR can be used for the quantification of biomarkers in complex matrices such as food, as shown 
for the peanut allergen Arah1 [281]. 
Plant defensins are small, highly structured peptides [20, 42, 43, 136, 137] that possess biological 
activity towards a broad range of organisms. Their activity is primarily directed against fungi, but 
bactericidal and insecticidal actions have also been reported [102-104]. The plant defensin RsAFP2, 
from radish seeds, is known for its fungal-specific activity [18], and binds to fungal-specific 
glucosylceramides (GlcCer) in fungal membranes [27]. These fungal-specific GlcCer structures are not 
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present in bacteria, nor plant or human cells, thereby explaining the high selectivity of RsAFP2 for 
fungi, but not for bacteria. These selective fungal binding properties of RsAFP2 make this plant 
defensin an ideal candidate to serve as a bioligand on the FUNGDETECT sensor, enabling detection 
of fungal cells, but not of bacterial cells, in samples.  
8.2 Materials and methods 
8.2.1 Materials 
8.2.1.1 Strains  
The yeast strains used in this study were Candida albicans strain SC5314, CAI4 and CAI4-derived 
gcs1 deletion mutant. The bacterial strain used was Escherichia coli K12. Yeast strains and bacterial 
strain were cultured in YPD (1% yeast extract, 2% peptone and 2% glucose) at 30°C and in LB Broth 
(1% peptone, 0.5% yeast extract and 0.5% NaCl (VWR International, USA)) at 37°C, respectively, with 
all products purchased from LabM (UK) unless stated otherwise. 
8.2.1.2 Materials 
The plant defensin RsAFP2 was produced and purified using the protocol described in [43]. 
Glucosylceramides from Tamogitake (fungi), soy and human were respectively purchased from 
Nacalai Tesque (Japan), Avanti polar lipids (USA) and Matreya LLC (USA). Optical fibers were 
purchased from Thorlabs (USA). 
Anti-RsAFP2 sera from rabbit were used as previously described in [27]. Polyclonal anti-Candida 
albicans antibodies were purchased from GenWay BioTech (USA), while streptavidin-AP-conjugate 
and goat anti-rabbit IgG (whole molecule)–AP antibody were obtained from Sigma-Aldrich (USA). Both 
monoclonal anti-IFX antibodies (MA-IFX8E10), kindly provided by Prof. Gils [282-284], and goat  
anti-mouse IgG (H&L)-HRP (Abcam, UK) were utilised as non-GlcCer binding antibodies. ELISA plates 
were purchased by Greiner Bio-One (Austria). 4-nitrophenyl phosphate (4-NPP) disodium salt and 
Tween20 were respectively provided by Sigma-Aldrich (USA) and AppliChem GmbH (Germany). 
All buffer reagents were obtained from Sigma-Aldrich (USA), unless stated otherwise. Carboxylic acid-
SAM formation reagents were produced by Dojindo Laboratories (Japan).  
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC), N-hydroxysuccinimide (NHS) and bovine 
serum were obtained from Thermo Fisher Scientific (USA). AuNPs EMGC20 with the diameter of  
20 nm were provided by BBI Solutions (UK). Bovin serum albumin (BSA), gelatin and glass beads 
(425-600 µm diameter, acid-washed) were supplied by Sigma-Aldrich (USA). Phosphate buffer saline 
(PBS), 2-(N-morpholino)ethanesulfonic acid (MES) and sodium acetate buffers were 10 mM at pH 7.4, 
50 mM at pH 6 and 10 mM at pH 5, respectively. 10 mM Tris buffer was used at pH 8 (+ 0.5% BSA + 
0.14 M NaCl) or pH 8.6.  
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8.2.2 Methods 
8.2.2.1 Immobilization of antibody or plant defensins on fiber optic (FO) probes for glucosylceramide 
(GlcCer) or yeast cell detection 
Before coupling a bioligand to the fiber optic probe (FO probe), the glass fiber needs to be coated with 
several functional layers such as a gold and a PEG layer, as described in [279]. Optical fibers were 
prepared following the protocol of Lu and co-workers [282] with minor adaptations. To improve to speed 
of the assay for fiber functionalization and target detection, the fiber was subsequently dipped in (all 
different functionalization or detection) solutions that were continuously shaken at 1200 rpm. 
Glucosylceramide (GlcCer) detection was accomplished by exposing functionalized FO probes to 
either GlcCer in solution (100 µg/mL GlcCer in 150 mM NaCl + 0.5% BSA) or GlcCer-functionalized 
AuNPs (OD1). Yeast cells detection was performed on either intact or lysed C. albicans SC5314 cells 
(10-fold dilutions series of 100-106 cells/mL), wherein cell lysation was accomplished by vigorously 
shaking cell cultures with glass beads using a FastPrep® machine (MP Biomedicals, USA).  
In all FO-SPR assays, the detection of the target with the FO probe took 8 minutes. For the yeast cell 
assay, this could be followed by an amplification step of 15 minutes in C. albicans antibody-coated 
AuNPs solution and a dissociation step of 15 minutes in detection buffer.  
8.2.2.2 Immobilization of antibody or plant defensins on gold nanoparticles (AuNPs) 
The protocol described by Lu and colleagues [282] was used for the immobilization of Candida albicans 
antibodies or glucosylceramides (GlcCer) on AuNPs. In the standard procedure, AuNPs with adjusted 
pH were incubated on a rotator with 5 µg/mL antibodies or GlcCer at room temperature for 20 minutes. 
After a blocking step of 1 h, the functionalized AuNPs were centrifuged and resuspended in blocking 
buffer (PBS + 0.5% BSA). The OD of the AuNPs was measured using a spectrometer (SpectraMax 
M2e, Molecular Devices, USA) after which the OD was adjusted to OD1 (7 x 1011 AuNPs/mL). The 
adjustment of the pH of the AuNPs in the first step of the protocol, was different for both types of 
ligands. pH 7.4 and pH 9-10 were used for antibody and GlcCer immobilization on AuNPs, respectively. 
Quantification of the GlcCer load, immobilized on AuNPs, was done by salt titration. To this end, NaCl 
solutions were added to the functionalized AuNPs before BSA blocking (2-fold dilution series of  
750 mM-0.7 mM as final NaCl concentrations), where after OD500-800 nm with 1 nm steps was measured 
using the spectrometer. The higher the peak shift compared to bare AuNPs, the higher the GlcCer load 
on the AuNPs.  
8.2.2.3 Detection of yeast cells with antibody via whole cell ELISA 
Interactions of C. albicans antibodies with whole yeast (C. albicans SC5314) and bacterial (E. coli K12) 
cells were determined via whole ELISA assay, based on the protocol described by Matsuzaki and co-
workers [285] with certain adaptations. 100 µL of a concentration series of exponentially growing cells, 
102-105 cells/mL for C. albicans and 100-107 cells/mL for E. coli, were coated overnight at 30°C, washed 
and fixed in a microtiter plate. Then, 2 h incubation with the primary antibody, called C. albicans 
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antibodies (1/1200 diluted), was followed by 2 h incubation with the secondary antibody, called 
streptavidin-AP-conjugate (1/5000 diluted). 4-NPP absorbance (405 nm) was used for the 
quantification of the interaction.  
8.2.2.4 Competitive ELISA for RsAFP2 quantification 
RsAFP2 concentrations were determined in a competitive ELISA assay. All buffers, incubation 
temperature and antibodies used in this assay were described previously by Thevissen et al. (2004). 
Firstly, 50 ng/mL RsAFP2 was coated overnight at 4°C in ELISA plates, where after 2-3 h blocking with 
3% gelatine was applied. In the meantime yeast and bacterial cells, diluted in bovine serum, were 
incubated for 30 minutes with RsAFP2 at 12.5, 6.25 or 0 ng/mL. Then, 2-fold dilution series of the 
supernatants from corresponding cultures were prepared in 10% blocking buffer. After the blocking 
step, ELISA plates were incubated with 1:1 (dilutions of) supernatants and primary antibody  
(1/2000 diluted), called anti-RsAFP2 serum. Subsequently, incubation with secondary antibody 
(1/1000 diluted), called anti-rabbit IgG-AP, and AP substrate, 4-NPP, was performed. The highest 
values of the negative controls, samples without primary antibody, were used as background signal.  
8.3 Results and discussion 
8.3.1 Immobilization of antibodies or plant defensins on the surface of FO probes for target detection 
First, FO probes were functionalized with the target-detection component, called bioligand (Figure 1A). 
Bioligand coupling on FO probes was performed via EDC/NHS chemistry. EDC activates the carboxyl 
groups of the polyethylene glycol (PEG) layer of the sensor surface, which can then on their turn bind 
to free amine groups of the peptide. Using the FO probes, binding events at the sensor surface were 
detected as a shift in SPR wavelength dip in function of time [279], shown in sensorgrams (Figure 1B). 
In this study, the SPR wavelength shift during the detection process (Figure 1B), ranging from  
0-112 nm (Table 1), was used as a measure of the target binding event. Note that these detection 
signals are very high as compared to proteins or DNA detections via FO-SPR, which generally result 
in detection shifts up to 15 nm [280-282]. 
 
Figure 1: Target detection via FO probes resulting in SPR wavelengths shifts. (A) The fiber, containing a gold and PEG 
layer, and bioligand, was used for target detection. (B) The sensorgram, SPR wavelength in function of the time, was used for 
detection shift calculations.  
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Figure 2: Different FO probes developed in this study for the detection of glucosylceramides (GlcCer) (A,B) or Candida 
albicans cells (C-E). RsAFP2-functionalized FO probes were used for the detection of: (A) GlcCer in solution, (B) GlcCer-
coated AuNPs or (C) C. albicans cells. C. albicans antibodies-functionalized FO probes were applied for: (D) C. albicans or (E) 
C. albicans cell fragment detection. Yeast cells were sensed with (E) or without (C,D) signal amplification of C. albicans 
antibodies-coated AuNPs.  
Upon immobilization of RsAFP2 to the FO probes, an immobilization shift of 0-1 nm could be detected. 
This small binding shift might be explained by the low molecular weight of RsAFP2 (6 kDa) using SPR, 
which is a mass-based detection technique. Due to the higher molecular weight of the C. albicans 
antibodies (150 kDa), the corresponding immobilization signal was higher (around 7 nm). In this study, 
the RsAFP2-functionalized FO probe was applied for glucosylceramide (GlcCer) detection  
(Figure 2A-B), while both RsAFP2- and C. albicans antibodies-functionalized FO probes were used for 
yeast cell detection (Figure 2C-E).  
8.3.2 Detection of glucosylceramides with RsAFP2-functionalized FO probes 
Previous studies showed that RsAFP2 interacts with glucosylceramides from fungi (GlcCerF) using 
ELISA assays [27]. Here, we aimed at confirming this peptide-lipid interaction via FO-SPR as a first 
validation of this technology for fungal-specific detection. However, as seen in Figure 2A, we could not 
detect GlcCerF with the RsAFP2-functionalized FO probes, evidenced by the absence of a SPR shift. 
This is probably due to the low mass of GlcCerF (700-800 Da). To raise the signal, we increased the 
mass of the target by coupling the GlcCerF to AuNPs (Figure 2B) [280], and subsequently detected 
the GlcCerF-coated AuNPs with the RsAFP2-functionalized FO probes. Three negative controls were 
included: FO probes functionalized with random non-GlcCerF binding antibodies (MA-IFX8E10) or 
without any bioligand for the detection of GlcCerF-coated AuNPs on one hand, and RsAFP2-
functionalized FO probes for the detection of non-GlcCerF antibodies (IgG-HRP)-coated AuNPs on the 
other hand. The SPR detection shift for GlcCerF-coated AuNPs binding to the RsAFP2-functionalized 
FO probes was around 50 nm, while this was only 0-0.5 nm, 0 nm and 3.5-4 nm for the three negative 
controls respectively, pointing to specific RsAFP2 – GlcCerF interactions. 
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Thevissen et al. demonstrated specific interaction of RsAFP2 with fungal GlcCer, whereas no 
interaction of RsAFP2 with GlcCer from soybean (S) or humans (H) was detected [27]. Consequently, 
we aimed at distinguishing the RsAFP2-GlcCerF from the RsAFP2-GlcCerS/H interactions, using the 
FO-SPR technique and AuNPs coated with the three different GlcCer species (Figure 2B). However, 
we observed no significant differences between SPR binding shifts resulting from RsAFP2 binding to 
GlcCerF-coated AuNPs and those resulting from RsAFP2 binding to GlcCerS/H-coated AuNPs  
(Table 2). Therefore, the setup was further optimized focusing on both the bioligand and the target. On 
the level of the bioligand, the RsAFP2 immobilization concentration (0.2-10 nM) and immobilization 
buffer for FO probe functionalization were varied for a set batch of GlcCerF/S-coated AuNPs. We found 
that the use of a 1 nM RsAFP2 solution resulted in FO probes with the highest SPR detection shift for 
GlcCerF AuNPs and this condition was therefore selected as RsAFP2 immobilization concentration for 
further experiments. NaAc buffer at pH 5 was preferred as RsAFP2 immobilization buffer over MES 
(pH 6), PBS (pH 7.4) or Tris (pH 8.6) buffer as this buffer could distinguish best RsAFP2-GlcCerF from 
the RsAFP2-GlcCerS interactions (Table 1). 
Table 1: SPR detection shifts for the interaction of the RsAFP2-functionalized FO probe with AuNPs coated with GlcCer 
originated from fungi or soy, using different immobilization buffers for RsAFP2 functionalization on FO probes. 
SPR shift (nm) DETECTION GlcCerF-AuNPs GlcCerS-AuNPs 
 BUFFER IMMOBILIZATION RsAFP2 5 µg/mL 5 µg/mL 
NaAc pH 5 41 31 
MES pH 6 7 6 
PBS pH 7.4 0 0 
Tris pH 8.6 106 112 
On the level of the target, the AuNPs resuspension/detection buffer with regard to blocking agent, 
concentration of divalent cations and pH on one hand and the GlcCer immobilization concentration on 
the other hand were further investigated. The standard composition of AuNPs resuspension/detection 
buffer used in all previous experiments was PBS (containing 0.14 M NaCl) + 0.5% BSA at pH 7.4 
(Table 2). This standard condition was always examined in parallel with the newly tested condition as 
there were large variations in the SPR detection shift for repetitions, as seen in Table 2. First we 
compared standard BSA blocking with gelatin blocking, since gelatin was selected as preferred 
blocking agent in previously performed RsAFP2 – GlcCerF ELISA assays [27]. Unfortunately, only a  
1 nm SPR detection shift was observed for GlcCerF-coated AuNPs resuspended in PBS (pH 7.4) + 
1% gelatin. As divalent cations are known to influence RsAFP2’s antifungal activity [18], we examined 
the effect of the addition of CaCl2 to the detection buffer, thereby hoping to reduce the non-specific 
binding between the GlcCerS-coated AuNPs and the RsAFP2-functionalized FO probes. However, 
addition of CaCl2 to the detection buffer resulted in undesirable outcomes as 31% higher SPR shifts 
were found for GlcCerS-coated AuNPs compared to standard GlcCerF-coated AuNPs. The last 
parameter of the detection buffer that was varied, was the buffer pH. RsAFP2 is (positively) charged 
using standard detection conditions (buffer at pH 7.4), as its pI is 8.9, which might result in non-specific 
binding. Therefore, we aimed at detecting GlcCer-coated AuNPs with RsAFP2-functionalized FO 
probes using detections buffer in which RsAFP2 is less (positively) charged. Hence, a higher pH buffer, 
Tris (pH 8), was compared to the standard PBS buffer at pH 7.4. Our results pointed to lower SPR 
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detection shifts using Tris buffers. Nevertheless, we observed increased binding of RsAFP2 to 
GlcCerF- as compared to GlcCerS-coated AuNPs using Tris buffer detection buffers.  
Apart from the AuNP resuspension buffer, the GlcCer load on AuNPs was also optimized. Increasing 
concentrations of GlcCer during the immobilization step allowed higher GlcCer loads on AuNPs  
(Figure 3-4). This resulted in only minor SPR detection shift differences for both types of GlcCer-coated 
AuNPs (Table 2). 
 
Figure 3: Salt titration of AuNPs functionalized with GlcCer. After functionalization the AuNPs with 5 µg/mL GlcCerF,  
50 µg/mL GlcCerF, 5 µg/mL GlcCerS or control (ethanol), a concentration series of NaCl was added to the GlcCer-coated 
AuNPs. Pink coloured AuNPs were stable AuNPs, whereas blue coloured AuNPs were aggregated AuNPs. 
 
Figure 4: Absorption spectrum of the GlcCer-coated AuNPs (Figure 3). Stable AuNPs solutions showed a peak around  
520 nm, while the absorption signal was low for the other measured wavelengths. In contrast, the absorption spectrum of 
aggregated AuNPs did not have a sharp peak in the absorption spectrum. 
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Table 2: SPR detection shifts for the interaction of the RsAFP2-functionalized FO probe with AuNPs coated with GlcCer 
originated from fungi, soy or human, using different resuspension buffer conditions of the functionalized AuNPs and 
different GlcCer immobilization concentrations. ND: Not determined. 
SPR shift (nm) 
 
 
 DETECTION 
GlcCerF-
AuNPs 
GlcCerF-
AuNPs 
GlcCerS-
AuNPs 
GlcCerH-
AuNPs 
BUFFER CONDITIONS AuNPs 5 µg/mL 50 µg/mL 5 µg/mL 5 µg/mL 
Buffer Blocking Ions     
PBS (pH 7.4) 0.5% BSA  51 ND 46 44 
   7 ND 5 ND 
PBS (pH 7.4) 1% gelatin  1 ND ND ND 
PBS (pH 7.4) 0.5% BSA 0.5 mM CaCl2 40 ND ND 58 
Tris (pH 8) 0.5% BSA  7-11 ND 1 ND 
   5 6 ND ND 
In summary, it was possible to detect GlcCerF-RsAFP2 interactions on the FO probes. However, 
specificity of this interaction was lacking. To resolve this, we optimized the setup with respect to several 
parameters. On the level of the bioligand, 1 nM RsAFP2 in 10 mM sodium acetate pH 5 was identified 
as the optimal RsAFP2 immobilization condition using this assay. On the level of the target, 
resuspension of GlcCer-coated AuNPs in Tris buffer (pH 8) resulted in specific RsAFP2 – GlcCerF 
interactions, irrespective of RsAFP2 immobilization concentrations. However, for all conditions tested, 
there was no clear difference in SPR shift between GlcCerF-coated AuNPs and GlcCerS-coated 
AuNPs. Hence, the current immobilization technique for GlcCer on the AuNPs seems not adequate. 
GlcCer consist of a polar head group, which is mainly responsible for plant defensin interactions [27], 
and a hydrophobic tail. As the strategy for functionalizing AuNPs was based on physical absorption, 
the charged groups of the GlcCer might preferentially participate at the immobilization event and 
consequently, may not be available for GlcCer interactions. Instead, the hydrophobic GlcCer tails will 
be positioned at the outside of the functionalized AuNPs, hampering RsAFP2 interactions. Therefore, 
in the future, it could be worth to test RsAFP2 – GlcCer interactions with GlcCer oriented reversely on 
AuNPs using hydrophobic AuNPs. This could be achieved by immobilizing GlcCer on hydrophobic 
AuNPs, using hydrophobic buffers. However, as GlcCer are very good soluble in hydrophobic 
solutions, the GlcCer load on AuNPs might be negligible small. Moreover, the hydrophobic buffer of 
the AuNPs might be not compatible with the aqueous medium of the RsAFP2 detection system. 
Therefore, we tried to detect yeast cells instead of yeast targets, as explained below. 
8.3.3 Detection of intact Candida albicans cells with FO probes 
In a second series of experiments, coated FO probes were employed for the detection of C. albicans 
cells in a suspension. After testing the specificity of the C. albicans antibodies (Figure 5), we 
functionalized the FO probes with either C. albicans antibodies (Figure 2D-E) or RsAFP2 (Figure 2C) 
and obtained proper bioligand immobilization (section 8.3.1 and box1 in Figure 6A-B). Subsequently, 
we aimed at the specific detection of intact yeast cells using both types of bioligands, using a cell 
density series ranging from 100-106 cells/mL. In parallel, we used the same cell density range for the 
pathogenic bacterium E. coli K12 as a negative control, as we found that the C. albicans antibodies 
did not interact with this pathogen (Figure 5). We obtained negligible small SPR detection signals for 
C. albicans cells in both setups, as shown in a representative graph in Figure 6A. To increase the 
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detection signal, cells were lysed prior to their detection, expecting increased interactions at the sensor 
zone and as a result increased SPR detection shifts.  
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Figure 5: Interaction of Candida albicans and Escherichia coli cells with C. albicans antibodies. Dose-response curves 
are presented for the interaction of seeded C. albicans (circles) or E. coli (squares) with C. albicans antibodies.  
 
Figure 6: Representative sensorgrams for the detection of Candida albicans SC5314 and Escherichia coli K12 cells 
using RsAFP2- or C. albicans antibodies-functionalized FO probes. Sensorgram of C. albicans antibodies-functionalized 
FO probes detecting a cell density series (100-106 cells/mL) of (A) intact C. albicans cells or (B) lysed C. albicans cells, from the 
lowest to the higher cell density. Box1 and box2 representing respectively antibody immobilization on the FO probe and  
C. albicans binding to the functionalized FO probe. (C) Zoom-in picture of Figure 6B with SPR detection shifts corresponding to 
the detection of lysed yeast cells with original cell density of 100, 101 and 102 C. albicans cells/mL. 
However, as lysed cells did not increase the detection signal (Figure 6B-C), an alternative approach 
was investigated, which consisted of a signal amplification via functionalized AuNPs (Figure 2E), as 
previously described [279]. To this end, RsAFP2 or C. albicans antibodies were immobilized on AuNPs 
via physical absorption. To obtain optimal immobilization conditions for physical absorption, the pH of 
the solution buffer of the AuNPs was adjusted to the pI of RsAFP2 (8.9), causing minimal electrostatic 
repulsion [286]. Unfortunately, immediately after the addition of RsAFP2 to the AuNPs, particle 
aggregation occurred. Therefore, we tested RsAFP2 immobilization at pH > pI of the plant defensin, 
as Lu and co-workers successfully immobilized antibodies on AuNPs at a pH exceeding the pI of the 
antibody with 2-3 pH units [282]. We tested RsAFP2 immobilization with AuNPs at pH 10, but the 
AuNPs were also aggregating after RsAFP2 addition. Bare AuNPs at pH 11, even without the addition 
of RsAFP2, were destabilized upon occurrence of aggregation. 
In contrast to RsAFP2, the coating of AuNPs with C. albicans antibodies was successful. The  
C. albicans antibodies-coated AuNPs were subsequently used for the amplification of the generated 
signal of the yeast cell fragments bound to the C. albicans antibodies-functionalized FO probes  
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(Figure 2E). Unfortunately, similar low SPR detection shifts as for the detection of lysed yeast cell 
fragments without AuNPs signal amplification (Figure 6B) were obtained (data not shown).  
In summary, we investigated different strategies for the detection of cell (fragments) with both plant 
defensins and specific antibodies as FO probe bioligands, but none of them was successful. It might 
be that the cells or even the cell fragments were too big to be detected via FO-SPR. Therefore, we 
tried an alternative approach in which yeast cells were detected indirectly using an ELISA assay, as 
described below. 
8.3.4 Detection yeast cells via competitive assays 
Here we used RsAFP2 as a readout to detect C. albicans (CAI4 WT) cells, based on its fungal-specific 
binding with GlcCer. In short, upon the incubation of a sample containing C. albicans cells with 
RsAFP2, the amount of ‘free’ RsAFP2 (left-over) can serve as a measure of the amount of yeast cells: 
the lower the RsAFP2 left-over in a sample, the higher the amount of yeast cells in the sample  
(Figure 7). These RsAFP2 left-overs were measured in an indirect ELISA assay [23]. As negative 
controls, we focused on C. albicans Δgcs1 and E. coli K12. C. albicans Δgcs1 was selected as this 
strain does not produce the RsAFP2-fungal target, GlcCer, and hence should respond negatively in 
this setup. 
 
Figure 7: Schematic overview of the indirect detection of yeast cells. Firstly, a fixed RsAFP2 concentration was added to 
both the control sample without yeast cells (left) and the sample with yeast cells (right). Upon binding of RsAFP2 to the cells, 
cells were centrifuged and the supernatant was analysed for the presence of RsAFP2 via a competitive ELISA. 
In all tests, we determined the RsAFP2 concentration based on a competitive ELISA setup [287], after 
incubation with (on average 100 cells/mL) yeast or bacterial cells, as shown in Figure 7. To this end, 
anti-RsAFP2 antibodies are incubated with the left-over RsAFP2 in the sample in RsAFP2-coated 
wells, resulting in competition between the coated and free RsAFP2 (Supplementary Figure S1). The 
results of the competitive ELISA with RsAFP2 are shown in Figure 8, with the ΔOD = OD(sample with 
yeast/bacterial cells) – OD(background) as a measure for the amount of plant defensins bound to the 
yeast or bacterial cells. We found specific interactions for RsAFP2 with C. albicans WT, for which the 
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ΔOD was noticeably higher than for C. albicans Δgcs1 or E. coli K12 cells, indicating that this technique 
can be used to discriminate between bacterial and fungal (C. albicans) sample loads. Despite the clear 
trend towards higher ΔOD’s in all three biological repeats, no significant differences in ΔOD’s were 
found between C. albicans WT and the negative controls (C. albicans Δgcs1 or E. coli K12) (Figure 8). 
This might be explained by the difficulty to work with cell concentrations of exactly 100 cells/mL. The 
limit of detections of the RsAFP2-based rELISA assay is at least with 53 cells/mL, as this is the lowest 
fungal load tested.  
Since the proof-of-concept for specific yeast cell detection via a competitive ELISA-based assay is 
working, the next step would be to translate this concept to the more sensitive FO-SPR setup and to 
optimize the assay in terms of detection limits. Our aim is to detect 1 yeast cell/mL, as the fungal load 
in blood of patients suffering from systemic fungal candidaemia is 1-2.5 yeast cells/mL [288].  
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Figure 8: Specific interaction of RsAFP2 with Candida albicans CAI4 WT. Detection of approx. 100 cells/mL of C. albicans 
WT, C. albicans Δgsc1 and Escherichia coli K12 via a competitive ELISA assay. The ΔOD405 nm = OD(sample) – OD(background) 
was used as a measure for the amount of plant defensins bound to the yeast or bacterial cells. Data are means ± SEM for 
triplicates and were obtained for two different initial concentrations of RsAFP2. Significant differences in bound RsAFP2 between 
C. albicans WT and the 2 negative control strains (C. albicans Δgsc1 and E. coli K12) for each RsAFP2 concentration were 
determined via two-way ANOVA followed by Dunnett multiple comparison.  
8.4 Conclusions 
This study reported the relevance of using plant defensins for the development of novel fungal-specific 
detection techniques. First, the plant defensin RsAFP2 was used for fungal-specific target detection 
using FO-SPR technology. In this setup, the specific interaction between RsAFP2 and fungal 
glucosylceramide was detected, although the interaction was not fungi-specific as binding of RsAFP2 
to non-fungal glucosylceramides resulted in similar detection signals. Nevertheless, specific detection 
of whole yeast cells was accomplished using competitive ELISA assays. The lowest fungal load 
detected in this way was 53 yeast cells/mL. By further optimizing the competitive ELISA assay, the 
detection limit should be further reduced to clinically relevant yeast cell concentrations  
(e.g. 1-2.5 cells/mL blood) [288]. 
 
  
 
 
8.5 Supplementary material 
 
Supplementary Figure S1: Competitive ELISA assay. All consecutive steps are presented: detection of target via primary antibodies, detection of bound primary antibodies via secondary antibodies 
containing an enzyme that can cleave the substrate into a coloured product which will be detected in the last step (OD405 nm). This ELISA is a competitive assay because there will be a competition between 
the primary antibodies for the plant defensins present in the sample and on the walls of the microtiter plate. 
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9.1 General discussion and perspectives 
Fungal pathogens can be detrimental for all kind of organisms, leading to severe infections as well as 
die-offs and extinctions of wild life species [289, 290]. From all infection-related species extinctions, 
fungi comprise the highest threat for both animals (72%) and plant (64%) species [289]. In agriculture, 
pathogens belonging to a large diversity of fungal species ranging from the lower fungal-like 
Oomycetes to the more complex Actinomycetes and Basidiomycetes, infect plants and harvested 
fruits, resulting in significant economic impacts on plant yield and quality, with the Irish ‘potato famine’ 
in the 19th century as an extreme example [291]. 
In human health, the mortality rate associated with invasive fungal infections (IFIs) is 50%, which 
corresponds worldwide to 1.5 million deaths per year [2, 6]. These infections are mainly caused by 
Candida and Aspergillus species, from which C. albicans is the most common species [6]. However, 
in the past years a trend towards an increasing prevalence of non-albicans Candida species in 
candidemia was observed [7, 292]. The incidence of IFIs is still rising by the increasing number of 
immunocompromised patients or hospitalized patients with a severe underlying disease and by the 
increased use of implants and invasive devices as potential substrates for the formation of microbial 
biofilms [172-174]. Biofilms are microbial cultures that adhere on a (a)biotic substrate and that are 
embedded by a self-produced polymeric matrix [110]. These biofilms are typically more tolerant to 
antimicrobial treatments as compared to planktonic cultures as they differ in terms of phenotype and 
physiology and are generally exposed to lower drug concentrations [113, 293, 294]. To date, only few 
antifungal drugs, including echinocandins and liposomal formulations of amphotericin B, are effective 
against fungal biofilms [3, 4]. Hence, there is a need for the identification and development of novel 
antifungal treatments that can effectively combat biofilm-related IFIs.  
Besides novel antifungal/antibiofilm drugs, there is also a necessity for better diagnostic techniques to 
lower the mortality rate associated with IFIs. To date, a retrospective study showed that 80% of all 
hospitalized patients with an IFI obtained an inadequate antifungal treatment [295]. This latter mainly 
results from the poor diagnostic techniques that are currently available, such as culture-, DNA- or 
antigen-based methods. They are all associated with serious drawbacks, such as poor sensitivity and 
long times-to-result [5]. 
Antimicrobial peptides (AMPs) have great potential to be used in novel antifungal treatments. These 
peptides are characterized by broad-spectrum antimicrobial activities, cause rapid killing of microbial 
cells and have diverse modes of action (that differ from conventional drugs) and are therefore 
supposed to be associated with low frequencies of resistance occurrence [296-298]. In this PhD, we 
focussed on a specific class of AMPs present in plants, called plant defensins. Although various 
biological activities are attributed to plant defensins, such as antimicrobial activity, insecticidal activity 
and protease inhibition [102, 103], their antifungal activity has been studied most. Interestingly, as 
these peptides can be effective against fungi at low concentrations (0.1-10 µM) and can specifically 
interact with fungal membrane targets (Chapters 2, 6-7), they are generally not toxic to plant or human 
cells (Chapters 4-5) [19, 97], though anti-tumour activity of some plant defensins like NaD1 has been 
documented [60].  
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In the following sections, the results which I obtained during my PhD research are debated in a broader 
context, thereby focussing on the use of plant defensins in agricultural and clinical applications.  
9.1.1 Plant defensins in agricultural applications 
Fungal infections on plants are a major threat for food security. To date, losses associated with low-
level persistent diseases on the five major staple crops worldwide (rice, wheat, maize, potato and 
soybean) have been estimated to be sufficient to feed 8.5% of all people worldwide [289]. To control 
fungal diseases on crops, various fungicides (i.e. 10-times more than in the case of human fungal 
infections) are available [299, 300]. However, by the increasing incidence of fungal infections on plants 
as well as by emerging number of resistant fungal strains, there is a need for the development of novel 
fungicides [301]. To facilitate this process, it would be interesting to assemble all information from both 
pesticide and pharmaceutical drug development, so that lead pharmaceuticals can be re-formulated 
as pesticides and vice versa [299, 302, 303]. However, so far only one fungicide (fluconazole) is used 
in both fields [304].  
In this PhD, we mainly focused on the use of plant defensins to control human fungal infections. 
However, as these peptides have broad-spectrum antifungal activities, plant defensins might be used 
in agricultural applications as well. A first strategy includes the direct use of plant defensins to combat 
fungal plant infections, via a spray-on technique, albeit rather in small-scale applications  
(e.g. greenhouses). Moreover, as relatively huge amounts of antifungals are needed for this technique, 
only plant defensins that can be cost-effectively produced are qualified. A good strategy to reduce 
(correctly folded) plant defensin production costs as compared to chemical synthesis, is their 
heterologous production using fungal expression systems [297]. In this PhD, we demonstrated 
successful production of RsAFP2 and HsAFP1 by using Pichia pastoris as a yeast expression system 
(Chapter 3-4). A second, more cost-effective, strategy is the production of transgenic plants that 
express the introduced plant defensin to control fungal infections in agriculture (as reviewed in [97]). 
As an example, the plant defensin AlfAFP from Medicago sativa, which is active against the 
agronomical important fungal pathogen Verticillium dahliae, was expressed in transgenic potato plants. 
Agronomical losses were substantially reduced in these transgenic plants. Moreover, this strategy was 
found more efficient to lower fungal infections as compared to chemical methods [16]. Note that in 
agriculture, biofilm lifestyle is also critical for pathogenesis of fungal diseases on plants [305]. To 
prevent fungal biofilm formation, heterologous production of plant defensins is supposed to be a good 
strategy, as we showed that RsAFP2 and HsAFP1 can effectively inhibit fungal biofilm formation 
(Chapters 3-4).  
A third strategy includes the indirect use of plant defensin research to combat fungal infections, thereby 
focusing on plant defensin targets. As an example, the plant defensins RsAFP2, Psd1 and MsDef1 as 
well as the insect defensin heliomycin interact with fungal-specific glucosylceramides (GlcCerF)  
[27, 72, 82]. GlcCerF are suggested to be an attractive target for antifungal drug development as their 
structure is well-conserved in a broad-spectrum of fungi, but different from human GlcCer. In addition, 
GlcCerF are important fungal virulence factors, which implicates that fungi with altered GlcCerF are 
non-infective. Therefore, GlcCerF-targeted drugs are expected to be associated with low levels of 
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resistance development. Recently we evaluated such an approach in our research group by applying 
camelid single domain antibodies against GlcCerF to effectively combat fungal plant diseases [306]. 
9.1.2 Plant defensin-based therapeutics 
Plant defensins are also good candidates for antifungal drug development as they have interesting 
characteristics in terms of activity (9.1.2.2), selectivity (9.1.2.3) and stability (9.1.2.5). Studying the 
mode of action is a crucial first step in drug development.  
9.1.2.1 Mode of action of plant defensins  
In this PhD, we focused on the 2 plant defensins RsAFP2 and HsAFP1, isolated from Heuchera 
sanguinea and Raphanus sativus, respectively. The past decades, extensive studies were done on 
RsAFP2, one of the pioneer peptides in plant defensin research, resulting in the identification of its 
fungal membrane target, unravelling of its mode of action as well as evaluating its in vivo efficacies 
[21, 23-25, 27, 89, 156, 157]. As a large number of information is already available on RsAFP2’s mode 
of action, we explored other biological activities of RsAFP2 in this PhD (9.1.2.2). 
As compared to RsAFP2, less research has been performed on HsAFP1, while both plant defensins 
were already isolated more than 20 years ago [18]. HsAFP1 also interacts with specific sites on fungal 
membranes [26], which were not yet identified, but known from deletion mutant studies to not (only) 
consist of GlcCerF, as in the case of RsAFP2. As HsAFP1 also has interesting characteristics 
regarding antifungal drug development, such as low in vitro frequencies of resistance occurrence and 
broad-spectrum antifungal activity [19], we further unraveled HsAFP1’s antifungal mode of action. We 
demonstrated binding of HsAFP1 to phospholipids, such as phosphatidic acid and various 
phosphatidylinositolphosphates (Chapter 6) and suggested HsAFP1 interactions specifically with 
phospholipids of GPI-anchored proteins (Chapter 7). The basis of these interactions is probably 
electrostatic in nature, as we identified positively charged amino acids (arginine and histidine) of 
HsAFP1 and negatively charged phosphate groups of the phospholipid to be essential for them. We 
further showed that HsAFP1’s internalization in yeast, involving (at least partially) endocytosis, is 
crucial to exert its antifungal activity, as well as subsequent membrane permeabilization (Chapter 6). 
Using transcriptome analysis and additional genetic and biochemical tests, endoplasmic reticulum (ER) 
stress tolerance pathways were identified as part of yeast’s tolerance to HsAFP1 treatments. Whether 
HsAFP1 induces ER stress needs to be confirmed in future experiments. In addition, we revealed 
HsAFP1’s effect on vacuolar function (Chapter 7). In parallel with RsAFP2, additional biological 
activities of HsAFP1 were further evaluated (9.1.2.2). 
9.1.2.2 Activity of plant defensins  
Plant defensins are known for their broad-spectrum antifungal activity, including killing or growth 
inhibition of human fungal pathogens such as Candida species (e.g. C. albicans, C. krusei, C. glabrata 
and C. tropicalis [19, 88]), Aspergillus species (e.g. A. flavus and A. niger [15, 19]) and Fusarium 
species (e.g. F. solani, F. oxysporum and F. moniliforme [15, 19, 62, 75]). So far, only antifungal effects 
on planktonic fungal/yeast cultures were investigated for plant defensins. In view of the increased drug 
tolerance of fungal biofilms, we further investigated potential antibiofilm activity of plant defensins in 
this PhD. We showed that the plant defensins RsAFP2 and HsAFP1 as well as truncated HsAFP1 
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peptides can inhibit C. albicans biofilm formation as well as act synergistically with the common 
antifungal drugs caspofungin and amphotericin B (Chapters 3-5). Hence, plant defensins can be used 
to combat both planktonic and biofilm cultures, which makes these peptides attractive for antifungal 
drug development. It should be noted that most biofilms formed under natural conditions consist of 
multiple species. The susceptibility of the latter against antimicrobials depends on the presence of the 
other species and the antimicrobials used [307]. As an example, Escherichia coli does not affect  
C. albicans’ tolerance to amphotericin B or caspofungin in a mixed E. coli/C. albicans biofilm, while  
C. albicans increases E. coli’s tolerance to ofloxacin [308]. Therefore it would also be interesting in 
future experiments to evaluate antibiofilm activity of plant defensins on multispecies biofilms. 
Using truncated plant defensins, the minimal region needed for their antifungal activity could be 
identified. For RsAFP2, this minimal sequence was previously determined as the 19-mer RsAFP2-
derived peptide RsLin (Figure 1A) [157]. For HsAFP1 this minimal region for antifungal activity 
comprises at least 25 amino acids (Chapter 4). However, HsAFP1’s minimal region for synergistic 
activity with caspofungin as well as antibiofilm activity, situated in its C-terminal part (Chapter 4), only 
contains 19 amino acids (HsLin06_18; Figure 1B) and maximal 16 amino acids (HsLin06_38;  
Figure 1B), respectively (Chapter 5). All three activity regions comprises at least the γ-core, already 
known as important for their biological activity. 
 
Figure 1: Minimal peptide sequence of (A) RsAFP2 for antifungal activity (RsLin) and of (B) HsAFP1 for synergistic 
activity with caspofungin (HsLin06_18) and antibiofilm activity (HsLin06_38). All sequences include the γ-core of plant 
defensins (box). Grey regions represent conserved amino acids among plant defensins. (-) denote gaps in the alignment. 
9.1.2.3 Selectivity of plant defensins 
Plant defensins target fungal-specific phospho- or sphingolipids and are therefore suggested to be 
non-toxic to mammalian and plant cells. In this respect, the plant defensin RsAFP2 was shown to 
interact with glucosylceramides of yeast, but not with those of plant or human cells ([27] and 9.1.1). 
The presence of the fungal membrane target is essential for the plant defensin to fulfill its antifungal 
activity, as mutants depleted in the membrane target are resistant to the corresponding plant defensin 
[60, 70, 72, 82, 140]. Moreover, we showed that RsAFP2 was unable to bind to mutant yeast depleted 
in its target (GlcCerF), in contrast to WT cells (Chapter 8). The selectivity of HsAFP1 for fungal cells is 
not yet clear. We hypothesize that HsAFP1 interacts with the anchor of GPI-anchored proteins, 
resulting in peptide internalization (Chapter 7) being crucial for HsAFP1’s antifungal activity  
(Chapter 6). It remains possible that HsAFP1 subsequently interacts with other (intracellularly located) 
membrane targets, such as PA and PIP’s, ultimately leading to fungal cell death. 
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Besides antimicrobial activity, some defensins are toxic to human tumor cells. To date, the tobacco 
defensin NaD1 has been shown to permeabilize mammalian tumor cells [60]. Tumor cell membranes 
are characterized by a negative net charge, in contrast to the rather neutrally charged non-tumor cell 
membranes, explaining the tumor-specific activity of AMPs [309]. Hence, the activity of plant defensins 
appears to depend on the presence of both fungal-specific targets and/or the negative membrane 
charges. It should be noted that some AMPs such as the human neutrophil defensins HNP-1-3, were 
also found toxic to non-tumor mammalian cells at high concentrations [310, 311]. Hence, though 
generally considered as non-toxic for human cells, the potential cytotoxicity of plant defensins should 
always be studied carefully on various cell lines and under different conditions. In this PhD, we show 
that HsAFP1 and HsLin06_18, a HsAFP1-derived peptide, are not cytotoxic to HepG2 cells (i.e. human 
liver tumor cells). 
9.1.2.4 In vivo potential of plant defensins 
A next step in the development of plant defensin-based antifungal drugs is the translation from in vitro 
to in vivo conditions. To the best of our knowledge, in vivo tests with plant defensins have only been 
performed in the case of the plant defensin RsAFP2. Tavares and colleagues previously showed that 
RsAFP2 is prophylactically effective against murine candidiasis after intravenous injection [21], 
indicating that plant defensins can preserve their antifungal activity in vivo, even in the presence of 
serum proteases [21]. This can be explained by the stability of plant defenins. They have a highly-
conserved 3D structure that is stabilized by 4-5 disulphide bridges (Chapter 2). Results from plant 
defensin research, more specifically on their cellular targets, have also been used indirectly to treat 
fungal infections in vivo. Indeed, anti-GlcCerF antibodies have successfully been used to prolong 
survival of mice lethally infected by Cryptococcus neoformans [312]. More recently, even 
administration of GlcCerF prior to infection has been shown to protect mice from lethal doses of  
C. neoformans. This effect was explained by an immunity response as the presence of anti-GlcCerF 
antibodies response were demonstrated in these mice [313], thereby suggesting their potential as 
vaccination strategies against Cryptococcus spp.. 
In this PhD, we investigated whether the linear plant defensin-derived peptides, exhibiting in vitro 
antibiofilm activity (Chapter 5), were also effective in vivo, using a subcutaneous rat catheter model 
(Chapter 5). We showed that the plant defensin-derived peptide, HsLin06_18, could only slightly 
enhance caspofungin’s antibiofilm activity in vivo as compared to in vitro conditions. This reduced in 
vivo efficacy was (at least partially) resulting from HsLin06_18 binding to serum albumin, making the 
peptide less assessable for interactions with fungal cells. In contrast to HsLin06_18, HsAFP1 could 
still enhance caspofungin’s antibiofilm activity in vitro in the presence of serum albumin, which might 
explain the difference in in vivo potential of native plant defensins (e.g. RsAFP2 [21]) and their linear 
derived peptides (Chapter 5). Therefore, it would be interesting to also investigate whether native plant 
defensins, such as HsAFP1 and RsAFP2, can still enhance caspofungin’s antibiofilm activity in vivo.  
9.1.2.5 Development of peptide-based antifungal drugs 
Nowadays, generally two types of drugs are available, including either small molecules or proteins 
(e.g. antibodies or peptides). In the following section, both types are compared based on their position 
in the global market and characteristics regarding drug development. Worldwide, the development of 
Discussion and perspectives 
 
181 
 
peptide-based drugs has gained interest, as these drugs have advantages (as discussed below) over 
small molecule- and antibody-based drugs, resulting in a peptide drug market growing twice as fast as 
that of the small molecules [314]. Compared to antibody-based drugs, peptides are mostly non-
immunogenic and can penetrate deeper into tissues, because of their small size [315]. Therefore, one 
could opt to circumvent these disadvantages of antibody-based drugs by reducing their size (on 
average 150 kDa). In that context, we recently developed an anti-GlcCerF camelid single domain 
antibody (15 kDa) for antifungal treatments that is still stable and selective for GlcCerF [306].  
Compared to small molecules, peptides are in general characterized by higher binding specificity to 
their in vivo targets, resulting in high potencies [316], and greater safety [317]. The latter is also 
supported by their low half-live in serum, as small peptides (< 5 kDa) are rapidly cleared by the kidneys 
and can therefore not accumulate in the body, and by their non-toxic degradation products (i.e. amino 
acids) [315, 318]. The major drawback of short half-lives is that the peptide cannot fulfill its (antifungal) 
activities long enough to be effective. Peptide half-lives can be extended by increasing its molecular 
weight by coupling the peptide to the Fc domain of antibody or by PEGylation [315]. Other 
disadvantages associated with peptide-based drugs include limited stability, oral bio-availability and 
membrane permeability as well as elevated binding to serum components and production costs  
[314-316, 319]. Interestingly, RsAFP2 (6 kDa) has previously been shown prophylactically active 
against murine candidiasis [21], indicating that native plant defensins are stable in vivo and not cleared 
immediately by the kidneys. In contrast to native plant defensins, we show reduced activities of linear 
plant defensin-derived peptides (HsLin06_18) in in vivo conditions (Chapter 5).  
Although the rigid structure of native plant defensins enables them to be more stable in vivo, their 
production costs are higher than for linear peptides (cfr. infra). Hence, we tried in first instance various 
strategies to stabilize HsLin06_18. Peptides are prone to degradation by proteases present in the 
gastrointestinal tract or serum [320, 321]. Strategies to overcome degradation by proteases are 
acetylation, amidation, peptide cyclization and the use of non-natural amino acids [315, 320]. Note that 
these strategies can change the biological activities of the peptide, which is often not desired. In this 
PhD, we used peptide cyclization and the introduction of non-natural amino as strategies to stabilize 
HsLin06_18. We found that both strategies reduced HsLin06_18’s synergistic activity with caspofungin 
in RPMI (Chapter 5) and hence, other peptide stabilizing strategies were investigated. As retro-inverso 
peptides, in which both the L-amino acids were replaced by D-amino acids and the order of the amino 
acids was reversed, present a side chain orientation that is very similar to that of the native peptide 
[322, 323], we tested the retro-inverso peptide of HsLin06_18 in RPMI as well. Unfortunately, this 
peptide also lost its synergistic activity with caspofungin against C. albicans biofilms. The last 
HsLin06_18 stabilizing strategy that we tested was PEGylation. PEGylated HsLin06_18 peptides still 
acted synergistically with caspofungin against C. albicans in RPMI, while not in serum (Chapter 5). In 
the future, it would be interesting to further optimize HsLin06_18 in terms of activity in serum. 
On the other side, one can envisage strategies to reduce the relatively high production costs of peptide-
based drugs. The standard method for peptide production is via chemical synthesis. As each amino 
acid is associated with an additional cost, peptide size reduction is recommended. Therefore, we 
identified the smallest HsAFP1-derived peptide that still acts synergistically with caspofungin (i.e. 
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HsLin06_18), which corresponds to a 2.8-fold decrease in peptide size (Chapter 4-5). For larger and/or 
more complex peptides (i.e. native plant defensins with a specific folding in our case), an alternative 
strategy to produce peptides is their heterologous production using fungal expression systems (9.1.1) 
[297]. In addition, the costs of peptide-based drugs can be lowered by increasing their specific 
biological activity leading to reduced effective doses to be administered. Firstly, structure-activity-
relationship (SAR) studies are a good strategy to identify amino acids important for biological activity. 
In this PhD, the amino acids important for HsLin06_18’s synergistic activity with caspofungin against  
C. albicans were identified via an alanine scan, in which every amino acid of HsLin06_18 was once 
replaced by alanine. However, the latter did not reduce HsLin06_18’s synergistic activity with 
caspofungin, indicating that the exact amino acid sequence of HsLin06_18 is not important for its 
activity (Chapter 5). Secondly, it has been shown that chimera peptide production can result in peptides 
with elevated biological activity. For example, chimeras consisting of regions of the either the Nicotiana 
alata defensins NaD1 and NaD2 were characterized by improved biological activities (i.e. antifungal) 
as compared to both native peptides [63]. Therefore, as the amino acids important for biological activity 
in HsAFP1 and RsAFP2 are located in the same regions (9.1.2.2), it would also be interesting to 
produce RsAFP2-HsAFP1 chimeras aiming at increased antifungal and antibiofilm activity.  
To meet the advantages of both peptide- and small molecule-based drugs, active peptides can be 
transformed into peptidomimetics or small molecules (as reviewed in [324]). This translation process 
consist of various steps. Firstly, the minimal peptide sequence important for the peptide’s biological 
activity is identified. Secondly, the amino acids important for the peptide’s biological activity are 
identified via structure-activity-relationship (SAR) studies. Thirdly, the peptide is translated into a 
peptidomimetics, by placing these essential amino acid side chains on a non-peptide scaffold that 
resembles the conformation of the original peptide, but has a more rigid structure than the native 
peptide. Note that native plant defensins have more rigid structures than its linear derived peptides, 
making them more interesting candidates for transformations into peptidomimetics or small molecules. 
Advantages of peptides with more rigid structures are: (i) potentially improved binding to its target and 
more importantly, (ii) easier for the development of 3D pharmacophore models, which is an important 
(fourth) step for the translation of peptides into small molecules. This 3D pharmacophore model is 
developed based on all available information on receptor-bound and/or biologically active 
conformations of the peptide, obtained from SAR, X-ray and NMR studies. In a fifth step, this 3D model 
is used to screen small molecule libraries for compounds with similar characteristics as the biologically 
active peptide-scaffold. Note that this is a difficult process and, hence, no guarantee of success [324]. 
9.1.2.6 Administration routes for peptide-based drugs 
When the peptide(-derived) drug is developed, its administration route should be considered. For 
topical, vaginal or oral fungal infections, mouthwash, creams or gels can be used, whether or not 
accompanied by delivery carriers [325]. Some AMP-based drugs, including cZEN-002 and histatins, 
are currently tested in the clinical trials for their use to combat fungal infections. A gel containing  
cZEN-002 is proposed for treatment of vaginal candidiasis [298] and a gel or mouthwash containing 
histatins is proposed for treatment of HIV patients with oral candidiasis [326].  
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For invasive fungal infections, drugs are generally administered intravenously. For example, the AMP 
hLF-11 is currently tested in clinical trials for its efficacy to combat bacterial and fungal infections in 
immunocompromised patients after intravenous administration [298]. As the latter is also the standard 
administration route for caspofungin [327] as well as for plant defensins to preserve their activity in vivo 
[21], this would be a good strategy to administer the drug combination studied in this PhD research 
such as [caspofungin + HsAFP1/RsAFP2] or [caspofungin + modified HsLin06_18], if a non-albumin 
binding HsLin06_18-variant could be developed. 
However, especially for chronic administrations, non-invasive patient-friendly oral delivery routes are 
clearly preferred. In such applications drugs can only be therapeutically active when adsorbed from 
the intestinal lumen into the bloodstream and without being significantly degraded in the intestine [328]. 
In the last years, progress has been made to overcome peptide-related disadvantages (as discussed 
in 9.1.2.5) by using co-administrations, including delivery carriers, protease inhibitors or penetration 
enhancers [329, 330]. Delivery carriers that are commonly used include nanoparticles, liposomes or 
polymers [330]. As an example, Maculotti and colleagues developed an oral delivery system for 
ovalbumin, in which the protein was encapsulated in polymer-consisting microspheres [331]. Hence, 
ovalbumin can pass though the upper part of the gastrointestinal tract without being degraded by 
proteases [331]. To translocate across cell membranes, drugs are often coupled to cell-penetrating 
peptides (CPPs). This strategy has already been successfully used to deliver diverse compounds, 
including proteins, inside cells without affecting their biological activity [329, 332]. As an example,  
β-galactosidase has been fused to a TAT protein (i.e. a viral CPP), resulting in increased membrane 
permeability and thus the delivery of the fusion protein to all tissues of treated mice, including the brain 
[333]. In the future, it would be interesting to investigate similar oral administration routes for modified 
plant defensins or their derivatives such as HsLin06_18. 
9.1.2.7 Plant defensin-based coatings of medical substrates 
In the clinic, the use of medical devices, such as catheters and implants, is rising. These medical 
devices serve as ideal substrates for microbial cells to adhere and form biofilms [174]. To cope with 
this problem, surface coatings that prevent microbial biofilm formation have attracted great attention, 
as prevention of biofilm formation appears easier than curing. Problems regarding drug bio-availability, 
dosages and toxicity are, in that manner, also circumvented [334]. Effective surface coatings can be 
anti-adhesive-based (passive coatings) and/or antimicrobial-based (active coatings). Passive coatings 
prevent adhesion of microbial cells, by for example polymers chains or hydrogels, while active coatings 
include bio-degradable carrier materials for the delivery of antimicrobial substances [335, 336]. In this 
case, the antimicrobial agent is either linked to the surface (directly or via a linker molecule) or released 
from a porous material or nanoparticle [337, 338]. Controlled release of antimicrobials has advantages 
over surface coatings, such as killing of micro-organisms before they adhere, better antimicrobial 
activities (especially for antimicrobials that need to penetrate deeply into target cell (membranes)) and 
prolonged exposure times. Our group recently demonstrated this for dental implants releasing effective 
doses of the antibiofilm compound toremifene for at least 9 days [339]. Moreover, a proof-of-concept 
for (re)loading the internal reservoir of dental implants with antimicrobial compounds was proposed 
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[340]. Stavrakis and colleagues proved in vivo efficacy of PEG-PPS (propylene sulfide) coatings for 
the delivery of antibiotics, such as vancomycin and tigecycline [341]. 
Clinically relevant coatings should have low production costs, broad-spectrum antimicrobial activities 
and be safe. Regarding the activity and safety, AMP-based approaches have been developed, 
including AMPs covalently linked to medical surfaces or released from coatings on medical devices. 
For example, it was demonstrated that the salivary AMP histatin 5 (and variants) covalently linked to 
polydimethylsiloxane (PDMS) discs via a linker molecule, can prevent C. albicans biofilm formation 
[342]. Prevention of biofilm formation was also demonstrated for catheters coated with poly-L-glutamic 
acid (PGA) and poly-L-lysine (PLL) infused with β-peptide, a derivative of host antimicrobial α-peptides 
(e.g. magainin 2), which was released up to 4 months from the catheter coating [343, 344]. Similarly, 
in the future it would be interesting to develop RsAFP2-, HsAFP1- or (modified) HsLin06_18-coated 
medical substrates and evaluate their potential to prevent Candida biofilm formation in vitro and in vivo. 
9.1.3 Plant defensin-based diagnostics 
Prior to antifungal drug treatments, fungal infections needs to be diagnosed from patient samples. 
Currently, there are three main diagnostic techniques used in hospitals, being culture-, DNA- or 
antigen-based. The golden standard is the culture-based method, only resulting in the identification of 
50% of the infections. Besides the lack of sensitivity, this method takes 2-4 days before the results are 
apparent, which can be a critical period for the patient [5]. DNA- and antigen-based techniques 
generally perform better than culture-based techniques in terms of sensitivity and time-to-result, but 
the frequency with which such tests are performed in the clinic is on average only 1-3 times a week, 
due to the high complexity of these analysis and the need for specialized staff. Moreover, DNA- and 
antigen-based diagnostic techniques are costly and can result in false-positives [275]. A fourth, 
upcoming technique for micro-organism identification is a proteomic approach using the  
MALDI-TOF-MS technique. Despite many advantages, this techniques still starts from a colony of 
micro-organisms on a plate and has in this respect the same disadvantages as the culture-based 
method [345, 346]. Taken together, there is currently no diagnostic technique for the detection of 
invasive fungal infections that combines a high sensitivity with a fast time-to-result and easy handling. 
Therefore, in the current study we evaluated the fiber-optic surface plasmon resonance (FO-SPR) 
technology and plant defensins, as fungal-specific bioligand, for the development of such diagnostic 
techniques (FUNGDETECT sensor; Chapter 8).  
FO-SPR has previously been used for rapid quantifications of DNA and proteins present in very 
complex matrices at very low concentrations. This points to the low time-to-results, broad applicability, 
high sensitivity and high specificity of the FO-SPR technology [278-280]. Moreover, Lu and colleagues 
recently developed a point-of-care FO-SPR-based bioassay for the detection of micromolar antibody 
concentrations in serum or blood and this within 10 minutes [347]. Regarding these interesting 
characteristics, we selected FO-SPR for the development of a rapid fungal infection detection 
technique. To ensure high specificity, we propose that plant defensins, such as RsAFP2, are good 
candidates for bioligands for the FUNGDETECT sensor. RsAFP2 has a broad-spectrum antifungal 
activity and more importantly, only bind with fungal-specific glucosylceramides [27]) and with fungal 
cells, while not with bacterial cells (Chapter 8). 
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So far, no high sensitivities could be obtained for our FUNGDETECT sensor as we could not detect 
whole or lysed C. albicans cells by using RsAFP2 as a bioligand in a FO-SPR assay (Chapter 8). As 
direct detection of fungal cells by RsAFP2 was not feasible, indirect detection via competitive assays 
(Figure 7 in Chapter 8) was evaluated as an alternative approach. Indeed, using RsAFP2 as a bioligand 
in competitive ELISA assay, whole C. albicans cells could be successfully detected with 53 yeast 
cells/mL being the limit of detection. In the future, it would be interesting to translate this competitive 
ELISA assay to the FO-SPR setup, as ELISA assays are not suitable for point-of-care diagnostics. As 
we are currently working with RsAFP2 antiserum, containing RsAFP2-specific antibodies as well as 
various other blood components, our first step is to collect RsAFP2-specific antibodies (either by 
purification from blood of immunized animals or by monoclonal antibody production). The competitive 
FO-SPR assay will be further developed similarly to that of the competitive ELISA assay. 
9.2 Conclusions and future perspectives 
Plant defensins research has great potential as basis for the development of novel treatment of fungal 
infections in agricultural and clinical applications. These peptides or their derivatives can be used in 
agriculture and/or clinical applications: directly as (i) antifungal agents and (ii) antibiofilm agents, or 
indirectly as (iii) potentiators of commonly used antifungal/antibiofilm agents, or based on plant 
defensin targets (iv) as other antifungal agents (e.g. peptidomimetics or antibody-based drugs), and 
(v) in diagnostics (Figure 2). However, as we showed in Chapters 3, 6-8 that plant defensin – target 
binding and/or plant defensin antifungal activity is influenced by buffer/medium conditions, such as pH, 
divalent cations, salt and phosphate ions, it might be that plant defensins cannot fulfil their antifungal 
activity optimally in all circumstances. 
In this PhD, we further characterized antibiofilm activities of specific plant defensins as well as 
unravelled their mode of action and tolerance mechanisms induced in the fungus/yeast. In addition, 
the first steps towards the development of HsAFP1-based antifungal drugs (i.e. HsLin06_18) were 
taken. However, it is clear that more fundamental and translational research is needed to develop a 
HsAFP1-based antifungal drug. To this end, the antifungal mode of action of HsAFP1 and its 
derivatives (e.g. HsLin06_18) needs to be further unravelled. Moreover, it would be interesting to 
evaluate whether the [caspofungin + HsLin06_18] combination treatment can indeed halt or slow down 
resistance development in C. albicans biofilms as compared to single treatments via artificial evolution 
experiments, followed by whole genome sequencing. In addition, it would also be valuable to 
investigate resistance development and/or the induction of tolerance mechanisms upon plant defensin 
treatments at single cell level. Until now only general responses of plant defensin-treated yeast cell 
cultures were investigated (i.e. bulk experiments). However, these cultures show cellular 
heterogeneity, including individual cells that behave differently to plant defensin treatment in, for 
example, the induction of tolerance mechanisms, as compared to the majority of the cells in the culture. 
As these outliers can be crucial for the development of for example tolerance/resistance, our lab is 
currently performing single cell analysis in real time on plant defensin-treated yeast cultures using a 
digital microfluidics-based approach in collaboration with the MeBioS-Biosensor group (headed by 
Prof. Lammertyn, Department of Biosystems, KU Leuven) [348, 349]. As such, our laboratory aims at 
advancing mode of action research on plant defensins at a higher resolution. 
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It would also be interesting to further unravel the antifungal mode of action of HsAFP1 by focusing on 
its up- and downstream targets and/or processes. In this PhD, we showed that internalization of 
HsAFP1 is a prerequisite for its activity. Although this internalization seems to be at least partially 
endocytosis-dependent, the exact mechanism for HsAFP1 uptake is not yet know, as is the case for 
plant defensins in general. Research in this respect points to the importance of the cell wall and/or 
specific cell wall receptors enabling internalization of NaD1 and MtDef4 [61, 69, 84]. Hence, further 
research might reveal the role of cell wall receptors in HsAFP1’s internalization in yeast. For HsAFP1, 
these cell wall receptors might be GPI-anchored proteins as suggested from Chapter 7. Regarding 
downstream processes, it would be interesting to zoom-in on the induction of regulated cell death 
processes. It has been shown previously that HsAFP1 induces apoptosis in 10% of the treated cell 
culture [22], but the cell (death) process(es) that is induced in the remaining 90% of the population has 
not yet been identified. As we showed that only at later time points 50-90% of the HsAFP1-treated cells 
are characterized by permeabilized membranes (Chapter 6), we suggest that HsAFP1 is not forming 
pores in yeast membranes as this process generally occurs more rapidly. Therefore, other regulated 
cell death process, such as necrosis, which generally occur at later time points, will be studied in the 
future. 
Regarding translational research, HsLin06_18 needs to be further optimized in terms of in vivo efficacy 
(including peptide stability and low albumin binding capacity), followed by investigating its 
administration route and/or potential to be coated on medical devices. For the development of plant 
defensin-based diagnostics, it would be interesting to translate our optimized competitive assay for 
fungal cells detections to the FO-SPR technology. 
  
 
  
 
 
 
Figure 2: Plant defensin (PDF)-based applications. Plant defensin or their derivatives can be used (i) directly for their antifungal activity, (ii) directly for their antibiofilm activity, (iii) directly as potentiator of 
common antifungal drugs, such as caspofungin (CAS), (iv) indirectly as peptidomimetics or small molecule with similar biological activity as their corresponding native plant defensin or as antibody(-derived 
peptides) that bind to PDF targets or (v) directly as bioligand on a sensor surface to detect yeast/fungal cells.
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